

# March 2015

## Volume 3 Number 0

**Editor:** Kaye Wilson

email: hml@pharmac.govt.nz

Telephone +64 4 460 4990

Facsimile +64 4 460 4995

Level 9, 40 Mercer Street

PO Box 10 254 Wellington 6143

**Freephone Information Line**

**0800 66 00 50** (9am – 5pm weekdays)

### Circulation

Accessible in an electronic format at no cost from the Health Professionals section of the PHARMAC website [www.pharmac.govt.nz](http://www.pharmac.govt.nz)

You can register to have an electronic version of the Pharmaceutical Schedule (link to PDF copy) emailed to your nominated email address each month. Alternatively there is a nominal charge for an annual subscription to the printed Schedule publications. To access either of these subscriptions visit our subscription website [www.schedule.co.nz](http://www.schedule.co.nz).

### Production

Typeset automatically from XML and T<sub>E</sub>X.

XML version of the Schedule available from [www.pharmac.govt.nz/pub/schedule/archive/](http://www.pharmac.govt.nz/pub/schedule/archive/)

### Programmers

Anrik Drenth & John Geering

email: [texschedule@pharmac.govt.nz](mailto:texschedule@pharmac.govt.nz)

©Pharmaceutical Management Agency



ISSN 1179-3708 pdf  
ISSN 1172-9694 print

This work is licensed under the Creative Commons Attribution 3.0 New Zealand licence. In essence, you are free to copy, distribute and adapt it, as long as you attribute the work to PHARMAC and abide by the other licence terms. To view a copy of this licence, visit:

[creativecommons.org/licenses/by/3.0/nz/](http://creativecommons.org/licenses/by/3.0/nz/).

Attribution to PHARMAC should be in written form and not by reproduction of the PHARMAC logo. While care has been taken in compiling this Schedule, PHARMAC takes no responsibility for any errors or omissions, and shall not be liable for any consequences arising there from.

## Part I General Rules 6

## Part II Alimentary Tract and Metabolism 14

### Blood and Blood Forming Organs 28

### Cardiovascular System 38

### Dermatologicals 49

### Genito-Urinary System 55

### Hormone Preparations 59

### Infections 69

### Musculoskeletal System 92

### Nervous System 102

### Oncology Agents and Immunosuppressants 128

### Respiratory System and Allergies 170

### Sensory Organs 176

### Various 182

### Extemporaneous Compounds (ECPs) 190

### Special Foods 193

### Vaccines 207

## Part III Optional Pharmaceuticals 213

## Index 215

## Introducing PHARMAC

PHARMAC, the Pharmaceutical Management Agency, is a Crown entity established pursuant to the New Zealand Public Health and Disability Act 2000 (The Act). The primary objective of PHARMAC is to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided.

The PHARMAC Board consists of up to six members appointed by the Minister of Health. All decisions relating to PHARMAC's operation are made by or under the authority of the Board. More information on the Board can be found at [www.pharmac.govt.nz](http://www.pharmac.govt.nz). The functions of PHARMAC are set out in section 48 of the Act. PHARMAC is required to perform these functions within the amount of funding provided to it and in accordance with its statement of intent and any directions given by the Minister (Section 103 of the Crown Entities Act). The Government has agreed that PHARMAC will assume responsibility for the assessment, prioritisation and procurement of medical devices on behalf of DHBs. Medical devices come within the definition of Pharmaceuticals in the Act. PHARMAC is assuming responsibility for procurement of some medical devices categories immediately, as a first step to full PHARMAC management of these categories within the Pharmaceutical Schedule.

## Decision Criteria

PHARMAC takes into account the following criteria when considering amendments to the Schedule:

- a) the health needs of all eligible people within New Zealand;
- b) the particular health needs of Māori and Pacific peoples;
- c) the availability and suitability of existing medicines, therapeutic medical devices and related products and related things;
- d) the clinical benefits and risks of pharmaceuticals;
- e) the cost-effectiveness of meeting health needs by funding pharmaceuticals rather than using other publicly funded health and disability support services;
- f) the budgetary impact (in terms of the pharmaceutical budget and the Government's overall health budget) of any changes to the Schedule;
- g) the direct cost to health service users;
- h) the Government's priorities for health funding, as set out in any objectives notified by the Crown to PHARMAC, or in PHARMAC's Funding Agreement, or elsewhere; and
- i) such other criteria as PHARMAC thinks fit. PHARMAC will carry out appropriate consultation when it intends to take any such "other criteria" into account.

## PHARMAC's clinical advisors

### Pharmacology and Therapeutics Advisory Committee (PTAC)

PHARMAC works closely with the Pharmacology and Therapeutics Advisory Committee (PTAC), an expert medical committee which provides independent advice to PHARMAC on health needs and the clinical benefits of particular pharmaceuticals for use in the community and/or in DHB Hospitals. The chair of PTAC sits with the PHARMAC Board in an advisory capacity.

Contact PTAC C/-PTAC Secretary, Pharmaceutical Management Agency, PO Box 10 254, WELLINGTON 6143, Email: [PTAC@pharmac.govt.nz](mailto:PTAC@pharmac.govt.nz)

### PTAC Subcommittees

PTAC has subcommittees from which it can seek specialist advice in relation to funding applications. PTAC may seek advice from one or more subcommittees in relation to a funding application, or may make recommendations to PHARMAC without seeking the advice of a subcommittee:

Analgesic Subcommittee

Anti-Infective Subcommittee

Cancer Treatments Subcommittee

Cardiovascular Subcommittee

Dermatology Subcommittee

Diabetes Subcommittee

Endocrinology Subcommittee

Gastrointestinal Subcommittee

Haematology Subcommittee

Hospital Pharmaceuticals Subcommittee

Immunisation Subcommittee

Mental Health Subcommittee

Neurological Subcommittee

Nephrology Subcommittee

Ophthalmology Subcommittee

Pulmonary Arterial Hypertension Subcommittee

Rare Disorders Subcommittee

Reproductive and Sexual Health Subcommittee

Respiratory Subcommittee

Rheumatology Subcommittee

Special Foods Subcommittee

Tenders Subcommittee

Transplant Immunosuppressants Subcommittee

PTAC also has a Tender Medical Evaluation Subcommittee to provide advice on clinical matters relating to PHARMAC's annual multi-product tender and other purchasing strategies. Current membership of PTAC's subcommittees can be found on PHARMAC's website: <http://www.pharmac.health.nz/about/committees/ptac>

# Named Patient Pharmaceutical Assessment policy

Named Patient Pharmaceutical Assessment (NPPA) provides a mechanism for individual patients to receive funding for medicines not listed in the Pharmaceutical Schedule (either at all or for their clinical circumstances). PHARMAC will assess applications that meet the prerequisites according to its Decision Criteria before deciding whether to approve applications for funding. The Decision Criteria will be used to assess both the individual clinical circumstances of each NPPA applicant, and the implications of each NPPA funding decision on PHARMAC's ability to carry out its legislative functions.

For more information on NPPA, or to apply, visit the PHARMAC website at <http://www.pharmac.health.nz/tools-resources/forms/named-patient-pharmaceutical-assessment-nppa-forms>, or call the Panel Coordinators at (04) 9167553 or (04) 9167521.

## The Pharmaceutical Schedule

The purpose of the Schedule is to list:

- the Community Pharmaceuticals that are subsidised by the Government and to show the amount of the subsidy paid to contractors, as well as the manufacturer's price and any access conditions that may apply;
- the Hospital Pharmaceuticals that may be used in DHB Hospitals, as well as any access conditions that may apply; and
- the Pharmaceuticals, including Medical Devices, used in DHB Hospitals for which national prices have been negotiated by PHARMAC.

The purpose of the Schedule is not to show the final cost to Government of subsidising each Community Pharmaceutical or to DHBs in purchasing each Hospital Pharmaceutical or other Pharmaceuticals, including Medical Devices, used in DHB Hospitals, since that will depend on any rebate and other arrangements PHARMAC has with the supplier and, for some Hospital Pharmaceuticals, or other Pharmaceuticals, including Medical Devices, used in DHB Hospitals, on any logistics arrangements put in place by individual DHB Hospitals.

## Finding Information in Section H

Section H lists Pharmaceuticals that can be used in DHB Hospitals, and is split into the following parts:

- Part I lists the rules in relation to use of Pharmaceuticals by DHB Hospitals.
- Part II lists Hospital Pharmaceuticals that are funded for use in DHB Hospitals. These are classified based on the Anatomical Therapeutic Chemical (ATC) system used for Community Pharmaceuticals. It also provides information on any National Contracts that exist, and an indication of which products have Hospital Supply Status (HSS).
- Part III lists Optional Pharmaceuticals for which National Contracts exist, and DHB Hospitals may choose to fund. These are listed alphabetically by generic chemical entity name and line item, the relevant Price negotiated by PHARMAC and, if applicable, an indication of whether it has Hospital Supply Status (HSS) and any associated Discretionary Variance Limit (DV Limit).

The index located at the back of the Section H can be used to find page numbers for generic chemical entities and product brand names, for Hospital Pharmaceuticals The listings are displayed alphabetically (where practical) within each level of the classification system. Each anatomical section contains a series of therapeutic headings, some of which may contain a further classification

## Glossary

### Units of Measure

gram .....	g	microgram.....	mcg	millimole.....	mmol
kilogram .....	kg	milligram .....	mg	unit.....	u
international unit .....	iu	millilitre.....	ml		

### Abbreviations

application .....	app	enteric coated .....	EC	ointment.....	oint
capsule .....	cap	granules.....	grans	solution .....	soln
cream.....	crm	injection .....	inj	suppository .....	suppos
dispersible .....	disp	linctus .....	linc	tablet.....	tab
effervescent.....	eff	liquid .....	liq	tincture.....	tinc
emulsion .....	emul	lotion .....	lotn		

HSS    Hospital Supply Status (Refer to Rule 20)

Guide to Section H listings

Example

ANATOMICAL HEADING			
	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
THERAPEUTIC HEADING			
Generic name listed by therapeutic group and subgroup	CHEMICAL A - <b>Restricted</b> see terms below ⚡ Presentation A.....10.00 ➡ <b>Restricted</b> Only for use in children under 12 years of age	100	Brand A
Indicates only presentation B1 is Restricted	CHEMICAL B - <b>Some items restricted</b> see terms below ⚡ Presentation B1.....1,589.00 Presentation B2 ➡ <b>Restricted</b> Oncologist or haematologist	1	Brand B1 e.g. Brand B2
From 1 January 2012 to 30 June 2014, at least 99% of the total volume of this item purchased must be Brand C	CHEMICAL C Presentation C - <b>-1% DV Limit Jan-12 to 2014</b> .....15.00	28	Brand C
	CHEMICAL D - <b>Restricted</b> see terms below ⚡ Presentation D - <b>-1% DV Limit Mar-13 to 2014</b> .....38.65	500	Brand D
Standard national price excluding GST	➡ <b>Restricted</b> <i>Limited to five weeks' treatment</i> Either: 1 For the prophylaxis of venous thromboembolism following a total hip replacement; or 2 For the prophylaxis of venous thromboembolism following a total knee replacement.		Product with Hospital Supply Status (HSS) Quantity the Price applies to
Form and strength	CHEMICAL E Presentation E.....		e.g. Brand E Not a contracted product
⚡ Item restricted (see above); ⚡ Item restricted (see below) Products with Hospital Supply Status (HSS) are in <b>bold</b>			

### INTRODUCTION

Section H contains general rules that apply, and other information relating, to Hospital Pharmaceuticals and Optional Pharmaceuticals.

Where relevant, Section H shows the Price at which a Pharmaceutical can be purchased directly from the Pharmaceutical supplier by DHBs, providers of logistics services, wholesalers or other such distributors, or Contract Manufacturers.

The Price is determined via contractual arrangements between PHARMAC and the relevant Pharmaceutical supplier. Where a Pharmaceutical is listed in Part II of Section H, but no Price and/or brand of Pharmaceutical is indicated, each DHB may purchase any brand and/or pay the price that the DHB negotiates with the relevant Pharmaceutical supplier.

As required by section 23(7) of the Act, in performing any of its functions in relation to the supply of Pharmaceuticals, a DHB must not act inconsistently with the Pharmaceutical Schedule.

### INTERPRETATION AND DEFINITIONS

#### 1 Interpretation and Definitions

1.1 In this Schedule, unless the context otherwise requires:

**“Act”**, means the New Zealand Public Health and Disability Act 2000.

**“Combined Pharmaceutical Budget”**, means the pharmaceutical budget set for PHARMAC by the Crown for the subsidised supply of Community Pharmaceuticals and Pharmaceutical Cancer Treatments including for named patients in exceptional circumstances.

**“Community”**, means any setting outside of a DHB Hospital.

**“Community Pharmaceutical”**, means a Pharmaceutical listed in Sections A to G or I of the Pharmaceutical Schedule that is subsidised by the Funder from the Combined Pharmaceutical Budget and, for the purposes of this Section H, includes Pharmaceutical Cancer Treatments (PCTs).

**“Contract Manufacturer”**, means a manufacturer or a supplier that is a party to a contract with the relevant DHB Hospital to compound Pharmaceuticals, on request from that DHB Hospital.

**“Designated Delivery Point”**, means at a DHB Hospital's discretion:

- a) a delivery point agreed between a Pharmaceutical supplier and the relevant DHB Hospital, to which delivery point that Pharmaceutical supplier must supply a National Contract Pharmaceutical directly at the Price; and/or
- b) any delivery point designated by the relevant DHB Hospital or PHARMAC, such delivery point being within 30 km of the relevant Pharmaceutical supplier's national distribution centre.

**“DHB”**, means an organisation established as a District Health Board by or under Section 19 of the Act.

**“DHB Hospital”**, means a hospital (including community trust hospitals) and/or an associated health service that is funded by a DHB including (but not limited to) district nursing services and child dental services.

**“DV Limit”**, means, for a particular National Contract Pharmaceutical with HSS, the National DV Limit or the Individual DV Limit.

**“DV Pharmaceutical”**, means a discretionary variance Pharmaceutical that does not have HSS but is used in place of one that does. Usually this means it is the same chemical entity, at the same strength, and in the same or a similar presentation or form, as the relevant National Contract Pharmaceutical with HSS. Where this is not the case, a note will be included with the listing of the relevant Hospital Pharmaceutical.

**“Extemporaneously Compounded Product”**, means a Pharmaceutical that is compounded from two or more Pharmaceuticals, for the purposes of reconstitution, dilution or otherwise.

**“First Transition Period”**, means the period of time after notification that a Pharmaceutical has been awarded HSS and before HSS is implemented.

**“Funder”**, means the body or bodies responsible, pursuant to the Act, for the funding of Pharmaceuticals listed on the Schedule (which may be one or more DHBs and/or the Ministry of Health) and their successors.

**“Give”**, means to administer, provide or dispense (or, in the case of a Medical Device, use) a Pharmaceutical, or to arrange for the administration, provision or dispensing (or, in the case of a Medical Device, use) of a Pharmaceutical, and “Given” has a corresponding meaning.

**“Hospital Pharmaceuticals”**, means the list of Pharmaceuticals set out in Section H Part II of the Schedule which includes some National Contract Pharmaceuticals.

**“HSS”**, stands for hospital supply status, which means the status of being the brand of the relevant National Contract Pharmaceutical that DHBs are obliged to purchase, subject to any DV Limit, for the period of hospital supply,

as awarded under an agreement between PHARMAC and the relevant Pharmaceutical supplier. Pharmaceuticals with HSS are listed in Section H in bold text.

**“Indication Restriction”**, means a limitation placed by PHARMAC on the funding of a Hospital Pharmaceutical which restricts funding to treatment of particular clinical circumstances.

**“Individual DV Limit”**, means, for a particular National Contract Pharmaceutical with HSS and a particular DHB Hospital, the discretionary variance limit, being the specified percentage of that DHB Hospital's Total Market Volume up to which that DHB Hospital may purchase DV Pharmaceuticals of that National Contract Pharmaceutical.

**“Local Restriction”**, means a restriction on the use of a Pharmaceutical in specific DHB Hospitals on the basis of prescriber type that is implemented by the relevant DHB in accordance with rule 7.

**“Medical Device”**, has the meaning set out in the Medicines Act 1981.

**“Named Patient Pharmaceutical Assessment Advisory Panel”**, means the panel of clinicians, appointed by the PHARMAC Board, that is responsible for advising PHARMAC, in accordance with its Terms of Reference, on Named Patient Pharmaceutical Assessment applications and any Exceptional Circumstances renewal applications submitted after 1 March 2012.

**“National Contract”**, means a contractual arrangement between PHARMAC and a Pharmaceutical supplier which sets out the basis on which any Pharmaceutical may be purchased for use in a DHB Hospital, including an agreement as to a national price.

**“National Contract Pharmaceutical”**, means a brand of Pharmaceutical listed in Section H, where PHARMAC has entered into contractual arrangements with the relevant Pharmaceutical supplier that specify the terms and conditions of listing, including the Price. Such Pharmaceuticals are recognisable in Section H because the relevant listing identifies the brand and Price.

**“National DV Limit”**, means, for a particular National Contract Pharmaceutical with HSS, the discretionary variance limit, being the specified percentage of the Total Market Volume up to which all DHB Hospitals may collectively purchase DV Pharmaceuticals of that National Contract Pharmaceutical.

**“Optional Pharmaceuticals”**, means the list of National Contract Pharmaceuticals set out in Section H Part III of the Schedule.

**“PHARMAC”**, means the Pharmaceutical Management Agency established by Section 46 of the Act.

**“Pharmacode”**, means the six or seven digit identifier assigned to a Pharmaceutical by the Pharmacy Guild following application from a Pharmaceutical supplier.

**“Pharmaceutical”**, means a medicine, therapeutic medical device, or related product or related thing listed in Sections B to I of the Schedule.

**“Pharmaceutical Cancer Treatment”**, means Pharmaceuticals for the treatment of cancer, listed in Sections A to G of the Schedule and identified therein as a “PCT” or “PCT only” Pharmaceutical that DHBs must fund for use in their DHB hospitals, and/or in association with outpatient services provided by their DHB Hospitals, in relation to the treatment of cancers.

**“Prescriber Restriction”**, means a restriction placed by PHARMAC on the funding of a Pharmaceutical on the basis of prescriber type (and where relevant in these rules, includes a Local Restriction).

**“Price”**, means the standard national price for a National Contract Pharmaceutical, and, unless agreed otherwise between PHARMAC and the Pharmaceutical supplier, includes any costs associated with the supply of the National Contract Pharmaceutical to, at a DHB Hospital's discretion, any Designated Delivery Point, or to a Contract Manufacturer (expressly for the purpose of compounding), but does not include the effect of any rebates which may have been negotiated between PHARMAC and the Pharmaceutical supplier.

**“Restriction”**, means a limitation, put in place by PHARMAC or a DHB, restricting the funding of a Pharmaceutical and includes Indication Restrictions, Local Restrictions and Prescriber Restrictions (as defined in this Part I of Section H).

**“Schedule”**, means this Pharmaceutical Schedule and all its sections and appendices.

**“Special Authority Approval”**, means an approval for funding of a Community Pharmaceutical that is marked in Sections B-G of the Schedule as being subject to a Special Authority restriction.

**“Total Market Volume”**, means, for a particular Hospital Pharmaceutical with HSS in any given period, in accordance with the data available to PHARMAC, the sum of:

- the total number of Units of the relevant Hospital Pharmaceutical with HSS purchased by all DHB Hospitals, or by a particular DHB Hospital in the case of the Individual DV Limit; and
- the total number of Units of all the relevant DV Pharmaceuticals purchased by all DHB Hospitals, or by a particular DHB Hospital in the case of the Individual DV Limit.

**“Unapproved Indication”**, means, for a Pharmaceutical, an indication for which it is not approved under the Medicines Act 1981. Clinicians prescribing Pharmaceuticals for Unapproved Indications should be aware of, and comply with, their obligations under Section 25 and/or Section 29 of the Medicines Act 1981 and as set out in rule 23.

**“Unit”**, means an individual unit of a Pharmaceutical (e.g. a tablet, 1 ml of an oral liquid, an ampoule or a syringe).

**“Unlisted Pharmaceutical”**, means a Pharmaceutical that is within the scope of a Hospital Pharmaceutical, but is not listed in Section H Part II.

- 1.2 In addition to the above interpretations and definitions, unless the content requires otherwise, a reference in the Schedule to:
  - a) the singular includes the plural; and
  - b) any legislation includes a modification and re-enactment of, legislation enacted in substitution for, and a regulation, Order in Council, and other instrument from time to time issued or made under, that legislation.

## HOSPITAL SUPPLY OF PHARMACEUTICALS

### 2 Hospital Pharmaceuticals

- 2.1 Section H Part II contains the list of Hospital Pharmaceuticals that must be funded by DHB Hospitals. Section H Part II does not currently encompass the following categories of pharmaceuticals except for any items specifically listed in this Section H Part II:
  - a) Medical Devices;
  - b) whole or fractionated blood products;
  - c) diagnostic products which have an ex vivo use, such as pregnancy tests and reagents;
  - d) disinfectants and sterilising products, except those that are to be used in or on a patient;
  - e) foods and probiotics;
  - f) radioactive materials;
  - g) medical gases; and
  - h) parenteral nutrition.

Subject to rule 2.2, the funding of pharmaceuticals identified in a)–h) above is a decision for individual DHB Hospitals.

- 2.2 Section H Part III lists Optional Pharmaceuticals that PHARMAC and the relevant Pharmaceutical supplier have entered into contractual arrangements for the purchase of, including an agreement on a national price and other obligations such as HSS. DHB Hospitals may choose whether or not to fund the Optional Pharmaceuticals listed in Part III of Section H, but if they do, they must comply with any National Contract requirements.
- 2.3 Section H Part II does not encompass the provision of pharmaceutical treatments for DHB Hospital staff as part of an occupational health and safety programme. DHB Hospitals may choose whether or not to fund pharmaceutical treatments for such use, but if they do, they must comply with any National Contract requirements.

### 3 DHB Supply Obligations

- 3.1 In accordance with section 23(7) of the Act, in performing any of its functions in relation to the supply of pharmaceuticals, a DHB must not act inconsistently with the Pharmaceutical Schedule, which includes these General Rules.
- 3.2 DHB Hospitals are not required to hold stock of every Hospital Pharmaceutical listed in Section H Part II, but they must Give it within a reasonable time if it is prescribed.
- 3.3 DHB Hospitals are able to hold stock of an Unlisted Pharmaceutical if doing so is considered necessary for the DHB Hospital to be able to Give the Unlisted Pharmaceutical in a timely manner under rules 11–17 inclusive.
- 3.4 Except where permitted in accordance with rule 11, DHBs must not Give:
  - a) an Unlisted Pharmaceutical; or
  - b) a Hospital Pharmaceutical outside of any relevant Restrictions.

### 4 Funding

- 4.1 The purchase costs of Hospital Pharmaceuticals or Optional Pharmaceuticals administered, provided or dispensed by DHB Hospitals must be funded by the relevant DHB Hospital from its own budget, with the exception of:
  - a) Pharmaceutical Cancer Treatments;
  - b) Community Pharmaceuticals that have been brought to the DHB hospital by the patient who is being treated by outpatient Services or who is admitted as an inpatient;
  - c) Community Pharmaceuticals that have been dispensed to a mental health day clinic under a Practitioner's



- Supply Order; and
  - d) Unlisted Pharmaceutical that have been brought to the DHB Hospital by the patient who is admitted as an inpatient.
- 4.2 For the avoidance of doubt, Pharmaceutical Cancer Treatments and Community Pharmaceuticals are funded through the Combined Pharmaceutical Budget, and Unlisted Pharmaceuticals are funded by the patient.

## LIMITS ON SUPPLY

### 5 Prescriber Restrictions

- 5.1 A DHB Hospital may only Give a Hospital Pharmaceutical that has a Prescriber Restriction if it is prescribed:
- a) by a clinician of the type specified in the restriction for that Pharmaceutical or, subject to rule 5.2, pursuant to a recommendation from such a clinician;
  - b) in accordance with a protocol or guideline that has been endorsed by the DHB Hospital; or
  - c) in an emergency situation, provided that the prescriber has made reasonable attempts to comply with rule 5.1(a) above. If on-going treatment is required (i.e. beyond 24 hours) subsequent prescribing must comply with rule 5.1(a).
- 5.2 Where a Hospital Pharmaceutical is prescribed pursuant to a recommendation from a clinician of the type specified in the restriction for that Pharmaceutical:
- a) the prescriber must consult with a clinician of the type specified in the restriction for that Pharmaceutical; and
  - b) the consultation must relate to the patient for whom the prescription is written; and
  - c) the consultation may be in person, by telephone, letter, facsimile or email; and
  - d) appropriate records are kept of the consultation, including recording the name of the advising clinician on the prescription/chart.
- 5.3 Where a clinician is working under supervision of a consultant who is of the type specified in the restriction for that Pharmaceutical, the requirements of rule 5.2 can be deemed to have been met.

### 6 Indication Restrictions

- 6.1 A DHB Hospital may only Give a Hospital Pharmaceutical that has an Indication Restriction, if it is prescribed for treatment of a patient with the particular clinical circumstances set out in the Indication Restriction.
- 6.2 If a patient has a current Special Authority Approval for the Hospital Pharmaceutical that the DHB Hospital wishes to Give, then the Indication Restriction is deemed to have been met.
- 6.3 If a Hospital Pharmaceutical has an Indication Restriction that is “for continuation only” then the DHB Hospital should only Give the Hospital Pharmaceutical where:
- a) the patient has been treated with the Pharmaceutical in the Community; or
  - b) the patient is unable to be treated with an alternative Hospital Pharmaceutical, and the prescriber has explained to the patient that the Pharmaceutical is not fully subsidised in the Community.

### 7 Local Restrictions

- 7.1 A DHB Hospital may implement a Local Restriction, provided that:
- a) in doing so, it ensures that the Local Restriction does not unreasonably limit funded access to the Hospital Pharmaceutical or undermine PHARMAC’s decision that the Hospital Pharmaceutical must be funded;
  - b) it provides PHARMAC with details of each Local Restriction that it implements; and
- 7.2 PHARMAC may, when it considers that a Local Restriction does not conform to rule 7.1 above, require a DHB to amend or remove that Local Restriction.

### 8 Community use of Hospital Pharmaceuticals

- 8.1 Except where otherwise specified in Section H, DHB Hospitals can Give any Hospital Pharmaceutical to a patient for use in the Community, provided that:
- a) the quantity does not exceed that sufficient for up to 30 days’ treatment, unless:
    - i) it would be inappropriate to provide less than the amount in an original pack; or
    - ii) the relevant DHB Hospital has a Dispensing for Discharge Policy and the quantity dispensed is in accordance with that policy; and
  - b) the Hospital Pharmaceutical is supplied consistent with any applicable Restrictions.

### 9 Community use of Medical Devices

- 9.1 Subject to rules 9.2 and 9.3, DHB Hospitals may Give a Medical Device for patients for use in the Community.
- 9.2 Where a Medical Device (or a similar Medical Device) is a Community Pharmaceutical, the DHB Hospital must supply:

- a) the brand of Medical Device that is listed in Sections A-G of the Schedule; and
  - b) only to patients who meet the funding eligibility criteria set out in Sections A-G of the Schedule.
- 9.3 Where a DHB Hospital has supplied a Medical Device to a patient; and
- a) that Medical Device (or a similar Medical Device) is subsequently listed in Sections A-G of the Schedule; and
  - b) the patient would not meet any funding eligibility criteria for the Medical Device set out in Sections A-G of the Schedule; and
  - c) the Medical Device has consumable components that need to be replaced throughout its usable life; then DHB Hospitals may continue to fund consumable products for that patient until the end of the usable life of the Medical Device. At the end of the usable life of the device, funding for a replacement device must be consistent with the Pharmaceutical Schedule and/or in accordance with the Named Patient Pharmaceutical Assessment policy.
- 9.4 DHB Hospitals may also continue to fund consumable products, as in rule 9.3 above, in situations where the DHB has been funding consumable products but where the Medical Device was funded by the patient.

### 10 Extemporaneous Compounding

- 10.1 A DHB Hospital may Give any Extemporaneously Compounded Product for a patient in its care, provided that:
- a) all of the component Pharmaceuticals of the Extemporaneously Compounded Product are Hospital Pharmaceuticals; and
  - b) the Extemporaneously Compounded Product is supplied consistent with any applicable rules or Restrictions for its component Hospital Pharmaceuticals.
- 10.2 For the avoidance of doubt, this rule 10.1 applies to any Extemporaneously Compounded Product, whether it is manufactured by the DHB Hospital or by a Contract Manufacturer.

## EXCEPTIONS

### 11 Named Patient Pharmaceutical Assessment

- 11.1 A DHB Hospitals may only Give:
- a) an Unlisted Pharmaceutical; or
  - b) a Hospital Pharmaceutical outside of any relevant Restrictions,
- in accordance with the Named Patient Pharmaceutical Assessment Policy or rules 12–17 inclusive.

### 12 Continuation

- 12.1 Where a patient's clinical circumstances have been stabilised via treatment in the Community with a pharmaceutical that has not been funded by the Funder, and that patient is admitted to hospital as an inpatient, a DHB Hospital may fund that pharmaceutical for the duration of the patient's stay, where:
- a) the patient has not brought (or cannot arrange to bring) the pharmaceuticals to the DHB Hospital, or pharmacy staff consider that the pharmaceuticals brought to the DHB Hospital by the patient cannot be used; and
  - b) interrupted or delayed treatment would have significant adverse clinical consequences; and
  - c) it is not considered appropriate to switch treatment to a Hospital Pharmaceutical.

### 13 Pre-Existing Use

- 13.1 Subject to 13.2, where a DHB Hospital has Given a pharmaceutical for a patient prior to 1 July 2013, and the pharmaceutical:
- a) is an Unlisted Pharmaceutical; or
  - b) treatment of the patient would not comply with any relevant Restrictions;
- the DHB Hospital may continue to Give that pharmaceutical if it is considered that there would be significant adverse clinical consequences from ceasing or switching treatment.
- 13.2 Each DHB Hospital must, by no later than 1 October 2013, provide PHARMAC with a report on pharmaceuticals it has Given in accordance with this rule 13 where treatment has continued beyond 1 August 2013.

### 14 Clinical Trials and Free Stock

- 14.1 DHB Hospitals may Give any pharmaceutical that is funded by a third party and is being used:
- 14.1.1 as part of a clinical trial that has Ethics Committee approval; or
  - 14.1.2 for on-going treatment of patients following the end of such a clinical trial.
- 14.2 DHB Hospitals may Give any pharmaceutical that is provided free of charge by a supplier, provided that the pharmaceutical is provided as part of a programme of which the DHB, or supplier, has notified PHARMAC.

### 15 Pharmaceutical Cancer Treatments in Paediatrics

DHB Hospitals may Give any pharmaceutical for use within a paediatric oncology/haematology service for the treatment of

cancer.

#### 16 Other Government Funding

DHB Hospitals may Give any pharmaceutical where funding for that pharmaceutical has been specifically provided by a Government entity other than PHARMAC or a DHB.

#### 17 Other Exceptions

- 17.1 PHARMAC may also approve the funding of a pharmaceutical within a single DHB Hospital for information gathering purposes or otherwise related to PHARMAC's decision-making process for considering additions to or amendments to the Pharmaceutical Schedule.
- 17.2 Funding approvals granted under rule 17.1 will be subject to specific limitations on use as determined appropriate by PHARMAC in each circumstance, in consultation with the relevant DHB Hospital and/or DHB.

## NATIONAL CONTRACTING

#### 18 Hospital Pharmaceutical Contracts

- 18.1 A DHB Hospital may enter into a contract for the purchase of any Pharmaceutical, including any Medical Device, that it is entitled to fund in accordance with this Schedule H and that is not a National Contract Pharmaceutical, provided that such a contract:
  - a) does not oblige the relevant DHB Hospital to purchase a volume of that Pharmaceutical, if that Pharmaceutical is a DV Pharmaceutical, that is greater than the relevant DV Limit;
  - b) enables PHARMAC to access and use future price and volume data in respect of that Pharmaceutical; and
  - c) enables the relevant DHB Hospital to terminate the contract or relevant parts of the contract in order to give full effect to the National Contract on no more than 3 months' written notice to the Pharmaceutical supplier.
- 18.2 From 1 July 2013, where a DHB Hospital has a pre-existing supply contract for a particular brand of chemical entity for which there is a National Contract Pharmaceutical, the DHB may continue purchasing the chemical entity in accordance with its pre-existing supply contract however:
  - a) from the day its pre-existing supply contract expires, that DHB Hospital is to purchase the relevant National Contract Pharmaceutical listed in Section H at the Price, and is to comply with any DV Limits for the National Contract Pharmaceutical where it has HSS;
  - b) if purchase of the relevant National Contract Pharmaceutical listed in Section H at the Price, where it has HSS, would not cause the relevant DHB Hospital to be in breach of its pre-existing supply contract for a particular brand of chemical entity; the DHB Hospital must purchase the National Contract Pharmaceutical.
- 18.3 Following written notification from PHARMAC that a Pharmaceutical is a National Contract Pharmaceutical, either through Section H updates or otherwise, DHB Hospitals must, unless PHARMAC expressly notifies otherwise:
  - a) take any steps available to them to terminate pre-existing contracts or relevant parts of such a contract, and
  - b) not enter any new contracts or extend the period of any current contracts, for the supply of that National Contract Pharmaceutical or the relevant chemical entity or Medical Device.

#### 19 National Contract Pharmaceuticals

- 19.1 DHB Hospitals must take all necessary steps to enable any contracts between PHARMAC and a Pharmaceutical supplier in relation to National Contract Pharmaceuticals to be given full effect.
- 19.2 The contractual arrangement between PHARMAC and the relevant supplier of a National Contract Pharmaceutical requires it to be made available for purchase at the relevant Price by any or all of the following:
  - a) DHB Hospitals at Designated Delivery Points; and/or
  - b) Contract Manufacturers (expressly for the purpose of compounding).

In the case of Medical Devices, a National Contract may require the Medical Device to be purchased by, and/or supplied to, a third party logistics provider.

#### 20 Hospital Supply Status (HSS)

- 20.1 The DV Limit for any National Contract Pharmaceutical which has HSS is set out in the listing of the relevant National Contract Pharmaceutical in Section H, and may be amended from time to time.
- 20.2 If a National Contract Pharmaceutical is listed in Section H as having HSS, DHB Hospitals:
  - a) are expected to use up any existing stocks of DV Pharmaceuticals during the First Transition Period;
  - b) must not purchase DV Pharmaceuticals in volumes exceeding their usual requirements, or in volumes exceeding those which they reasonably expect to use, within the First Transition Period;
  - c) must ensure that Contract Manufacturers, when manufacturing an Extemporaneously Compounded Product on their behalf, use the National Contract Pharmaceutical with HSS; and

- d) must purchase the National Contract Pharmaceutical with HSS except:
  - i) to the extent that the DHB Hospital may use its discretion to purchase a DV Pharmaceutical within the DV Limit, provided that (subject to rule 20.2(d)(iii) below) the DV Limit has not been exceeded nationally;
  - ii) if the Pharmaceutical supplier fails to supply that National Contract Pharmaceutical, in which case the relevant DHB Hospital does not have to comply with the DV Limit for that National Contract Pharmaceutical during that period of non-supply (and any such month(s) included in a period of non-supply will be excluded in any review of the DV Limit in accordance with rule 20.3 below);
  - iii) that where the DV Limit has been exceeded nationally, the DHB Hospital may negotiate with the Pharmaceutical supplier that supplies the National Contract Pharmaceutical with HSS for written permission to vary the application of that DHB Hospital's Individual DV Limit for any patient whose exceptional needs require a DV Pharmaceutical.

**20.3 PHARMAC may, in its discretion, for any period or part period:**

- a) review usage by DHB Hospitals of the National Contract Pharmaceutical and DV Pharmaceuticals to determine whether the DV Limit has been exceeded; and
- b) audit compliance by DHB Hospitals with the DV Limits and related requirements.

**20.4 PHARMAC will address any issues of non-compliance by any individual DHB or DHB Hospital with a DV Limit by:**

- a) obtaining the relevant DHB or DHB Hospital's assurance that it will comply with the DV Limit for that National Contract Pharmaceutical with HSS in the remainder of the applicable period and any subsequent periods; and
- b) informing the relevant supplier of the HSS Pharmaceutical of any individual DHB or DHB Hospital's non-compliance with the DV Limit for that HSS Pharmaceutical.

**20.5 In addition to the steps taken by PHARMAC under rule 20.4 above to address any issues of non-compliance by any individual DHB or DHB Hospital with a DV Limit, the relevant Pharmaceutical supplier may require, in its discretion, financial compensation from the relevant DHB or DHB Hospital:**

- a) an amount representing that DHB or DHB Hospital's contribution towards exceeding the DV Limit (where PHARMAC is able to quantify this based on the information available to it); or
- b) the sum of \$1,000 or \$5,000 (depending on the terms of the applicable national contract applying to the HSS Pharmaceutical),

whichever is the greater as between sub-paragraphs (a) and (b) within the number of business days specified in the notice from the Pharmaceutical supplier requiring such payment to be made.

**21 Collection of rebates and payment of financial compensation**

21.1 Following the receipt of any rebates from a Pharmaceutical supplier in respect of a particular National Contract Pharmaceutical, PHARMAC will notify each relevant DHB and DHB Hospital of the amount of the rebate owing to it, being a portion of the total rebate determined by PHARMAC on the basis of that DHB Hospital's usage of that National Contract Pharmaceutical, where this is able to be determined. Where data to determine individual DHB Hospitals' usage is not available, PHARMAC will apportion rebates on the basis of an alternative method agreed between the relevant DHBs and PHARMAC.

21.2 PHARMAC will pay each DHB Hospital the rebate amounts (if any) owing to it, no less frequently than once each calendar quarter in respect of rebates received quarterly (or more often).

**22 Price and Volume Data**

22.1 DHB Hospitals must provide to PHARMAC, on a monthly basis in accordance with PHARMAC's requirements, any volume data and, unless it would result in a breach of a pre-existing contract, price data held by those DHB Hospitals in respect of any Pharmaceutical (including any Medical Device) listed in Section H.

22.2 All price and volume data provided to PHARMAC under rule 22.1 above should identify the relevant Hospital Pharmaceutical by using a Pharmacode or some other unique numerical identifier, and the date (month and year) on which the DHB Hospital incurred a cost for the purchase of that Hospital Pharmaceutical. Volume is to be measured in units (that being the smallest possible whole Unit – e.g. a capsule, a vial, a millilitre etc).

## MISCELLANEOUS PROVISIONS

**23 Unapproved Pharmaceuticals**

Prescribers should, where possible, prescribe Hospital Pharmaceuticals that are approved under the Medicines Act 1981. However, the funding criteria (including Restrictions) under which a Hospital Pharmaceutical is listed in Section H of the

Schedule may:

- 23.1 in some cases, explicitly permit a DHB to fund a Pharmaceutical that is not approved under the Medicines Act 1981 or for an Unapproved Indication; or
- 23.2 not explicitly prohibit a DHB from funding a Pharmaceutical for use for an Unapproved Indication;

Accordingly, if clinicians are planning on prescribing an unapproved Pharmaceutical or a Pharmaceutical for an Unapproved Indication, they should:

- 23.1 be aware of and comply with their obligations under sections 25 and/or 29 of the Medicines Act 1981, as applicable, and otherwise under that Act and the Medicines Regulations 1984;
- 23.2 be aware of and comply with their obligations under the Health and Disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that clinicians obtain written consent); and
- 23.3 exercise their own skill, judgment, expertise and discretion, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical or a Pharmaceutical for an Unapproved Indication.

Clinicians should be aware that simply by listing a Pharmaceutical on the Pharmaceutical Schedule, PHARMAC makes no representations about whether that Pharmaceutical has any form of approval or consent under, or whether the supply or use of the Pharmaceutical otherwise complies with, the Medicines Act 1981. Further, the Pharmaceutical Schedule does not constitute an advertisement, advertising material or a medical advertisement as defined in the Medicines Act or otherwise.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Antacids and Antiflatulents</b>			
<b>Antacids and Reflux Barrier Agents</b>			
ALUMINIUM HYDROXIDE WITH MAGNESIUM HYDROXIDE AND SIMETHICONE			
Tab 200 mg with magnesium hydroxide 200 mg and simethicone 20 mg			<i>e.g. Mylanta</i>
Oral liq 200 mg with magnesium hydroxide 200 mg and simethicone 20 mg per 5 ml			<i>e.g. Mylanta</i>
Oral liq 400 mg with magnesium hydroxide 400 mg and simethicone 30 mg per 5 ml			<i>e.g. Mylanta Double Strength</i>
SIMETHICONE			
Oral drops 100 mg per ml			
SODIUM ALGINATE WITH MAGNESIUM ALGINATE			
Powder for oral soln 225 mg with magnesium alginate 87.5 mg, sachet			<i>e.g. Gaviscon Infant</i>
SODIUM ALGINATE WITH SODIUM BICARBONATE AND CALCIUM CARBONATE			
Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg			<i>e.g. Gaviscon Double Strength</i>
Oral liq 500 mg with sodium bicarbonate 267 mg and calcium carbon- ate 160 mg per 10 ml .....	4.95	500 ml	Acidex
SODIUM CITRATE			
Oral liq 8.8% (300 mmol/l)			
<b>Phosphate Binding Agents</b>			
ALUMINIUM HYDROXIDE			
Tab 600 mg			
CALCIUM CARBONATE – <b>Restricted</b> see terms below			
☞ Oral liq 250 mg per ml (100 mg elemental per ml) .....	39.00	500 ml	Roxane
☞ <b>Restricted</b>			
Only for use in children under 12 years of age for use as a phosphate binding agent			
<b>Antidiarrhoeals and Intestinal Anti-Inflammatory Agents</b>			
<b>Antipropulsives</b>			
DIPHENOXYLATE HYDROCHLORIDE WITH ATROPINE SULPHATE			
Tab 2.5 mg with atropine sulphate 25 mg			
LOPERAMIDE HYDROCHLORIDE			
Tab 2 mg			
Cap 2 mg – 1% DV Jul-14 to 2016 .....	7.84	400	Diamide Relief
<b>Rectal and Colonic Anti-Inflammatories</b>			
BUDESONIDE – <b>Restricted</b> see terms on the next page			
☞ Cap 3 mg			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>➔ Restricted</b>			
<b>Crohn's disease</b>			
Both:			
1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and			
2 Any of the following:			
2.1 Diabetes; or			
2.2 Cushingoid habitus; or			
2.3 Osteoporosis where there is significant risk of fracture; or			
2.4 Severe acne following treatment with conventional corticosteroid therapy; or			
2.5 History of severe psychiatric problems associated with corticosteroid treatment; or			
2.6 History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or			
2.7 Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated).			
<b>Collagenous and lymphocytic colitis (microscopic colitis)</b>			
Patient has a diagnosis of microscopic colitis (collagenous or lymphocytic colitis) by colonoscopy with biopsies			
<b>Gut Graft versus Host disease</b>			
Patient has a gut Graft versus Host disease following allogeneic bone marrow transplantation			
<b>HYDROCORTISONE ACETATE</b>			
Rectal foam 10% (14 applications) – <b>1% DV Jan-13 to 2015</b> .....	25.30	21.1 g	<b>Colifoam</b>
<b>MESALAZINE</b>			
Tab EC 400 mg .....	49.50	100	Asacol
Tab EC 500 mg .....	49.50	100	Asamax
Tab long-acting 500 mg .....	59.05	100	Pentasa
Modified release granules 1 g .....	141.72	120 g	Pentasa
Suppos 500 mg .....	22.80	20	Asacol
Suppos 1 g .....	54.60	30	Pentasa
Enema 1 g per 100 ml – <b>1% DV Sep-12 to 2015</b> .....	44.12	7	<b>Pentasa</b>
<b>OLSALAZINE</b>			
Tab 500 mg			
Cap 250 mg			
<b>SODIUM CROMOGLYCATE</b>			
Cap 100 mg			
<b>SULPHASALAZINE</b>			
Tab 500 mg – <b>1% DV Oct-13 to 2016</b> .....	11.68	100	<b>Salazopyrin</b>
Tab EC 500 mg – <b>1% DV Oct-13 to 2016</b> .....	12.89	100	<b>Salazopyrin EN</b>
<b>Local Preparations for Anal and Rectal Disorders</b>			
<b>Antihæmorrhoidal Preparations</b>			
<b>CINCHOCAINE HYDROCHLORIDE WITH HYDROCORTISONE</b>			
Oint 5 mg with hydrocortisone 5 mg per g .....	15.00	30 g	Proctosedyl
Suppos 5 mg with hydrocortisone 5 mg per g .....	9.90	12	Proctosedyl
<b>FLUOCORTOLONE CAPROATE WITH FLUOCORTOLONE PIVALATE AND CINCHOCAINE</b>			
Oint 950 mcg with fluocortolone pivalate 920 mcg and cinchocaine hydrochloride 5 mg per g .....	6.35	30 g	Ultraproct
Suppos 630 mcg with fluocortolone pivalate 610 mcg and cinchocaine hydrochloride 1 mg .....	2.66	12	Ultraproct
Products with Hospital Supply Status (HSS) are in <b>bold</b>			
Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Management of Anal Fissures</b>			
GLYCERYL TRINITRATE			
Oint 0.2% .....	22.00	30 g	Rectogesic
<b>Rectal Sclerosants</b>			
OILY PHENOL [PHENOL OILY]			
Inj 5%, 5 ml vial			
<b>Antispasmodics and Other Agents Altering Gut Motility</b>			
GLYCOPYRRONIUM BROMIDE			
Inj 200 mcg per ml, 1 ml ampoule – 1% DV Oct-13 to 2016 .....	28.56	10	Max Health
HYOSCINE BUTYLBROMIDE			
Tab 10 mg .....	1.48	20	Gastrosoothe
Inj 20 mg, 1 ml ampoule .....	9.57	5	Buscopan
MEBEVERINE HYDROCHLORIDE			
Tab 135 mg – 1% DV Sep-14 to 2017 .....	18.00	90	Colofac
<b>Antiulcerants</b>			
<b>Antisecretory and Cytoprotective</b>			
MISOPROSTOL			
Tab 200 mcg			
<b>H2 Antagonists</b>			
CIMETIDINE			
Tab 200 mg			
Tab 400 mg			
RANITIDINE			
Tab 150 mg – 1% DV Nov-14 to 2017 .....	10.30	500	Ranitidine Relief
Tab 300 mg – 1% DV Nov-14 to 2017 .....	14.73	500	Ranitidine Relief
Oral liq 150 mg per 10 ml – 1% DV Sep-14 to 2017 .....	4.92	300 ml	Peptisoothe
Inj 25 mg per ml, 2 ml ampoule .....	8.75	5	Zantac
<b>Proton Pump Inhibitors</b>			
LANSOPRAZOLE			
Cap 15 mg – 1% DV Jan-13 to 2015 .....	2.00	28	Solox
Cap 30 mg – 1% DV Jan-13 to 2015 .....	2.32	28	Solox
OMEPRAZOLE			
☞ Tab dispersible 20 mg			
☞ Restricted			
Only for use in tube-fed patients			
Cap 10 mg – 1% DV Jan-15 to 2017 .....	2.23	90	Omezol Relief
Cap 20 mg – 1% DV Jan-15 to 2017 .....	2.91	90	Omezol Relief
Cap 40 mg – 1% DV Jan-15 to 2017 .....	4.42	90	Omezol Relief
Powder for oral liq .....	42.50	5 g	Midwest
Inj 40 mg ampoule .....	19.00	5	Dr Reddy's Omeprazole
Inj 40 mg ampoule with diluent .....	28.65	5	Dr Reddy's Omeprazole



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>PANTOPRAZOLE</b>			
Tab EC 20 mg – 1% DV May-14 to 2016 .....	2.68	100	<b>Pantoprazole Actavis 20</b>
Tab EC 40 mg – 1% DV May-14 to 2016 .....	3.54	100	<b>Pantoprazole Actavis 40</b>
Inj 40 mg vial			

### Site Protective Agents

<b>BISMUTH TRIOXIDE</b>			
Tab 120 mg .....	32.50	112	De-Nol
<b>SUCRALFATE</b>			
Tab 1 g			

### Bile and Liver Therapy

L-ORNITHINE L-ASPARTATE – **Restricted** see terms below

⚡ Grans for oral liquid 3 g

➔**Restricted**

For patients with chronic hepatic encephalopathy who have not responded to treatment with, or are intolerant to lactulose, or where lactulose is contraindicated.

RIFAXIMIN – **Restricted** see terms below

⚡ Tab 550 mg – 1% DV Oct-14 to 2017 ..... 625.00 56 **Xifaxan**

➔**Restricted**

For patients with hepatic encephalopathy despite an adequate trial of maximum tolerated doses of lactulose.

### Diabetes

#### Alpha Glucosidase Inhibitors

<b>ACARBOSE</b>			
Tab 50 mg – 1% DV Dec-12 to 2015 .....	9.82	90	<b>Accarb</b>
Tab 100 mg – 1% DV Dec-12 to 2015 .....	15.83	90	<b>Accarb</b>

#### Hyperglycaemic Agents

DIAZOXIDE – **Restricted** see terms below

⚡ Cap 25 mg .....	110.00	100	Proglycem
⚡ Cap 100 mg .....	280.00	100	Proglycem
⚡ Oral liq 50 mg per ml .....	620.00	30 ml	Proglycem

➔**Restricted**

For patients with confirmed hypoglycaemia caused by hyperinsulinism.

<b>GLUCAGON HYDROCHLORIDE</b>			
Inj 1 mg syringe kit .....	32.00	1	Glucagen Hypokit

**GLUCOSE [DEXTROSE]**

Tab 1.5 g  
Tab 3.1 g  
Tab 4 g  
Gel 40%

**GLUCOSE WITH SUCROSE AND FRUCTOSE**

Gel 19.7% with sucrose 35% and fructose 19.7%, 18 g sachet

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Insulin - Intermediate-Acting Preparations</b>			
INSULIN ASPART WITH INSULIN ASPART PROTAMINE			
Inj insulin aspart 30% with insulin aspart protamine 70%, 100 u per ml, 3 ml prefilled pen .....	52.15	5	NovoMix 30 FlexPen
INSULIN ISOPHANE			
Inj insulin human 100 u per ml, 10 ml vial			
Inj insulin human 100 u per ml, 3 ml cartridge			
INSULIN LISPRO WITH INSULIN LISPRO PROTAMINE			
Inj insulin lispro 25% with insulin lispro protamine 75%, 100 u per ml, 3 ml cartridge .....	42.66	5	Humalog Mix 25
Inj insulin lispro 50% with insulin lispro protamine 50%, 100 u per ml, 3 ml cartridge .....	42.66	5	Humalog Mix 50
INSULIN NEUTRAL WITH INSULIN ISOPHANE			
Inj insulin neutral 30% with insulin isophane 70%, 100 u per ml, 10 ml vial			
Inj insulin neutral 30% with insulin isophane 70%, 100 u per ml, 3 ml cartridge			
Inj insulin neutral 40% with insulin isophane 60%, 100 u per ml, 3 ml cartridge			
Inj insulin neutral 50% with insulin isophane 50%, 100 u per ml, 3 ml cartridge			
<b>Insulin - Long-Acting Preparations</b>			
INSULIN GLARGINE			
Inj 100 u per ml, 3 ml disposable pen .....	94.50	5	Lantus SoloStar
Inj 100 u per ml, 3 ml cartridge .....	94.50	5	Lantus
Inj 100 u per ml, 10 ml vial .....	63.00	1	Lantus
<b>Insulin - Rapid-Acting Preparations</b>			
INSULIN ASPART			
Inj 100 u per ml, 10 ml vial			
Inj 100 u per ml, 3 ml cartridge			
Inj 100 u per ml, 3 ml syringe .....	51.19	5	NovoRapid FlexPen
INSULIN GLULISINE			
Inj 100 u per ml, 10 ml vial .....	27.03	1	Apidra
Inj 100 u per ml, 3 ml cartridge .....	46.07	5	Apidra
Inj 100 u per ml, 3 ml disposable pen .....	46.07	5	Apidra Solostar
INSULIN LISPRO			
Inj 100 u per ml, 10 ml vial			
Inj 100 u per ml, 3 ml cartridge			
<b>Insulin - Short-Acting Preparations</b>			
INSULIN NEUTRAL			
Inj human 100 u per ml, 10 ml vial			
Inj human 100 u per ml, 3 ml cartridge			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Oral Hypoglycaemic Agents</b>			
GLIBENCLAMIDE			
Tab 5 mg			
GLICLAZIDE			
Tab 80 mg – 1% DV Nov-14 to 2017 .....	11.50	500	<b>Glizide</b>
GLIPIZIDE			
Tab 5 mg – 1% DV Dec-12 to 2015 .....	3.00	100	<b>Minidiab</b>
METFORMIN			
Tab immediate-release 500 mg – 1% DV Oct-12 to 2015 .....	12.30	1,000	<b>Apotex</b>
Tab immediate-release 850 mg – 1% DV Oct-12 to 2015 .....	10.10	500	<b>Apotex</b>
PIOGLITAZONE			
Tab 15 mg – 1% DV Sep-12 to 2015 .....	1.50	28	<b>Pizaccord</b>
Tab 30 mg – 1% DV Sep-12 to 2015 .....	2.50	28	<b>Pizaccord</b>
Tab 45 mg – 1% DV Sep-12 to 2015 .....	3.50	28	<b>Pizaccord</b>

## Digestives Including Enzymes

### PANCREATIC ENZYME

Cap EC 10,000 BP u lipase, 9,000 BP u amylase and 210 BP u protease

Cap EC 25,000 BP u lipase, 18,000 BP u amylase and 1,000 BP u protease

Cap EC 25,000 BP u lipase, 22,500 BP u amylase and 1,250 BP u protease

Powder 25,000 u lipase with 30,000 u amylase and 1,400 u protease per g

URSODEOXYCHOLIC ACID – **Restricted** see terms below

⚡ Cap 250 mg – 1% DV Sep-14 to 2017 ..... 53.40 100 **Ursosan**

### ➡ **Restricted**

#### **Alagille syndrome or progressive familial intrahepatic cholestasis**

Either:

- 1 Patient has been diagnosed with Alagille syndrome; or
- 2 Patient has progressive familial intrahepatic cholestasis.

#### **Chronic severe drug induced cholestatic liver injury**

All of the following:

- 1 Patient has chronic severe drug induced cholestatic liver injury; and
- 2 Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults; and
- 3 Treatment with ursodeoxycholic acid may prevent hospital admission or reduce duration of stay.

### **Cirrhosis**

Both:

- 1 Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative by liver biopsy; and
- 2 Patient not requiring a liver transplant (bilirubin > 100  $\mu\text{mol/l}$ ; decompensated cirrhosis).

### **Pregnancy**

Patient diagnosed with cholestasis of pregnancy.

### **Haematological transplant**

Both:

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 1 Patient at risk of veno-occlusive disease or has hepatic impairment and is undergoing conditioning treatment prior to allogeneic stem cell or bone marrow transplantation; and
- 2 Treatment for up to 13 weeks.

## Total parenteral nutrition induced cholestasis

Both:

- 1 Paediatric patient has developed abnormal liver function as indicated on testing which is likely to be induced by TPN; and
- 2 Liver function has not improved with modifying the TPN composition.

## Laxatives

### Bowel-Cleansing Preparations

#### CITRIC ACID WITH MAGNESIUM OXIDE AND SODIUM PICOSULFATE

Powder for oral soln 12 g with magnesium oxide 3.5 g and sodium picosulfate 10 mg per sachet

e.g. *PicoPrep*

#### MACROGOL 3350 WITH ASCORBIC ACID, POTASSIUM CHLORIDE AND SODIUM CHLORIDE

Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 210 g sachet

e.g. *Glycoprep-C*

Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 70 g sachet

e.g. *Glycoprep-C*

#### MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE AND SODIUM SULPHATE

Powder for oral soln 59 g with potassium chloride 0.7425 g, sodium bicarbonate 1.685 g, sodium chloride 1.465 g and sodium sulphate 5.685 g per sachet

14.31 4 Klean Prep

### Bulk-Forming Agents

#### ISPAGHULA (PSYLLIUM) HUSK

Powder for oral soln – 1% DV Sep-13 to 2016.....5.51

500 g Konsyl-D

#### STERCULIA WITH FRANGULA – **Restricted:** For continuation only

➡ Powder for oral soln

### Faecal Softeners

#### DOCUSATE SODIUM

Tab 50 mg – 1% DV Jan-15 to 2017.....2.31

100 Coloxyl

Tab 120 mg – 1% DV Jan-15 to 2017.....3.13

100 Coloxyl

#### DOCUSATE SODIUM WITH SENNOSIDES

Tab 50 mg with sennosides 8 mg .....4.40

200 Laxsol

#### PARAFFIN

Oral liquid 1 mg per ml

Enema 133 ml

#### POLOXAMER

Oral drops 10% – 1% DV Sep-14 to 2017 .....3.78

30 ml Coloxyl

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Osmotic Laxatives</b>			
GLYCEROL			
Suppos 1.27 g			
Suppos 2.55 g			
Suppos 3.6 g – 1% DV Jan-13 to 2015 .....	6.50	20	PSM
LACTULOSE			
Oral liq 10 g per 15 ml .....	3.84	500 ml	Laevolac
MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE AND SODIUM CHLORIDE – <b>Restricted</b> see terms below			
⚡ Powder for oral soln 6.563 g with potassium chloride 23.3 mg, sodium bicarbonate 89.3 mg and sodium chloride 175.4 mg			
⚡ Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg – 1% DV Oct-14 to 2017 .....	7.65	30	Lax-Sachets
➔ <b>Restricted</b>			
Either:			
1 Both:			
1.1 The patient has problematic constipation despite an adequate trial of other oral pharmacotherapies including lactulose where lactulose is not contraindicated; and			
1.2 The patient would otherwise require a per rectal preparation; or			
2 For short-term use for faecal disimpaction.			
SODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE			
Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml – 1% DV Sep-13 to 2016 .....	19.95	50	Micolette
SODIUM PHOSPHATE WITH PHOSPHORIC ACID			
Oral liq 16.4% with phosphoric acid 25.14%			
Enema 10% with phosphoric acid 6.58% .....	2.50	1	Fleet Phosphate Enema
<b>Stimulant Laxatives</b>			
BISACODYL			
Tab 5 mg .....	4.99	200	Lax-Tabs
Suppos 5 mg .....	3.00	6	Dulcolax
Suppos 10 mg .....	3.00	6	Dulcolax
DANTHRON WITH POLOXAMER – <b>Restricted</b> see terms below			
⚡ Oral liq 25 mg with poloxamer 200 mg per 5 ml .....	21.30	300 ml	Pinorax
⚡ Oral liq 75 mg with poloxamer 1 g per 5 ml .....	43.60	300 ml	Pinorax Forte
(Pinorax Oral liq 25 mg with poloxamer 200 mg per 5 ml to be delisted 1 April 2015)			
(Pinorax Forte Oral liq 75 mg with poloxamer 1 g per 5 ml to be delisted 1 April 2015)			
➔ <b>Restricted</b>			
Only for the prevention or treatment of constipation in the terminally ill			
SENNOSIDES			
Tab 7.5 mg			
<b>Metabolic Disorder Agents</b>			
ARGININE			
Powder			
Inj 600 mg per ml, 25 ml vial			

# ALIMENTARY TRACT AND METABOLISM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>BETAINE – Restricted</b> see terms below			
☯ Powder			
☛ <b>Restricted</b>			
Metabolic disorders physician or metabolic disorders dietitian			
<b>BIOTIN – Restricted</b> see terms below			
☯ Cap 50 mg			
☯ Cap 100 mg			
☯ Inj 10 mg per ml, 5 ml vial			
☛ <b>Restricted</b>			
Metabolic disorders physician or metabolic disorders dietitian.			
<b>HAEM ARGINATE</b>			
Inj 25 mg per ml, 10 ml ampoule			
<b>IMIGLUCERASE – Restricted</b> see terms below			
☯ Inj 40 iu per ml, 5 ml vial			
☯ Inj 40 iu per ml, 10 ml vial			
☛ <b>Restricted</b>			
Only for use in patients with approval by the Gaucher's Treatment Panel			
<b>LEVOCARNITINE – Restricted</b> see terms below			
☯ Cap 500 mg			
☯ Oral soln 1,100 mg per 15 ml			
☯ Oral soln 500 mg per 15 ml			
☯ Inj 200 mg per ml, 5 ml vial			
<i>(Any Oral soln 500 mg per 15 ml to be delisted 1 July 2015)</i>			
☛ <b>Restricted</b>			
Metabolic disorders physician, metabolic disorders dietitian or neurologist			
<b>PYRIDOXAL-5-PHOSPHATE – Restricted</b> see terms below			
☯ Tab 50 mg			
☛ <b>Restricted</b>			
Metabolic disorders physician, metabolic disorders dietitian or neurologist			
<b>SODIUM BENZOATE</b>			
Cap 500 mg			
Powder			
Soln 100 mg per ml			
Inj 20%, 10 ml ampoule			
<b>SODIUM PHENYLBUTYRATE</b>			
Tab 500 mg			
Oral liq 250 mg per ml			
Inj 200 mg per ml, 10 ml ampoule			
<b>TRIENTINE DIHYDROCHLORIDE</b>			
Cap 300 mg			

## Minerals

### Calcium

#### CALCIUM CARBONATE

Tab 1.25 g (500 mg elemental) – 1% DV Sep-14 to 2017.....	5.38	250	<b>Arrow-Calcium</b>
Tab eff 1.75 g (1 g elemental) .....	6.21	30	Calsource

☛ Item restricted (see ☛ above); ☯ Item restricted (see ☛ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Fluoride</b>			
SODIUM FLUORIDE			
Tab 1.1 mg (0.5 mg elemental)			
<b>Iodine</b>			
POTASSIUM IODATE			
Tab 253 mcg (150 mcg elemental iodine) – 1% DV Dec-14 to 2017	3.65	90	<b>NeuroTabs</b>
POTASSIUM IODATE WITH IODINE			
Oral liq 10% with iodine 5%			
<b>Iron</b>			
FERRIC CARBOXYMALTOSE – <b>Restricted</b> see terms below			
⚡ Inj 50 mg per ml, 10 ml vial	150.00	1	Ferinject
⚡ <b>Restricted</b>			
Treatment with oral iron has proven ineffective or is clinically inappropriate.			
FERROUS FUMARATE			
Tab 200 mg (65 mg elemental)	4.35	100	Ferro-tab
FERROUS FUMARATE WITH FOLIC ACID			
Tab 310 mg (100 mg elemental) with folic acid 350 mcg	4.75	60	Ferro-F-Tabs
FERROUS GLUCONATE WITH ASCORBIC ACID			
Tab 170 mg (20 mg elemental) with ascorbic acid 40 mg			
FERROUS SULPHATE			
Tab long-acting 325 mg (105 mg elemental)	2.06	30	Ferrograd
Oral liq 30 mg (6 mg elemental) per ml – 1% DV Apr-14 to 2016	10.28	500 ml	<b>Ferodan</b>
FERROUS SULPHATE WITH ASCORBIC ACID			
Tab long-acting 325 mg (105 mg elemental) with ascorbic acid 500 mg			
FERROUS SULPHATE WITH FOLIC ACID			
Tab long-acting 325 mg (105 mg elemental) with folic acid 350 mcg			
IRON POLYMALTOSE			
Inj 50 mg per ml, 2 ml ampoule – 1% DV Sep-14 to 2017	15.22	5	<b>Ferrum H</b>
IRON SUCROSE			
Inj 20 mg per ml, 5 ml ampoule	100.00	5	Venofer
<b>Magnesium</b>			
MAGNESIUM HYDROXIDE			
Tab 311 mg (130 mg elemental)			
MAGNESIUM OXIDE			
Cap 663 mg (400 mg elemental)			
MAGNESIUM SULPHATE			
Inj 0.4 mmol per ml, 250 ml bag			
Inj 2 mmol per ml, 5 ml ampoule – 1% DV Oct-14 to 2017	12.65	10	<b>DBL</b>
<b>Zinc</b>			
ZINC			
Oral liq 5 mg per 5 drops			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
ZINC CHLORIDE Inj 5.3 mg per ml (5.1 mg per ml elemental), 2 ml ampoule			
ZINC SULPHATE Cap 137.4 mg (50 mg elemental) – 1% DV Mar-15 to 2017 .....	11.00	100	Zincaps

## Mouth and Throat



### Agents Used in Mouth Ulceration

BENZYDAMINE HYDROCHLORIDE Soln 0.15% Spray 0.15% Spray 0.3%			
BENZYDAMINE HYDROCHLORIDE WITH CETYLPIRIDINIUM CHLORIDE Lozenge 3 mg with cetylpyridinium chloride			
CARBOXYMETHYLCELLULOSE Oral spray			
CHLORHEXIDINE GLUCONATE Mouthwash 0.2% – 1% DV Dec-12 to 2015 .....	2.68	200 ml	healthE
CHOLINE SALICYLATE WITH CETALKONIUM CHLORIDE Adhesive gel 8.7% with cetalkonium chloride 0.01%			
DICHLOROBENZYL ALCOHOL WITH AMYLMETACRESOL Lozenge 1.2 mg with amylmetacresol 0.6 mg			
SODIUM CARBOXYMETHYLCELLULOSE WITH PECTIN AND GELATINE Paste Powder			
TRIAMCINOLONE ACETONIDE Paste 0.1% – 1% DV Apr-15 to 2017 .....	4.34 5.33	5 g	Oracort Kenalog in Orabase
<i>(Oracort Paste 0.1% to be delisted 1 April 2015)</i>			

### Oropharyngeal Anti-Infectives

AMPHOTERICIN B Lozenge 10 mg .....	5.86	20	Fungilin
MICONAZOLE Oral gel 20 mg per g – 1% DV Feb-13 to 2015 .....	4.95	40 g	Decozol
NYSTATIN Oral liquid 100,000 u per ml .....	3.35	24 ml	Niostat

### Other Oral Agents

SODIUM HYALURONATE – <b>Restricted</b> see terms below  Inj 20 mg per ml, 1 ml syringe  <b>Restricted</b> Otolaryngologist THYMOL GLYCERIN Compound, BPC			
---	--	--	--



Price (ex man. excl. GST)	Brand or Generic
\$	Per Manufacturer

## Vitamins

### Multivitamin Preparations

#### MULTIVITAMINS

Tab (BPC cap strength)

*e.g. Mvite*

- Cap vitamin A 2500 u, betacarotene 3 mg, cholecalciferol 11 mcg, alpha tocopherol 150 u, phytomenadione 150 mcg, folic acid 0.2 mg, ascorbic acid 100 mg, thiamine 1.5 mg, pantothenic acid 12 mg, riboflavin 1.7 mg, niacin 20 mg, pyridoxine hydrochloride 1.9 mg, cyanocobalamin 3 mcg, zinc 7.5 mg and biotin 100 mcg

*e.g. Vitabdeck*

#### ➔Restricted

Either:

- 1 Patient has cystic fibrosis with pancreatic insufficiency; or
- 2 Patient is an infant or child with liver disease or short gut syndrome.

- Powder vitamin A 4200 mcg with vitamin D 155.5 mcg, vitamin E 21.4 mg, vitamin C 400 mg, vitamin K1 166 mcg thiamine 3.2 mg, riboflavin 4.4 mg, niacin 35 mg, vitamin B6 3.4 mg, folic acid 303 mcg, vitamin B12 8.6 mcg, biotin 214 mcg, pantothenic acid 17 mg, choline 350 mg and inositol 700 mg

*e.g. Paediatric Seravit*

#### ➔Restricted

Patient has inborn errors of metabolism.

Inj thiamine hydrochloride 250 mg with riboflavin 4 mg and pyridoxine hydrochloride 50 mg, 5 ml ampoule (1) and inj ascorbic acid 500 mg with nicotinamide 160 mg and glucose 1000 mg, 5 ml ampoule (1)

*e.g. Pabrinex IV*

Inj thiamine hydrochloride 250 mg with riboflavin 4 mg and pyridoxine hydrochloride 50 mg, 5 ml ampoule (1) and inj ascorbic acid 500 mg with nicotinamide 160 mg, 2 ml ampoule (1)

*e.g. Pabrinex IM*

Inj thiamine hydrochloride 500 mg with riboflavin 8 mg and pyridoxine hydrochloride 100 mg, 10 ml ampoule (1) and inj ascorbic acid 1000 mg with nicotinamide 320 mg and glucose 2000 mg, 10 ml ampoule (1)

*e.g. Pabrinex IV*

#### VITAMIN A WITH VITAMINS D AND C

Soln 1,000 u with vitamin D 400 u and ascorbic acid 30 mg per 10 drops

*e.g. Vitadol C*

### Vitamin A

#### RETINOL

Tab 10,000 iu

Cap 25,000 iu

Oral liq 150,000 iu per ml

### Vitamin B

#### HYDROXOCOBALAMIN ACETATE

Inj 1 mg per ml, 1 ml ampoule – 1% DV Sep-12 to 2015.....5.10

3

**ABM**

**Hydroxocobalamin**

# ALIMENTARY TRACT AND METABOLISM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>PYRIDOXINE HYDROCHLORIDE</b>			
Tab 25 mg .....	2.15	90	<b>PyridoxADE Vitamin B6 25</b>
a) 1% DV Jan-15 to 31 Mar 2015			
b) 1% DV Apr-15 to 2017			
Tab 50 mg – 1% DV Oct-14 to 2017 .....	11.55	500	<b>Apo-Pyridoxine</b>
Inj 100 mg per ml, 1 ml ampoule			
<i>(PyridoxADE Tab 25 mg to be delisted 1 April 2015)</i>			
<b>THIAMINE HYDROCHLORIDE</b>			
Tab 50 mg			
Tab 100 mg			
Inj 100 mg per ml, 2 ml vial			
<b>VITAMIN B COMPLEX</b>			
Tab strong, BPC			
<b>Vitamin C</b>			
<b>ASCORBIC ACID</b>			
Tab 100 mg – 1% DV Nov-13 to 2016 .....	7.00	500	<b>Cvite</b>
Tab chewable 250 mg			
<b>Vitamin D</b>			
<b>ALFACALCIDOL</b>			
Cap 0.25 mcg .....	26.32	100	One-Alpha
Cap 1 mcg .....	87.98	100	One-Alpha
Oral drops 2 mcg per ml			
<b>CALCITRIOL</b>			
Cap 0.25 mcg .....	3.03	30	Airflow
	10.10	100	Calcitriol-AFT
Cap 0.5 mcg .....	5.62	30	Airflow
	18.73	100	Calcitriol-AFT
Oral liq 1 mcg per ml			
Inj 1 mcg per ml, 1 ml ampoule			
<b>CHOLECALCIFEROL</b>			
Tab 1.25 mg (50,000 iu) .....	7.76	12	Cal-d-Forte
<b>Vitamin E</b>			
<b>ALPHA TOCOPHERYL ACETATE – Restricted</b> see terms below			
⚡ Cap 100 u			
⚡ Cap 500 u			
⚡ Oral liq 156 u per ml			
<b>➡Restricted</b>			
<b>Cystic fibrosis</b>			
Both:			
1 Cystic fibrosis patient; and			
2 Either:			
2.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck); or			
continued...			
⚡Item restricted (see ➡ above); ⚡Item restricted (see ➡ below) e.g. Brand indicates brand example only. It is not a contracted product.			

	Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
--	------------------------------------	-------------------------------------

continued...

- 2.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for the patient.

**Osteoradionecrosis**

For the treatment of osteoradionecrosis

**Other indications**

All of the following:

- 1 Infant or child with liver disease or short gut syndrome; and
- 2 Requires vitamin supplementation; and
- 3 Either:
  - 3.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplements (Vitabdeck); or
  - 3.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for patient.

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

## Antianaemics

### Hypoplastic and Haemolytic

EPOETIN ALFA [ERYTHROPOIETIN ALFA] – **Restricted** see terms below

⚡ Inj 1,000 iu in 0.5 ml syringe – 5% DV Mar-15 to 28 Feb 2018	48.68	6	Eprex
⚡ Inj 2,000 iu in 0.5 ml syringe – 5% DV Mar-15 to 28 Feb 2018	120.18	6	Eprex
⚡ Inj 3,000 iu in 0.3 ml syringe – 5% DV Mar-15 to 28 Feb 2018	166.87	6	Eprex
⚡ Inj 4,000 iu in 0.4 ml syringe – 5% DV Mar-15 to 28 Feb 2018	193.13	6	Eprex
⚡ Inj 5,000 iu in 0.5 ml syringe – 5% DV Mar-15 to 28 Feb 2018	243.26	6	Eprex
⚡ Inj 6,000 iu in 0.6 ml syringe – 5% DV Mar-15 to 28 Feb 2018	291.92	6	Eprex
⚡ Inj 10,000 iu in 1 ml syringe – 5% DV Mar-15 to 28 Feb 2018	395.18	6	Eprex

#### ➡ Restricted

#### Initiation - chronic renal failure

All of the following:

- 1 Patient in chronic renal failure; and
- 2 Haemoglobin  $\leq$  100g/L; and
- 3 Any of the following:
  - 3.1 Both:
    - 3.1.1 Patient does not have diabetes mellitus; and
    - 3.1.2 Glomerular filtration rate  $\leq$  30ml/min; or
  - 3.2 Both:
    - 3.2.1 Patient has diabetes mellitus; and
    - 3.2.2 Glomerular filtration rate  $\leq$  45ml/min; or
- 4 Patient is on haemodialysis or peritoneal dialysis.

#### Initiation - myelodysplasia\*

Re-assessment required after 2 months

All of the following:

- 1 Patient has a confirmed diagnosis of myelodysplasia (MDS); and
- 2 Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent; and
- 3 Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplastic syndrome (WPSS); and
- 4 Other causes of anaemia such as B12 and folate deficiency have been excluded; and
- 5 Patient has a serum erythropoietin level of < 500 IU/L; and
- 6 The minimum necessary dose of erythropoietin would be used and will not exceed 80,000 iu per week.

#### Continuation - myelodysplasia\*

Re-assessment required after 12 months

All of the following:

- 1 The patient's transfusion requirement continues to be reduced with erythropoietin treatment; and
- 2 Transformation to acute myeloid leukaemia has not occurred; and
- 3 The minimum necessary dose of erythropoietin would be used and will not exceed 80,000 iu per week.

#### Initiation - all other indications

Haematologist

For use in patients where blood transfusion is not a viable treatment alternative.

\*Note: Indications marked with \* are Unapproved Indications.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Megaloblastic</b>			
FOLIC ACID			
Tab 0.8 mg			
Tab 5 mg			
Oral liq 50 mcg per ml .....	24.00	25 ml	Biomed
Inj 5 mg per ml, 10 ml vial			
<b>Antifibrinolytics, Haemostatics and Local Sclerosants</b>			
APROTININ – <b>Restricted</b> see terms below			
⚡ Inj 10,000 kIU per ml (equivalent to 200 mg per ml), 50 ml vial			
➡ <b>Restricted</b>			
Cardiac anaesthetist			
Either:			
1 Paediatric patient undergoing cardiopulmonary bypass procedure; or			
2 Adult patient undergoing cardiac surgical procedure where the significant risk of massive bleeding outweighs the potential adverse effects of the drug.			
ELTROMBOPAG – <b>Restricted</b> see terms below			
⚡ Tab 25 mg .....	1,771.00	28	Revolade
⚡ Tab 50 mg .....	3,542.00	28	Revolade
➡ <b>Restricted</b>			
Haematologist			
<b>Initiation (idiopathic thrombocytopenic purpura - post-splenectomy)</b>			
<i>Re-assessment required after 6 weeks</i>			
All of the following:			
1 Patient has had a splenectomy; and			
2 Two immunosuppressive therapies have been trialled and failed after therapy of 3 months each (or 1 month for rituximab); and			
3 Any of the following:			
3.1 Patient has a platelet count of 20,000 to 30,000 platelets per microlitre and has evidence of significant mucocutaneous bleeding; or			
3.2 Patient has a platelet count of $\leq$ 20,000 platelets per microlitre and has evidence of active bleeding; or			
3.3 Patient has a platelet count of $\leq$ 10,000 platelets per microlitre.			
<b>Initiation - (idiopathic thrombocytopenic purpura - preparation for splenectomy)</b>			
<i>Re-assessment required after 6 weeks</i>			
The patient requires eltrombopag treatment as preparation for splenectomy.			
<b>Continuation - (idiopathic thrombocytopenic purpura - post-splenectomy)</b>			
<i>Re-assessment required after 12 months</i>			
The patient has obtained a response (see Note) from treatment during the initial approval or subsequent renewal periods and further treatment is required.			
Note: Response to treatment is defined as a platelet count of $>$ 30,000 platelets per microlitre.			
FERRIC SUBSULFATE			
Gel 25.9%			
Soln 500 ml			
POLIDOCANOL			
Inj 0.5%, 30 ml vial			
SODIUM TETRADECYL SULPHATE			
Inj 3%, 2 ml ampoule			
THROMBIN			
Powder			

# BLOOD AND BLOOD FORMING ORGANS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>TRANEXAMIC ACID</b>			
Tab 500 mg – 1% DV Oct-14 to 2016 .....	23.00	100	<b>Cyklokapron</b>
Inj 100 mg per ml, 5 ml ampoule .....	124.73	10	Cyklokapron

## Blood Factors

### EPTACOG ALFA [RECOMBINANT FACTOR VIIA] – **Restricted** see terms below

☞ Inj 1 mg syringe .....	1,163.75	1	NovoSeven RT
☞ Inj 2 mg syringe .....	2,327.50	1	NovoSeven RT
☞ Inj 5 mg syringe .....	5,818.75	1	NovoSeven RT
☞ Inj 8 mg syringe .....	9,310.00	1	NovoSeven RT

#### ☞ **Restricted**

When used in the treatment of haemophilia, treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

### FACTOR EIGHT INHIBITORS BYPASSING AGENT – **Restricted** see terms below

☞ Inj 500 U .....	1,640.00	1	FEIBA
☞ Inj 1,000 U .....	3,280.00	1	FEIBA

#### ☞ **Restricted**

When used in the treatment of haemophilia, treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

### MOROCTOCOG ALFA [RECOMBINANT FACTOR VIII] – **Restricted** see terms below

☞ Inj 250 iu vial .....	225.00	1	Xyntha
☞ Inj 500 iu vial .....	450.00	1	Xyntha
☞ Inj 1,000 iu vial .....	900.00	1	Xyntha
☞ Inj 2,000 iu vial .....	1,800.00	1	Xyntha
☞ Inj 3,000 iu vial .....	2,700.00	1	Xyntha

#### ☞ **Restricted**

When used in the treatment of haemophilia, treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

### NONACOG ALFA [RECOMBINANT FACTOR IX] – **Restricted** see terms below

☞ Inj 250 iu vial .....	310.00	1	BeneFIX
☞ Inj 500 iu vial .....	620.00	1	BeneFIX
☞ Inj 1,000 iu vial .....	1,240.00	1	BeneFIX
☞ Inj 2,000 iu vial .....	2,480.00	1	BeneFIX

#### ☞ **Restricted**

When used in the treatment of haemophilia, treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

### OCTOCOG ALFA [RECOMBINANT FACTOR VIII] – **Restricted** see terms on the next page

☞ Inj 250 iu vial .....	237.50	1	Advate
	250.00		Kogenate FS
☞ Inj 500 iu vial .....	475.00	1	Advate
	500.00		Kogenate FS
☞ Inj 1,000 iu vial .....	950.00	1	Advate
	1,000.00		Kogenate FS
☞ Inj 1,500 iu vial .....	1,425.00	1	Advate
☞ Inj 2,000 iu vial .....	1,900.00	1	Advate
	2,000.00		Kogenate FS
☞ Inj 3,000 iu vial .....	2,850.00	1	Advate
	3,000.00		Kogenate FS

☞ Item restricted (see ☞ above); ☞ Item restricted (see ☞ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➔ **Restricted**

When used in the treatment of haemophilia, treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

**Vitamin K**

PHYTOMENADIONE

Inj 2 mg in 0.2 ml ampoule .....	8.00	5	Konakion MM
Inj 10 mg per ml, 1 ml ampoule .....	9.21	5	Konakion MM

**Antithrombotics**

**Anticoagulants**

BIVALIRUDIN – **Restricted** see terms below

⚡ Inj 250 mg vial

➔ **Restricted**

Either:

- 1 For use in heparin-induced thrombocytopenia, heparin resistance or heparin intolerance; or
- 2 For use in patients undergoing endovascular procedures.

DABIGATRAN

Cap 75 mg .....	148.00	60	Pradaxa
Cap 110 mg .....	148.00	60	Pradaxa
Cap 150 mg .....	148.00	60	Pradaxa

DALTEPARIN

Inj 2,500 iu in 0.2 ml syringe .....	19.97	10	Fragmin
Inj 5,000 iu in 0.2 ml syringe .....	39.94	10	Fragmin
Inj 7,500 iu in 0.75 ml syringe .....	60.03	10	Fragmin
Inj 10,000 iu in 1 ml syringe .....	77.55	10	Fragmin
Inj 12,500 iu in 0.5 ml syringe .....	99.96	10	Fragmin
Inj 15,000 iu in 0.6 ml syringe .....	120.05	10	Fragmin
Inj 18,000 iu in 0.72 ml syringe .....	158.47	10	Fragmin

DANAPAROID – **Restricted** see terms below

⚡ Inj 750 u in 0.6 ml ampoule

➔ **Restricted**

For use in heparin-induced thrombocytopenia, heparin resistance or heparin intolerance

DEFIBROTIDE – **Restricted** see terms below

⚡ Inj 80 mg per ml, 2.5 ml ampoule

➔ **Restricted**

Haematologist

Patient has moderate or severe sinusoidal obstruction syndrome as a result of chemotherapy or regimen-related toxicities

DEXTROSE WITH SODIUM CITRATE AND CITRIC ACID [ACID CITRATE DEXTROSE A]

Inj 24.5 mg with sodium citrate 22 mg and citric acid 7.3 mg per ml,  
100 ml bag

## BLOOD AND BLOOD FORMING ORGANS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>ENOXAPARIN</b>			
Inj 20 mg in 0.2 ml syringe – 1% DV Sep-12 to 2015 .....	37.24	10	<b>Clexane</b>
Inj 40 mg in 0.4 ml ampoule			
Inj 40 mg in 0.4 ml syringe – 1% DV Sep-12 to 2015 .....	49.69	10	<b>Clexane</b>
Inj 60 mg in 0.6 ml syringe – 1% DV Sep-12 to 2015 .....	74.91	10	<b>Clexane</b>
Inj 80 mg in 0.8 ml syringe – 1% DV Sep-12 to 2015 .....	99.86	10	<b>Clexane</b>
Inj 100 mg in 1 ml syringe – 1% DV Sep-12 to 2015 .....	125.06	10	<b>Clexane</b>
Inj 120 mg in 0.8 ml syringe – 1% DV Sep-12 to 2015 .....	155.40	10	<b>Clexane</b>
Inj 150 mg in 1 ml syringe – 1% DV Sep-12 to 2015 .....	177.60	10	<b>Clexane</b>
<b>FONDAPARINUX SODIUM – Restricted</b> see terms below			
⚡ Inj 2.5 mg in 0.5 ml syringe			
⚡ Inj 7.5 mg in 0.6 ml syringe			
➡ <b>Restricted</b>			
For use in heparin-induced thrombocytopenia, heparin resistance or heparin intolerance			
<b>HEPARIN SODIUM</b>			
Inj 100 iu per ml, 250 ml bag			
Inj 1,000 iu per ml, 1 ml ampoule .....	66.80	50	Hospira
Inj 1,000 iu per ml, 35 ml ampoule			
Inj 1,000 iu per ml, 5 ml ampoule .....	61.04	50	Pfizer
Inj 5,000 iu in 0.2 ml ampoule			
Inj 5,000 iu per ml, 1 ml ampoule .....	14.20	5	Hospira
Inj 5,000 iu per ml, 5 ml ampoule .....	236.60	50	Pfizer
<b>HEPARINISED SALINE</b>			
Inj 10 iu per ml, 5 ml ampoule .....	39.00	50	Pfizer
Inj 100 iu per ml, 2 ml ampoule			
Inj 100 iu per ml, 5 ml ampoule			
<b>PHENINDIONE</b>			
Tab 10 mg			
Tab 25 mg			
Tab 50 mg			
<b>PROTAMINE SULPHATE</b>			
Inj 10 mg per ml, 5 ml ampoule			
<b>RIVAROXABAN – Restricted</b> see terms below			
⚡ Tab 10 mg .....	153.00	15	Xarelto
➡ <b>Restricted</b>			
Either:			
1 Limited to five weeks' treatment for the prophylaxis of venous thromboembolism following a total hip replacement; or			
2 Limited to two weeks' treatment for the prophylaxis of venous thromboembolism following a total knee replacement.			
<b>SODIUM CITRATE WITH SODIUM CHLORIDE AND POTASSIUM CHLORIDE</b>			
Inj 4.2 mg with sodium chloride 5.7 mg and potassium chloride			
74.6 mcg per ml, 5,000 ml bag			
<b>TRISODIUM CITRATE</b>			
Inj 4%, 5 ml ampoule			
Inj 46.7%, 3 ml syringe			
Inj 46.7%, 5 ml ampoule			

⚡ Item restricted (see ➡ above); ⚡ Item restricted (see ➡ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>WARFARIN SODIUM</b>			
Tab 1 mg .....	6.86	100	Marevan
Tab 2 mg .....			
Tab 3 mg .....	9.70	100	Marevan
Tab 5 mg .....	11.75	100	Marevan
<b>Antiplatelets</b>			
<b>ASPIRIN</b>			
Tab 100 mg – <b>1% DV Mar-14 to 2016</b> .....	1.60	90	<b>Ethics Aspirin EC</b>
	10.50	990	<b>Ethics Aspirin EC</b>
Suppos 300 mg			
<b>CLOPIDOGREL</b>			
Tab 75 mg – <b>1% DV Dec-13 to 2016</b> .....	5.48	84	<b>Arrow - Clopid</b>
<b>DIPYRIDAMOLE</b>			
Tab 25 mg			
Tab long-acting 150 mg .....	11.52	60	Pytazen SR
Inj 5 mg per ml, 2 ml ampoule			
<b>EPTIFIBATIDE – Restricted</b> see terms below			
⚡ Inj 2 mg per ml, 10 ml vial .....	111.00	1	Integrilin
⚡ Inj 750 mcg per ml, 100 ml vial .....	324.00	1	Integrilin
<b>➡Restricted</b>			
Either:			
1 For use in patients with acute coronary syndromes undergoing percutaneous coronary intervention; or			
2 For use in patients with definite or strongly suspected intra-coronary thrombus on coronary angiography.			
<b>PRASUGREL – Restricted</b> see terms below			
⚡ Tab 5 mg .....	108.00	28	Effient
⚡ Tab 10 mg .....	120.00	28	Effient
<b>➡Restricted</b>			
<b>Bare metal stents</b>			
Limited to 6 months' treatment			
Patient has undergone coronary angioplasty in the previous 4 weeks and is clopidogrel-allergic.			
<b>Drug-eluting stents</b>			
Limited to 12 months' treatment			
Patient has had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic.			
<b>Stent thrombosis</b>			
Patient has experienced cardiac stent thrombosis whilst on clopidogrel.			
<b>Myocardial infarction</b>			
Limited to 7 days' treatment			
For short term use while in hospital following ST-elevated myocardial infarction.			
Note: Clopidogrel allergy is defined as a history of anaphylaxis, urticaria, generalised rash or asthma (in non-asthmatic patients) developing soon after clopidogrel is started and is considered unlikely to be caused by any other treatment.			
<b>TICAGRELOR – Restricted</b> see terms below			
⚡ Tab 90 mg .....	90.00	56	Brilinta
<b>➡Restricted</b>			
Restricted to treatment of acute coronary syndromes specifically for patients who have recently been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome, and in whom fibrinolytic therapy has not been given in the last 24 hours and is not planned.			
<b>TICLOPIDINE</b>			
Tab 250 mg			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Fibrinolytic Agents</b>			
<b>ALTEPLASE</b>			
Inj 10 mg vial			
Inj 50 mg vial			
<b>TENECTEPLASE</b>			
Inj 50 mg vial			
<b>UROKINASE</b>			
Inj 10,000 iu vial			
Inj 50,000 iu vial			
Inj 100,000 iu vial			
Inj 500,000 iu vial			
<b>Colony-Stimulating Factors</b>			
<b>Granulocyte Colony-Stimulating Factors</b>			
<b>FILGRASTIM – Restricted</b> see terms below			
☞ Inj 300 mcg in 0.5 ml syringe – 1% DV Jan-13 to 31 Dec 2015	540.00	5	<b>Zarzio</b>
☞ Inj 300 mcg in 1 ml vial	650.00	5	<b>Neupogen</b>
☞ Inj 480 mcg in 0.5 ml syringe – 1% DV Jan-13 to 31 Dec 2015	864.00	5	<b>Zarzio</b>
<b>☞ Restricted</b>			
Oncologist or haematologist			
<b>PEGFILGRASTIM – Restricted</b> see terms below			
☞ Inj 6 mg per 0.6 ml syringe	1,080.00	1	<b>Neulastim</b>
<b>☞ Restricted</b>			
For prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk $\geq$ 20%*).			
*Febrile neutropenia risk $\geq$ 20% after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines.			
<b>Fluids and Electrolytes</b>			
<b>Intravenous Administration</b>			
<b>CALCIUM CHLORIDE</b>			
Inj 100 mg per ml, 10 ml vial			
<b>CALCIUM GLUCONATE</b>			
Inj 10%, 10 ml ampoule	21.40	10	<b>Hospira</b>
<b>COMPOUND ELECTROLYTES</b>			
Inj sodium 140 mmol/l with potassium 5 mmol/l, magnesium 1.5 mmol/l, chloride 98 mmol/l, acetate 27 mmol/l and gluconate 23 mmol/l, bag	5.00	500 ml	<b>Baxter</b>
	3.10	1,000 ml	<b>Baxter</b>
<b>COMPOUND ELECTROLYTES WITH GLUCOSE</b>			
Inj glucose 50 g with 140 mmol/l sodium, 5 mmol/l potassium, 1.5 mmol/l magnesium, 98 mmol/l chloride, 27 mmol/l acetate and 23 mmol/l gluconate, bag	7.00	1,000 ml	<b>Baxter</b>

☞ Item restricted (see ☞ above); ☞ Item restricted (see ☞ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>COMPOUND SODIUM LACTATE [HARTMANN'S SOLUTION]</b>			
Inj sodium 131 mmol/l with potassium 5 mmol/l, calcium 2 mmol/l, bi-carbonate 29 mmol/l, chloride 111 mmol/l, bag .....	1.77	500 ml	Baxter
	1.80	1,000 ml	Baxter
<b>COMPOUND SODIUM LACTATE WITH GLUCOSE</b>			
Inj sodium 131 mmol/l with potassium 5 mmol/l, calcium 2 mmol/l, bi-carbonate 29 mmol/l, chloride 111 mmol/l and glucose 5%, bag .....	5.38	1,000 ml	Baxter
<b>GLUCOSE [DEXTROSE]</b>			
Inj 5%, bag .....	2.87	50 ml	Baxter
	2.84	100 ml	Baxter
	3.87	250 ml	Baxter
	1.77	500 ml	Baxter
	1.80	1,000 ml	Baxter
Inj 10%, bag .....	3.70	500 ml	Baxter
	5.29	1,000 ml	Baxter
Inj 50%, bag .....	6.84	500 ml	Baxter
Inj 50%, 10 ml ampoule – 1% DV Oct-14 to 2017 .....	27.50	5	<b>Biomed</b>
Inj 50%, 90 ml bottle – 1% DV Oct-14 to 2017 .....	14.50	1	<b>Biomed</b>
Inj 70%, 1,000 ml bag			
Inj 70%, 500 ml bag			
<b>GLUCOSE WITH POTASSIUM CHLORIDE</b>			
Inj 5% glucose with 20 mmol/l potassium chloride, bag .....	7.36	1,000 ml	Baxter
Inj 5% glucose with 30 mmol/l potassium chloride, 1,000 ml bag			
Inj 10% glucose with 10 mmol/l potassium chloride, 500 ml bag			
<b>GLUCOSE WITH POTASSIUM CHLORIDE AND SODIUM CHLORIDE</b>			
Inj 4% glucose with potassium chloride 20 mmol/l and sodium chloride 0.18%, bag .....	3.45	500 ml	Baxter
	4.30	1,000 ml	Baxter
Inj 4% glucose with potassium chloride 30 mmol/l and sodium chloride 0.18%, bag .....	3.62	1,000 ml	Baxter
Inj 2.5% glucose with potassium chloride 20 mmol/l and sodium chloride 0.45%, 3,000 ml bag			
Inj 10% glucose with potassium chloride 10 mmol/l and sodium chloride 15 mmol/l, 500 ml bag			
<b>GLUCOSE WITH SODIUM CHLORIDE</b>			
Inj glucose 2.5% with sodium chloride 0.45%, bag .....	4.95	500 ml	Baxter
Inj glucose 5% with sodium chloride 0.45%, bag .....	9.87	500 ml	Baxter
	5.80	1,000 ml	Baxter
Inj glucose 5% with sodium chloride 0.9%, bag .....	4.54	1,000 ml	Baxter
Inj glucose 5% with sodium chloride 0.2%, 500 ml bag			
<b>POTASSIUM CHLORIDE</b>			
Inj 75 mg (1 mmol) per ml, 10 ml ampoule			
Inj 225 mg (3 mmol) per ml, 20 ml ampoule			

## BLOOD AND BLOOD FORMING ORGANS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>POTASSIUM CHLORIDE WITH SODIUM CHLORIDE</b>			
Inj 20 mmol/l potassium chloride with 0.9% sodium chloride, bag .....	3.85	1,000 ml	Baxter
Inj 30 mmol/l potassium chloride with 0.9% sodium chloride, bag .....	2.59	1,000 ml	Baxter
Inj 40 mmol/l potassium chloride with 0.9% sodium chloride, bag .....	6.62	1,000 ml	Baxter
Inj 10 mmol potassium chloride with 0.29% sodium chloride, 100 ml bag			
Inj 40 mmol potassium chloride with 0.9% sodium chloride, 100 ml bag			
<b>POTASSIUM DIHYDROGEN PHOSPHATE</b>			
Inj 1 mmol per ml, 10 ml ampoule			
<b>RINGER'S SOLUTION</b>			
Inj sodium 147 mmol/l with potassium 4 mmol/l, calcium 2.2 mmol/l, chloride 156 mmol/l, bag .....	5.13	1,000 ml	Baxter
<b>SODIUM ACETATE</b>			
Inj 4 mmol per ml, 20 ml ampoule			
<b>SODIUM BICARBONATE</b>			
Inj 8.4%, 10 ml vial			
Inj 8.4%, 50 ml vial .....	19.95	1	Biomed
Inj 8.4%, 100 ml vial .....	20.50	1	Biomed
<b>SODIUM CHLORIDE</b>			
Inj 0.45%, bag .....	5.50	500 ml	Baxter
☞ Inj 0.9%, 3 ml syringe			
☞ <b>Restricted</b>			
For use in flushing of in-situ vascular access devices only.			
Inj 0.9%, bag .....	1.70	500 ml	Freeflex
	1.71	1,000 ml	Freeflex
	3.01	50 ml	Baxter
	2.28	100 ml	Baxter
	3.60	250 ml	Baxter
	1.77	500 ml	Baxter
	1.80	1,000 ml	Baxter
☞ Inj 0.9%, 5 ml syringe			
☞ <b>Restricted</b>			
For use in flushing of in-situ vascular access devices only.			
☞ Inj 0.9%, 10 ml syringe			
☞ <b>Restricted</b>			
For use in flushing of in-situ vascular access devices only.			
Inj 3%, bag .....	5.69	1,000 ml	Baxter
Inj 0.9%, 5 ml ampoule .....	10.85	50	Multichem
	15.50		Pfizer
Inj 0.9%, 10 ml ampoule .....	11.50	50	Multichem
	15.50		Pfizer
Inj 0.9%, 20 ml ampoule .....	8.41	20	Multichem
Inj 23.4% (4 mmol/ml), 20 ml – 1% DV Sep-13 to 2016 .....	31.25	5	<b>Biomed</b>
Inj 1.8%, 500 ml bottle			
<b>SODIUM DIHYDROGEN PHOSPHATE [SODIUM ACID PHOSPHATE]</b>			
Inj 1 mmol per ml, 20 ml ampoule			

☞ Item restricted (see ☞ above); ☞ Item restricted (see ☞ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>WATER</b>			
Inj, bag .....	2.75	1,000 ml	Baxter
Inj 5 ml ampoule .....	10.25	50	Multichem
Inj 10 ml ampoule .....	11.25	50	Multichem
Inj 20 ml ampoule .....	6.50	20	Multichem
Inj 250 ml bag			
Inj 500 ml bag			
<b>Oral Administration</b>			
<b>CALCIUM POLYSTYRENE SULPHONATE</b>			
Powder .....	169.85	300 g	Calcium Resonium
<b>COMPOUND ELECTROLYTES</b>			
Powder for oral soln			
<b>COMPOUND ELECTROLYTES WITH GLUCOSE</b>			
Soln with electrolytes			
<b>PHOSPHORUS</b>			
Tab eff 500 mg (16 mmol)			
<b>POTASSIUM CHLORIDE</b>			
Tab eff 548 mg (14 mmol) with chloride 285 mg (8 mmol)			
Tab long-acting 600 mg (8 mmol) – <b>1% DV Oct-12 to 2015</b> .....	7.42	200	<b>Span-K</b>
Oral liq 2 mmol per ml			
<b>SODIUM BICARBONATE</b>			
Cap 840 mg .....	8.52	100	Sodibic
<b>SODIUM CHLORIDE</b>			
Tab 600 mg			
Oral liq 2 mmol/ml			
<b>SODIUM POLYSTYRENE SULPHONATE</b>			
Powder			
<b>Plasma Volume Expanders</b>			
<b>GELATINE, SUCCINYLATED</b>			
Inj 4%, 500 ml bag .....	92.50	10	Gelafusal
	108.00		Gelofusine
<i>(Gelafusal Inj 4%, 500 ml bag to be delisted 1 May 2015)</i>			
<b>HYDROXYETHYL STARCH 130/0.4 WITH MAGNESIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ACETATE AND SODIUM CHLORIDE</b>			
Inj 6% with magnesium chloride 0.03%, potassium chloride 0.03%, sodium acetate 0.463% and sodium chloride 0.6%, 500 ml bag .....	198.00	20	Volulyte 6%
<b>HYDROXYETHYL STARCH 130/0.4 WITH SODIUM CHLORIDE</b>			
Inj 6% with sodium chloride 0.9%, 500 ml bag .....	198.00	20	Voluven

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Agents Affecting the Renin-Angiotensin System</b>			
<b>ACE Inhibitors</b>			
<b>CAPTOPRIL</b>			
☞ Oral liq 5 mg per ml .....	94.99	95 ml	Capoten
☞ <b>Restricted</b>			
Any of the following:			
1 For use in children under 12 years of age; or			
2 For use in tube-fed patients; or			
3 For management of rebound transient hypertension following cardiac surgery.			
<b>CILAZAPRIL</b>			
Tab 0.5 mg – 1% DV Sep-13 to 2016 .....	2.00	90	<b>Zapril</b>
Tab 2.5 mg – 1% DV Sep-13 to 2016 .....	4.31	90	<b>Zapril</b>
Tab 5 mg – 1% DV Sep-13 to 2016 .....	6.98	90	<b>Zapril</b>
<b>ENALAPRIL MALEATE</b>			
Tab 5 mg .....	1.19	100	Ethics Enalapril
Tab 10 mg .....	1.47	100	Ethics Enalapril
Tab 20 mg .....	1.91	100	Ethics Enalapril
<b>LISINOPRIL</b>			
Tab 5 mg – 1% DV Jan-13 to 2015 .....	3.58	90	<b>Arrow-Lisinopril</b>
Tab 10 mg – 1% DV Jan-13 to 2015 .....	4.08	90	<b>Arrow-Lisinopril</b>
Tab 20 mg – 1% DV Jan-13 to 2015 .....	4.88	90	<b>Arrow-Lisinopril</b>
<b>PERINDOPRIL</b>			
Tab 2 mg – 1% DV Oct-14 to 2017 .....	3.75	30	<b>Apo-Perindopril</b>
Tab 4 mg – 1% DV Oct-14 to 2017 .....	4.80	30	<b>Apo-Perindopril</b>
<b>QUINAPRIL</b>			
Tab 5 mg – 1% DV Apr-13 to 2015 .....	3.44	90	<b>Arrow-Quinapril 5</b>
Tab 10 mg – 1% DV Apr-13 to 2015 .....	4.64	90	<b>Arrow-Quinapril 10</b>
Tab 20 mg – 1% DV Apr-13 to 2015 .....	6.34	90	<b>Arrow-Quinapril 20</b>
<b>TRANDOLAPRIL – Restricted:</b> For continuation only			
☞ Cap 1 mg			
☞ Cap 2 mg			
<b>ACE Inhibitors with Diuretics</b>			
<b>CILAZAPRIL WITH HYDROCHLOROTHIAZIDE</b>			
Tab 5 mg with hydrochlorothiazide 12.5 mg – 1% DV Mar-14 to 2016 .....	10.72	100	<b>Apo-Cilazapril/ Hydrochlorothiazide</b>
<b>ENALAPRIL MALEATE WITH HYDROCHLOROTHIAZIDE – Restricted:</b> For continuation only			
☞ Tab 20 mg with hydrochlorothiazide 12.5 mg			
<b>QUINAPRIL WITH HYDROCHLOROTHIAZIDE</b>			
Tab 10 mg with hydrochlorothiazide 12.5 mg – 1% DV Aug-12 to 2015 .....	3.37	30	<b>Accuretic 10</b>
Tab 20 mg with hydrochlorothiazide 12.5 mg – 1% DV Aug-12 to 2015 .....	4.57	30	<b>Accuretic 20</b>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Angiotensin II Antagonists</b>			
CANDESARTAN CILEXETIL – <b>Restricted</b> see terms below			
⚡ Tab 4 mg – 1% DV Nov-12 to 2015 .....	4.13	90	<b>Candestar</b>
⚡ Tab 8 mg – 1% DV Nov-12 to 2015 .....	6.10	90	<b>Candestar</b>
⚡ Tab 16 mg – 1% DV Nov-12 to 2015 .....	10.18	90	<b>Candestar</b>
⚡ Tab 32 mg – 1% DV Nov-12 to 2015 .....	17.66	90	<b>Candestar</b>
➡ <b>Restricted</b>			
<b>ACE inhibitor intolerance</b>			
Either:			
1 Patient has persistent ACE inhibitor induced cough that is not resolved by ACE inhibitor retrial (same or new ACE inhibitor); or			
2 Patient has a history of angioedema.			
<b>Unsatisfactory response to ACE inhibitor</b>			
Patient is not adequately controlled on maximum tolerated dose of an ACE inhibitor.			
LOSARTAN POTASSIUM			
Tab 12.5 mg – 1% DV Jan-15 to 2017 .....	1.55	84	<b>Losartan Actavis</b>
Tab 25 mg – 1% DV Jan-15 to 2017 .....	1.90	84	<b>Losartan Actavis</b>
Tab 50 mg – 1% DV Jan-15 to 2017 .....	2.25	84	<b>Losartan Actavis</b>
Tab 100 mg – 1% DV Jan-15 to 2017 .....	2.60	84	<b>Losartan Actavis</b>
<b>Angiotensin II Antagonists with Diuretics</b>			
LOSARTAN POTASSIUM WITH HYDROCHLOROTHIAZIDE			
Tab 50 mg with hydrochlorothiazide 12.5 mg – 1% DV Oct-14 to 2017 .....	2.18	30	<b>Arrow-Losartan &amp; Hydrochlorothiazide</b>
<b>Alpha-Adrenoceptor Blockers</b>			
DOXAZOSIN			
Tab 2 mg – 1% DV Sep-14 to 2017 .....	6.75	500	<b>Apo-Doxazosin</b>
Tab 4 mg – 1% DV Sep-14 to 2017 .....	9.67	500	<b>Apo-Doxazosin</b>
PHENOXYBENZAMINE HYDROCHLORIDE			
Cap 10 mg			
Inj 50 mg per ml, 2 ml ampoule			
PHENTOLAMINE MESYLATE			
Inj 10 mg per ml, 1 ml ampoule			
PRAZOSIN			
Tab 1 mg .....	5.53	100	<b>Apo-Prazosin</b>
Tab 2 mg .....	7.00	100	<b>Apo-Prazosin</b>
Tab 5 mg .....	11.70	100	<b>Apo-Prazosin</b>
TERAZOSIN			
Tab 1 mg – 1% DV Sep-13 to 2016 .....	0.50	28	<b>Arrow</b>
Tab 2 mg – 1% DV Sep-13 to 2016 .....	0.45	28	<b>Arrow</b>
Tab 5 mg – 1% DV Sep-13 to 2016 .....	0.68	28	<b>Arrow</b>

## Antiarrhythmics

ADENOSINE			
Inj 3 mg per ml, 2 ml vial			
⚡ Inj 3 mg per ml, 10 ml vial			

# CARDIOVASCULAR SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>➡Restricted</b>			
For use in cardiac catheterisation, electrophysiology and MRI.			
AJMALINE – <b>Restricted</b> see terms below			
⚡ Inj 5 mg per ml, 10 ml ampoule			
<b>➡Restricted</b>			
Cardiologist			
AMIODARONE HYDROCHLORIDE			
Tab 100 mg			
Tab 200 mg			
Inj 50 mg per ml, 3 ml ampoule – 1% DV Aug-13 to 2016.....	22.80	6	Cordarone-X
ATROPINE SULPHATE			
Inj 600 mcg per ml, 1 ml ampoule – 1% DV Jan-13 to 2015 .....	71.00	50	AstraZeneca
DIGOXIN			
Tab 62.5 mcg			
Tab 250 mcg			
Oral liq 50 mcg per ml			
Inj 250 mcg per ml, 2 ml vial			
DISOPYRAMIDE PHOSPHATE			
Cap 100 mg			
Cap 150 mg			
FLECAINIDE ACETATE			
Tab 50 mg .....	38.95	60	Tambocor
Tab 100 mg .....	68.78	60	Tambocor
Cap long-acting 100 mg .....	38.95	30	Tambocor CR
Cap long-acting 200 mg .....	68.78	30	Tambocor CR
Inj 10 mg per ml, 15 ml ampoule .....	52.45	5	Tambocor
MEXILETINE HYDROCHLORIDE			
Cap 150 mg .....	65.00	100	Mexiletine Hydrochloride USP
Cap 250 mg .....	102.00	100	Mexiletine Hydrochloride USP
PROPAFENONE HYDROCHLORIDE			
Tab 150 mg			

## Antihypotensives

MIDODRINE – **Restricted** see terms below

⚡ Tab 2.5 mg

⚡ Tab 5 mg

**➡Restricted**

Patient has disabling orthostatic hypotension not due to drugs.

## Beta-Adrenoceptor Blockers

ATENOLOL

Tab 50 mg – 1% DV Oct-12 to 2015 .....	5.56	500	Mylan Atenolol
Tab 100 mg – 1% DV Oct-12 to 2015 .....	9.12	500	Mylan Atenolol
Oral liq 5 mg per ml .....	21.25	300 ml	Atenolol-AFT



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>BISOPROLOL FUMARATE</b>			
Tab 2.5 mg – 1% DV Mar-15 to 2017 .....	2.40	30	<b>Bosvate</b>
Tab 5 mg – 1% DV Mar-15 to 2017 .....	3.50	30	<b>Bosvate</b>
Tab 10 mg – 1% DV Mar-15 to 2017 .....	6.40	30	<b>Bosvate</b>
<b>CARVEDILOL</b>			
Tab 6.25 mg .....	21.00	30	Dilatrend
Tab 12.5 mg .....	27.00	30	Dilatrend
Tab 25 mg .....	33.75	30	Dilatrend
<b>CELIPROLOL</b>			
Tab 200 mg .....	19.00	180	Celol
<b>ESMOLOL HYDROCHLORIDE</b>			
Inj 10 mg per ml, 10 ml vial			
<b>LABETALOL</b>			
Tab 50 mg .....	8.23	100	Hybloc
Tab 100 mg .....	10.06	100	Hybloc
Tab 200 mg .....	17.55	100	Hybloc
Tab 400 mg			
Inj 5 mg per ml, 20 ml ampoule			
<b>METOPROLOL SUCCINATE</b>			
Tab long-acting 23.75 mg – 1% DV Sep-12 to 2015 .....	0.96	30	<b>Metoprolol - AFT CR</b>
Tab long-acting 47.5 mg – 1% DV Sep-12 to 2015 .....	1.41	30	<b>Metoprolol - AFT CR</b>
Tab long-acting 95 mg – 1% DV Sep-12 to 2015 .....	2.42	30	<b>Metoprolol - AFT CR</b>
Tab long-acting 190 mg – 1% DV Sep-12 to 2015 .....	4.66	30	<b>Metoprolol - AFT CR</b>
<b>METOPROLOL TARTRATE</b>			
Tab 50 mg – 1% DV Aug-12 to 2015 .....	16.00	100	<b>Lopresor</b>
Tab 100 mg – 1% DV Aug-12 to 2015 .....	21.00	60	<b>Lopresor</b>
Tab long-acting 200 mg – 1% DV Aug-12 to 2015 .....	18.00	28	<b>Slow-Lopresor</b>
Inj 1 mg per ml, 5 ml vial – 1% DV Dec-12 to 2015 .....	24.00	5	<b>Lopresor</b>
<b>NADOLOL</b>			
Tab 40 mg – 1% DV Apr-13 to 2015 .....	15.57	100	<b>Apo-Nadolol</b>
Tab 80 mg – 1% DV Apr-13 to 2015 .....	23.74	100	<b>Apo-Nadolol</b>
<b>PINDOLOL</b>			
Tab 5 mg – 1% DV Nov-13 to 2016 .....	9.72	100	<b>Apo-Pindolol</b>
Tab 10 mg – 1% DV Nov-13 to 2016 .....	15.62	100	<b>Apo-Pindolol</b>
Tab 15 mg – 1% DV Nov-13 to 2016 .....	23.46	100	<b>Apo-Pindolol</b>
<b>PROPRANOLOL</b>			
Tab 10 mg .....	3.65	100	Apo-Propранolol
Tab 40 mg .....	4.65	100	Apo-Propранolol
Cap long-acting 160 mg .....	16.06	100	Cardinol LA
Oral liq 4 mg per ml			
Inj 1 mg per ml, 1 ml ampoule			
<b>SOTALOL</b>			
Tab 80 mg .....	27.50	500	Mylan
Tab 160 mg .....	10.50	100	Mylan
Inj 10 mg per ml, 4 ml ampoule .....	65.39	5	Sotacor
<b>TIMOLOL MALEATE</b>			
Tab 10 mg			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Calcium Channel Blockers</b>			
<b>Dihydropyridine Calcium Channel Blockers</b>			
<b>AMLODIPINE</b>			
Tab 2.5 mg – 1% DV Feb-15 to 2017 .....	2.21	100	<b>Apo-Amlodipine</b>
Tab 5 mg – 1% DV May-15 to 2017 .....	5.04	250	<b>Apo-Amlodipine</b>
Tab 10 mg – 1% DV May-15 to 2017 .....	7.21	250	<b>Apo-Amlodipine</b>
<b>FELODIPINE</b>			
Tab long-acting 2.5 mg – 1% DV Sep-12 to 2015 .....	2.90	30	<b>Plendil ER</b>
Tab long-acting 5 mg – 1% DV Nov-12 to 2015 .....	3.10	30	<b>Plendil ER</b>
Tab long-acting 10 mg – 1% DV Nov-12 to 2015 .....	4.60	30	<b>Plendil ER</b>
<b>ISRADIPINE</b>			
Tab 2.5 mg			
Cap long-acting 2.5 mg			
Cap long-acting 5 mg			
<b>NIFEDIPINE</b>			
Tab long-acting 10 mg			
Tab long-acting 20 mg .....	9.59	100	<b>Nyefax Retard</b>
Tab long-acting 30 mg – 1% DV Sep-14 to 2017 .....	3.75	30	<b>Adefin XL</b>
Tab long-acting 60 mg – 1% DV Sep-14 to 2017 .....	5.75	30	<b>Adefin XL</b>
Cap 5 mg			
<b>NIMODIPINE</b>			
Tab 30 mg			
Inj 200 mcg per ml, 50 ml vial			
<b>Other Calcium Channel Blockers</b>			
<b>DILTIAZEM HYDROCHLORIDE</b>			
Tab 30 mg – 5% DV Sep-12 to 2015 .....	4.60	100	<b>Dilzem</b>
Tab 60 mg – 5% DV Sep-12 to 2015 .....	8.50	100	<b>Dilzem</b>
Cap long-acting 120 mg .....	1.91	30	<b>Cardizem CD</b>
	31.83	500	<b>Apo-Diltiazem CD</b>
Cap long-acting 180 mg .....	7.56	30	<b>Cardizem CD</b>
	47.67	500	<b>Apo-Diltiazem CD</b>
Cap long-acting 240 mg .....	10.22	30	<b>Cardizem CD</b>
	63.58	500	<b>Apo-Diltiazem CD</b>
Inj 5 mg per ml, 5 ml vial			
<b>PERHEXILINE MALEATE</b>			
Tab 100 mg .....	62.90	100	<b>Pexsig</b>
<b>VERAPAMIL HYDROCHLORIDE</b>			
Tab 40 mg .....	7.01	100	<b>Isoptin</b>
Tab 80 mg – 1% DV Sep-14 to 2017 .....	11.74	100	<b>Isoptin</b>
Tab long-acting 120 mg .....	15.20	250	<b>Verpamil SR</b>
Tab long-acting 240 mg .....	25.00	250	<b>Verpamil SR</b>
Inj 2.5 mg per ml, 2 ml ampoule .....	7.54	5	<b>Isoptin</b>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Centrally-Acting Agents</b>			
<b>CLONIDINE</b>			
Patch 2.5 mg, 100 mcg per day – 1% DV Jul-14 to 2017 .....	12.80	4	<b>Catapres-TTS-1</b>
Patch 5 mg, 200 mcg per day – 1% DV Jul-14 to 2017 .....	18.04	4	<b>Catapres-TTS-2</b>
Patch 7.5 mg, 300 mcg per day – 1% DV Jul-14 to 2017 .....	22.68	4	<b>Catapres-TTS-3</b>
<b>CLONIDINE HYDROCHLORIDE</b>			
Tab 25 mcg – 1% DV Jul-13 to 2015 .....	15.09	112	<b>Clonidine BNM</b>
Tab 150 mcg – 1% DV Feb-13 to 2015 .....	34.32	100	<b>Catapres</b>
Inj 150 mcg per ml, 1 ml ampoule – 1% DV Nov-12 to 2015 .....	16.07	5	<b>Catapres</b>
<b>METHYLDOPA</b>			
Tab 125 mg .....	14.25	100	<b>Prodopa</b>
Tab 250 mg .....	15.10	100	<b>Prodopa</b>
Tab 500 mg .....	23.15	100	<b>Prodopa</b>
<b>Diuretics</b>			
<b>Loop Diuretics</b>			
<b>BUMETANIDE</b>			
Tab 1 mg .....	16.36	100	<b>Burinex</b>
Inj 500 mcg per ml, 4 ml vial			
<b>FUROSEMIDE (FRUSEMIDE)</b>			
Tab 40 mg – 1% DV Sep-12 to 2015 .....	10.25	1,000	<b>Diurin 40</b>
Tab 500 mg – 1% DV Feb-13 to 2015 .....	25.00	50	<b>Urex Forte</b>
Oral liq 10 mg per ml			
Inj 10 mg per ml, 2 ml ampoule .....	1.30	5	<b>Frusemide-Claris</b>
Inj 10 mg per ml, 25 ml ampoule			
<b>Osmotic Diuretics</b>			
<b>MANNITOL</b>			
Inj 10%, 1,000 ml bag .....	14.21	1,000 ml	<b>Baxter</b>
Inj 15%, 500 ml bag .....	9.84	500 ml	<b>Baxter</b>
Inj 20%, 500 ml bag .....	10.80	500 ml	<b>Baxter</b>
<b>Potassium Sparing Combination Diuretics</b>			
<b>AMILORIDE HYDROCHLORIDE WITH FUROSEMIDE</b>			
Tab 5 mg with furosemide 40 mg			
<b>AMILORIDE HYDROCHLORIDE WITH HYDROCHLOROTHIAZIDE</b>			
Tab 5 mg with hydrochlorothiazide 50 mg			
<b>Potassium Sparing Diuretics</b>			
<b>AMILORIDE HYDROCHLORIDE</b>			
Tab 5 mg .....	17.50	100	<b>Apo-Amiloride</b>
Oral liq 1 mg per ml .....	30.00	25 ml	<b>Biomed</b>
<b>SPIRONOLACTONE</b>			
Tab 25 mg – 1% DV Sep-13 to 2016 .....	3.65	100	<b>Spiractin</b>
Tab 100 mg – 1% DV Sep-13 to 2016 .....	11.80	100	<b>Spiractin</b>
Oral liq 5 mg per ml .....	30.00	25 ml	<b>Biomed</b>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Thiazide and Related Diuretics</b>			
<b>BENDROFLUMETHIAZIDE [BENDROFLUAZIDE]</b>			
Tab 2.5 mg – 1% DV Sep-14 to 2017 .....	5.48	500	<b>Arrow-Bendrofluaizide</b>
Tab 5 mg – 1% DV Sep-14 to 2017 .....	8.95	500	<b>Arrow-Bendrofluaizide</b>
<b>CHLOROTHIAZIDE</b>			
Oral liq 50 mg per ml .....	26.00	25 ml	Biomed
<b>CHLORTALIDONE [CHLORTHALIDONE]</b>			
Tab 25 mg .....	8.00	50	Hygroton
<b>INDAPAMIDE</b>			
Tab 2.5 mg – 1% DV Oct-13 to 2016 .....	2.25	90	<b>Dapa-Tabs</b>
<b>METOLAZONE – Restricted</b> see terms below			
⚡ Tab 5 mg			
<b>➡Restricted</b>			
Either:			
1 Patient has refractory heart failure and is intolerant or has not responded to loop diuretics and/or loop-thiazide combination therapy; or			
2 Patient has severe refractory nephrotic oedema unresponsive to high dose loop diuretics and concentrated albumin infusions			
<b>Lipid-Modifying Agents</b>			
<b>Fibrates</b>			
<b>BEZAFIBRATE</b>			
Tab 200 mg – 1% DV Mar-13 to 2015 .....	9.70	90	<b>Bezalip</b>
Tab long-acting 400 mg – 1% DV Oct-12 to 2015 .....	5.70	30	<b>Bezalip Retard</b>
<b>GEMFIBROZIL</b>			
Tab 600 mg – 1% DV Nov-13 to 2016 .....	17.60	60	<b>Lipazil</b>
<b>HMG CoA Reductase Inhibitors (Statins)</b>			
<b>ATORVASTATIN</b>			
Tab 10 mg – 1% DV Oct-12 to 2015 .....	2.52	90	<b>Zarator</b>
Tab 20 mg – 1% DV Oct-12 to 2015 .....	4.17	90	<b>Zarator</b>
Tab 40 mg – 1% DV Oct-12 to 2015 .....	7.32	90	<b>Zarator</b>
Tab 80 mg – 1% DV Oct-12 to 2015 .....	16.23	90	<b>Zarator</b>
<b>PRAVASTATIN</b>			
Tab 10 mg			
Tab 20 mg – 1% DV Oct-14 to 2017 .....	3.45	30	<b>Cholvastin</b>
Tab 40 mg – 1% DV Oct-14 to 2017 .....	6.36	30	<b>Cholvastin</b>
<b>SIMVASTATIN</b>			
Tab 10 mg – 1% DV Sep-14 to 2017 .....	0.95	90	<b>Arrow-Simva</b>
Tab 20 mg – 1% DV Sep-14 to 2017 .....	1.61	90	<b>Arrow-Simva</b>
Tab 40 mg – 1% DV Sep-14 to 2017 .....	2.83	90	<b>Arrow-Simva</b>
Tab 80 mg – 1% DV Sep-14 to 2017 .....	7.91	90	<b>Arrow-Simva</b>
<b>Resins</b>			
<b>CHOLESTYRAMINE</b>			
Powder for oral liq 4 g			

Price (ex man. excl. GST)	Brand or Generic
\$ Per	Manufacturer

## COLESTIPOL HYDROCHLORIDE

Grans for oral liq 5 g

## Selective Cholesterol Absorption Inhibitors

EZETIMIBE – **Restricted** see terms below

⚡ Tab 10 mg

➔ **Restricted**

All of the following:

- 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and
- 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
- 3 Any of the following:
  - 3.1 The patient has rhabdomyolysis (defined as muscle aches and creatine kinase more than 10 × normal) when treated with one statin; or
  - 3.2 The patient is intolerant to both simvastatin and atorvastatin; or
  - 3.3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

EZETIMIBE WITH SIMVASTATIN – **Restricted** see terms below

⚡ Tab 10 mg with simvastatin 10 mg

⚡ Tab 10 mg with simvastatin 20 mg

⚡ Tab 10 mg with simvastatin 40 mg

⚡ Tab 10 mg with simvastatin 80 mg

➔ **Restricted**

All of the following:

- 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and
- 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
- 3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

## Other Lipid-Modifying Agents

## ACIPIMOX

Cap 250 mg

## NICOTINIC ACID

Tab 50 mg – 1% DV Oct-14 to 2017 .....3.96 100 **Apo-Nicotinic Acid**Tab 500 mg – 1% DV Oct-14 to 2017 .....17.37 100 **Apo-Nicotinic Acid**

## Nitrates

## GLYCERYL TRINITRATE

Tab 600 mcg .....	8.00	100	Lycinate
Inj 1 mg per ml, 5 ml ampoule – 1% DV Dec-12 to 2015 .....	22.70	10	<b>Nitronal</b>
Inj 1 mg per ml, 50 ml vial – 1% DV Dec-12 to 2015 .....	86.60	10	<b>Nitronal</b>
Inj 5 mg per ml, 10 ml ampoule .....	100.00	5	Hospira
Oral spray, 400 mcg per dose .....	4.45	250 dose	Glytrin
Patch 25 mg, 5 mg per day – 1% DV Sep-14 to 2017 .....	15.73	30	<b>Nitroderm TTS 5</b>
Patch 50 mg, 10 mg per day – 1% DV Sep-14 to 2017 .....	18.62	30	<b>Nitroderm TTS 10</b>

## ISOSORBIDE MONONITRATE

Tab 20 mg – 1% DV Sep-14 to 2017 .....	17.10	100	<b>Ismo-20</b>
Tab long-acting 40 mg .....	7.50	30	Ismo 40 Retard
Tab long-acting 60 mg .....	3.94	90	Duride

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Other Cardiac Agents</b>			
LEVOSIMENDAN – <b>Restricted</b> see terms below			
☞ Inj 2.5 mg per ml, 5 ml vial			
☞ Inj 2.5 mg per ml, 10 ml vial			
☞ <b>Restricted</b>			
<b>Heart transplant</b>			
Either:			
1 For use as a bridge to heart transplant, in patients who have been accepted for transplant; or			
2 For the treatment of heart failure following heart transplant.			
<b>Heart failure</b>			
cardiologist or intensivist			
For the treatment of severe acute decompensated heart failure that is non-responsive to dobutamine.			
<b>Sympathomimetics</b>			
<b>ADRENALINE</b>			
Inj 1 in 1,000, 1 ml ampoule .....	4.98	5	Aspen Adrenaline
	5.25		Hospira
Inj 1 in 1,000, 30 ml vial			
Inj 1 in 10,000, 10 ml ampoule .....	27.00	5	Hospira
	49.00	10	Aspen Adrenaline
Inj 1 in 10,000, 10 ml syringe			
<b>DOBUTAMINE HYDROCHLORIDE</b>			
Inj 12.5 mg per ml, 20 ml vial			
<b>DOPAMINE HYDROCHLORIDE</b>			
Inj 40 mg per ml, 5 ml ampoule – 1% DV Sep-12 to 2015 .....	69.77	10	Martindale
<b>EPHEDRINE</b>			
Inj 3 mg per ml, 10 ml syringe			
Inj 30 mg per ml, 1 ml ampoule – 1% DV Mar-15 to 2017 .....	51.48	10	Max Health
<b>ISOPRENALINE</b>			
Inj 200 mcg per ml, 1 ml ampoule			
Inj 200 mcg per ml, 5 ml ampoule			
<b>METARAMINOL</b>			
Inj 0.5 mg per ml, 20 ml syringe			
Inj 1 mg per ml, 1 ml ampoule			
Inj 1 mg per ml, 10 ml syringe			
Inj 10 mg per ml, 1 ml ampoule			
<b>NORADRENALINE</b>			
Inj 0.06 mg per ml, 100 ml bag			
Inj 0.06 mg per ml, 50 ml syringe			
Inj 0.1 mg per ml, 100 ml bag			
Inj 0.12 mg per ml, 100 ml bag			
Inj 0.12 mg per ml, 50 ml syringe			
Inj 0.16 mg per ml, 50 ml syringe			
Inj 1 mg per ml, 100 ml bag			
Inj 1 mg per ml, 2 ml ampoule			
Inj 1 mg per ml, 4 ml ampoule			
(Any Inj 1 mg per ml, 2 ml ampoule to be delisted 1 June 2015)			

☞ Item restricted (see ☞ above); ☞ Item restricted (see ☞ below)

e.g. Brand indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
PHENYLEPHRINE HYDROCHLORIDE			
Inj 10 mg per ml, 1 ml vial .....	115.50	25	Neosynephrine HCL
<b>Vasodilators</b>			
ALPROSTADIL HYDROCHLORIDE			
Inj 500 mcg per ml, 1 ml ampoule – 1% DV Oct-12 to 2015 .....	1,417.50	5	Prostin VR
AMYL NITRITE			
Liq 98% in 3 ml capsule			
DIAZOXIDE			
Inj 15 mg per ml, 20 ml ampoule			
HYDRALAZINE HYDROCHLORIDE			
⚡ Tab 25 mg			
➡ <b>Restricted</b>			
Either:			
1 For the treatment of refractory hypertension; or			
2 For the treatment of heart failure, in combination with a nitrate, in patients who are intolerant or have not responded to ACE inhibitors and/or angiotensin receptor blockers.			
Inj 20 mg ampoule .....	25.90	5	Apresoline
MILRINONE			
Inj 1 mg per ml, 10 ml ampoule			
MINOXIDIL – <b>Restricted</b> see terms below			
⚡ Tab 10 mg .....	70.00	100	Loniten
➡ <b>Restricted</b>			
For patients with severe refractory hypertension who have failed to respond to extensive multiple therapies.			
NICORANDIL			
Tab 10 mg .....	27.95	60	Ikorel
Tab 20 mg .....	33.28	60	Ikorel
PAPAVERINE HYDROCHLORIDE			
Inj 30 mg per ml, 1 ml vial			
Inj 12 mg per ml, 10 ml ampoule .....	73.12	5	Hospira
PENTOXIFYLLINE [OXPENTIFYLLINE]			
Tab 400 mg			
SODIUM NITROPRUSSIDE			
Inj 50 mg vial			

### Endothelin Receptor Antagonists

AMBRISENTAN – <b>Restricted</b> see terms below			
⚡ Tab 5 mg .....	4,585.00	30	Volibris
⚡ Tab 10 mg .....	4,585.00	30	Volibris
➡ <b>Restricted</b>			
1 For use in patients with approval by the Pulmonary Arterial Hypertension Panel; or			
2 In hospital stabilisations in emergency situations.			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>BOSENTAN – Restricted</b> see terms below			
☞ Tab 62.5 mg .....	1,500.00	60	pms-Bosentan
	4,585.00		Tracleer
☞ Tab 125 mg .....	1,500.00	60	pms-Bosentan
	4,585.00		Tracleer

## ☞Restricted

- 1 For use in patients with approval by the Pulmonary Arterial Hypertension Panel; or
- 2 In hospital stabilisation in emergency situations.

## Phosphodiesterase Type 5 Inhibitors

**SILDENAFIL – Restricted** see terms below

☞ Tab 25 mg .....	1.85	4	Silagra
☞ Tab 50 mg .....	1.85	4	Silagra
☞ Tab 100 mg .....	7.45	4	Silagra

## ☞Restricted

Any of the following:

- 1 For use in patients with approval by the Pulmonary Arterial Hypertension Panel; or
- 2 For use in neonatal units for persistent pulmonary hypertension of the newborn (PPHN); or
- 3 For use in weaning patients from inhaled nitric oxide; or
- 4 For perioperative use in cardiac surgery patients; or
- 5 For use in intensive care as an alternative to nitric oxide; or
- 6 In-hospital stabilisation in emergency situations; or
- 7 All of the following:
  - 7.1 Patient has Raynaud's phenomenon; and
  - 7.2 Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene); and
  - 7.3 Patient is following lifestyle management (proper body insulation, avoidance of cold exposure, smoking cessation support, avoidance of sympathomimetic drugs); and
  - 7.4 Patient has persisting severe symptoms despite treatment with calcium channel blockers and nitrates (unless contraindicated or not tolerated).

## Prostacyclin Analogues

**ILOPROST**

Inj 50 mcg in 0.5 ml ampoule .....	89.50	1	Arrow-Iloprost
☞ Nebuliser soln 10 mcg per ml, 2 ml .....	1,185.00	30	Ventavis

## ☞Restricted

Any of the following:

- 1 For use in patients with approval by the Pulmonary Arterial Hypertension Panel; or
- 2 For diagnostic use in catheter laboratories; or
- 3 For use following mitral or tricuspid valve surgery; or
- 4 In hospital stabilisation in emergency situations.



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Anti-Infective Preparations</b>			
<b>Antibacterials</b>			
FUSIDIC ACID			
Crm 2% – 1% DV Jan-15 to 2016 .....	2.52	15 g	<b>DP Fusidic Acid Cream Foban</b>
Oint 2% – 1% DV Sep-13 to 2016 .....	3.45	15 g	
HYDROGEN PEROXIDE			
Crm 1% .....	8.56	15 g	Crystaderm
Soln 3% (10 vol)			
MAFENIDE ACETATE – <b>Restricted</b> see terms below			
↓ Powder 50 g sachet			
➔ <b>Restricted</b>			
For the treatment of burns patients.			
MUPIROCIN			
Oint 2%			
SULPHADIAZINE SILVER			
Crm 1% .....	12.30	50 g	Flamazine
<b>Antifungals</b>			
AMOROLFINE			
Nail soln 5% – 1% DV Jan-15 to 2017 .....	19.95	5 ml	<b>MycoNail</b>
CICLOPIROX OLAMINE			
Nail soln 8%			
➔ Soln 1% – <b>Restricted</b> : For continuation only			
CLOTTRIMAZOLE			
Crm 1% – 1% DV Sep-14 to 2017 .....	0.52	20 g	<b>Clomazol</b>
➔ Soln 1% – <b>Restricted</b> : For continuation only			
ECONAZOLE NITRATE			
➔ Crm 1% – <b>Restricted</b> : For continuation only			
Foaming soln 1%			
KETOCONAZOLE			
Shampoo 2% – 1% DV Dec-14 to 2017 .....	2.99	100 ml	<b>Sebizole</b>
METRONIDAZOLE			
Gel 0.75%			
MICONAZOLE NITRATE			
Crm 2% – 1% DV Mar-15 to 2017 .....	0.55	15 g	<b>Multichem</b>
➔ Lotn 2% – <b>Restricted</b> : For continuation only			
Tinc 2%			
NYSTATIN			
Crm 100,000 u per g			
<b>Antiparasitics</b>			
LINDANE [GAMMA BENZENE HEXACHLORIDE]			
Crm 1%			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
MALATHION [MALDISON] Lotn 0.5% Shampoo 1%			
MALATHION WITH PERMETHRIN AND PIPERONYL BUTOXIDE Spray 0.25% with permethrin 0.5% and piperonyl butoxide 2% Note: Temporary listing to cover out-of-stock.			
PERMETHRIN Crm 5% – 1% DV Apr-15 to 2017 .....	4.20	30 g	Lyderm
Lotn 5% – 1% DV Sep-14 to 2017 .....	3.19	30 ml	A-Scabies

## Antiacne Preparations

ADAPALENE Crm 0.1% Gel 0.1%			
BENZOYL PEROXIDE Soln 5%			
ISOTRETINOIN Cap 10 mg – 1% DV Jan-13 to 2015 .....	18.71	120	Oratane
Cap 20 mg – 1% DV Jan-13 to 2015 .....	28.91	120	Oratane
TRETINOIN Crm 0.05%			

## Antipruritic Preparations

CALAMINE Crm, aqueous, BP – 1% DV Mar-13 to 2015 .....	1.77	100 g	Pharmacy Health
Lotn, BP – 1% DV Nov-12 to 2015 .....	13.45	2,000 ml	PSM
CROTAMITON Crm 10% – 1% DV Sep-12 to 2015 .....	3.48	20 g	Itch-Soothe

## Barrier Creams and Emollients

### Barrier Creams

DIMETHICONE Crm 5% tube – 1% DV Apr-14 to 2016 .....	1.65	100 g	healthE Dimethicone 5%
Crm 5% pump bottle – 1% DV Apr-14 to 2016 .....	4.73	500 ml	healthE Dimethicone 5%
ZINC Crm			e.g. Zinc Cream (Orion); Zinc Cream (PSM)
Oint Paste			e.g. Zinc oxide (PSM)
ZINC AND CASTOR OIL Crm .....	1.63	20 g	Orion
Oint, BP			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
ZINC WITH WOOL FAT			
Crm zinc 15.25% with wool fat 4%			<i>e.g. Sudocrem</i>
<b>Emollients</b>			
AQUEOUS CREAM			
Crm 100 g .....	1.23	100 g	AFT
Note: DV limit applies to the pack sizes of 100 g or less.			
Crm 500 g .....	1.96	500 g	AFT
Note: DV limit applies to the pack sizes of greater than 100 g.			
CETOMACROGOL			
Crm BP, 500 g .....	3.50	500 g	Pharmacy Health
Crm BP, 100 g .....	1.65	1	healthE
CETOMACROGOL WITH GLYCEROL			
Crm 90% with glycerol 10%, .....	2.10	100 g	Pharmacy Health
	2.00		Pharmacy Health
	3.20		healthE
Crm 90% with glycerol 10% .....	4.50	500 ml	Pharmacy Health
			Sorbolene with
			Glycerin
	6.50	1,000 ml	Pharmacy Health
			Sorbolene with
			Glycerin
Crm 90% with glycerol 10%, 500 ml, 1 bottle .....	5.46	1	healthE
EMULSIFYING OINTMENT			
Oint BP – <b>1% DV Apr-15 to 2017</b> .....	1.84	100 g	<b>Jaychem</b>
Note: DV limit applies to pack sizes of greater than 200 g.			
Oint BP, 500 g .....	3.04	500 g	AFT
Note: DV limit applies to pack sizes of greater than 100 g.			
GLYCEROL WITH PARAFFIN			
Crm glycerol 10% with white soft paraffin 5% and liquid paraffin 10%			<i>e.g. QV cream</i>
OIL IN WATER EMULSION			
Crm – <b>1% DV Dec-12 to 2015</b> .....	2.63	500 g	<b>healthE Fatty Cream</b>
Crm, 100 g .....	1.60	1	healthE Fatty Cream
PARAFFIN			
Oint liquid paraffin 50% with white soft paraffin 50% .....	3.10	100 g	healthE
White soft – <b>1% DV Feb-13 to 2015</b> .....	0.92	10 g	<b>healthE</b>
Note: DV limit applies to pack sizes of 30 g or less, and to both white soft paraffin and yellow soft paraffin.			
Yellow soft			
PARAFFIN WITH WOOL FAT			
Lotn liquid paraffin 15.9% with wool fat 0.6%			<i>e.g. AlphaKeri;BK ;DP; Hydroderm Lotn</i>
Lotn liquid paraffin 91.7% with wool fat 3%			<i>e.g. Alpha Keri Bath Oil</i>
UREA			
Crm 10%			
WOOL FAT			
Crm			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Corticosteroids</b>			
BETAMETHASONE DIPROPIONATE			
Crm 0.05%			
Oint 0.05%			
BETAMETHASONE VALERATE			
Crm 0.1%			
Oint 0.1%			
Lotn 0.1%			
CLOBETASOL PROPIONATE			
Crm 0.05% .....	3.68	30 g	Dermol
Oint 0.05% .....	3.68	30 g	Dermol
CLOBETASONE BUTYRATE			
Crm 0.05%			
DIFLUCORTOLONE VALERATE – <b>Restricted:</b> For continuation only			
➡ Crm 0.1%			
➡ Fatty oint 0.1%			
HYDROCORTISONE			
Crm 1%, 100 g .....	3.75	100 g	Pharmacy Health
Crm 1%, 500 g .....	14.00	500 g	Pharmacy Health
Note: DV limit applies to the pack sizes of greater than 100 g.			
HYDROCORTISONE ACETATE			
Crm 1% .....	2.48	14.2 g	AFT
HYDROCORTISONE AND PARAFFIN LIQUID AND LANOLIN			
Lotn 1% with paraffin liquid 15.9% and lanolin 0.6% – <b>1% DV Dec-14</b>			
<b>to 2017</b> .....	10.57	250 ml	DP Lotn HC
HYDROCORTISONE BUTYRATE			
Crm 0.1% – <b>1% DV Mar-13 to 2015</b> .....	2.30	30 g	Locoid Lipocream
	6.85	100 g	Locoid Lipocream
Oint 0.1% – <b>1% DV Mar-13 to 2015</b> .....	6.85	100 g	Locoid
Milky emul 0.1% – <b>1% DV Mar-13 to 2015</b> .....	6.85	100 ml	Locoid Crelo
HYDROCORTISONE WITH PARAFFIN AND WOOL FAT			
Lotn 1% with paraffin liquid 15.9% and wool fat 0.6%			
METHYLPREDNISOLONE ACEPONATE			
Crm 0.1% .....	4.95	15 g	Advantan
Oint 0.1% .....	4.95	15 g	Advantan
MOMETASONE FUROATE			
Crm 0.1% – <b>1% DV Sep-12 to 2015</b> .....	1.78	15 g	m-Mometasone
	3.42	45 g	m-Mometasone
Oint 0.1% – <b>1% DV Sep-12 to 2015</b> .....	1.78	15 g	m-Mometasone
	3.42	45 g	m-Mometasone
Lotn 0.1%			
TRIAMCINOLONE ACETONIDE			
Crm 0.02% – <b>1% DV Apr-15 to 2017</b> .....	6.30	100 g	Aristocort
Oint 0.02% – <b>1% DV Apr-15 to 2017</b> .....	6.35	100 g	Aristocort

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Corticosteroids with Anti-Infective Agents</b>			
BETAMETHASONE VALERATE WITH CLIOQUINOL – <b>Restricted</b> see terms below			
☞ Crm 0.1% with clioquinol 3%			
➔ <b>Restricted</b>			
Either:			
1 For the treatment of intertrigo; or			
2 For continuation use			
BETAMETHASONE VALERATE WITH FUSIDIC ACID			
Crm 0.1% with fusidic acid 2%			
HYDROCORTISONE WITH MICONAZOLE			
Crm 1% with miconazole nitrate 2% .....	2.20	15 g	Micreme H
HYDROCORTISONE WITH NATAMYCIN AND NEOMYCIN			
Crm 1% with natamycin 1% and neomycin sulphate 0.5% .....	2.79	15 g	Pimafucort
Oint 1% with natamycin 1% and neomycin sulphate 0.5% .....	2.79	15 g	Pimafucort
TRIAMCINOLONE ACETONIDE WITH NEOMYCIN SULPHATE, GRAMICIDIN AND NYSTATIN			
Crm 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g			

## Psoriasis and Eczema Preparations

ACITRETIN			
Cap 10 mg – 1% DV Nov-14 to 2017 .....	17.86	60	<b>Novatretin</b>
Cap 25 mg – 1% DV Nov-14 to 2017 .....	41.36	60	<b>Novatretin</b>
BETAMETHASONE DIPROPIONATE WITH CALCIPOTRIOL			
Gel 500 mcg with calcipotriol 50 mcg per g .....	26.12	30 g	Daivobet
Oint 500 mcg with calcipotriol 50 mcg per g .....	26.12	30 g	Daivobet
CALCIPOTRIOL			
Crm 50 mcg per g .....	45.00	100 g	Daivonex
Oint 50 mcg per g .....	45.00	100 g	Daivonex
Soln 50 mcg per ml .....	16.00	30 ml	Daivonex
COAL TAR WITH SALICYLIC ACID AND SULPHUR			
Oint 12% with salicylic acid 2% and sulphur 4%			
COAL TAR WITH TRIETHANOLAMINE LAURYL SULPHATE AND FLUORESCEIN			
Soln 2.3% with triethanolamine lauryl sulphate and fluorescein sodium .....	3.36	500 ml	Pinetarsol
	5.82	1,000 ml	Pinetarsol
METHOXSALEN [8-METHOXYPsorALEN]			
Cap 10 mg			
Lotn 1.2%			
POTASSIUM PERMANGANATE			
Tab 400 mg			
Crystals			

## Scalp Preparations

BETAMETHASONE VALERATE			
Scalp app 0.1% .....	7.75	100 ml	Beta Scalp

## DERMATOLOGICALS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
CLOBETASOL PROPIONATE			
Scalp app 0.05% .....	6.96	30 ml	Dermol
HYDROCORTISONE BUTYRATE			
Scalp lotn 0.1% – 1% DV Mar-13 to 2015 .....	3.65	100 ml	Locoid

### Wart Preparations

IMIQUIMOD			
Crm 5%, 250 mg sachet – 1% DV Feb-15 to 2017 .....	17.98	12	Apo-Imiquimod Cream 5%
PODOPHYLLOTOXIN			
Soln 0.5% .....	33.60	3.5 ml	Condyline

SILVER NITRATE  
Sticks with applicator

### Other Skin Preparations

DIPHEMANIL METILSULFATE			
Powder 2%			
SUNSCREEN, PROPRIETARY			
Crm			
Lotn .....	3.30	100 g	Marine Blue Lotion SPF 50+
	5.10	200 g	Marine Blue Lotion SPF 50+

### Antineoplastics

FLUOROURACIL SODIUM			
Crm 5% – 1% DV Feb-13 to 2015 .....	25.16	20 g	Efudix
METHYL AMINOLEVULINATE HYDROCHLORIDE – Restricted see terms below			
☞ Crm 16%			
☞ Restricted			
Dermatologist or plastic surgeon			

### Wound Management Products

CALCIUM GLUCONATE			
Gel 2.5% .....	21.00	1	healthE

Price (ex man. excl. GST)	Brand or Generic
\$	Per Manufacturer

## Anti-Infective Agents

### ACETIC ACID

Soln 3%

Soln 5%

### ACETIC ACID WITH HYDROXYQUINOLINE, GLYCEROL AND RICINOLEIC ACID

Jelly 0.94% with hydroxyquinoline sulphate 0.025%, glycerol 5% and  
ricinoleic acid 0.75% with applicator

### CHLORHEXIDINE

Crm 1% – **1% DV Oct-12 to 2015** ..... 1.24 50 g **healthE**

### CHLORHEXIDINE GLUCONATE

Lotn 1%, 200 ml ..... 6.75 1 **healthE**

### CLOTRIMAZOLE

Vaginal crm 1% with applicator – **1% DV Dec-13 to 2016** ..... 1.45 35 g **Clomazol**

Vaginal crm 2% with applicator – **1% DV Dec-13 to 2016** ..... 2.20 20 g **Clomazol**

### MICONAZOLE NITRATE

Vaginal crm 2% with applicator – **1% DV Oct-14 to 2017** ..... 3.95 40 g **Micreme**

### NYSTATIN

Vaginal crm 100,000 u per 5 g with applicator(s)

## Contraceptives

### Antiandrogen Oral Contraceptives

#### CYPROTERONE ACETATE WITH ETHINYLOESTRADIOL

Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tablets – **1% DV**

**Dec-14 to 2017** ..... 5.36 168 **Ginet**

### Combined Oral Contraceptives

#### ETHINYLOESTRADIOL WITH DESOGESTREL

Tab 20 mcg with desogestrel 150 mcg

Tab 30 mcg with desogestrel 150 mcg

#### ETHINYLOESTRADIOL WITH LEVONORGESTREL

Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets ..... 2.65 84 **Ava 20 ED**

Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets ..... 2.30 84 **Ava 30 ED**

Tab 20 mcg with levonorgestrel 100 mcg

Tab 30 mcg with levonorgestrel 150 mcg

Tab 50 mcg with levonorgestrel 125 mcg ..... 9.45 84 **Microgynon 50 ED**

#### ETHINYLOESTRADIOL WITH NORETHISTERONE

Tab 35 mcg with norethisterone 1 mg

Tab 35 mcg with norethisterone 500 mcg

#### NORETHISTERONE WITH MESTRANOL

Tab 1 mg with mestranol 50 mcg

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Contraceptive Devices</b>			
INTRA-UTERINE DEVICE			
IUD 29.1 mm length × 23.2 mm width .....	31.60	1	Choice TT380 Short MiniTT380 Slimline
IUD 33.6 mm length × 29.9 mm width .....	31.60	1	Choice TT380 Standard TT380 Slimline
<i>(MiniTT380 Slimline IUD 29.1 mm length × 23.2 mm width to be delisted 1 April 2015)</i>			
<i>(TT380 Slimline IUD 33.6 mm length × 29.9 mm width to be delisted 1 April 2015)</i>			
<b>Emergency Contraception</b>			
LEVONORGESTREL			
Tab 1.5 mg – 1% DV Jul-13 to 2016 .....	3.50	1	Postinor-1
<b>Progestogen-Only Contraceptives</b>			
LEVONORGESTREL			
Tab 30 mcg			
Subdermal implant (2 × 75 mg rods) – 5% DV Oct-14 to 31 Dec 2017 .....	133.65	1	Jadelle
¶ Intra-uterine system, 20 mcg per day			e.g. Mirena
➡ <b>Restricted</b>			
Obstetrician or gynaecologist			
<b>Initiation – heavy menstrual bleeding</b>			
All of the following:			
1 The patient has a clinical diagnosis of heavy menstrual bleeding; and			
2 The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and			
3 Any of the following:			
3.1 Serum ferritin level < 16 mcg/l (within the last 12 months); or			
3.2 Haemoglobin level < 120 g/l; or			
3.3 The patient has had a uterine ultrasound and either a hysteroscopy or endometrial biopsy.			
<b>Continuation – heavy menstrual bleeding</b>			
Either:			
1 Patient demonstrated clinical improvement of heavy menstrual bleeding; or			
2 Previous insertion was removed or expelled within 3 months of insertion.			
<b>Initiation – endometriosis</b>			
The patient has a clinical diagnosis of endometriosis confirmed by laparoscopy.			
<b>Continuation – endometriosis</b>			
Either:			
1 Patient demonstrated satisfactory management of endometriosis; or			
2 Previous insertion was removed or expelled within 3 months of insertion.			
Note: endometriosis is an unregistered indication.			
MEDROXYPROGESTERONE ACETATE			
Inj 150 mg per ml, 1 ml syringe – 1% DV Sep-13 to 2016 .....	7.00	1	Depo-Provera
NORETHISTERONE			
Tab 350 mcg			



Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

## Obstetric Preparations

### Antiprogestogens

MIFEPRISTONE

Tab 200 mg

### Oxytocics

CARBOPROST TROMETAMOL

Inj 250 mcg per ml, 1 ml ampoule

DINOPROSTONE

Pessaries 10 mg

Gel 1 mg in 2.5 ml .....52.65

Gel 2 mg in 2.5 ml .....64.60

1

Prostin E2

1

Prostin E2

ERGOMETRINE MALEATE

Inj 500 mcg per ml, 1 ml ampoule – 1% DV Oct-14 to 2017 .....94.70

5

DBL Ergometrine

OXYTOCIN

Inj 5 iu per ml, 1 ml ampoule – 1% DV Feb-14 to 2015 .....4.75

5

Oxytocin BNM

Inj 10 iu per ml, 1 ml ampoule – 1% DV Feb-14 to 2015 .....5.98

5

BNM

OXYTOCIN WITH ERGOMETRINE MALEATE

Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml ampoule – 1%

DV Oct-12 to 2015 .....11.13

5

Syntometrine

### Tocolytics

PROGESTERONE – **Restricted** see terms below

☞ Cap 100 mg .....16.50

30

Utrogestan

☞ **Restricted**

Obstetrician or gynaecologist

Both:

1 For the prevention of pre-term labour\*; and

2 Either:

2.1 The patient has a short cervix on ultrasound (defined as < 25mm at 16 to 28 weeks) or

2.2 The patient has a history of pre-term birth at less than 28 weeks.

Note: Indications marked with \* are Unapproved Indications (refer to Section A: General Rules, Part I (Interpretations and Definitions) and Part IV (Miscellaneous Provisions) rule 23.1).

TERBUTALINE – **Restricted** see terms below

☞ Inj 500 mcg ampoule

☞ **Restricted**

Obstetrician

### Oestrogens

OESTRIOL

Crm 1 mg per g with applicator

Pessaries 500 mcg

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Urologicals</b>			
<b>5-Alpha Reductase Inhibitors</b>			
FINASTERIDE – <b>Restricted</b> see terms below			
♣ Tab 5 mg – 1% DV Dec-14 to 2017 .....	1.95	28	<b>Finpro</b>
➡ <b>Restricted</b>			
Both:			
1 Patient has symptomatic benign prostatic hyperplasia; and			
2 Either:			
2.1 The patient is intolerant of non-selective alpha blockers or these are contraindicated; or			
2.2 Symptoms are not adequately controlled with non-selective alpha blockers.			
<b>Alpha-1A Adrenoceptor Blockers</b>			
TAMSULOSIN – <b>Restricted</b> see terms below			
♣ Cap 400 mcg – 1% DV Dec-13 to 2016 .....	13.51	100	<b>Tamsulosin-Rex</b>
➡ <b>Restricted</b>			
Both:			
1 Patient has symptomatic benign prostatic hyperplasia; and			
2 The patient is intolerant of non-selective alpha blockers or these are contraindicated.			
<b>Urinary Alkalisers</b>			
POTASSIUM CITRATE – <b>Restricted</b> see terms below			
♣ Oral liq 3 mmol per ml .....	30.00	200 ml	<b>Biomed</b>
➡ <b>Restricted</b>			
Both:			
1 The patient has recurrent calcium oxalate urolithiasis; and			
2 The patient has had more than two renal calculi in the two years prior to the application.			
SODIUM CITRO-TARTRATE			
Grans eff 4 g sachets – 1% DV Feb-15 to 2017 .....	2.93	28	<b>Ural</b>
<b>Urinary Antispasmodics</b>			
OXYBUTYNIN			
Tab 5 mg – 1% DV Jun-13 to 2016 .....	11.20	500	<b>Apo-Oxybutynin</b>
Oral liq 5 mg per 5 ml – 1% DV Jun-13 to 2016 .....	56.45	473 ml	<b>Apo-Oxybutynin</b>
SOLIFENACIN SUCCINATE – <b>Restricted</b> see terms below			
♣ Tab 5 mg .....	37.50	30	<b>Vesicare</b>
♣ Tab 10 mg .....	37.50	30	<b>Vesicare</b>
➡ <b>Restricted</b>			
Patient has overactive bladder and a documented intolerance of, or is non-responsive to, oxybutynin.			
TOLTERODINE TARTRATE – <b>Restricted</b> see terms below			
♣ Tab 1 mg .....	14.56	56	<b>Arrow-Tolterodine</b>
♣ Tab 2 mg .....	14.56	56	<b>Arrow-Tolterodine</b>
➡ <b>Restricted</b>			
Patient has overactive bladder and a documented intolerance of, or is non-responsive to, oxybutynin.			

Price (ex man. excl. GST)	Brand or Generic Manufacturer
\$	Per

## Anabolic Agents

### OXANDROLINE

⚡ Tab 2.5 mg

➡ **Restricted**

For the treatment of burns patients.

## Androgen Agonists and Antagonists

### CYPROTERONE ACETATE

Tab 50 mg – 1% DV Oct-12 to 2015 .....	18.80	50	<b>Siterone</b>
Tab 100 mg – 1% DV Oct-12 to 2015 .....	34.25	50	<b>Siterone</b>

### TESTOSTERONE

Patch 2.5 mg per day .....	80.00	60	<b>Androderm</b>
----------------------------	-------	----	------------------

### TESTOSTERONE CYPIONATE

Inj 100 mg per ml, 10 ml vial – 1% DV Sep-14 to 2017 .....	76.50	1	<b>Depo-Testosterone</b>
--	-------	---	--------------------------

### TESTOSTERONE ESTERS

Inj testosterone decanoate 100 mg, testosterone isocarproate 60 mg,  
testosterone phenylpropionate 60 mg and testosterone propionate  
30 mg per ml, 1 ml ampoule

### TESTOSTERONE UNDECANOATE

Cap 40 mg – 1% DV Oct-12 to 2015 .....	31.17	60	<b>Andriol Testocaps</b>
Inj 250 mg per ml, 4 ml vial .....	86.00	1	<b>Reandron 1000</b>

## Calcium Homeostasis

### CALCITONIN

Inj 100 iu per ml, 1 ml ampoule – 1% DV Oct-14 to 2017 .....	121.00	5	<b>Miacalcic</b>
--	--------	---	------------------

### ZOLEDRONIC ACID

⚡ Inj 4 mg per 5 ml, vial ..... 550.00      1      **Zometa**

➡ **Restricted**

Oncologist, haematologist or palliative care specialist

Any of the following:

- 1 Patient has hypercalcaemia of malignancy; or
- 2 Both:
  - 2.1 Patient has bone metastases or involvement; and
  - 2.2 Patient has severe bone pain resistant to standard first-line treatments; or
- 3 Both:
  - 3.1 Patient has bone metastases or involvement; and
  - 3.2 Patient is at risk of skeletal-related events (pathological fracture, spinal cord compression, radiation to bone or surgery to bone).

## Corticosteroids

### BETAMETHASONE

Tab 500 mcg  
Inj 4 mg per ml, 1 ml ampoule

### BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHASONE ACETATE

Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml ampoule

# HORMONE PREPARATIONS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>DEXAMETHASONE</b>			
Tab 1 mg – 1% DV Aug-12 to 2015 .....	5.87	100	<b>Douglas</b>
Tab 4 mg – 1% DV Aug-12 to 2015 .....	8.16	100	<b>Douglas</b>
Oral liq 1 mg per ml .....	45.00	25 ml	Biomed
<b>DEXAMETHASONE PHOSPHATE</b>			
Inj 4 mg per ml, 1 ml ampoule – 1% DV Apr-14 to 2016 .....	25.80	10	<b>Dexamethasone- hameln</b>
Inj 4 mg per ml, 2 ml ampoule – 1% DV Apr-14 to 2016 .....	17.98	5	<b>Dexamethasone- hameln</b>
<b>FLUDROCORTISONE ACETATE</b>			
Tab 100 mcg .....	14.32	100	Florinef
<b>HYDROCORTISONE</b>			
Tab 5 mg – 1% DV Nov-12 to 2015 .....	8.10	100	<b>Douglas</b>
Tab 20 mg – 1% DV Nov-12 to 2015 .....	20.32	100	<b>Douglas</b>
Inj 100 mg vial – 1% DV Oct-13 to 2016 .....	4.99	1	<b>Solu-Cortef</b>
<b>METHYLPREDNISOLONE (AS SODIUM SUCCINATE)</b>			
Tab 4 mg – 1% DV Oct-12 to 2015 .....	60.00	100	<b>Medrol</b>
Tab 100 mg – 1% DV Oct-12 to 2015 .....	166.52	20	<b>Medrol</b>
Inj 40 mg vial – 1% DV Oct-12 to 2015 .....	7.50	1	<b>Solu-Medrol</b>
Inj 125 mg vial – 1% DV Oct-12 to 2015 .....	18.50	1	<b>Solu-Medrol</b>
Inj 500 mg vial – 1% DV Oct-12 to 2015 .....	18.00	1	<b>Solu-Medrol</b>
Inj 1 g vial – 1% DV Oct-12 to 2015 .....	37.50	1	<b>Solu-Medrol</b>
<b>METHYLPREDNISOLONE ACETATE</b>			
Inj 40 mg per ml, 1 ml vial – 1% DV Oct-12 to 2015 .....	33.50	5	<b>Depo-Medrol</b>
<b>METHYLPREDNISOLONE ACETATE WITH LIGNOCAINE</b>			
Inj 40 mg with lignocaine 10 mg per ml, 1 ml vial – 1% DV Oct-12 to 2015 .....	7.50	1	<b>Depo-Medrol with Lidocaine</b>
<b>PREDNISOLONE</b>			
Oral liq 5 mg per ml .....	7.50	30 ml	Redipred
Enema 200 mcg per ml, 100 ml			
<b>PREDNISONE</b>			
Tab 1 mg .....	2.13	100	Apo-Prednisone S29
	10.68	500	Apo-Prednisone
Tab 2.5 mg .....	12.09	500	Apo-Prednisone
Tab 5 mg .....	11.09	500	Apo-Prednisone
Tab 20 mg .....	29.03	500	Apo-Prednisone
<b>TRIAMCINOLONE ACETONIDE</b>			
Inj 10 mg per ml, 1 ml ampoule – 1% DV Apr-15 to 2017 .....	20.80	5	<b>Kenacort-A 10</b>
Inj 40 mg per ml, 1 ml ampoule – 1% DV Apr-15 to 2017 .....	51.70	5	<b>Kenacort-A 40</b>
<b>TRIAMCINOLONE HEXACETONIDE</b>			
Inj 20 mg per ml, 1 ml vial			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Hormone Replacement Therapy

Oestrogens

- OESTRADIOL
  - Tab 1 mg
  - Tab 2 mg
  - Patch 25 mcg per day
  - Patch 50 mcg per day
  - Patch 100 mcg per day

- OESTRADIOL VALERATE
  - Tab 1 mg
  - Tab 2 mg

- OESTROGENS (CONJUGATED EQUINE)
  - Tab 300 mcg
  - Tab 625 mcg

Progestogen and Oestrogen Combined Preparations

- OESTRADIOL WITH NORETHISTERONE ACETATE
  - Tab 1 mg with 0.5 mg norethisterone acetate
  - Tab 2 mg with 1 mg norethisterone acetate
  - Tab 2 mg with 1 mg norethisterone acetate (10), and tab 2 mg oestra-  
diol (12) and tab 1 mg oestradiol (6)

- OESTROGENS WITH MEDROXYPROGESTERONE ACETATE
  - Tab 625 mcg conjugated equine with 2.5 mg medroxyprogesterone  
acetate
  - Tab 625 mcg conjugated equine with 5 mg medroxyprogesterone ac-  
etate

Progestogens

MEDROXYPROGESTERONE ACETATE			
Tab 2.5 mg – 1% DV Sep-13 to 2016	3.09	30	Provera
Tab 5 mg – 1% DV Sep-13 to 2016	13.06	100	Provera
Tab 10 mg – 1% DV Sep-13 to 2016	6.85	30	Provera

Other Endocrine Agents

CABERGOLINE – <b>Restricted</b> see terms below			
⚡ Tab 0.5 mg – 1% DV Sep-12 to 2015	6.25	2	Dostinex
	25.00	8	Dostinex

➡Restricted

- Any of the following:
- 1 Inhibition of lactation; or
  - 2 Patient has pathological hyperprolactinemia; or
  - 3 Patient has acromegaly.

CLOMIPHENE CITRATE			
Tab 50 mg – 1% DV Sep-13 to 2016	29.84	10	Serophene

## HORMONE PREPARATIONS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
DANAZOL			
Cap 100 mg .....	68.33	100	Azol
Cap 200 mg .....	97.83	100	Azol
GESTRINONE			
Cap 2.5 mg			
METYRAPONE			
Cap 250 mg			
PENTAGASTRIN			
Inj 250 mcg per ml, 2 ml ampoule			

### Other Oestrogen Preparations

ETHINYLOESTRADIOL
Tab 10 mcg
OESTRADIOL
Implant 50 mg
OESTRIOL
Tab 2 mg

### Other Progestogen Preparations

MEDROXYPROGESTERONE			
Tab 100 mg – 1% DV Sep-13 to 2016 .....	96.50	100	Provera
NORETHISTERONE			
Tab 5 mg .....	26.50	100	Primolut N

### Pituitary and Hypothalamic Hormones and Analogues

CORTICOTRORELIN (OVINE)
Inj 100 mcg vial
THYROTROPIN ALFA
Inj 900 mcg vial

### Adrenocorticotrophic Hormones

TETRACOSACTIDE [TETRACOSACTRIN]			
Inj 250 mcg per ml, 1 ml ampoule .....	177.18	10	Synacthen
Inj 1 mg per ml, 1 ml ampoule .....	29.56	1	Synacthen Depot

### GnRH Agonists and Antagonists

BUSERELIN			
Inj 1 mg per ml, 5.5 ml vial			
GONADORELIN			
Inj 100 mcg vial			
GOSERELIN			
Implant 3.6 mg .....	166.20	1	Zoladex
Implant 10.8 mg .....	443.76	1	Zoladex

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>LEUPRORELIN ACETATE</b>			
Inj 3.75 mg syringe .....	221.60	1	Lucrin Depot PDS
Inj 7.5 mg syringe .....	166.20	1	Eligard
Inj 11.25 mg syringe .....	591.68	1	Lucrin Depot PDS
Inj 22.5 mg syringe .....	443.76	1	Eligard
Inj 30 mg syringe .....	1,109.40	1	Lucrin Depot PDS
Inj 30 mg vial .....	591.68	1	Eligard
Inj 45 mg syringe .....	832.05	1	Eligard

## Gonadotrophins

### CHORIOGONADOTROPIN ALFA

Inj 250 mcg in 0.5 ml syringe

## Growth Hormone

**SOMATROPIN – Restricted** see terms below

⚡ Inj 5 mg cartridge – 1% DV Jan-15 to 31 Dec 2017 .....	109.50	1	<b>Omnitrope</b>
⚡ Inj 10 mg cartridge – 1% DV Jan-15 to 31 Dec 2017 .....	219.00	1	<b>Omnitrope</b>
⚡ Inj 15 mg cartridge – 1% DV Jan-15 to 31 Dec 2017 .....	328.50	1	<b>Omnitrope</b>

### ➡ Restricted

#### Initiation - growth hormone deficiency in children

Endocrinologist

Paediatric Endocrinologist

Either:

- Growth hormone deficiency causing symptomatic hypoglycaemia, or with other significant growth hormone deficient sequelae (e.g. cardiomyopathy, hepatic dysfunction) and diagnosed with GH < 5 mcg/l on at least two random blood samples in the first 2 weeks of life, or from samples during established hypoglycaemia (whole blood glucose < 2 mmol/l using a laboratory device); or
- All of the following:
  - Height velocity < 25th percentile for age; and adjusted for bone age/pubertal status if appropriate over 6 or 12 months using the standards of Tanner and Davies (1985); and
  - A current bone age is < 14 years (female patients) or < 16 years (male patients); and
  - Peak growth hormone value of < 5.0 mcg per litre in response to two different growth hormone stimulation tests. In children who are 5 years or older, GH testing with sex steroid priming is required; and
  - If the patient has been treated for a malignancy, they should be disease free for at least one year based upon follow-up laboratory and radiological imaging appropriate for the malignancy, unless there are strong medical reasons why this is either not necessary or appropriate; and
  - Appropriate imaging of the pituitary gland has been obtained.

#### Continuation - growth hormone deficiency in children

Endocrinologist

Paediatric Endocrinologist

*Re-assessment required after 12 months*

All of the following:

- A current bone age is ≤ 14 years (female patients) or ≤ 16 years (male patients); and
- Height velocity is ≥ 25th percentile for age (adjusted for bone age/pubertal status if appropriate) while on growth hormone treatment, as calculated over six months using the standards of Tanner and Davis (1985); and
- Height velocity is ≥ 2.0 cm per year, as calculated over 6 months; and
- No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- No malignancy has developed since starting growth hormone.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

## Initiation - Turner syndrome

Endocrinologist

Paediatric Endocrinologist

All of the following:

- 1 The patient has a post-natal genotype confirming Turner Syndrome; and
- 2 Height velocity is < 25th percentile over 6-12 months using the standards of Tanner and Davies (1985); and
- 3 A current bone age is < 14 years.

## Continuation - Turner syndrome

Endocrinologist

Paediatric Endocrinologist

*Re-assessment required after 12 months*

All of the following:

- 1 Height velocity  $\geq$  50th percentile for age (while on growth hormone calculated over 6 to 12 months using the Ranke's Turner Syndrome growth velocity charts); and
- 2 Height velocity is  $\geq$  2 cm per year, calculated over six months; and
- 3 A current bone age is  $\leq$  14 years; and
- 4 No serious adverse effect that the specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed since starting growth hormone.

## Initiation - short stature without growth hormone deficiency

Endocrinologist

Paediatric Endocrinologist

All of the following:

- 1 The patient's height is more than 3 standard deviations below the mean for age or for bone age if there is marked growth acceleration or delay; and
- 2 Height velocity is < 25th percentile for age (adjusted for bone age/pubertal status if appropriate), as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 3 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
- 4 The patient does not have severe chronic disease (including malignancy or recognized severe skeletal dysplasia) and is not receiving medications known to impair height velocity.

## Continuation - short stature without growth hormone deficiency

Endocrinologist

Paediatric Endocrinologist

*Re-assessment required after 12 months*

All of the following:

- 1 Height velocity is  $\geq$  50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is  $\geq$  2 cm per year as calculated over six months; and
- 3 Current bone age is  $\leq$  14 years (female patients) or  $\leq$  16 years (male patients); and
- 4 No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone treatment has occurred.

## Initiation - short stature due to chronic renal insufficiency

Endocrinologist

Paediatric Endocrinologist

Renal Physician on the recommendation of a Paediatric Endocrinologist or Endocrinologist

All of the following:

- 1 The patient's height is more than 2 standard deviations below the mean; and

continued...



Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

continued...

- 2 Height velocity is < 25th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 3 A current bone age is  $\leq$  to 14 years (female patients) or  $\leq$  to 16 years (male patients); and
- 4 The patient is metabolically stable, has no evidence of metabolic bone disease and absence of any other severe chronic disease; and
- 5 The patient is under the supervision of a specialist with expertise in renal medicine; and
- 6 Either:
  - 6.1 The patient has a  $\text{GFR} \leq 30 \text{ ml/min/1.73 m}^2$  as measured by the Schwartz method ( $\text{Height(cm)/plasma creatinine (umol/l)} \times 40 = \text{corrected GFR (ml/min/1.73 m}^2)$ ) in a child who may or may not be receiving dialysis; or
  - 6.2 The patient has received a renal transplant and has received < 5mg/  $\text{m}^2$  /day of prednisone or equivalent for at least 6 months.

#### Continuation - short stature due to chronic renal insufficiency

Endocrinologist

Paediatric Endocrinologist

Renal Physician on the recommendation of a Paediatric Endocrinologist or Endocrinologist

*Re-assessment required after 12 months*

All of the following:

- 1 Height velocity is  $\geq$  50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is  $\geq$  2 cm per year as calculated over six months; and
- 3 A current bone age is  $\leq$  14 years (female patients) or  $\leq$  16 years (male patients); and
- 4 No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone has occurred; and
- 5 No malignancy has developed after growth hormone therapy was commenced; and
- 6 The patient has not experienced significant biochemical or metabolic deterioration confirmed by diagnostic results; and
- 7 The patient has not received renal transplantation since starting growth hormone treatment; and
- 8 If the patient requires transplantation, growth hormone prescription should cease before transplantation and a new application should be made after transplantation based on the above criteria.

#### Initiation - Prader-Willi syndrome

Endocrinologist

Paediatric Endocrinologist

All of the following:

- 1 The patient has a diagnosis of Prader-Willi syndrome that has been confirmed by genetic testing or clinical scoring criteria; and
- 2 The patient's height velocity is < 25th percentile for bone age adjusted for bone age/pubertal status if appropriate as calculated over 6 to 12 months using the standards of Tanner and Davies (1985) or pubertal status over 6 to 12 months; and
- 3 Either:
  - 3.1 The patient is under two years of age and height velocity has been assessed over a minimum six month period from the age of 12 months, with at least three supine length measurements over this period demonstrating clear and consistent evidence of linear growth failure (with height velocity < 25th percentile); or
  - 3.2 The patient is aged two years or older; and
- 4 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
- 5 Sleep studies or overnight oximetry have been performed and there is no obstructive sleep disorder requiring treatment, or if an obstructive sleep disorder is found, it has been adequately treated under the care of a paediatric respiratory physician and/or ENT surgeon; and
- 6 There is no evidence of type II diabetes or uncontrolled obesity defined by BMI that has increased by  $\geq 0.5$  standard deviations in the preceding 12 months.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

## Continuation - Prader-Willi syndrome

Endocrinologist

Paediatric Endocrinologist

*Re-assessment required after 12 months*

All of the following:

- 1 Height velocity is  $\geq$  50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is  $\geq$  2 cm per year as calculated over six months; and
- 3 A current bone age is  $\leq$  14 years (female patients) or  $\leq$  16 years (male patients); and
- 4 No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed after growth hormone therapy was commenced; and
- 6 The patient has not developed type II diabetes or uncontrolled obesity as defined by BMI that has increased by  $\geq$  0.5 standard deviations in the preceding 12 months.

## Initiation - adults and adolescents

Endocrinologist

Paediatric Endocrinologist

All of the following:

- 1 The patient has a medical condition that is known to cause growth hormone deficiency (e.g. surgical removal of the pituitary for treatment of a pituitary tumour); and
- 2 The patient has undergone appropriate treatment of other hormonal deficiencies and psychological illnesses; and
- 3 The patient has severe growth hormone deficiency (see notes); and
- 4 The patient's serum IGF-I is more than 1 standard deviation below the mean for age and sex; and
- 5 The patient has poor quality of life, as defined by a score of 16 or more using the disease-specific quality of life questionnaire for adult growth hormone deficiency (QoL-AGHDA<sup>®</sup>).

### Notes:

For the purposes of adults and adolescents, severe growth hormone deficiency is defined as a peak serum growth hormone level of  $\leq$  3 mcg per litre during an adequately performed insulin tolerance test (ITT) or glucagon stimulation test.

Patients with one or more additional anterior pituitary hormone deficiencies and a known structural pituitary lesion only require one test. Patients with isolated growth hormone deficiency require two growth hormone stimulation tests, of which, one should be ITT unless otherwise contraindicated. Where an additional test is required, an arginine provocation test can be used with a peak serum growth hormone level of  $\leq$  0.4 mcg per litre.

The dose of somatropin should be started at 0.2 mg daily and be titrated by 0.1 mg monthly until it is within 1 standard deviation of the mean normal value for age and sex; and

The dose of somatropin not to exceed 0.7 mg per day for male patients, or 1 mg per day for female patients.

At the commencement of treatment for hypopituitarism, patients must be monitored for any required adjustment in replacement doses of corticosteroid and levothyroxine.

## Continuation - adults and adolescents

Endocrinologist

Paediatric Endocrinologist

*Re-assessment required after 12 months*

Either:

- 1 All of the following:
  - 1.1 The patient has been treated with somatropin for < 12 months; and
  - 1.2 There has been an improvement in the Quality of Life Assessment defined as a reduction of at least 8 points on the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA<sup>®</sup>) score from baseline; and
  - 1.3 Serum IGF-I levels have increased to within  $\pm$ 1SD of the mean of the normal range for age and sex; and
  - 1.4 The dose of somatropin does not exceed 0.7 mg per day for male patients, or 1 mg per day for female patients; or

continued...

Price (ex man. excl. GST)	Brand or Generic Manufacturer
\$	Per

continued...

2 All of the following:

- 2.1 The patient has been treated with somatropin for more than 12 months; and
- 2.2 The patient has not had a deterioration in Quality of Life defined as a 6 point or greater increase from their lowest QoL-AGHDA<sup>®</sup> score on treatment (other than due to obvious external factors such as external stressors); and
- 2.3 Serum IGF-I levels have continued to be maintained within  $\pm 1SD$  of the mean of the normal range for age and sex (other than for obvious external factors); and
- 2.4 The dose of somatropin has not exceeded 0.7 mg per day for male patients or 1 mg per day for female patients.

## Thyroid and Antithyroid Preparations

### CARBIMAZOLE

Tab 5 mg

### IODINE

Soln BP 50 mg per ml

### LEVOTHYROXINE

Tab 25 mcg

Tab 50 mcg

Tab 100 mcg

### LIOTHYRONINE SODIUM

☯ Tab 20 mcg

#### ☛ Restricted

For a maximum of 14 days' treatment in patients with thyroid cancer who are due to receive radioiodine therapy

Inj 20 mcg vial

### POTASSIUM IODATE

Tab 170 mg

### POTASSIUM PERCHLORATE

Cap 200 mg

### PROPYLTHIOURACIL – **Restricted** see terms below

☯ Tab 50 mg .....	35.00	100	PTU
-------------------	-------	-----	-----

#### ☛ Restricted

Both:

- 1 The patient has hyperthyroidism; and
- 2 The patient is intolerant of carbimazole or carbimazole is contraindicated.

Note: Propylthiouracil is not recommended for patients under the age of 18 years unless the patient is pregnant and other treatments are contraindicated.

### PROTIRELIN

Inj 100 mcg per ml, 2 ml ampoule

## Vasopressin Agents

### ARGIPRESSIN [VASOPRESSIN]

Inj 20 u per ml, 1 ml ampoule

### DESMOPRESSIN ACETATE – **Some items restricted** see terms on the next page

☯ Tab 100 mcg .....	36.40	30	Minirin
☯ Tab 200 mcg .....	93.60	30	Minirin
Nasal spray 10 mcg per dose – 1% DV Sep-14 to 2017 .....	22.95	6 ml	<b>Desmopressin-PH&amp;T</b>
Inj 4 mcg per ml, 1 ml ampoule			
Inj 15 mcg per ml, 1 ml ampoule			
Nasal drops 100 mcg per ml			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>➡Restricted</b>			
<b>Nocturnal enuresis</b>			
Either:			
1 The nasal forms of desmopressin are contraindicated; or			
2 An enuresis alarm is contraindicated.			
Cranial diabetes insipidus and the nasal forms of desmopressin are contraindicated			
<b>TERLIPRESSIN</b>			
Inj 0.1 mg per ml, 8.5 ml ampoule .....	450.00	5	Glypressin
Inj 1 mg per 8.5 ml ampoule .....	450.00	5	Glypressin

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Antibacterials</b>			
<b>Aminoglycosides</b>			
AMIKACIN – <b>Restricted</b> see terms below			
⌚ Inj 5 mg per ml, 10 ml syringe			
⌚ Inj 5 mg per ml, 5 ml syringe .....	176.00	10	Biomed
⌚ Inj 15 mg per ml, 5 ml syringe			
⌚ Inj 250 mg per ml, 2 ml vial – 1% DV Oct-14 to 2017 .....	431.20	5	<b>DBL Amikacin</b>
➔ <b>Restricted</b>			
Infectious disease physician, clinical microbiologist or respiratory physician			
GENTAMICIN SULPHATE			
Inj 10 mg per ml, 1 ml ampoule .....	8.56	5	Hospira
Inj 10 mg per ml, 2 ml ampoule .....	175.10	25	APP Pharmaceuticals
Inj 40 mg per ml, 2 ml ampoule – 1% DV Sep-12 to 2015 .....	6.50	10	<b>Pfizer</b>
PAROMOMYCIN – <b>Restricted</b> see terms below			
⌚ Cap 250 mg .....	126.00	16	Humatin
➔ <b>Restricted</b>			
Infectious disease physician or clinical microbiologist			
STREPTOMYCIN SULPHATE – <b>Restricted</b> see terms below			
⌚ Inj 400 mg per ml, 2.5 ml ampoule			
➔ <b>Restricted</b>			
Infectious disease physician, clinical microbiologist or respiratory physician			
TOBRAMYCIN			
⌚ Inj 40 mg per ml, 2 ml vial .....	29.32	5	DBL Tobramycin
➔ <b>Restricted</b>			
Infectious disease physician, clinical microbiologist or respiratory physician			
⌚ Inj 100 mg per ml, 5 ml vial			
➔ <b>Restricted</b>			
Infectious disease physician, clinical microbiologist or respiratory physician			
⌚ Solution for inhalation 60 mg per ml, 5 ml .....	2,200.00	56 dose	TOBI
➔ <b>Restricted</b>			
Patient has cystic fibrosis			
<b>Carbapenems</b>			
ERTAPENEM – <b>Restricted</b> see terms below			
⌚ Inj 1 g vial .....	70.00	1	Invanz
➔ <b>Restricted</b>			
Infectious disease physician or clinical microbiologist			
IMIPENEM WITH CILASTATIN – <b>Restricted</b> see terms below			
⌚ Inj 500 mg with 500 mg cilastatin vial .....	18.37	1	Primaxin
➔ <b>Restricted</b>			
Infectious disease physician or clinical microbiologist			
MEROPENEM – <b>Restricted</b> see terms below			
⌚ Inj 500 mg vial – 1% DV Oct-14 to 2017.....	35.22	10	<b>DBL Meropenem</b>
⌚ Inj 1 g vial – 1% DV Oct-14 to 2017.....	65.21	10	<b>DBL Meropenem</b>
➔ <b>Restricted</b>			
Infectious disease physician or clinical microbiologist			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Cephalosporins and Cephamycins - 1st Generation</b>			
<b>CEFALEXIN</b>			
Cap 500 mg – 1% DV Oct-13 to 2016 .....	5.70	20	<b>Cephalexin ABM</b>
Grans for oral liq 25 mg per ml – 1% DV Oct-13 to 2016 .....	8.50	100 ml	<b>Cefalexin Sandoz</b>
Grans for oral liq 50 mg per ml – 1% DV Oct-13 to 2016 .....	11.50	100 ml	<b>Cefalexin Sandoz</b>
<b>CEFAZOLIN</b>			
Inj 500 mg vial – 1% DV Sep-14 to 2017 .....	3.99	5	<b>AFT</b>
Inj 1 g vial – 1% DV Sep-14 to 2017 .....	3.38	5	<b>AFT</b>
<b>Cephalosporins and Cephamycins - 2nd Generation</b>			
<b>CEFACLOR</b>			
Cap 250 mg – 1% DV Dec-13 to 2016 .....	26.00	100	<b>Ranbaxy-Cefaclor</b>
Grans for oral liq 25 mg per ml – 1% DV Dec-13 to 2016 .....	3.53	100 ml	<b>Ranbaxy-Cefaclor</b>
<b>CEFOXITIN</b>			
Inj 1 g vial .....	74.25	5	<b>Hospira</b>
<b>CEFUROXIME</b>			
Tab 250 mg .....	29.40	50	<b>Zinnat</b>
Inj 750 mg vial – 1% DV Nov-14 to 2017 .....	3.70	5	<b>Zinacef</b>
Inj 1.5 g vial – 1% DV Nov-14 to 2017 .....	1.30	1	<b>Zinacef</b>
<b>Cephalosporins and Cephamycins - 3rd Generation</b>			
<b>CEFOTAXIME</b>			
Inj 500 mg vial .....	1.90	1	<b>Cefotaxime Sandoz</b>
Inj 1 g vial – 1% DV Oct-14 to 2017 .....	17.10	10	<b>DBL Cefotaxime</b>
<b>CEFTAZIDIME – Restricted</b> see terms below			
⚡ Inj 500 mg vial – 1% DV Jan-15 to 2017 .....	5.30	1	<b>Fortum</b>
⚡ Inj 1 g vial – 1% DV Jan-15 to 2017 .....	1.55	1	<b>Fortum</b>
⚡ Inj 2 g vial – 1% DV Jan-15 to 2017 .....	3.34	1	<b>Fortum</b>
<b>➡Restricted</b>			
Infectious disease physician, clinical microbiologist or respiratory physician			
<b>CEFTRIAXONE</b>			
Inj 500 mg vial – 1% DV Mar-14 to 2016 .....	1.50	1	<b>Ceftriaxone-AFT</b>
Inj 1 g vial – 1% DV Mar-14 to 2016 .....	5.22	5	<b>Ceftriaxone-AFT</b>
Inj 2 g vial – 1% DV Mar-14 to 2016 .....	2.75	1	<b>Ceftriaxone-AFT</b>
<b>Cephalosporins and Cephamycins - 4th Generation</b>			
<b>CEFEPIME – Restricted</b> see terms below			
⚡ Inj 1 g vial .....	8.80	1	<b>DBL Cefepime</b>
⚡ Inj 2 g vial .....	17.60	1	<b>DBL Cefepime</b>
<b>➡Restricted</b>			
Infectious disease physician or clinical microbiologist			
<b>Cephalosporins and Cephamycins - 5th Generation</b>			
<b>CEFTAROLINE FOSAMIL – Restricted</b> see terms on the next page			
⚡ Inj 600 mg vial .....	1,450.00	10	<b>Zinforo</b>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>➔Restricted</b>			
Infectious disease physician or clinical microbiologist			
<b>Multi-resistant organism salvage therapy</b>			
Either:			
1 for patients where alternative therapies have failed; or			
2 for patients who have a contraindication or hypersensitivity to standard current therapies.			
<b>Macrolides</b>			
AZITHROMYCIN – <b>Restricted</b> see terms below			
⚡ Tab 250 mg .....	10.00	30	Apo-Azithromycin
⚡ Tab 500 mg – <b>1% DV Feb-13 to 2015</b> .....	1.25	2	<b>Apo-Azithromycin</b>
⚡ Oral liq 40 mg per ml .....	6.60	15 ml	Zithromax
<b>➔Restricted</b>			
Any of the following:			
1 Patient has received a lung transplant and requires treatment or prophylaxis for bronchiolitis obliterans syndrome; or			
2 Patient has cystic fibrosis and has chronic infection with Pseudomonas aeruginosa or Pseudomonas related gram negative organisms; or			
3 For any other condition for five days' treatment, with review after five days.			
CLARITHROMYCIN – <b>Restricted</b> see terms below			
⚡ Tab 250 mg – <b>1% DV Sep-14 to 2017</b> .....	3.98	14	<b>Apo-Clarithromycin</b>
⚡ Tab 500 mg – <b>1% DV Sep-14 to 2017</b> .....	10.40	14	<b>Apo-Clarithromycin</b>
⚡ Grans for oral liq 25 mg per ml .....	23.12	70 ml	Klacid
⚡ Inj 500 mg vial – <b>1% DV Mar-15 to 2017</b> .....	20.40	1	<b>Martindale</b>
<b>➔Restricted</b>			
<b>Tab 250 mg and oral liquid</b>			
Tab 250 mg and oral liquid			
1 Atypical mycobacterial infection; or			
2 Mycobacterium tuberculosis infection where there is drug resistance or intolerance to standard pharmaceutical agents.			
<b>Tab 500 mg</b>			
Helicobacter pylori eradication.			
<b>Infusion</b>			
Infusion			
1 Atypical mycobacterial infection; or			
2 Mycobacterium tuberculosis infection where there is drug resistance or intolerance to standard pharmaceutical agents; or			
3 Community-acquired pneumonia (clarithromycin is not to be used as the first-line macrolide).			
ERYTHROMYCIN (AS ETHYLSUCCINATE)			
Tab 400 mg .....	16.95	100	E-Mycin
Grans for oral liq 200 mg per 5 ml .....	5.00	100 ml	E-Mycin
Grans for oral liq 400 mg per 5 ml .....	6.77	100 ml	E-Mycin
ERYTHROMYCIN (AS LACTOBIONATE)			
Inj 1 g vial .....	16.00	1	Erythrocin IV
ERYTHROMYCIN (AS STEARATE) – <b>Restricted</b> : For continuation only			
➔ Tab 250 mg			
➔ Tab 500 mg			
ROXITHROMYCIN			
Tab 150 mg – <b>1% DV Sep-12 to 2015</b> .....	7.48	50	<b>Arrow-Roxithromycin</b>
Tab 300 mg – <b>1% DV Sep-12 to 2015</b> .....	14.40	50	<b>Arrow-Roxithromycin</b>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Penicillins</b>			
<b>AMOXICILLIN</b>			
Cap 250 mg – 1% DV Mar-14 to 2016 .....	16.18	500	<b>Apo-Amoxi</b>
Cap 500 mg – 1% DV Jul-14 to 2016 .....	20.94	500	<b>Apo-Amoxi</b>
Grans for oral liq 125 mg per 5 ml .....	0.88	100 ml	<b>Amoxicillin Actavis</b>
Grans for oral liq 250 mg per 5 ml .....	0.97	100 ml	<b>Amoxicillin Actavis</b>
Inj 250 mg vial – 1% DV Oct-14 to 2017 .....	10.67	10	<b>Ibiamox</b>
Inj 500 mg vial – 1% DV Oct-14 to 2017 .....	12.41	10	<b>Ibiamox</b>
Inj 1 g vial – 1% DV Oct-14 to 2017 .....	17.29	10	<b>Ibiamox</b>
<b>AMOXICILLIN WITH CLAVULANIC ACID</b>			
Tab 500 mg with clavulanic acid 125 mg .....	1.95	20	<b>Augmentin</b>
	9.75	100	<b>Curam Duo</b>
Grans for oral liq 25 mg with clavulanic acid 6.25 mg per ml – 1% DV Nov-12 to 2015 .....	1.61	100 ml	<b>Augmentin</b>
Grans for oral liq 50 mg with clavulanic acid 12.5 mg per ml – 1% DV Nov-12 to 2015 .....	2.19	100 ml	<b>Augmentin</b>
Inj 500 mg with clavulanic acid 100 mg vial – 1% DV Jan-13 to 2015 .....	10.14	10	<b>m-Amoxiclav</b>
Inj 1,000 mg with clavulanic acid 200 mg vial – 1% DV Jan-13 to 2015 .....	14.03	10	<b>m-Amoxiclav</b>
<b>BENZATHINE BENZYL PENICILLIN</b>			
Inj 900 mg (1.2 million units) in 2.3 ml syringe – 1% DV Sep-12 to 2015 .....	315.00	10	<b>Bicillin LA</b>
<b>BENZYL PENICILLIN SODIUM [PENICILLIN G]</b>			
Inj 600 mg (1 million units) vial – 1% DV Sep-14 to 2017 .....	10.35	10	<b>Sandoz</b>
<b>FLUCLOXACILLIN</b>			
Cap 250 mg – 1% DV Oct-12 to 2015 .....	22.00	250	<b>Staphlex</b>
Cap 500 mg – 1% DV Oct-12 to 2015 .....	74.00	500	<b>Staphlex</b>
Grans for oral liq 25 mg per ml – 1% DV Sep-12 to 2015 .....	2.49	100 ml	<b>AFT</b>
Grans for oral liq 50 mg per ml – 1% DV Sep-12 to 2015 .....	3.25	100 ml	<b>AFT</b>
Inj 250 mg vial – 1% DV Sep-14 to 2017 .....	8.80	10	<b>Flucloxin</b>
Inj 500 mg vial – 1% DV Sep-14 to 2017 .....	9.20	10	<b>Flucloxin</b>
Inj 1 g vial – 1% DV Sep-14 to 2017 .....	11.60	10	<b>Flucloxin</b>
<b>PHENOXYMETHYL PENICILLIN [PENICILLIN V]</b>			
Cap 250 mg .....	11.99	50	<b>Cilicaine VK</b>
Cap 500 mg .....	14.45	50	<b>Cilicaine VK</b>
Grans for oral liq 125 mg per 5 ml – 1% DV Apr-14 to 2016 .....	1.64	100 ml	<b>AFT</b>
Grans for oral liq 250 mg per 5 ml – 1% DV Apr-14 to 2016 .....	1.74	100 ml	<b>AFT</b>
<b>PIPERACILLIN WITH TAZOBACTAM – Restricted see terms below</b>			
⚡ Inj 4 g with tazobactam 0.5 g vial – 1% DV Oct-13 to 2016 .....	5.84	1	<b>Tazocin EF</b>
<b>➡ Restricted</b>			
Infectious disease physician, clinical microbiologist or respiratory physician			
<b>PROCAINE PENICILLIN</b>			
Inj 1.5 g in 3.4 ml syringe – 1% DV Sep-14 to 2017 .....	123.50	5	<b>Cilicaine</b>
<b>TICARCILLIN WITH CLAVULANIC ACID – Restricted see terms below</b>			
⚡ Inj 3 g with clavulanic acid 0.1 mg vial			
<b>➡ Restricted</b>			
Infectious disease physician, clinical microbiologist or respiratory physician			



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Quinolones</b>			
CIPROFLOXACIN – <b>Restricted</b> see terms below			
☞ Tab 250 mg – 1% DV Sep-14 to 2017 .....	1.75	28	<b>Cipflox</b>
☞ Tab 500 mg – 1% DV Sep-14 to 2017 .....	2.00	28	<b>Cipflox</b>
☞ Tab 750 mg – 1% DV Sep-14 to 2017 .....	3.75	28	<b>Cipflox</b>
☞ Oral liq 50 mg per ml			
☞ Oral liq 100 mg per ml			
☞ Inj 2 mg per ml, 100 ml bag .....	41.00	10	Aspen Ciprofloxacin
➔ <b>Restricted</b>			
Infectious disease physician or clinical microbiologist			
MOXIFLOXACIN – <b>Restricted</b> see terms below			
☞ Tab 400 mg .....	52.00	5	Avelox
☞ Inj 1.6 mg per ml, 250 ml bag .....	70.00	1	Avelox IV 400
➔ <b>Restricted</b>			
<b>Mycobacterium infection</b>			
Infectious disease physician, clinical microbiologist or respiratory physician			
Either:			
1 Active tuberculosis, with any of the following:			
1.1 Documented resistance to one or more first-line medications; or			
1.2 Suspected resistance to one or more first-line medications (tuberculosis assumed to be contracted in an area with known resistance), as part of regimen containing other second-line agents; or			
1.3 Impaired visual acuity (considered to preclude ethambutol use); or			
1.4 Significant pre-existing liver disease or hepatotoxicity from tuberculosis medications; or			
1.5 Significant documented intolerance and/or side effects following a reasonable trial of first-line medications; or			
2 Mycobacterium avium-intracellulare complex not responding to other therapy or where such therapy is contraindicated			
<b>Pneumonia</b>			
Infectious disease physician or clinical microbiologist			
1 Immunocompromised patient with pneumonia that is unresponsive to first-line treatment; or			
2 Pneumococcal pneumonia or other invasive pneumococcal disease highly resistant to other antibiotics.			
<b>Penetrating eye injury</b>			
Ophthalmologist			
Five days treatment for patients requiring prophylaxis following a penetrating eye injury			
<b>Mycoplasma genitalium</b>			
All of the following:			
1 Has nucleic acid amplification test (NAAT) confirmed Mycoplasma genitalium; and			
2 Has tried and failed to clear infection using azithromycin; and			
3 Treatment is only for 7 days.			
NORFLOXACIN			
Tab 400 mg – 1% DV Sep-14 to 2017 .....	13.50	100	<b>Arrow-Norfloxacin</b>
<b>Tetracyclines</b>			
DEMECLOXYCLINE HYDROCHLORIDE			
Cap 150 mg			
DOXYCYCLINE			
➔ Tab 50 mg – <b>Restricted</b> : For continuation only			
Tab 100 mg – 1% DV Sep-14 to 2017 .....	6.75	250	<b>Doxine</b>
Inj 5 mg per ml, 20 ml vial			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
MINOCYCLINE Tab 50 mg ➔ Cap 100 mg – <b>Restricted</b> : For continuation only			
TETRACYCLINE Tab 250 mg Cap 500 mg .....	46.00	30	Tetracyclin Wolff
TIGECYCLINE – <b>Restricted</b> see terms below ⚡ Inj 50 mg vial ➔ <b>Restricted</b> Infectious disease physician or clinical microbiologist			
<b>Other Antibacterials</b>			
AZTREONAM – <b>Restricted</b> see terms below ⚡ Inj 1 g vial .....	131.00	5	Azactam
➔ <b>Restricted</b> Infectious disease physician or clinical microbiologist			
CHLORAMPHENICOL – <b>Restricted</b> see terms below ⚡ Inj 1 g vial ➔ <b>Restricted</b> Infectious disease physician or clinical microbiologist			
CLINDAMYCIN – <b>Restricted</b> see terms below ⚡ Cap 150 mg – <b>1% DV Oct-13 to 2016</b> .....	5.80	16	Clindamycin ABM
⚡ Oral liq 15 mg per ml ⚡ Inj 150 mg per ml, 4 ml ampoule – <b>1% DV Sep-13 to 2016</b> .....	100.00	10	Dalacin C
➔ <b>Restricted</b> Infectious disease physician or clinical microbiologist			
COLISTIN SULPHOMETHATE [COLESTIMETHATE] – <b>Restricted</b> see terms below ⚡ Inj 150 mg per ml, 1 ml vial .....	65.00	1	Colistin-Link
➔ <b>Restricted</b> Infectious disease physician, clinical microbiologist or respiratory physician			
DAPTOMYCIN – <b>Restricted</b> see terms below ⚡ Inj 350 mg vial ⚡ Inj 500 mg vial ➔ <b>Restricted</b> Infectious disease physician or clinical microbiologist			
FOSFOMYCIN – <b>Restricted</b> see terms below ⚡ Powder for oral solution, 3 g sachet ➔ <b>Restricted</b> Infectious disease physician or clinical microbiologist			
FUSIDIC ACID – <b>Restricted</b> see terms below ⚡ Tab 250 mg .....	34.50	12	Fucidin
➔ <b>Restricted</b> Infectious disease physician or clinical microbiologist			
HEXAMINE HIPPURATE Tab 1 g			
LINCOMYCIN – <b>Restricted</b> see terms on the next page ⚡ Inj 300 mg per ml, 2 ml vial			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>➔Restricted</b>			
Infectious disease physician or clinical microbiologist			
LINEZOLID – <b>Restricted</b> see terms below			
☯ Tab 600 mg			
☯ Oral liq 20 mg per ml			
☯ Inj 2 mg per ml, 300 ml bag			
<b>➔Restricted</b>			
Infectious disease physician or clinical microbiologist			
NITROFURANTOIN			
Tab 50 mg			
Tab 100 mg			
PIVMECILLINAM – <b>Restricted</b> see terms below			
☯ Tab 200 mg			
<b>➔Restricted</b>			
Infectious disease physician or clinical microbiologist			
SULPHADIAZINE – <b>Restricted</b> see terms below			
☯ Tab 500 mg			
<b>➔Restricted</b>			
Infectious disease physician, clinical microbiologist or maternal-foetal medicine specialist			
TEICOPLANIN – <b>Restricted</b> see terms below			
☯ Inj 400 mg vial			
<b>➔Restricted</b>			
Infectious disease physician or clinical microbiologist			
TRIMETHOPRIM			
Tab 100 mg			
Tab 300 mg .....	9.28	50	TMP
TRIMETHOPRIM WITH SULPHAMETHOXAZOLE [CO-TRIMOXAZOLE]			
Tab 80 mg with sulphamethoxazole 400 mg			
Oral liq 8 mg with sulphamethoxazole 40 mg per ml .....	2.15	100 ml	Deprim
Inj 16 mg with sulphamethoxazole 80 mg per ml, 5 ml ampoule			
VANCOMYCIN – <b>Restricted</b> see terms below			
☯ Inj 500 mg vial – 1% DV Oct-14 to 2017 .....	2.64	1	Mylan
<b>➔Restricted</b>			
Infectious disease physician or clinical microbiologist			

## Antifungals

### Imidazoles

KETOCONAZOLE

☯ Tab 200 mg

**➔Restricted**

Oncologist

### Polyene Antimycotics

AMPHOTERICIN B

☯ Inj (liposomal) 50 mg vial – 1% DV Oct-12 to 2015 ..... 3,450.00 10 **AmBisome**

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**➡Restricted**

Infectious disease physician, clinical microbiologist, haematologist, oncologist, transplant specialist or respiratory physician

Either:

- 1 Proven or probable invasive fungal infection, to be prescribed under an established protocol; or
- 2 Both:
  - 2.1 Possible invasive fungal infection; and
  - 2.2 A multidisciplinary team (including an infectious disease physician or a clinical microbiologist) considers the treatment to be appropriate.

⚡ Inj 50 mg vial

**➡Restricted**

Infectious disease physician, clinical microbiologist, haematologist, oncologist, transplant specialist or respiratory physician

**NYSTATIN**

Tab 500,000 u .....	17.09	50	Nilstat
Cap 500,000 u .....	15.47	50	Nilstat

**Triazoles**

FLUCONAZOLE – **Restricted** see terms below

⚡ Cap 50 mg – 1% DV Nov-14 to 2017 .....	3.49	28	<b>Ozole</b>
⚡ Cap 150 mg – 1% DV Nov-14 to 2017 .....	0.71	1	<b>Ozole</b>
⚡ Cap 200 mg – 1% DV Nov-14 to 2017 .....	9.69	28	<b>Ozole</b>
⚡ Oral liquid 50 mg per 5 ml .....	34.56	35 ml	Diflucan
⚡ Inj 2 mg per ml, 50 ml vial – 1% DV Oct-13 to 2016 .....	4.95	1	<b>Fluconazole-Clarix</b>
⚡ Inj 2 mg per ml, 100 ml vial – 1% DV Oct-13 to 2016 .....	6.47	1	<b>Fluconazole-Clarix</b>

**➡Restricted**

Consultant

ITRACONAZOLE – **Restricted** see terms below

⚡ Cap 100 mg – 1% DV Oct-13 to 2016 .....	2.99	15	<b>Itrazole</b>
⚡ Oral liquid 10 mg per ml			

**➡Restricted**

Infectious disease physician, clinical microbiologist, clinical immunologist or dermatologist

POSACONAZOLE – **Restricted** see terms below

⚡ Oral liq 40 mg per ml .....	761.13	105 ml	Noxafil
-------------------------------	--------	--------	---------

**➡Restricted**

Infectious disease physician or haematologist

**Initiation**

*Re-assessment required after 6 weeks*

Both:

- 1 Either:
  - 1.1 Patient has acute myeloid leukaemia; or
  - 1.2 Patient is planned to receive a stem cell transplant and is at high risk for aspergillus infection; and
- 2 Patient is to be treated with high dose remission induction therapy or re-induction therapy

**Continuation**

*Re-assessment required after 6 weeks*

Both:

- 1 Patient has previously received posaconazole prophylaxis during remission induction therapy; and
- 2 Any of the following:
  - 2.1 Patient is to be treated with high dose remission re-induction therapy; or
  - 2.2 Patient is to be treated with high dose consolidation therapy; or
  - 2.3 Patient is receiving a high risk stem cell transplant.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>VORICONAZOLE – Restricted</b> see terms below			
☞ Tab 50 mg .....	730.00	56	Vfend
☞ Tab 200 mg .....	2,930.00	56	Vfend
☞ Oral liq 40 mg per ml .....	730.00	70 ml	Vfend
☞ Inj 200 mg vial .....	185.00	1	Vfend

#### ☞ Restricted

Infectious disease physician, clinical microbiologist or haematologist

#### Proven or probable aspergillus infection

Both:

- 1 Patient is immunocompromised; and
- 2 Patient has proven or probable invasive aspergillus infection.

#### Possible aspergillus infection

All of the following:

- 1 Patient is immunocompromised; and
- 2 Patient has possible invasive aspergillus infection; and
- 3 A multidisciplinary team (including an infectious disease physician) considers the treatment to be appropriate.

#### Resistant candidiasis infections and other moulds

All of the following:

- 1 Patient is immunocompromised, and
- 2 Either:
  - 2.1 Patient has fluconazole resistant candidiasis; or
  - 2.2 Patient has mould strain such as *Fusarium* spp. and *Scedosporium* spp; and
- 3 A multidisciplinary team (including an infectious disease physician or clinical microbiologist) considers the treatment to be appropriate.

### Other Antifungals

**CASPOFUNGIN – Restricted** see terms below

☞ Inj 50 mg vial – 1% DV Oct-12 to 2015 .....	667.50	1	<b>Candidas</b>
☞ Inj 70 mg vial – 1% DV Oct-12 to 2015 .....	862.50	1	<b>Candidas</b>

#### ☞ Restricted

Infectious disease physician, clinical microbiologist, haematologist, oncologist, transplant specialist or respiratory physician

Either:

- 1 Proven or probable invasive fungal infection, to be prescribed under an established protocol; or
- 2 Both:
  - 2.1 Possible invasive fungal infection; and
  - 2.2 A multidisciplinary team (including an infectious disease physician or a clinical microbiologist) considers the treatment to be appropriate.

**FLUCYTOSINE – Restricted** see terms below

☞ Cap 500 mg

#### ☞ Restricted

Infectious disease physician or clinical microbiologist.

**TERBINAFINE**

Tab 250 mg – 1% DV Sep-14 to 2017 .....	1.50	14	<b>Dr Reddy's Terbinafine</b>
---	------	----	-------------------------------

### Antimycobacterials

#### Antileprotics

**CLOFAZIMINE – Restricted** see terms on the next page

☞ Cap 50 mg

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>➡Restricted</b>			
Infectious disease physician, clinical microbiologist or dermatologist			
DAPSONE – <b>Restricted</b> see terms below			
⚡ Tab 25 mg – 1% DV Sep-14 to 2017 .....	95.00	100	<b>Dapsone</b>
⚡ Tab 100 mg – 1% DV Sep-14 to 2017 .....	110.00	100	<b>Dapsone</b>
<b>➡Restricted</b>			
Infectious disease physician, clinical microbiologist or dermatologist			
<b>Antituberculotics</b>			
CYCLOSERINE – <b>Restricted</b> see terms below			
⚡ Cap 250 mg			
<b>➡Restricted</b>			
Infectious disease physician, clinical microbiologist or respiratory physician			
ETHAMBUTOL HYDROCHLORIDE – <b>Restricted</b> see terms below			
⚡ Tab 100 mg .....	48.01	56	Myambutol
⚡ Tab 400 mg .....	49.34	56	Myambutol
<b>➡Restricted</b>			
Infectious disease physician, clinical microbiologist or respiratory physician			
ISONIAZID – <b>Restricted</b> see terms below			
⚡ Tab 100 mg – 1% DV Mar-13 to 2015 .....	20.00	100	<b>PSM</b>
<b>➡Restricted</b>			
Internal medicine physician, paediatrician, clinical microbiologist, dermatologist or public health physician			
ISONIAZID WITH RIFAMPICIN – <b>Restricted</b> see terms below			
⚡ Tab 100 mg with rifampicin 150 mg			
⚡ Tab 150 mg with rifampicin 300 mg			
<b>➡Restricted</b>			
Internal medicine physician, paediatrician, clinical microbiologist, dermatologist or public health physician			
PARA-AMINOSALICYLIC ACID – <b>Restricted</b> see terms below			
⚡ Grans for oral liq 4 g .....	280.00	30	Paser
<b>➡Restricted</b>			
Infectious disease physician, clinical microbiologist or respiratory physician			
PROTIONAMIDE – <b>Restricted</b> see terms below			
⚡ Tab 250 mg .....	305.00	100	Peteha
<b>➡Restricted</b>			
Infectious disease physician, clinical microbiologist or respiratory physician			
PYRAZINAMIDE – <b>Restricted</b> see terms below			
⚡ Tab 500 mg			
<b>➡Restricted</b>			
Infectious disease physician, clinical microbiologist or respiratory physician			
RIFABUTIN – <b>Restricted</b> see terms below			
⚡ Cap 150 mg – 1% DV Sep-13 to 2016 .....	213.19	30	<b>Mycobutin</b>
<b>➡Restricted</b>			
Infectious disease physician, clinical microbiologist, respiratory physician or gastroenterologist			
RIFAMPICIN – <b>Restricted</b> see terms on the next page			
⚡ Tab 600 mg – 1% DV Nov-14 to 2017 .....	108.70	30	<b>Rifadin</b>
⚡ Cap 150 mg – 1% DV Nov-14 to 2017 .....	55.75	100	<b>Rifadin</b>
⚡ Cap 300 mg – 1% DV Nov-14 to 2017 .....	116.25	100	<b>Rifadin</b>
⚡ Oral liq 100 mg per 5 ml – 1% DV Nov-14 to 2017 .....	12.00	60 ml	<b>Rifadin</b>
⚡ Inj 600 mg vial – 1% DV Nov-14 to 2017 .....	128.85	1	<b>Rifadin</b>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>➔Restricted</b>			
Internal medicine physician, clinical microbiologist, dermatologist, paediatrician or public health physician			
<b>Antiparasitics</b>			
<b>Anthelmintics</b>			
ALBENDAZOLE – <b>Restricted</b> see terms below			
⚡ Tab 200 mg			
⚡ Tab 400 mg			
<b>➔Restricted</b>			
Infectious disease physician or clinical microbiologist			
IVERMECTIN – <b>Restricted</b> see terms below			
⚡ Tab 3 mg .....	17.20	4	Stromectol
<b>➔Restricted</b>			
Infectious disease physician, clinical microbiologist or dermatologist.			
MEBENDAZOLE			
Tab 100 mg .....	24.19	24	De-Worm
Oral liq 100 mg per 5 ml			
PRAZIQUANTEL			
Tab 600 mg			
<b>Antiprotozoals</b>			
ARTEMETHER WITH LUMEFANTRINE – <b>Restricted</b> see terms below			
⚡ Tab 20 mg with lumefantrine 120 mg			
<b>➔Restricted</b>			
Infectious disease physician or clinical microbiologist			
ARTESUNATE – <b>Restricted</b> see terms below			
⚡ Inj 60 mg vial			
<b>➔Restricted</b>			
Infectious disease physician or clinical microbiologist			
ATOVAQUONE WITH PROGUANIL HYDROCHLORIDE – <b>Restricted</b> see terms below			
⚡ Tab 62.5 mg with proguanil hydrochloride 25 mg – <b>1% DV Nov-14 to 2017</b> .....	25.00	12	Malarone Junior
⚡ Tab 250 mg with proguanil hydrochloride 100 mg – <b>1% DV Nov-14 to 2017</b> .....	64.00	12	Malarone
<b>➔Restricted</b>			
Infectious disease physician or clinical microbiologist			
CHLOROQUINE PHOSPHATE – <b>Restricted</b> see terms below			
⚡ Tab 250 mg			
<b>➔Restricted</b>			
Infectious disease physician, clinical microbiologist, dermatologist or rheumatologist			
MEFLOQUINE – <b>Restricted</b> see terms below			
⚡ Tab 250 mg – <b>1% DV Dec-14 to 2017</b> .....	33.48	8	Lariam
<b>➔Restricted</b>			
Infectious disease physician, clinical microbiologist, dermatologist or rheumatologist			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>METRONIDAZOLE</b>			
Tab 200 mg .....	10.45	100	Trichozole
Tab 400 mg .....	18.15	100	Trichozole
Oral liq benzoate 200 mg per 5 ml .....	25.00	100 ml	Flagyl-S
Inj 5 mg per ml, 100 ml bag – 1% DV Apr-15 to 2017 .....	2.46	1	Baxter
	6.94	5	<b>AFT</b>
Suppos 500 mg .....	24.48	10	Flagyl
<i>(Baxter Inj 5 mg per ml, 100 ml bag to be delisted 1 April 2015)</i>			
<b>NITAZOXANIDE – Restricted</b> see terms below			
☞ Tab 500 mg .....	1,680.00	30	Alinia
☞ Oral liq 100 mg per 5 ml			
☞ <b>Restricted</b>			
Infectious disease physician or clinical microbiologist			
<b>ORNIDAZOLE</b>			
Tab 500 mg .....	16.50	10	Arrow-Ornidazole
<b>PENTAMIDINE ISETHIONATE – Restricted</b> see terms below			
☞ Inj 300 mg vial – 1% DV Mar-15 to 2017 .....	180.00	5	<b>Pentacarinat</b>
☞ <b>Restricted</b>			
Infectious disease physician or clinical microbiologist			
<b>PRIMAQUINE PHOSPHATE – Restricted</b> see terms below			
☞ Tab 7.5 mg			
☞ <b>Restricted</b>			
Infectious disease physician or clinical microbiologist			
<b>PYRIMETHAMINE – Restricted</b> see terms below			
☞ Tab 25 mg			
☞ <b>Restricted</b>			
Infectious disease physician, clinical microbiologist or maternal-foetal medicine specialist			
<b>QUININE DIHYDROCHLORIDE – Restricted</b> see terms below			
☞ Inj 60 mg per ml, 10 ml ampoule			
☞ Inj 300 mg per ml, 2 ml vial			
☞ <b>Restricted</b>			
Infectious disease physician or clinical microbiologist			
<b>QUININE SULPHATE</b>			
Tab 300 mg .....	54.06	500	Q 300
<b>SODIUM STIBOGLUCONATE – Restricted</b> see terms below			
☞ Inj 100 mg per ml, 1 ml vial			
☞ <b>Restricted</b>			
Infectious disease physician or clinical microbiologist			
<b>SPIRAMYCIN – Restricted</b> see terms below			
☞ Tab 500 mg			
☞ <b>Restricted</b>			
Maternal-foetal medicine specialist			
<b>Antiretrovirals</b>			
<b>HIV Fusion Inhibitors</b>			
<b>ENFUVIRTIDE – Restricted</b> see terms on the next page			
☞ Inj 108 mg vial × 60 .....	2,380.00	1	Fuzeon



Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

**➔ Restricted****Initiation**

*Re-assessment required after 12 months*

All of the following:

- 1 Confirmed HIV infection; and
- 2 Enfuvirtide to be given in combination with optimized background therapy (including at least 1 other antiretroviral drug that the patient has never previously been exposed to) for treatment failure; and
- 3 Either:
  - 3.1 Patient has evidence of HIV replication, despite ongoing therapy; or
  - 3.2 Patient has treatment-limiting toxicity to previous antiretroviral agents; and
- 4 Previous treatment with 3 different antiretroviral regimens has failed; and
- 5 All of the following:
  - 5.1 Previous treatment with a non-nucleoside reverse transcriptase inhibitor has failed; and
  - 5.2 Previous treatment with a nucleoside reverse transcriptase inhibitor has failed; and
  - 5.3 Previous treatment with a protease inhibitor has failed.

**Continuation**

Patient has had at least a 10-fold reduction in viral load at 12 months

**Non-Nucleoside Reverse Transcriptase Inhibitors****➔ Restricted****Confirmed HIV**

Both:

- 1 Confirmed HIV infection; and
- 2 Any of the following:
  - 2.1 Symptomatic patient; or
  - 2.2 Patient aged 12 months and under; or
  - 2.3 Both:
    - 2.3.1 Patient aged 1 to 5 years; and
    - 2.3.2 Any of the following:
      - 2.3.2.1 CD4 counts < 1000 cells/mm<sup>3</sup>; or
      - 2.3.2.2 CD4 counts < 0.25 × total lymphocyte count; or
      - 2.3.2.3 Viral load counts > 100000 copies per ml; or
  - 2.4 Both:
    - 2.4.1 Patient aged 6 years and over; and
    - 2.4.2 CD4 counts < 500 cells/mm<sup>3</sup>

**Prevention of maternal transmission**

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

**Post-exposure prophylaxis following non-occupational exposure to HIV**

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
  - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
  - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
  - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

**Percutaneous exposure**

Patient has percutaneous exposure to blood known to be HIV positive.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>EFAVIRENZ – Restricted</b> see terms on the preceding page			
† Tab 50 mg .....	158.33	30	Stocrin
† Tab 200 mg .....	474.99	90	Stocrin
† Tab 600 mg .....	474.99	30	Stocrin
† Oral liq 30 mg per ml			
<b>ETRAVIRINE – Restricted</b> see terms on the preceding page			
† Tab 200 mg .....	770.00	60	Intelence
<b>NEVIRAPINE – Restricted</b> see terms on the preceding page			
† Tab 200 mg – 1% DV Jan-13 to 2015 .....	95.94	60	<b>Nevirapine Alphapharm</b>
† Oral suspension 10 mg per ml .....	134.55	240 ml	Viramune Suspension

## Nucleoside Reverse Transcriptase Inhibitors

### ➔Restricted

#### Confirmed HIV

Both:

- 1 Confirmed HIV infection; and
- 2 Any of the following:
  - 2.1 Symptomatic patient; or
  - 2.2 Patient aged 12 months and under; or
  - 2.3 Both:
    - 2.3.1 Patient aged 1 to 5 years; and
    - 2.3.2 Any of the following:
      - 2.3.2.1 CD4 counts < 1000 cells/mm<sup>3</sup>; or
      - 2.3.2.2 CD4 counts < 0.25 × total lymphocyte count; or
      - 2.3.2.3 Viral load counts > 100000 copies per ml; or
  - 2.4 Both:
    - 2.4.1 Patient aged 6 years and over; and
    - 2.4.2 CD4 counts < 500 cells/mm<sup>3</sup>

#### Prevention of maternal transmission

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

#### Post-exposure prophylaxis following non-occupational exposure to HIV

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
  - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
  - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
  - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

#### Percutaneous exposure

Patient has percutaneous exposure to blood known to be HIV positive.

**ABACAVIR SULPHATE – Restricted** see terms above

† Tab 300 mg – 1% DV Oct-14 to 2017 .....	229.00	60	<b>Ziagen</b>
† Oral liq 20 mg per ml – 1% DV Oct-14 to 2017 .....	256.31	240 ml	<b>Ziagen</b>

**ABACAVIR SULPHATE WITH LAMIVUDINE – Restricted** see terms above

† Tab 600 mg with lamivudine 300 mg .....	630.00	30	Kivexa
---	--------	----	--------

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
DIDANOSINE [DDI] – <b>Restricted</b> see terms on the preceding page			
⌚ Cap 125 mg			
⌚ Cap 200 mg			
⌚ Cap 250 mg			
⌚ Cap 400 mg			
EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE – <b>Restricted</b> see terms on the preceding page			
⌚ Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg	1,313.19	30	Atripla
EMTRICITABINE – <b>Restricted</b> see terms on the preceding page			
⌚ Cap 200 mg	307.20	30	Emtriva
EMTRICITABINE WITH TENOFOVIR DISOPROXIL FUMARATE – <b>Restricted</b> see terms on the preceding page			
⌚ Tab 200 mg with tenofovir disoproxil fumarate 300 mg	838.20	30	Truvada
LAMIVUDINE – <b>Restricted</b> see terms on the preceding page			
⌚ Oral liq 10 mg per ml			
STAVUDINE – <b>Restricted</b> see terms on the preceding page			
⌚ Cap 30 mg			
⌚ Cap 40 mg			
⌚ Powder for oral soln 1 mg per ml			
ZIDOVUDINE [AZT] – <b>Restricted</b> see terms on the preceding page			
⌚ Cap 100 mg – 1% DV Oct-13 to 2016	152.25	100	Retrovir
⌚ Oral liq 10 mg per ml – 1% DV Oct-13 to 2016	30.45	200 ml	Retrovir
⌚ Inj 10 mg per ml, 20 ml vial – 1% DV Oct-14 to 2017	750.00	5	Retrovir IV
ZIDOVUDINE [AZT] WITH LAMIVUDINE – <b>Restricted</b> see terms on the preceding page			
⌚ Tab 300 mg with lamivudine 150 mg – 1% DV Sep-14 to 2017	44.00	60	Alphapharm

## Protease Inhibitors

### ➡ **Restricted**

#### **Confirmed HIV**

Both:

- 1 Confirmed HIV infection; and
- 2 Any of the following:
  - 2.1 Symptomatic patient; or
  - 2.2 Patient aged 12 months and under; or
  - 2.3 Both:
    - 2.3.1 Patient aged 1 to 5 years; and
    - 2.3.2 Any of the following:
      - 2.3.2.1 CD4 counts < 1000 cells/mm<sup>3</sup>; or
      - 2.3.2.2 CD4 counts < 0.25 × total lymphocyte count; or
      - 2.3.2.3 Viral load counts > 100000 copies per ml; or
  - 2.4 Both:
    - 2.4.1 Patient aged 6 years and over; and
    - 2.4.2 CD4 counts < 500 cells/mm<sup>3</sup>

#### **Prevention of maternal transmission**

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

continued...

continued...

### Post-exposure prophylaxis following non-occupational exposure to HIV

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
  - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
  - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
  - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

### Percutaneous exposure

Patient has percutaneous exposure to blood known to be HIV positive.

ATAZANAVIR SULPHATE – **Restricted** see terms on the preceding page

⬆ Cap 150 mg .....	568.34	60	Reyataz
⬆ Cap 200 mg .....	757.79	60	Reyataz

DARUNAVIR – **Restricted** see terms on the preceding page

⬆ Tab 400 mg .....	837.50	60	Prezista
⬆ Tab 600 mg .....	1,190.00	60	Prezista

INDINAVIR – **Restricted** see terms on the preceding page

- ⬆ Cap 200 mg
- ⬆ Cap 400 mg

LOPINAVIR WITH RITONAVIR – **Restricted** see terms on the preceding page

⬆ Tab 100 mg with ritonavir 25 mg .....	183.75	60	Kaletra
⬆ Tab 200 mg with ritonavir 50 mg .....	735.00	120	Kaletra
⬆ Oral liq 80 mg with ritonavir 20 mg per ml .....	735.00	300 ml	Kaletra

RITONAVIR – **Restricted** see terms on the preceding page

⬆ Tab 100 mg – 1% DV Oct-12 to 2015 .....	43.31	30	Norvir
⬆ Oral liq 80 mg per ml			

## Strand Transfer Inhibitors

### ➡Restricted

### Confirmed HIV

Both:

- 1 Confirmed HIV infection; and
- 2 Any of the following:
  - 2.1 Symptomatic patient; or
  - 2.2 Patient aged 12 months and under; or
  - 2.3 Both:
    - 2.3.1 Patient aged 1 to 5 years; and
    - 2.3.2 Any of the following:
      - 2.3.2.1 CD4 counts < 1000 cells/mm<sup>3</sup>; or
      - 2.3.2.2 CD4 counts < 0.25 × total lymphocyte count; or
      - 2.3.2.3 Viral load counts > 100000 copies per ml; or
  - 2.4 Both:
    - 2.4.1 Patient aged 6 years and over; and
    - 2.4.2 CD4 counts < 500 cells/mm<sup>3</sup>

### Prevention of maternal transmission

Either:

- 1 Prevention of maternal foetal transmission; or

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued. . .

- 2 Treatment of the newborn for up to eight weeks.

### Post-exposure prophylaxis following non-occupational exposure to HIV

- Both:
- 1 Treatment course to be initiated within 72 hours post exposure; and
  - 2 Any of the following:
    - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
    - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
    - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

### Percutaneous exposure

Patient has percutaneous exposure to blood known to be HIV positive.

RALTEGRAVIR POTASSIUM – **Restricted** see terms on the preceding page

⬇ Tab 400 mg .....	1,090.00	60	Isentress
--------------------	----------	----	-----------

## Antivirals

### Hepatitis B

ADEFOVIR DIPVOXIL – **Restricted** see terms below

⬇ Tab 10 mg .....	670.00	30	Hepsera
-------------------	--------	----	---------

#### ➡**Restricted**

Gastroenterologist or infectious disease physician

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg+); and

Documented resistance to lamivudine, defined as:

- 1 Patient has raised serum ALT ( $> 1 \times \text{ULN}$ ); and
- 2 Patient has HBV DNA greater than 100,000 copies per mL, or viral load  $\geq 10$ -fold over nadir; and
- 3 Detection of M204I or M204V mutation; and
- 4 Either:

- 4.1 Both:
  - 4.1.1 Patient is cirrhotic; and
  - 4.1.2 Adefovir dipivoxil to be used in combination with lamivudine; or
- 4.2 Both:
  - 4.2.1 Patient is not cirrhotic; and
  - 4.2.2 Adefovir dipivoxil to be used as monotherapy.

ENTECAVIR – **Restricted** see terms below

⬇ Tab 0.5 mg .....	400.00	30	Baraclude
--------------------	--------	----	-----------

#### ➡**Restricted**

Gastroenterologist or infectious disease physician

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
- 2 Patient is Hepatitis B nucleoside analogue treatment-naïve; and
- 3 Entecavir dose 0.5 mg/day; and
- 4 Either:
  - 4.1 ALT greater than upper limit of normal; or
  - 4.2 Bridging fibrosis or cirrhosis (Metavir stage 3 or greater or moderate fibrosis) on liver histology; and
- 5 Either:
  - 5.1 HBeAg positive; or
  - 5.2 Patient has  $\geq 2,000$  IU HBV DNA units per ml and fibrosis (Metavir stage 2 or greater) on liver histology; and

continued. . .

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
continued...			
6 No continuing alcohol abuse or intravenous drug use; and			
7 Not co-infected with HCV, HIV or HDV; and			
8 Neither ALT nor AST greater than 10 times upper limit of normal; and			
9 No history of hypersensitivity to entecavir; and			
10 No previous documented lamivudine resistance (either clinical or genotypic).			
<b>LAMIVUDINE – Restricted</b> see terms below			
⚡ Tab 100 mg – 1% DV Nov-14 to 2017 .....	6.00	28	<b>Zeffix</b>
⚡ Oral liq 5 mg per ml – 1% DV Nov-14 to 2017 .....	270.00	240 ml	<b>Zeffix</b>
➡ <b>Restricted</b>			
Gastroenterologist, infectious disease specialist, paediatrician or general physician			
<b>Initiation</b>			
<i>Re-assessment required after 12 months</i>			
Any of the following:			
1 HBV DNA positive cirrhosis prior to liver transplantation; or			
2 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; or			
3 Hepatitis B virus naive patient who has received a liver transplant from an anti-HBc (Hepatitis B core antibody) positive donor; or			
4 Hepatitis B surface antigen positive (HbsAg) patient who is receiving chemotherapy for a malignancy, or who has received such treatment within the previous two months; and			
5 Hepatitis B surface antigen positive patient who is receiving anti tumour necrosis factor treatment; or			
6 Hepatitis B core antibody (anti-HBc) positive patient who is receiving rituximab plus high dose steroids (e.g. R-CHOP).			
<b>Continuation - patients who have maintained continuous treatment and response to lamivudine</b>			
<i>Re-assessment required after 2 years</i>			
All of the following:			
1 Have maintained continuous treatment with lamivudine; and			
2 Most recent test result shows continuing biochemical response (normal ALT); and			
3 HBV DNA <100,000 copies per ml by quantitative PCR at a reference laboratory; or			
<b>Continuation - when given in combination with adefovir dipivoxil for patients with cirrhosis and resistance to lamivudine</b>			
<i>Re-assessment required after 2 years</i>			
All of the following:			
1 Lamivudine to be used in combination with adefovir dipivoxil; and			
2 Patient is cirrhotic; and			
Documented resistance to lamivudine, defined as:			
1 Patient has raised serum ALT ( $> 1 \times \text{ULN}$ ); and			
2 Patient has HBV DNA greater than 100,000 copies per mL, or viral load $\geq 10$ -fold over nadir; and			
3 Detection of M204I or M204V mutation; or			
<b>Continuation - when given in combination with adefovir dipivoxil for patients with resistance to adefovir dipivoxil</b>			
<i>Re-assessment required after 2 years</i>			
All of the following:			
1 Lamivudine to be used in combination with adefovir dipivoxil; and			
Documented resistance to adefovir, defined as:			
1 Patient has raised serum ALT ( $> 1 \times \text{ULN}$ ); and			
2 Patient has HBV DNA greater than 100,000 copies per mL, or viral load $\geq 10$ -fold over nadir; and			
3 Detection of N236T or A181T/V mutation.			
<b>TENOFOVIR DISOPROXIL FUMARATE – Restricted</b> see terms on the next page			
⚡ Tab 300 mg .....	531.00	30	<b>Viread</b>

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

➔ **Restricted**

**Confirmed hepatitis B**

Either:

- 1 All of the following:
  - 1.1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
  - 1.2 Patient has had previous lamivudine, adefovir or entecavir therapy; and
  - 1.3 HBV DNA greater than 20,000 IU/mL or increased  $\leq$  10-fold over nadir; and
  - 1.4 Any of the following:
    - 1.4.1 Lamivudine resistance - detection of M204I/V mutation; or
    - 1.4.2 Adefovir resistance - detection of A181T/V or N236T mutation; or
    - 1.4.3 Entecavir resistance - detection of relevant mutations including I169T, L180M T184S/A/I/L/G/C/M, S202C/G/I, M204V or M250I/V mutation; or
- 2 Patient is either listed or has undergone liver transplantation for HBV; or
- 3 Patient has a decompensated cirrhosis with a Mayo score > 20.

**Pregnant or Breastfeeding, Active hepatitis B**

Limited to twelve months' treatment

Both:

- 1 Patient is HBsAg positive and pregnant; and
- 2 HBV DNA > 20,000 IU/mL and ALT > ULN.

**Pregnant, prevention of vertical transmission**

Limited to six months' treatment

Both:

- 1 Patient is HBsAg positive and pregnant; and
- 2 HBV DNA > 20 million IU/mL and ALT normal.

**Confirmed HIV**

Both:

- 1 Confirmed HIV infection; and
- 2 Any of the following:
  - 2.1 Symptomatic patient; or
  - 2.2 Patient aged 12 months and under; or
  - 2.3 Both:
    - 2.3.1 Patient aged 1 to 5 years; and
    - 2.3.2 Any of the following:
      - 2.3.2.1 CD4 counts < 1000 cells/mm<sup>3</sup>; or
      - 2.3.2.2 CD4 counts < 0.25  $\times$  total lymphocyte count; or
      - 2.3.2.3 Viral load counts > 100000 copies per ml; or
  - 2.4 Both:
    - 2.4.1 Patient aged 6 years and over; and
    - 2.4.2 CD4 counts < 500 cells/mm<sup>3</sup>

**Prevention of maternal transmission**

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

**Post-exposure prophylaxis following non-occupational exposure to HIV**

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
  - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
  - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or

continued...

continued...

- 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

## Percutaneous exposure

Patient has percutaneous exposure to blood known to be HIV positive.

## Hepatitis C

BOCEPREVIR – **Restricted** see terms below

☞ Cap 200 mg .....	5,015.00	336	Victrelis
--------------------	----------	-----	-----------

### ☞Restricted

**Chronic hepatitis C - genotype 1, first-line from gastroenterologist, infectious disease physician or general physician**

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has not received prior pegylated interferon treatment; and
- 3 Patient has IL-28B genotype CT or TT; and
- 4 Patient is to be treated in combination with pegylated interferon and ribavirin; and
- 5 Patient is hepatitis C protease inhibitor treatment-naïve; and
- 6 Maximum of 44 weeks therapy.

**Chronic hepatitis C - genotype 1, second-line from gastroenterologist, infectious disease physician or general physician.**

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has received pegylated interferon treatment; and
- 3 Any one of:
  - 3.1 Patient was a responder relapser; or
  - 3.2 Patient was a partial responder; or
  - 3.3 Patient received pegylated interferon prior to 2004; and
- 4 Patient is to be treated in combination with pegylated interferon and ribavirin; and
- 5 Maximum of 44 weeks therapy.

Note: Due to risk of severe sepsis boceprevir should not be initiated if either Platelet count  $<100 \times 10^9 /l$  or Albumin  $<35 \text{ g/l}$ .

## Herpesviridae

ACICLOVIR

Tab dispersible 200 mg – <b>1% DV Sep-13 to 2016</b> .....	1.78	25	<b>Lovir</b>
Tab dispersible 400 mg – <b>1% DV Sep-13 to 2016</b> .....	5.98	56	<b>Lovir</b>
Tab dispersible 800 mg – <b>1% DV Sep-13 to 2016</b> .....	6.64	35	<b>Lovir</b>
Inj 250 mg vial – <b>1% DV Mar-13 to 2015</b> .....	14.09	5	<b>Zovirax IV</b>

CIDOFOVIR – **Restricted** see terms below

☞ Inj 75 mg per ml, 5 ml vial

### ☞Restricted

Infectious disease physician, clinical microbiologist, otolaryngologist or oral surgeon

FOSCARNET SODIUM – **Restricted** see terms below

☞ Inj 24 mg per ml, 250 ml bottle

### ☞Restricted

Infectious disease physician or clinical microbiologist

GANCICLOVIR – **Restricted** see terms below

☞ Inj 500 mg vial .....	380.00	5	Cymevene
-------------------------	--------	---	----------

### ☞Restricted

Infectious disease physician or clinical microbiologist

VALACICLOVIR – **Restricted** see terms on the next page

☞ Tab 500 mg .....	102.72	30	Valtrex
--------------------	--------	----	---------



Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

**➔Restricted**

Any of the following:

- 1 Patient has genital herpes with 2 or more breakthrough episodes in any 6 month period while treated with aciclovir 400 mg twice daily.
- 2 Patient has previous history of ophthalmic zoster and the patient is at risk of vision impairment.
- 3 Patient has undergone organ transplantation.

**Immunocompromised patients**

Limited to 7 days treatment

Both:

- 1 Patient is immunocompromised; and
- 2 Patient has herpes zoster.

VALGANCICLOVIR – **Restricted** see terms below

⚡ Tab 450 mg .....	3,000.00	60	Valcyte
--------------------	----------	----	---------

**➔Restricted****Transplant cytomegalovirus prophylaxis**

Limited to three months' treatment

Patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis.

**Lung transplant cytomegalovirus prophylaxis**

Limited to six months' treatment

Both:

- 1 Patient has undergone a lung transplant; and
- 2 Either:
  - 2.1 The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or
  - 2.2 The recipient is cytomegalovirus positive.

**Cytomegalovirus in immunocompromised patients**

Both:

- 1 Patient is immunocompromised; and
- 2 Any of the following:
  - 2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or
  - 2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or
  - 2.3 Patient has cytomegalovirus retinitis.

**Influenza**

OSELTAMIVIR – **Restricted** see terms below

⚡ Tab 75 mg

⚡ Powder for oral suspension 6 mg per ml

**➔Restricted**

Either:

- 1 Only for hospitalised patient with known or suspected influenza; or
- 2 For prophylaxis of influenza in hospitalised patients as part of a DHB hospital approved infections control plan.

ZANAMIVIR

⚡ Powder for inhalation 5 mg .....	37.38	20 dose	Relenza Rotadisk
------------------------------------	-------	---------	------------------

**➔Restricted**

Either:

- 1 Only for hospitalised patient with known or suspected influenza; or
- 2 For prophylaxis of influenza in hospitalised patients as part of a DHB hospital approved infections control plan.

## Immune Modulators

### INTERFERON ALFA-2A

- Inj 3 m iu prefilled syringe
- Inj 6 m iu prefilled syringe
- Inj 9 m iu prefilled syringe

### INTERFERON ALFA-2B

- Inj 18 m iu, 1.2 ml multidose pen
- Inj 30 m iu, 1.2 ml multidose pen
- Inj 60 m iu, 1.2 ml multidose pen

### INTERFERON GAMMA – **Restricted** see terms below

- ⚡ Inj 100 mcg in 0.5 ml vial

#### ➡ **Restricted**

Patient has chronic granulomatous disease and requires interferon gamma.

### PEGYLATED INTERFERON ALFA-2A – **Restricted** see terms below

⚡ Inj 135 mcg prefilled syringe			
⚡ Inj 135 mcg prefilled syringe (4) with ribavirin tab 200 mg (112)			
⚡ Inj 135 mcg prefilled syringe (4) with ribavirin tab 200 mg (168)			
⚡ Inj 180 mcg prefilled syringe .....	900.00	4	Pegasys
⚡ Inj 180 mcg prefilled syringe (4) with ribavirin tab 200 mg (112) .....	1,159.84	1	Pegasys RBV Combination Pack
⚡ Inj 180 mcg prefilled syringe (4) with ribavirin tab 200 mg (168) .....	1,290.00	1	Pegasys RBV Combination Pack

#### ➡ **Restricted**

**Initiation – Chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV or genotype 2 or 3 post liver transplant**

Both:

- Any of the following:
  - Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or
  - Patient has chronic hepatitis C and is co-infected with HIV; or
  - Patient has chronic hepatitis C genotype 2 or 3 and has received a liver transplant.
- Maximum of 48 weeks therapy.

Notes:

Consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.

Consider reducing treatment to 24 weeks if serum HCV RNA level at Week 4 is undetectable by sensitive PCR assay (less than 50IU/ml) AND Baseline serum HCV RNA is less than 400,000IU/ml.

**Continuation – (Chronic hepatitis C - genotype 1 infection) - gastroenterologist, infectious disease physician or general physician**

All of the following:

- Patient has chronic hepatitis C, genotype 1; and
- Patient has had previous treatment with pegylated interferon and ribavirin; and
- Either:
  - Patient has responder relapsed; or
  - Patient was a partial responder; and
- Patient is to be treated in combination with boceprevir; and
- Maximum of 48 weeks therapy.

continued...

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

continued...

**Initiation (Chronic Hepatitis C - genotype 1 infection treatment more than 4 years prior) - Gastroenterologist, infectious disease physician or general physician**

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has had previous treatment with pegylated interferon and ribavirin; and
- 3 Any of the following:
  - 3.1 Patient has responder relapsed; or
  - 3.2 Patient was a partial responder; or
  - 3.3 Patient received interferon treatment prior to 2004; and
- 4 Patient is to be treated in combination with boceprevir; and
- 5 Maximum of 48 weeks therapy.

**Initiation – Chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV**

Both:

- 1 Patient has chronic hepatitis C, genotype 2 or 3 infection; and
- 2 Maximum of 6 months therapy.

**Initiation – Hepatitis B**

Gastroenterologist, infectious disease specialist or general physician

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
- 2 Patient is Hepatitis B treatment-naïve; and
- 3 ALT > 2 times Upper Limit of Normal; and
- 4 HBV DNA < 10 log<sub>10</sub> IU/ml; and
- 5 Either:
  - 5.1 HBeAg positive; or
  - 5.2 Serum HBV DNA ≥ 2,000 units/ml and significant fibrosis (≥ Metavir Stage F2 or moderate fibrosis); and
- 6 Compensated liver disease; and
- 7 No continuing alcohol abuse or intravenous drug use; and
- 8 Not co-infected with HCV, HIV or HDV; and
- 9 Neither ALT nor AST > 10 times upper limit of normal; and
- 10 No history of hypersensitivity or contraindications to pegylated interferon; and
- 11 Maximum of 48 weeks therapy.

Notes:

Approved dose is 180 mcg once weekly.

The recommended dose of Pegylated Interferon alfa-2a is 180 mcg once weekly.

In patients with renal insufficiency (calculated creatinine clearance less than 50ml/min), Pegylated Interferon alfa-2a dose should be reduced to 135 mcg once weekly.

In patients with neutropaenia and thrombocytopaenia, dose should be reduced in accordance with the datasheet guidelines.

Pegylated Interferon alfa-2a is not approved for use in children.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Anticholinesterases</b>			
EDROPHONIUM CHLORIDE – <b>Restricted</b> see terms below			
☞ Inj 10 mg per ml, 15 ml vial			
☞ Inj 10 mg per ml, 1 ml ampoule			
☞ <b>Restricted</b>			
For the diagnosis of myasthenia gravis			
NEOSTIGMINE METILSULFATE			
Inj 2.5 mg per ml, 1 ml ampoule – <b>1% DV Sep-14 to 2017</b> .....	98.00	50	<b>AstraZeneca</b>
NEOSTIGMINE METILSULFATE WITH GLYCOPYRROLONIUM BROMIDE			
Inj 2.5 mg with glycopyrronium bromide 0.5 mg per ml, 1 ml ampoule – <b>1% DV Nov-13 to 2016</b> .....	27.86	10	<b>Max Health</b>
PYRIDOSTIGMINE BROMIDE			
Tab 60 mg .....	38.90	100	Mestinon
<b>Antirheumatoid Agents</b>			
AURANOFIN			
Tab 3 mg			
HYDROXYCHLOROQUINE			
Tab 200 mg – <b>1% DV Nov-12 to 2015</b> .....	18.00	100	<b>Plaquenil</b>
LEFLUNOMIDE			
Tab 10 mg .....	55.00	30	Arava
Tab 20 mg .....	76.00	30	Arava
Tab 100 mg .....	54.44	3	Arava
PENICILLAMINE			
Tab 125 mg .....	61.93	100	D-Penamine
Tab 250 mg .....	98.98	100	D-Penamine
SODIUM AUROTHIOMALATE			
Inj 10 mg in 0.5 ml ampoule			
Inj 20 mg in 0.5 ml ampoule			
Inj 50 mg in 0.5 ml ampoule			
<b>Drugs Affecting Bone Metabolism</b>			
<b>Bisphosphonates</b>			
ALENDRONATE SODIUM			
☞ Tab 40 mg .....	133.00	30	Fosamax
☞ <b>Restricted</b>			
Both:			
1	Paget's disease; and		
2	Any of the following:		
2.1	Bone or articular pain; or		
2.2	Bone deformity; or		
2.3	Bone, articular or neurological complications; or		
2.4	Asymptomatic disease, but risk of complications due to site (base of skull, spine, long bones of lower limbs); or		
2.5	Preparation for orthopaedic surgery.		
☞ Tab 70 mg .....	12.90	4	Fosamax

☞ Item restricted (see ☞ above); ☞ Item restricted (see ☞ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➔Restricted

**Osteoporosis**

Any of the following:

- History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD)  $\geq 2.5$  standard deviations below the mean normal value in young adults (i.e. T-Score  $\leq -2.5$ ) (see Note); or
- History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- History of two significant osteoporotic fractures demonstrated radiologically; or
- Documented T-Score  $\leq -3.0$  (see Note); or
- A 10-year risk of hip fracture  $\geq 3\%$ , calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
- Patient has had a Special Authority approval for zoledronic acid (osteoporosis) or raloxifene.

**Initiation - glucocorticosteroid therapy**

*Re-assessment required after 12 months*

Both:

- The patient is receiving systemic glucocorticosteroid therapy ( $\geq 5$  mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and
- Any of the following:
  - The patient has documented BMD  $\geq 1.5$  standard deviations below the mean normal value in young adults (i.e. T-Score  $\leq -1.5$ ) (see Note); or
  - The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
  - The patient has had a Special Authority approval for zoledronic acid (glucocorticosteroid therapy) or raloxifene.

**Continuation - glucocorticosteroid therapy**

*Re-assessment required after 12 months*

The patient is continuing systemic glucocorticosteroid therapy ( $\geq 5$  mg per day prednisone equivalents)

Notes:

- BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score  $\leq -2.5$  and, therefore, do not require BMD measurement for treatment with bisphosphonates.
- Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

ALENDRONATE SODIUM WITH CHOLECALCIFEROL – **Restricted** see terms below

⚡ Tab 70 mg with cholecalciferol 5,600 iu .....	12.90	4	Fosamax Plus
---	-------	---	--------------

➔Restricted

**Osteoporosis**

Any of the following:

- History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD)  $\geq 2.5$  standard deviations below the mean normal value in young adults (i.e. T-Score  $\leq -2.5$ ) (see Note); or

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
continued...			
<ol style="list-style-type: none"> <li>History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or</li> <li>History of two significant osteoporotic fractures demonstrated radiologically; or</li> <li>Documented T-Score <math>\leq -3.0</math> (see Note); or</li> <li>A 10-year risk of hip fracture <math>\geq 3\%</math>, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or</li> <li>Patient has had a Special Authority approval for zoledronic acid (osteoporosis) or raloxifene.</li> </ol>			
<b>Initiation - glucocorticosteroid therapy</b>			
<i>Re-assessment required after 12 months</i>			
Both:			
<ol style="list-style-type: none"> <li>The patient is receiving systemic glucocorticosteroid therapy (<math>\geq 5</math> mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and</li> <li>Any of the following: <ol style="list-style-type: none"> <li>The patient has documented BMD <math>\geq 1.5</math> standard deviations below the mean normal value in young adults (i.e. T-Score <math>\leq -1.5</math>) (see Note); or</li> <li>The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or</li> <li>The patient has had a Special Authority approval for zoledronic acid (glucocorticosteroid therapy) or raloxifene.</li> </ol> </li> </ol>			
<b>Continuation - glucocorticosteroid therapy</b>			
<i>Re-assessment required after 12 months</i>			
The patient is continuing systemic glucocorticosteroid therapy ( $\geq 5$ mg per day prednisone equivalents)			
Notes:			
<ol style="list-style-type: none"> <li>BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.</li> <li>Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score <math>\geq -2.5</math> and, therefore, do not require BMD measurement for treatment with bisphosphonates.</li> <li>Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.</li> <li>A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.</li> </ol>			
<b>ETIDRONATE DISODIUM</b>			
Tab 200 mg – 1% DV Sep-12 to 2015 .....	15.80	100	Arrow-Etidronate
<b>PAMIDRONATE DISODIUM</b>			
Inj 3 mg per ml, 10 ml vial .....	6.80	1	Pamisol
Inj 6 mg per ml, 10 ml vial .....	13.20	1	Pamisol
Inj 9 mg per ml, 10 ml vial .....	19.20	1	Pamisol
<b>RISEDRONATE SODIUM</b>			
Tab 35 mg .....	4.00	4	Risedronate Sandoz
<b>ZOLEDRONIC ACID – Restricted</b> see terms on the next page			
⚡ Inj 5 mg per 100 ml, vial .....	600.00	100 ml	Aclasta

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

➔ **Restricted**

**Osteogenesis imperfecta**

Patient has been diagnosed with clinical or genetic osteogenesis imperfecta.

**Osteoporosis**

Both:

- 1 Any of the following:
  - 1.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD)  $\geq$  2.5 standard deviations below the mean normal value in young adults (i.e. T-Score  $\leq$  -2.5) (see Note); or
  - 1.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
  - 1.3 History of two significant osteoporotic fractures demonstrated radiologically; or
  - 1.4 Documented T-Score  $\geq$  -3.0 (see Note); or
  - 1.5 A 10-year risk of hip fracture  $\geq$  3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
  - 1.6 Patient has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) or raloxifene; and
- 2 The patient will not be prescribed more than one infusion in a 12-month period.

**Initiation - glucocorticosteroid therapy**

*Re-assessment required after 12 months*

All of the following:

- 1 The patient is receiving systemic glucocorticosteroid therapy ( $\geq$  5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and
- 2 Any of the following:
  - 2.1 The patient has documented BMD  $\geq$  1.5 standard deviations below the mean normal value in young adults (i.e. T-Score  $\leq$  -1.5) (see Note); or
  - 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
  - 2.3 The patient has had a Special Authority approval for alendronate (Underlying cause - glucocorticosteroid therapy) or raloxifene; and
- 3 The patient will not be prescribed more than one infusion in the 12-month approval period.

**Continuation - glucocorticosteroid therapy**

*Re-assessment required after 12 months*

Both:

- 1 The patient is continuing systemic glucocorticosteroid therapy ( $\geq$  5 mg per day prednisone equivalents); and
- 2 The patient will not be prescribed more than one infusion in the 12-month approval period.

**Initiation - Paget's disease**

*Re-assessment required after 12 months*

All of the following:

- 1 Paget's disease; and
- 2 Any of the following:
  - 2.1 Bone or articular pain; or
  - 2.2 Bone deformity; or
  - 2.3 Bone, articular or neurological complications; or
  - 2.4 Asymptomatic disease, but risk of complications; or
  - 2.5 Preparation for orthopaedic surgery; and
- 3 The patient will not be prescribed more than one infusion in the 12-month approval period.

**Continuation - Paget's disease**

*Re-assessment required after 12 months*

Both:

- 1 Any of the following:

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 1.1 The patient has relapsed (based on increases in serum alkaline phosphatase); or
- 1.2 The patient's serum alkaline phosphatase has not normalised following previous treatment with zoledronic acid; or
- 1.3 Symptomatic disease (prescriber determined); and
- 2 The patient will not be prescribed more than one infusion in the 12-month approval period.

Notes:

- 1 BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- 2 Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score  $\leq -2.5$  and, therefore, do not require BMD measurement for treatment with bisphosphonates.
- 3 Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- 4 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

## Other Drugs Affecting Bone Metabolism

**RALOXIFENE – Restricted** see terms below

☞ Tab 60 mg .....53.76 28 Evista

☞ **Restricted**

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD)  $\geq 2.5$  standard deviations below the mean normal value in young adults (i.e. T-Score  $\leq -2.5$ ) (see Notes); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score  $\geq -3.0$  (see Notes); or
- 5 A 10-year risk of hip fracture  $\geq 3\%$ , calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Notes); or
- 6 Patient has had a prior Special Authority approval for zoledronic acid (Underlying cause - Osteoporosis) or alendronate (Underlying cause - Osteoporosis).

Notes:

- 1 BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- 2 Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score  $\leq -2.5$  and, therefore, do not require BMD measurement for raloxifene funding.
- 3 Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- 4 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
TERIPARATIDE – <b>Restricted</b> see terms below			
⚡ Inj 250 mcg per ml, 2.4 ml cartridge .....	490.00	1	Forteo

➔ **Restricted**

Limited to 18 months' treatment

All of the following:

- 1 The patient has severe, established osteoporosis; and
- 2 The patient has a documented T-score less than or equal to -3.0 (see Notes); and
- 3 The patient has had two or more fractures due to minimal trauma; and
- 4 The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antiresorptive agent at adequate doses (see Notes).

Notes:

- 1 The bone mineral density (BMD) measurement used to derive the T-score must be made using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable
- 2 Antiresorptive agents and their adequate doses for the purposes of this Special Authority are defined as: alendronate sodium tab 70 mg or tab 70 mg with cholecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily; zoledronic acid 5 mg per year. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialed so that the patient achieves the minimum requirement of 12 months' continuous therapy.
- 3 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

## Enzymes

### HYALURONIDASE

Inj 1,500 iu ampoule

## Hyperuricaemia and Antigout

### ALLOPURINOL

Tab 100 mg – 1% DV Mar-15 to 2017 .....	15.11	1,000	<b>Apo-Allopurinol</b>
Tab 300 mg – 1% DV Mar-15 to 2017 .....	15.91	500	<b>Apo-Allopurinol</b>

### BENZBROMARONE – **Restricted** see terms below

⚡ Tab 100 mg .....	45.00	100	Benzbromaron AL 100
--------------------	-------	-----	---------------------

➔ **Restricted**

Both:

- 1 Any of the following:
  - 1.1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and appropriate doses of probenecid; or
  - 1.2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite appropriate doses of probenecid; or
  - 1.3 Both:
    - 1.3.1 The patient has renal impairment and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note); and
    - 1.3.2 The patient has a rate of creatinine clearance greater than or equal to 20 ml/min; or
  - 1.4 All of the following:
    - 1.4.1 The patient is taking azathioprine and requires urate-lowering therapy; and
    - 1.4.2 Allopurinol is contraindicated; and
    - 1.4.3 Appropriate doses of probenecid are ineffective or probenecid cannot be used due to reduced renal function; and

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 2 The patient is receiving monthly liver function tests.

Notes: Benzbromarone has been associated with potentially fatal hepatotoxicity. Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose.

The New Zealand Rheumatology Association has developed information for prescribers which can be accessed from its website at [http://www.rheumatology.org.nz/benzbromarone\\_prescriber\\_information.cfm](http://www.rheumatology.org.nz/benzbromarone_prescriber_information.cfm)

## COLCHICINE

Tab 500 mcg – 1% DV Oct-13 to 2016 ..... 10.08 100 **Colgout**

## FEBUXOSTAT – Restricted see terms below

⚡ Tab 80 mg ..... 39.50 28 Adenuric  
⚡ Tab 120 mg ..... 39.50 28 Adenuric

## ➡ Restricted

Any of the following:

- The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and appropriate doses of probenecid; or
- The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite appropriate doses of probenecid; or
- Both:
  - The patient has renal impairment and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note); and
  - The patient has a rate of creatinine clearance greater than or equal to 30 ml/min.

Note: Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose.

## PROBENECID

Tab 500 mg

## RASBURICASE – Restricted see terms below

⚡ Inj 1.5 mg vial

## ➡ Restricted

Haematologist

## Muscle Relaxants and Related Agents

### ATRACURIUM BESYLATE

Inj 10 mg per ml, 2.5 ml ampoule – 1% DV Sep-12 to 2015 ..... 6.13 5 **Tracrium**  
Inj 10 mg per ml, 5 ml ampoule – 1% DV Sep-12 to 2015 ..... 9.19 5 **Tracrium**

### BACLOFEN

Tab 10 mg – 1% DV Jun-13 to 2016 ..... 3.85 100 **Pacifen**  
Oral liq 1 mg per ml  
Inj 0.05 mg per ml, 1 ml ampoule – 1% DV Oct-12 to 2015 ..... 11.55 1 **Lioresal Intrathecal**  
Inj 2 mg per ml, 5 ml ampoule – 1% DV Oct-12 to 2015 ..... 209.29 1 **Lioresal Intrathecal**

### CLOSTRIDIUM BOTULINUM TYPE A TOXIN

Inj 100 u vial ..... 467.50 1 Botox  
Inj 500 u vial ..... 1,295.00 2 Dysport

### DANTROLENE

Cap 25 mg ..... 65.00 100 Dantrium  
Cap 50 mg ..... 77.00 100 Dantrium  
Inj 20 mg vial ..... e.g. Dantrium IV

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>MIVACURIUM CHLORIDE</b>			
Inj 2 mg per ml, 5 ml ampoule .....	33.92	5	Mivacron
Inj 2 mg per ml, 10 ml ampoule .....	67.17	5	Mivacron
<b>ORPHENADRINE CITRATE</b>			
Tab 100 mg			
<b>PANCURONIUM BROMIDE</b>			
Inj 2 mg per ml, 2 ml ampoule – 1% DV Jan-13 to 2015 .....	260.00	50	<b>AstraZeneca</b>
<b>ROCURONIUM BROMIDE</b>			
Inj 10 mg per ml, 5 ml vial – 1% DV Sep-12 to 2015 .....	38.25	10	<b>DBL Rocuronium Bromide</b>
<b>SUXAMETHONIUM CHLORIDE</b>			
Inj 50 mg per ml, 2 ml ampoule – 1% DV Jun-14 to 2017 .....	78.00	50	<b>AstraZeneca</b>
<b>VECURONIUM BROMIDE</b>			
Inj 4 mg ampoule			
Inj 10 mg vial			

### Reversers of Neuromuscular Blockade

**SUGAMMADEX – Restricted** see terms below

⚡ Inj 100 mg per ml, 2 ml vial .....	1,200.00	10	Bridion
⚡ Inj 100 mg per ml, 5 ml vial .....	3,000.00	10	Bridion

#### ➡Restricted

Any of the following:

- 1 Patient requires reversal of profound neuromuscular blockade following rapid sequence induction that has been undertaken using rocuronium (i.e. suxamethonium is contraindicated or undesirable); or
- 2 Severe neuromuscular degenerative disease where the use of neuromuscular blockade is required; or
- 3 Patient has an unexpectedly difficult airway that cannot be intubated and requires a rapid reversal of anaesthesia and neuromuscular blockade; or
- 4 The duration of the patient's surgery is unexpectedly short; or
- 5 Neostigmine or a neostigmine/anticholinergic combination is contraindicated (for example the patient has ischaemic heart disease, morbid obesity or COPD); or
- 6 Patient has a partial residual block after conventional reversal.

### Non-Steroidal Anti-Inflammatory Drugs

**CELECOXIB – Restricted** see terms below

⚡ Cap 100 mg
⚡ Cap 200 mg
⚡ Cap 400 mg

#### ➡Restricted

For preoperative and/or postoperative use for a total of up to 8 days' use.

# MUSCULOSKELETAL SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>DICLOFENAC SODIUM</b>			
Tab EC 25 mg – 1% DV Mar-13 to 2015 .....	4.00	100	<b>Apo-Diclo</b>
Tab 50 mg dispersible .....	1.50	20	<b>Voltaren D</b>
Tab EC 50 mg – 1% DV Mar-13 to 2015 .....	16.00	500	<b>Apo-Diclo</b>
Tab long-acting 75 mg – 1% DV Dec-12 to 2015 .....	3.10	30	<b>Diclax SR</b>
	24.52	500	<b>Diclax SR</b>
Tab long-acting 100 mg – 1% DV Dec-12 to 2015 .....	42.25	500	<b>Diclax SR</b>
Inj 25 mg per ml, 3 ml ampoule – 1% DV Oct-14 to 2017 .....	13.20	5	<b>Voltaren</b>
Suppos 12.5 mg – 1% DV Oct-14 to 2017 .....	2.04	10	<b>Voltaren</b>
Suppos 25 mg – 1% DV Oct-14 to 2017 .....	2.44	10	<b>Voltaren</b>
Suppos 50 mg – 1% DV Oct-14 to 2017 .....	4.22	10	<b>Voltaren</b>
Suppos 100 mg – 1% DV Oct-14 to 2017 .....	7.00	10	<b>Voltaren</b>
<b>ETORICOXIB – Restricted</b> see terms below			
⚡ Tab 30 mg			
⚡ Tab 60 mg			
⚡ Tab 90 mg			
⚡ Tab 120 mg			
➡ <b>Restricted</b>			
For preoperative and/or postoperative use for a total of up to 8 days' use.			
<b>IBUPROFEN</b>			
Tab 200 mg			
➡ Tab 400 mg – <b>Restricted:</b> For continuation only			
➡ Tab 600 mg – <b>Restricted:</b> For continuation only			
Tab long-acting 800 mg .....	8.12	30	<b>Brufen SR</b>
Oral liq 20 mg per ml – 1% DV Mar-14 to 2016 .....	1.89	200 ml	<b>Fenpaed</b>
Inj 5 mg per ml, 2 ml ampoule			
<b>INDOMETHACIN</b>			
Cap 25 mg			
Cap 50 mg			
Cap long-acting 75 mg			
Inj 1 mg vial			
Suppos 100 mg			
<b>KETOPROFEN</b>			
Cap long-acting 200 mg .....	12.07	28	<b>Oruvail SR</b>
<b>MEFENAMIC ACID – Restricted:</b> For continuation only			
➡ Cap 250 mg			
<b>MELOXICAM – Restricted</b> see terms below			
⚡ Tab 7.5 mg			
➡ <b>Restricted</b>			
Either:			
1 Haemophilic arthropathy, with both of the following:			
1.1 The patient has moderate to severe haemophilia with less than or equal to 5% of normal circulating functional clotting factor; and			
1.2 Pain and inflammation associated with haemophilic arthropathy is inadequately controlled by alternative funded treatment options, or alternative funded treatment options are contraindicated; or			
2 For preoperative and/or postoperative use for a total of up to 8 days' use.			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>NAPROXEN</b>			
Tab 250 mg – 1% DV Jan-13 to 2015 .....	21.25	500	<b>Noflam 250</b>
Tab 500 mg – 1% DV Jan-13 to 2015 .....	22.25	250	<b>Noflam 500</b>
Tab long-acting 750 mg			
Tab long-acting 1 g			
<b>PARECOXIB</b>			
Inj 40 mg vial .....	100.00	10	Dynastat
<b>SULINDAC</b>			
Tab 100 mg			
Tab 200 mg			
<b>TENOXICAM</b>			
Tab 20 mg – 1% DV Jan-15 to 2016 .....	3.05	20	<b>Reutenox</b>
Inj 20 mg vial .....	9.95	1	<b>AFT</b>

### Topical Products for Joint and Muscular Pain

CAPSAICIN – **Restricted** see terms below

🔻 Crm 0.025% ..... 9.95 45 g Zostrix

➡ **Restricted**

Patient has osteoarthritis that is not responsive to paracetamol and oral non-steroidal anti-inflammatories are contraindicated.

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

## Agents for Parkinsonism and Related Disorders

### Agents for Essential Tremor, Chorea and Related Disorders

RILUZOLE – **Restricted** see terms below

⚡ Tab 50 mg .....	400.00	56	Rilutek
-------------------	--------	----	---------

#### ➡ **Restricted**

##### Initiation

Neurologist or respiratory specialist

*Re-assessment required after 6 months*

All of the following:

- 1 The patient has amyotrophic lateral sclerosis with disease duration of 5 years or less; and
- 2 The patient has at least 60 percent of predicted forced vital capacity within 2 months prior to the initial application; and
- 3 The patient has not undergone a tracheostomy; and
- 4 The patient has not experienced respiratory failure; and
- 5 Any of the following:
  - 5.1 The patient is ambulatory; or
  - 5.2 The patient is able to use upper limbs; or
  - 5.3 The patient is able to swallow.

##### Continuation

*Re-assessment required after 18 months*

All of the following:

- 1 The patient has not undergone a tracheostomy; and
- 2 The patient has not experienced respiratory failure; and
- 3 Any of the following:
  - 3.1 The patient is ambulatory; or
  - 3.2 The patient is able to use upper limb; or
  - 3.3 The patient is able to swallow.

TETRABENAZINE

Tab 25 mg – <b>1% DV Sep-13 to 2016</b> .....	118.00	112	Motetis
---	--------	-----	---------

### Anticholinergics

BENZTROPINE MESYLATE

Tab 2 mg .....	7.99	60	Benztrop
Inj 1 mg per ml, 2 ml ampoule .....	95.00	5	Cogentin

ORPHENADRINE HYDROCHLORIDE

Tab 50 mg

PROCYCLIDINE HYDROCHLORIDE

Tab 5 mg

### Dopamine Agonists and Related Agents

AMANTADINE HYDROCHLORIDE

Cap 100 mg – <b>1% DV Oct-14 to 2017</b> .....	38.24	60	Symmetrel
--	-------	----	-----------

APOMORPHINE HYDROCHLORIDE

Inj 10 mg per ml, 1 ml ampoule			
Inj 10 mg per ml, 2 ml ampoule .....	110.00	5	Apomine

BROMOCRIPTINE

Tab 2.5 mg

Cap 5 mg

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>ENTACAPONE</b>			
Tab 200 mg – <b>1% DV Dec-12 to 2015</b> .....	47.92	100	<b>Entapone</b>
<b>LEVODOPA WITH BENSERAZIDE</b>			
Tab dispersible 50 mg with benserazide 12.5 mg .....	10.00	100	Madopar Rapid
Cap 50 mg with benserazide 12.5 mg .....	8.00	100	Madopar 62.5
Cap 100 mg with benserazide 25 mg .....	12.50	100	Madopar 125
Cap long-acting 100 mg with benserazide 25 mg .....	17.00	100	Madopar HBS
Cap 200 mg with benserazide 50 mg .....	25.00	100	Madopar 250
<b>LEVODOPA WITH CARBIDOPA</b>			
Tab 100 mg with carbidopa 25 mg .....	20.00	100	Sinemet <i>e.g. Kinson</i>
Tab long-acting 200 mg with carbidopa 50 mg .....	47.50	100	Sinemet CR
Tab 250 mg with carbidopa 25 mg .....	40.00	100	Sinemet <i>e.g. Sindopa</i>
<b>LISURIDE HYDROGEN MALEATE</b>			
Tab 200 mcg .....	25.00	30	Dopergin
<b>PRAMIPEXOLE HYDROCHLORIDE</b>			
Tab 0.25 mg – <b>1% DV Oct-14 to 2016</b> .....	7.20	100	<b>Ramipex</b>
Tab 1 mg – <b>1% DV Oct-14 to 2016</b> .....	24.39	100	<b>Ramipex</b>
<b>ROPINIROLE HYDROCHLORIDE</b>			
Tab 0.25 mg – <b>1% DV Mar-14 to 2016</b> .....	2.36	100	<b>Apo-Ropinirole</b>
Tab 1 mg – <b>1% DV Mar-14 to 2016</b> .....	5.32	100	<b>Apo-Ropinirole</b>
Tab 2 mg – <b>1% DV Mar-14 to 2016</b> .....	7.72	100	<b>Apo-Ropinirole</b>
Tab 5 mg – <b>1% DV Mar-14 to 2016</b> .....	14.48	100	<b>Apo-Ropinirole</b>
<b>SELEGILINE HYDROCHLORIDE</b>			
Tab 5 mg			
<b>TOLCAPONE</b>			
Tab 100 mg .....	126.20	100	Tasmar

## Anaesthetics

### General Anaesthetics

<b>DESFLURANE</b>			
Soln for inhalation 100%, 240 ml bottle – <b>1% DV Dec-12 to 2015</b> .....	1,230.00	6	<b>Suprane</b>
<b>DEXMEDETOMIDINE</b>			
Inj 100 mcg per ml, 2 ml vial – <b>1% DV Oct-14 to 2017</b> .....	479.85	5	<b>Precedex</b>
<b>ETOMIDATE</b>			
Inj 2 mg per ml, 10 ml ampoule			
<b>ISOFLURANE</b>			
Soln for inhalation 100%, 250 ml bottle – <b>1% DV Dec-12 to 2015</b> .....	1,020.00	6	<b>Aerrane</b>
<b>KETAMINE</b>			
Inj 1 mg per ml, 100 ml bag – <b>1% DV Sep-14 to 2017</b> .....	27.00	1	<b>Biomed</b>
Inj 4 mg per ml, 50 ml syringe – <b>1% DV Sep-14 to 2017</b> .....	25.00	1	<b>Biomed</b>
Inj 10 mg per ml, 10 ml syringe – <b>1% DV Sep-14 to 2017</b> .....	14.00	1	<b>Biomed</b>
Inj 100 mg per ml, 2 ml vial			
<b>METHOHEXITAL SODIUM</b>			
Inj 10 mg per ml, 50 ml vial			

## NERVOUS SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>PROPOFOL</b>			
Inj 10 mg per ml, 20 ml ampoule .....	7.60	5	Fresofol 1%
Inj 10 mg per ml, 20 ml vial .....	7.60	5	Provide MCT-LCT 1%
	42.00		Diprivan
Inj 10 mg per ml, 50 ml syringe .....	47.00	1	Diprivan
Inj 10 mg per ml, 50 ml vial .....	4.00	1	Fresofol 1%
	25.00		Provide MCT-LCT 1%
			Diprivan
Inj 10 mg per ml, 100 ml vial .....	7.60	1	Fresofol 1%
	30.00		Provide MCT-LCT 1%
			Diprivan
<b>SEVOFLURANE</b>			
Soln for inhalation 100%, 250 ml bottle – 1% DV Dec-12 to 2015 .....	1,230.00	6	<b>Baxter</b>
<b>THIOPENTAL [THIOPENTONE] SODIUM</b>			
Inj 500 mg ampoule			
<b>Local Anaesthetics</b>			
<b>ARTICAINE HYDROCHLORIDE</b>			
Inj 1%			
<b>ARTICAINE HYDROCHLORIDE WITH ADRENALINE</b>			
Inj 4% with adrenaline 1:100,000, 1.7 ml dental cartridge			
Inj 4% with adrenaline 1:100,000, 2.2 ml dental cartridge			
Inj 4% with adrenaline 1:200,000, 1.7 ml dental cartridge			
Inj 4% with adrenaline 1:200,000, 2.2 ml dental cartridge			
<b>BENZOCAINE</b>			
Gel 20%			
<b>BUPIVACAINE HYDROCHLORIDE</b>			
Inj 5 mg per ml, 4 ml ampoule – 1% DV Jul-14 to 2017 .....	50.00	5	<b>Marcaïn Isobaric</b>
Inj 2.5 mg per ml, 20 ml ampoule			
Inj 2.5 mg per ml, 20 ml ampoule sterile pack – 1% DV Oct-12 to 2015 .....	35.00	5	<b>Marcaïn</b>
Inj 5 mg per ml, 10 ml ampoule .....	35.00	50	<b>Marcaïn</b>
Inj 5 mg per ml, 10 ml ampoule sterile pack – 1% DV Oct-12 to 2015 .....	28.00	5	<b>Marcaïn</b>
Inj 5 mg per ml, 20 ml ampoule			
Inj 5 mg per ml, 20 ml ampoule sterile pack – 1% DV Oct-12 to 2015 .....	28.00	5	<b>Marcaïn</b>
Inj 1.25 mg per ml, 100 ml bag			
Inj 1.25 mg per ml, 200 ml bag			
Inj 2.5 mg per ml, 100 ml bag – 1% DV Jul-14 to 2017 .....	150.00	5	<b>Marcaïn</b>
Inj 2.5 mg per ml, 200 ml bag			
Inj 1.25 mg per ml, 500 ml bag			
<b>BUPIVACAINE HYDROCHLORIDE WITH ADRENALINE</b>			
Inj 2.5 mg per ml with adrenaline 1:400,000, 20 ml vial – 1% DV Sep-14 to 2017 .....	135.00	5	<b>Marcaïn with Adrenaline</b>
Inj 5 mg per ml with adrenaline 1:200,000, 20 ml vial – 1% DV Sep-14 to 2017 .....	115.00	5	<b>Marcaïn with Adrenaline</b>

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>BUPIVACAINE HYDROCHLORIDE WITH FENTANYL</b>			
Inj 0.625 mg with fentanyl 2 mcg per ml, 100 ml bag			
Inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml syringe			
Inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml bag .....	210.00	10	Bupafen
Inj 1.25 mg with fentanyl 2 mcg per ml, 200 ml bag .....	210.00	10	Bupafen
Inj 1.25 mg with fentanyl 2 mcg per ml, 50 ml syringe			
Inj 1.25 mg with fentanyl 2 mcg per ml, 15 ml syringe .....	72.00	10	Biomed
Inj 1.25 mg with fentanyl 2 mcg per ml, 20 ml syringe .....	92.00	10	Biomed
<b>BUPIVACAINE HYDROCHLORIDE WITH GLUCOSE</b>			
Inj 0.5% with glucose 8%, 4 ml ampoule .....	38.00	5	Marcaïn Heavy
<b>COCAINE HYDROCHLORIDE</b>			
Paste 5%			
Soln 15%, 2 ml syringe			
Soln 4%, 2 ml syringe .....	25.46	1	Biomed
<b>COCAINE HYDROCHLORIDE WITH ADRENALINE</b>			
Paste 15% with adrenaline 0.06%			
Paste 25% with adrenaline 0.06%			
<b>ETHYL CHLORIDE</b>			
Spray 100%			
<b>LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE</b>			
Gel 2% – <b>1% DV Oct-12 to 2015</b> .....	3.40	20 ml	<b>Orion</b>
Soln 4%			
Spray 10% – <b>1% DV Sep-13 to 2016</b> .....	75.00	50 ml	<b>Xylocaine</b>
Oral (viscous) soln 2% – <b>1% DV Sep-14 to 2017</b> .....	55.00	200 ml	<b>Xylocaine Viscous</b>
Inj 1%, 20 ml ampoule, sterile pack			
Inj 2%, 20 ml ampoule, sterile pack			
Inj 1%, 5 ml ampoule – <b>1% DV Jul-13 to 2015</b> .....	8.75	25	<b>Lidocaine-Claris</b>
Inj 1%, 20 ml ampoule – <b>1% DV Jul-13 to 2015</b> .....	2.40	1	<b>Lidocaine-Claris</b>
Inj 2%, 5 ml ampoule – <b>1% DV Jul-13 to 2015</b> .....	6.90	25	<b>Lidocaine-Claris</b>
Inj 2%, 20 ml ampoule – <b>1% DV Jul-13 to 2015</b> .....	2.40	1	<b>Lidocaine-Claris</b>
Gel 2%, 10 ml urethral syringe .....	43.26	10	Pfizer
<b>LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE</b>			
Inj 1% with adrenaline 1:100,000, 5 ml ampoule .....	27.00	10	Xylocaine
Inj 1% with adrenaline 1:200,000, 20 ml vial .....	50.00	5	Xylocaine
Inj 2% with adrenaline 1:80,000, 1.7 ml dental cartridge			
Inj 2% with adrenaline 1:80,000, 1.8 ml dental cartridge			
Inj 2% with adrenaline 1:80,000, 2.2 ml dental cartridge			
Inj 2% with adrenaline 1:200,000, 20 ml vial .....	60.00	5	Xylocaine
<b>LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE AND TETRACAINE HYDROCHLORIDE</b>			
Soln 4% with adrenaline 0.1% and tetracaine hydrochloride 0.5%, 5 ml syringe – <b>1% DV Oct-14 to 2017</b> .....	17.50	1	<b>Topicaïne</b>
<b>LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH CHLORHEXIDINE</b>			
Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringe .....	43.26	10	Pfizer
<b>LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH PHENYLEPHRINE HYDROCHLORIDE</b>			
Nasal spray 5% with phenylephrine hydrochloride 0.5%			

## NERVOUS SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>LIDOCAINE [LIGNOCAINE] WITH PRILOCAINE</b>			
Crm 2.5% with prilocaine 2.5% .....	45.00	30 g	EMLA
Patch 25 mcg with prilocaine 25 mcg .....	115.00	20	EMLA
Crm 2.5% with prilocaine 2.5%, 5 g .....	45.00	5	EMLA
<b>MEPIVACAINE HYDROCHLORIDE</b>			
Inj 3%, 1.8 ml dental cartridge – 1% DV Oct-14 to 2017 .....	43.60	50	Scandonest 3%
Inj 3%, 2.2 ml dental cartridge – 1% DV Oct-14 to 2017 .....	43.60	50	Scandonest 3%
<b>PRILOCAINE HYDROCHLORIDE</b>			
Inj 0.5%, 50 ml vial .....	100.00	5	Citanest
Inj 2%, 5 ml ampoule .....	55.00	10	Citanest
<b>PRILOCAINE HYDROCHLORIDE WITH FELYPRESSIN</b>			
Inj 3% with felypressin 0.03 iu per ml, 1.8 ml dental cartridge			
Inj 3% with felypressin 0.03 iu per ml, 2.2 ml dental cartridge			
<b>ROPIVACAINE HYDROCHLORIDE</b>			
Inj 2 mg per ml, 10 ml ampoule			
Inj 2 mg per ml, 20 ml ampoule .....	75.00	5	Naropin
Inj 2 mg per ml, 100 ml bag .....	200.00	5	Naropin
Inj 2 mg per ml, 200 ml bag .....	265.00	5	Naropin
Inj 7.5 mg per ml, 10 ml ampoule .....	45.00	5	Naropin
Inj 7.5 mg per ml, 20 ml ampoule .....	84.00	5	Naropin
Inj 10 mg per ml, 10 ml ampoule .....	54.00	5	Naropin
Inj 10 mg per ml, 20 ml ampoule			
<b>ROPIVACAINE HYDROCHLORIDE WITH FENTANYL</b>			
Inj 2 mg with fentanyl 2 mcg per ml, 100 ml bag .....	198.50	5	Naropin
Inj 2 mg with fentanyl 2 mcg per ml, 200 ml bag .....	270.00	5	Naropin
<b>TETRACAINE [AMETHOCAINE] HYDROCHLORIDE</b>			
Gel 4%			

## Analgesics

### Non-Opoid Analgesics

#### ASPIRIN

Tab EC 300 mg

Tab dispersible 300 mg

#### CAPSAICIN – **Restricted** see terms below

☞ Crm 0.075% ..... 12.50 45 g Zostrix HP

#### ☞ **Restricted**

For post-herpetic neuralgia or diabetic peripheral neuropathy

#### METHOXYFLURANE – **Restricted** see terms below

☞ Soln for inhalation 99.9%, 3 ml bottle

#### ☞ **Restricted**

Both:

- 1 Patient is undergoing a painful procedure with an expected duration of less than one hour; and
- 2 Only to be used under supervision by a medical practitioner or nurse who is trained in the use of methoxyflurane.

#### NEFOPAM HYDROCHLORIDE

Tab 30 mg

☞ Item restricted (see ☞ above); ☞ Item restricted (see ☞ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>PARACETAMOL – Some items restricted</b> see terms below			
Tab soluble 500 mg			
Tab 500 mg			
Oral liq 120 mg per 5 ml – <b>20% DV Oct-14 to 2017</b> .....	4.15	1,000 ml	<b>Paracare</b>
Oral liq 250 mg per 5 ml – <b>20% DV Sep-14 to 2017</b> .....	4.35	1,000 ml	<b>Paracare Double Strength</b>
⚡ Inj 10 mg per ml, 50 ml vial – <b>1% DV Sep-14 to 2017</b> .....	12.90	12	<b>Perfalgan</b>
⚡ Inj 10 mg per ml, 100 ml vial – <b>1% DV Sep-14 to 2017</b> .....	12.90	12	<b>Perfalgan</b>
Suppos 25 mg .....	56.35	20	Biomed
Suppos 50 mg .....	56.35	20	Biomed
Suppos 125 mg .....	7.49	20	Panadol
Suppos 250 mg .....	14.40	20	Panadol
Suppos 500 mg – <b>1% DV Jan-13 to 2015</b> .....	20.70	50	<b>Paracare</b>

#### ➡Restricted

Intravenous paracetamol is only to be used where other routes are unavailable or impractical, or where there is reduced absorption. The need for IV paracetamol must be re-assessed every 24 hours.

#### SUCROSE

Oral liq 25%

### Opioid Analgesics

#### ALFENTANIL

Inj 0.5 mg per ml, 2 ml ampoule – **1% DV Jan-15 to 2017** .....39.07      10      **Hameln**

#### CODEINE PHOSPHATE

Tab 15 mg – **1% DV Jul-13 to 2016** .....4.75      100      **PSM**  
 Tab 30 mg – **1% DV Jul-13 to 2016** .....5.80      100      **PSM**  
 Tab 60 mg – **1% DV Jul-13 to 2016** .....12.50      100      **PSM**

#### DIHYDROCODEINE TARTRATE

Tab long-acting 60 mg – **1% DV Sep-13 to 2016** .....13.64      60      **DHC Continus**

# NERVOUS SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>FENTANYL</b>			
Inj 10 mcg per ml, 10 ml syringe			
Inj 50 mcg per ml, 2 ml ampoule – 1% DV Sep-12 to 2015 .....	4.50	10	<b>Boucher and Muir</b>
Inj 10 mcg per ml, 50 ml bag .....	210.00	10	Biomed
Inj 10 mcg per ml, 50 ml syringe .....	165.00	10	Biomed
Inj 50 mcg per ml, 10 ml ampoule – 1% DV Sep-12 to 2015 .....	11.77	10	<b>Boucher and Muir</b>
Inj 10 mcg per ml, 100 ml bag .....	210.00	10	Biomed
Inj 20 mcg per ml, 50 ml syringe .....	185.00	10	Biomed
Inj 20 mcg per ml, 100 ml bag			
Patch 12.5 mcg per hour – 1% DV Aug-15 to 2016 .....	2.92	5	<b>Fentanyl Sandoz</b>
	8.90		Mylan Fentanyl Patch
Patch 25 mcg per hour – 1% DV Aug-15 to 2016 .....	3.66	5	<b>Fentanyl Sandoz</b>
	9.15		Mylan Fentanyl Patch
Patch 50 mcg per hour – 1% DV Aug-15 to 2016 .....	6.64	5	<b>Fentanyl Sandoz</b>
	11.50		Mylan Fentanyl Patch
Patch 75 mcg per hour – 1% DV Aug-15 to 2016 .....	9.18	5	<b>Fentanyl Sandoz</b>
	13.60		Mylan Fentanyl Patch
Patch 100 mcg per hour – 1% DV Aug-15 to 2016 .....	11.29	5	<b>Fentanyl Sandoz</b>
	14.50		Mylan Fentanyl Patch
<i>(Mylan Fentanyl Patch Patch 12.5 mcg per hour to be delisted 1 August 2015)</i>			
<i>(Mylan Fentanyl Patch Patch 25 mcg per hour to be delisted 1 August 2015)</i>			
<i>(Mylan Fentanyl Patch Patch 50 mcg per hour to be delisted 1 August 2015)</i>			
<i>(Mylan Fentanyl Patch Patch 75 mcg per hour to be delisted 1 August 2015)</i>			
<i>(Mylan Fentanyl Patch Patch 100 mcg per hour to be delisted 1 August 2015)</i>			
<b>METHADONE HYDROCHLORIDE</b>			
Tab 5 mg .....	1.85	10	Methatabs
Oral liq 2 mg per ml – 1% DV Sep-12 to 2015 .....	5.55	200 ml	<b>Biodone</b>
Oral liq 5 mg per ml – 1% DV Sep-12 to 2015 .....	5.55	200 ml	<b>Biodone Forte</b>
Oral liq 10 mg per ml – 1% DV Sep-12 to 2015 .....	6.55	200 ml	<b>Biodone Extra Forte</b>
Inj 10 mg per ml, 1 ml vial .....	61.00	10	AFT
<b>MORPHINE HYDROCHLORIDE</b>			
Oral liq 1 mg per ml – 1% DV Oct-12 to 2015 .....	8.84	200 ml	<b>RA-Morph</b>
Oral liq 2 mg per ml – 1% DV Oct-12 to 2015 .....	11.62	200 ml	<b>RA-Morph</b>
Oral liq 5 mg per ml – 1% DV Oct-12 to 2015 .....	14.65	200 ml	<b>RA-Morph</b>
Oral liq 10 mg per ml – 1% DV Oct-12 to 2015 .....	21.55	200 ml	<b>RA-Morph</b>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>MORPHINE SULPHATE</b>			
Tab long-acting 10 mg – 1% DV Sep-13 to 2016 .....	1.95	10	<b>Arrow-Morphine LA</b>
Tab immediate-release 10 mg – 1% DV Apr-15 to 2017 .....	2.80	10	<b>Sevredol</b>
Tab immediate-release 20 mg – 1% DV Apr-15 to 2017 .....	5.52	10	<b>Sevredol</b>
Tab long-acting 30 mg – 1% DV Sep-13 to 2016 .....	2.98	10	<b>Arrow-Morphine LA</b>
Tab long-acting 60 mg – 1% DV Sep-13 to 2016 .....	5.75	10	<b>Arrow-Morphine LA</b>
Tab long-acting 100 mg – 1% DV Sep-13 to 2016 .....	6.45	10	<b>Arrow-Morphine LA</b>
Cap long-acting 10 mg – 1% DV Feb-14 to 2016 .....	1.70	10	<b>m-Eslon</b>
Cap long-acting 30 mg – 1% DV Feb-14 to 2016 .....	2.50	10	<b>m-Eslon</b>
Cap long-acting 60 mg – 1% DV Feb-14 to 2016 .....	5.40	10	<b>m-Eslon</b>
Cap long-acting 100 mg – 1% DV Feb-14 to 2016 .....	6.38	10	<b>m-Eslon</b>
Inj 1 mg per ml, 100 ml bag – 1% DV Oct-14 to 2017 .....	185.00	10	<b>Biomed</b>
Inj 1 mg per ml, 10 ml syringe – 1% DV Oct-14 to 2017 .....	45.00	10	<b>Biomed</b>
Inj 1 mg per ml, 50 ml syringe – 1% DV Oct-14 to 2017 .....	87.50	10	<b>Biomed</b>
Inj 1 mg per ml, 2 ml syringe .....			
Inj 2 mg per ml, 30 ml syringe .....	135.00	10	<b>Biomed</b>
Inj 5 mg per ml, 1 ml ampoule – 1% DV Oct-14 to 2017 .....	12.48	5	<b>DBL Morphine Sulphate</b>
Inj 10 mg per ml, 1 ml ampoule – 1% DV Oct-14 to 2017 .....	9.09	5	<b>DBL Morphine Sulphate</b>
Inj 10 mg per ml, 100 mg cassette .....			
Inj 10 mg per ml, 100 ml bag .....			
Inj 15 mg per ml, 1 ml ampoule – 1% DV Oct-14 to 2017 .....	9.77	5	<b>DBL Morphine Sulphate</b>
Inj 30 mg per ml, 1 ml ampoule – 1% DV Oct-14 to 2017 .....	12.43	5	<b>DBL Morphine Sulphate</b>
Inj 200 mcg in 0.4 ml syringe .....			
Inj 300 mcg in 0.3 ml syringe .....			
<b>MORPHINE TARTRATE</b>			
Inj 80 mg per ml, 1.5 ml ampoule – 1% DV Sep-13 to 2016 .....	35.60	5	<b>Hospira</b>
Inj 80 mg per ml, 5 ml ampoule – 1% DV Sep-13 to 2016 .....	107.67	5	<b>Hospira</b>

# NERVOUS SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>OXYCODONE HYDROCHLORIDE</b>			
Tab controlled-release 5 mg .....	7.51	20	OxyContin
Tab controlled-release 10 mg – 1% DV Oct-13 to 2015.....	6.75	20	<b>Oxycodone ControlledRelease Tablets(BNM)</b>
Tab controlled-release 20 mg – 1% DV Oct-13 to 2015.....	11.50	20	<b>Oxycodone ControlledRelease Tablets(BNM)</b>
Tab controlled-release 40 mg – 1% DV Oct-13 to 2015.....	18.50	20	<b>Oxycodone ControlledRelease Tablets(BNM)</b>
Tab controlled-release 80 mg – 1% DV Oct-13 to 2015.....	34.00	20	<b>Oxycodone ControlledRelease Tablets(BNM)</b>
Cap immediate-release 5 mg .....	2.83	20	OxyNorm
Cap immediate-release 10 mg .....	5.58	20	OxyNorm
Cap immediate-release 20 mg .....	9.77	20	OxyNorm
Oral liq 5 mg per 5 ml .....	11.20	250 ml	OxyNorm
Inj 1 mg per ml, 100 ml bag			
Inj 10 mg per ml, 1 ml ampoule – 1% DV Dec-12 to 2015.....	10.08	5	<b>Oxycodone Orion</b>
Inj 10 mg per ml, 2 ml ampoule – 1% DV Dec-12 to 2015.....	19.87	5	<b>Oxycodone Orion</b>
Inj 50 mg per ml, 1 ml ampoule – 1% DV May-13 to 2015.....	60.00	5	<b>OxyNorm</b>
<b>PARACETAMOL WITH CODEINE</b>			
Tab paracetamol 500 mg with codeine phosphate 8 mg .....	2.11	100	Paracetamol + Codeine (Relieve)
<b>PETHIDINE HYDROCHLORIDE</b>			
Tab 50 mg – 1% DV Mar-13 to 2015.....	3.95	10	<b>PSM</b>
Tab 100 mg – 1% DV Mar-13 to 2015.....	5.80	10	<b>PSM</b>
Inj 5 mg per ml, 10 ml syringe			
Inj 5 mg per ml, 100 ml bag			
Inj 10 mg per ml, 100 ml bag			
Inj 10 mg per ml, 50 ml syringe			
Inj 50 mg per ml, 1 ml ampoule – 1% DV Sep-14 to 2017.....	5.51	5	<b>DBL Pethidine Hydrochloride</b>
Inj 50 mg per ml, 2 ml ampoule – 1% DV Sep-14 to 2017.....	5.83	5	<b>DBL Pethidine Hydrochloride</b>
<b>REMIFENTANIL HYDROCHLORIDE</b>			
Inj 1 mg vial – 1% DV Nov-14 to 2017 .....	10.00	5	<b>Ultiva</b>
Inj 2 mg vial – 1% DV Nov-14 to 2017 .....	18.00	5	<b>Ultiva</b>
<b>TRAMADOL HYDROCHLORIDE</b>			
Tab sustained-release 100 mg – 1% DV Oct-14 to 2017.....	2.00	20	<b>Tramal SR 100</b>
Tab sustained-release 150 mg – 1% DV Oct-14 to 2017.....	3.00	20	<b>Tramal SR 150</b>
Tab sustained-release 200 mg – 1% DV Oct-14 to 2017.....	4.00	20	<b>Tramal SR 200</b>
Cap 50 mg – 1% DV Oct-14 to 2017 .....	2.50	100	<b>Arrow-Tramadol</b>
Oral drops 100 mg per ml			
Inj 10 mg per ml, 100 ml bag			
Inj 50 mg per ml, 1 ml ampoule – 1% DV Oct-14 to 2017 .....	4.50	5	<b>Tramal 50</b>
Inj 50 mg per ml, 2 ml ampoule – 1% DV Oct-14 to 2017 .....	4.50	5	<b>Tramal 100</b>

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Antidepressants

### Cyclic and Related Agents

#### AMITRIPTYLINE

Tab 10 mg – 1% DV Sep-14 to 2017 .....	1.68	100	<b>Arrow-Amitriptyline</b>
Tab 25 mg – 1% DV Jan-15 to 2017 .....	1.68	100	<b>Arrow-Amitriptyline</b>
Tab 50 mg – 1% DV Jan-15 to 2017 .....	2.82	100	<b>Arrow-Amitriptyline</b>

#### CLOMIPRAMINE HYDROCHLORIDE

Tab 10 mg – 1% DV Jan-13 to 2015 .....	12.60	100	<b>Apo-Clomipramine</b>
Tab 25 mg – 1% DV Jan-13 to 2015 .....	8.68	100	<b>Apo-Clomipramine</b>

#### DOTHIEPIN HYDROCHLORIDE

Tab 75 mg .....	10.50	100	Dopress
Cap 25 mg .....	6.17	100	Dopress

#### DOXEPIN HYDROCHLORIDE

Cap 10 mg  
Cap 25 mg  
Cap 50 mg

#### IMIPRAMINE HYDROCHLORIDE

Tab 10 mg .....	5.48	50	Tofranil
	6.58	60	Tofranil
Tab 25 mg .....	8.80	50	Tofranil

#### MAPROTILINE HYDROCHLORIDE

Tab 25 mg  
Tab 75 mg

#### MIANSERIN HYDROCHLORIDE – **Restricted** see terms below

⚡ Tab 30 mg

➡ **Restricted**

For continuation only

#### NORTRIPTYLINE HYDROCHLORIDE

Tab 10 mg – 1% DV Jun-13 to 2016 .....	4.00	100	<b>Norpress</b>
Tab 25 mg – 1% DV Jun-13 to 2016 .....	9.00	180	<b>Norpress</b>

### Monoamine-Oxidase Inhibitors - Non-Selective

#### PHENELZINE SULPHATE

Tab 15 mg

#### TRANLYCYPROMINE SULPHATE

Tab 10 mg

### Monoamine-Oxidase Type A Inhibitors

#### MOCLOBEMIDE

Tab 150 mg – 1% DV Apr-13 to 2015 .....	81.83	500	<b>Apo-Moclobemide</b>
Tab 300 mg – 1% DV Apr-13 to 2015 .....	29.51	100	<b>Apo-Moclobemide</b>

### Other Antidepressants

#### MIRTAZAPINE – **Restricted** see terms on the next page

⚡ Tab 30 mg – 1% DV Sep-12 to 2015 .....	8.78	30	<b>Avanza</b>
⚡ Tab 45 mg – 1% DV Sep-12 to 2015 .....	13.95	30	<b>Avanza</b>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>➡Restricted</b>			
<b>Initiation</b>			
<i>Re-assessment required after two years</i>			
Both:			
1 The patient has a severe major depressive episode; and			
2 Either:			
2.1 The patient must have had a trial of two different antidepressants and was unable to tolerate the treatments or failed to respond to an adequate dose over an adequate period of time (usually at least four weeks); or			
2.2 Both:			
2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and			
2.2.2 The patient must have had a trial of one other antidepressant and either could not tolerate it or failed to respond to an adequate dose over an adequate period of time.			
<b>Continuation</b>			
<i>Re-assessment required after two years</i>			
The patient has a high risk of relapse (prescriber determined)			
<b>VENLAFAXINE – Some items restricted see terms below</b>			
Tab modified release 37.5 mg .....	5.06	28	Arrow-Venlafaxine XR
Tab modified release 75 mg .....	6.44	28	Arrow-Venlafaxine XR
Tab modified release 150 mg .....	8.86	28	Arrow-Venlafaxine XR
Tab modified release 225 mg .....	14.34	28	Arrow-Venlafaxine XR
⚡ Cap modified release 37.5 mg .....	8.68	28	Efexor XR
⚡ Cap modified release 75 mg .....	12.18	28	Efexor XR
⚡ Cap modified release 150 mg .....	20.16	28	Efexor XR
<b>➡Restricted</b>			
<b>Initiation</b>			
<i>Re-assessment required after two years</i>			
Both:			
1 The patient has 'treatment-resistant' depression; and			
2 Either:			
2.1 The patient must have had a trial of two different antidepressants and have had an inadequate response from an adequate dose over an adequate period of time (usually at least four weeks); or			
2.2 Both:			
2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and			
2.2.2 The patient must have had a trial of one other antidepressant and have had an inadequate response from an adequate dose over an adequate period of time.			
<b>Continuation</b>			
<i>Re-assessment required after two years</i>			
The patient has a high risk of relapse (prescriber determined)			
<b>Selective Serotonin Reuptake Inhibitors</b>			
<b>CITALOPRAM HYDROBROMIDE</b>			
Tab 20 mg .....	2.34	84	Arrow-Citalopram
<b>ESCITALOPRAM</b>			
Tab 10 mg .....	2.65	28	Loxalate
Tab 20 mg .....	4.20	28	Loxalate
<b>FLUOXETINE HYDROCHLORIDE</b>			
Tab dispersible 20 mg, scored – 1% DV Apr-14 to 2016 .....	2.50	30	Arrow-Fluoxetine
Cap 20 mg – 1% DV Apr-14 to 2016 .....	1.74	90	Arrow-Fluoxetine
<b>PAROXETINE HYDROCHLORIDE</b>			
Tab 20 mg .....	4.32	90	Loxamine

⚡ Item restricted (see ➡ above); ⚡ Item restricted (see ➡ below)

e.g. Brand indicates brand example only. It is not a contracted product.



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
SERTRALINE			
Tab 50 mg – 1% DV Sep-13 to 2016 .....	3.64	90	Arrow-Sertraline
Tab 100 mg – 1% DV Sep-13 to 2016 .....	6.28	90	Arrow-Sertraline

## Antiepilepsy Drugs

### Agents for the Control of Status Epilepticus

CLONAZEPAM			
Inj 1 mg per ml, 1 ml ampoule .....	19.00	5	Rivotril
DIAZEPAM			
Inj 5 mg per ml, 2 ml ampoule .....	11.83	5	Hospira
Rectal tubes 5 mg .....	25.05	5	Stesolid
Rectal tubes 10 mg .....	30.50	5	Stesolid
LORAZEPAM			
Inj 2 mg vial			
Inj 4 mg per ml, 1 ml vial			
PARALDEHYDE			
Inj 5 ml ampoule			
PHENYTOIN SODIUM			
Inj 50 mg per ml, 2 ml ampoule			
Inj 50 mg per ml, 5 ml ampoule			

### Control of Epilepsy

CARBAMAZEPINE			
Tab 200 mg .....	14.53	100	Tegretol
Tab long-acting 200 mg .....	16.98	100	Tegretol CR
Tab 400 mg .....	34.58	100	Tegretol
Tab long-acting 400 mg .....	39.17	100	Tegretol CR
Oral liq 20 mg per ml .....	26.37	250 ml	Tegretol
CLOBAZAM			
Tab 10 mg			
CLONAZEPAM			
Oral drops 2.5 mg per ml			
ETHOSUXIMIDE			
Cap 250 mg			
Oral liq 50 mg per ml			
GABAPENTIN – <b>Restricted</b> see terms on the next page			
⚡ Tab 600 mg			
⚡ Cap 100 mg .....	7.16	100	Arrow-Gabapentin Nupentin
⚡ Cap 300 mg .....	11.00	100	Arrow-Gabapentin Nupentin
⚡ Cap 400 mg .....	13.75	100	Arrow-Gabapentin Nupentin

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>➡Restricted</b>			
1 For preoperative and/or postoperative use for up to a total of 8 days' use; or 2 For the pain management of burns patients with monthly review.			
<b>Initiation - epilepsy</b>			
<i>Re-assessment required after 15 months</i>			
Either:			
1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or 2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents.			
Note: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.			
<b>Continuation - epilepsy</b>			
Patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life.			
Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.			
<b>Initiation - Neuropathic pain or Chronic Kidney Disease-associated pruritus</b>			
<i>Re-assessment required after 3 months</i>			
Either:			
1 The patient has been diagnosed with neuropathic pain; or 2 Both: <ul style="list-style-type: none"> <li>2.1 The patient has Chronic Kidney Disease Stage 5-associated pruritus* where no other cause for pruritus can be identified (e.g. scabies, allergy); and</li> <li>2.2 The patient has persistent pruritus not relieved with a trial of emollient/moisturising creams alone.</li> </ul>			
<b>Continuation - Neuropathic pain or Chronic Kidney Disease-associated pruritus</b>			
Either:			
1 The patient has demonstrated a marked improvement in their control of pain or itch (prescriber determined); or 2 The patient has previously demonstrated clinical responsiveness to gabapentin and has now developed neuropathic pain in a new site.			
Notes: Indications marked with * are Unapproved Indications. Dosage adjustment of gabapentin is recommended for patients with renal impairment.			
LACOSAMIDE – <b>Restricted</b> see terms below			
⚡ Tab 50 mg .....	25.04	14	Vimpat
⚡ Tab 100 mg .....	50.06	14	Vimpat
	200.24	56	Vimpat
⚡ Tab 150 mg .....	75.10	14	Vimpat
	300.40	56	Vimpat
⚡ Tab 200 mg .....	400.55	56	Vimpat
⚡ Inj 10 mg per ml, 20 ml vial			
<b>➡Restricted</b>			
<b>Initiation</b>			
<i>Re-assessment required after 15 months</i>			
Both:			
1 Patient has partial-onset epilepsy; and 2 Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam and any two of carbamazepine, lamotrigine and phenytoin sodium (see Note).			
continued...			
⚡Item restricted (see ➡ above); ⚡Item restricted (see ➡ below) e.g. Brand indicates brand example only. It is not a contracted product.			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
continued...			
Note: "Optimal treatment" is defined as treatment which is indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Women of childbearing age are not required to have a trial of sodium valproate.			
<b>Continuation</b>			
Patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life compared with that prior to starting lamotrigine treatment (see Note).			
Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.			
<b>LAMOTRIGINE</b>			
Tab dispersible 2 mg .....	6.74	30	Lamictal
Tab dispersible 5 mg .....	9.64	30	Lamictal
	15.00	56	Arrow-Lamotrigine
Tab dispersible 25 mg .....	19.38	56	Logem
	20.40		Arrow-Lamotrigine
	29.09		Mogine
Tab dispersible 50 mg .....	32.97	56	Lamictal
	34.70		Logem
			Arrow-Lamotrigine
	47.89		Mogine
Tab dispersible 100 mg .....	56.91	56	Lamictal
	59.90		Logem
			Arrow-Lamotrigine
			Mogine
	79.16		Lamictal
<b>LEVETIRACETAM</b>			
Tab 250 mg .....	24.03	60	Levetiracetam-Rex
Tab 500 mg .....	28.71	60	Levetiracetam-Rex
Tab 750 mg .....	45.23	60	Levetiracetam-Rex
Inj 100 mg per ml, 5 ml vial			
<b>PHENOBARBITONE</b>			
Tab 15 mg – 1% DV Mar-13 to 2015 .....	28.00	500	<b>PSM</b>
Tab 30 mg – 1% DV Mar-13 to 2015 .....	29.00	500	<b>PSM</b>
<b>PHENYTOIN</b>			
Tab 50 mg			
<b>PHENYTOIN SODIUM</b>			
Cap 30 mg			
Cap 100 mg			
Oral liq 6 mg per ml			
<b>PRIMIDONE</b>			
Tab 250 mg			
<b>SODIUM VALPROATE</b>			
Tab 100 mg			
Tab EC 200 mg			
Tab EC 500 mg			
Oral liq 40 mg per ml			
Inj 100 mg per ml, 4 ml vial			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>STIRIPENTOL – Restricted</b> see terms below			
☞ Cap 250 mg .....	509.29	60	Diacomit
☞ Powder for oral liq 250 mg sachet .....	509.29	60	Diacomit

## ☞Restricted

Paediatric neurologist

## Initiation

*Re-assessment required after 6 months*

Both:

- 1 Patient has confirmed diagnosis of Dravet syndrome; and
- 2 Seizures have been inadequately controlled by appropriate courses of sodium valproate, clobazam and at least two of the following: topiramate, levetiracetam, ketogenic diet.

## Continuation

Patient continues to benefit from treatment as measured by reduced seizure frequency from baseline.

## TOPIRAMATE

Tab 25 mg .....	11.07	60	Arrow-Topiramate Topiramate Actavis Topamax
Tab 50 mg .....	18.81	60	Arrow-Topiramate Topiramate Actavis Topamax
Tab 100 mg .....	31.99	60	Arrow-Topiramate Topiramate Actavis Topamax
Tab 200 mg .....	55.19	60	Arrow-Topiramate Topiramate Actavis Topamax
Cap sprinkle 15 mg .....	20.84	60	Topamax
Cap sprinkle 25 mg .....	26.04	60	Topamax

## VIGABATRIN – Restricted

☞ Tab 500 mg

## ☞Restricted

Both:

- 1 Either:
  - 1.1 Patient has infantile spasms; or
  - 1.2 Both:
    - 1.2.1 Patient has epilepsy; and
    - 1.2.2 Either:
      - 1.2.2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
      - 1.2.2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents; and
- 2 Either:
  - 2.1 Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6-monthly basis thereafter); or
  - 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes:

"Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

## Antimigraine Preparations

### Acute Migraine Treatment

DIHYDROERGOTAMINE MESYLATE

Inj 1 mg per ml, 1 ml ampoule

ERGOTAMINE TARTRATE WITH CAFFEINE

Tab 1 mg with caffeine 100 mg

METOCLOPRAMIDE HYDROCHLORIDE WITH PARACETAMOL

Tab 5 mg with paracetamol 500 mg

RIZATRIPTAN

Tab orodispersible 10 mg – 1% DV Sep-14 to 2017 .....8.10 30 **Rizamelt**

SUMATRIPTAN

Tab 50 mg – 1% DV Sep-13 to 2016 .....29.80 100 **Arrow-Sumatriptan**

Tab 100 mg – 1% DV Sep-13 to 2016 .....54.80 100 **Arrow-Sumatriptan**

Inj 12 mg per ml, 0.5 ml cartridge – 1% DV Sep-13 to 2016 .....13.80 2 **Arrow-Sumatriptan**

### Prophylaxis of Migraine

PIZOTIFEN

Tab 500 mcg – 1% DV Mar-13 to 2015 .....23.21 100 **Sandomigran**

### Antinausea and Vertigo Agents

APREPITANT – **Restricted** see terms below

⚡ Cap 2 × 80 mg and 1 × 125 mg – 1% DV Sep-14 to 2017 .....100.00 3 **Emend Tri-Pack**

➡ **Restricted**

Patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy.

BETAHISTINE DIHYDROCHLORIDE

Tab 16 mg – 1% DV Jun-14 to 2017 .....4.95 84 **Vergo 16**

CYCLIZINE HYDROCHLORIDE

Tab 50 mg – 1% DV Sep-12 to 2015 .....0.59 10 **Nausicalm**

CYCLIZINE LACTATE

Inj 50 mg per ml, 1 ml ampoule .....14.95 5 **Nausicalm**

DOMPERIDONE

Tab 10 mg – 1% DV Mar-13 to 2015 .....3.25 100 **Prokinex**

DROPERIDOL

Inj 2.5 mg per ml, 1 ml ampoule

GRANISETRON

Tab 1 mg – 1% DV Jan-15 to 2017 .....5.98 50 **Granirex**

HYOSCINE HYDROBROMIDE

Inj 400 mcg per ml, 1 ml ampoule .....46.50 5 **Hospira**

⚡ Patch 1.5 mg – 1% DV Dec-13 to 2016 .....11.95 2 **Scopoderm TTS**

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>➔Restricted</b>			
Any of the following:			
1 Control of intractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease where the patient cannot tolerate or does not adequately respond to oral anti-nausea agents; or			
2 Control of clozapine-induced hypersalivation where trials of at least two other alternative treatments have proven ineffective; or			
3 For treatment of post-operative nausea and vomiting where cyclizine, droperidol and a 5HT <sub>3</sub> antagonist have proven ineffective, are not tolerated or are contraindicated.			
<b>METOCLOPRAMIDE HYDROCHLORIDE</b>			
Tab 10 mg – 1% DV Sep-14 to 2017 .....	1.82	100	Metamide
Oral liq 5 mg per 5 ml			
Inj 5 mg per ml, 2 ml ampoule – 1% DV Sep-14 to 2017 .....	4.50	10	Pfizer
<b>ONDANSETRON</b>			
Tab 4 mg – 1% DV Jan-14 to 2016 .....	5.51	50	Onrex
Tab dispersible 4 mg – 1% DV Oct-14 to 2017 .....	1.00	10	Dr Reddy's Ondansetron
Tab 8 mg – 1% DV Jan-14 to 2016 .....	6.19	50	Onrex
Tab dispersible 8 mg – 1% DV Oct-14 to 2017 .....	1.50	10	Ondansetron ODT-DRLA
Inj 2 mg per ml, 2 ml ampoule – 1% DV Sep-13 to 2016 .....	1.82	5	Ondanaccord
Inj 2 mg per ml, 4 ml ampoule – 1% DV Sep-13 to 2016 .....	2.18	5	Ondanaccord
<b>PROCHLORPERAZINE</b>			
Tab buccal 3 mg			
Tab 5 mg – 1% DV Jun-14 to 2017 .....	9.75	500	Antinaus
Inj 12.5 mg per ml, 1 ml ampoule			
Suppos 25 mg			
<b>PROMETHAZINE THEOCLATE – Restricted:</b> For continuation only			
➔ Tab 25 mg			
<b>TROPISETRON</b>			
Inj 1 mg per ml, 2 ml ampoule – 1% DV May-14 to 2015 .....	8.95	1	Tropisetron-AFT
Inj 1 mg per ml, 5 ml ampoule – 1% DV May-14 to 2015 .....	13.95	1	Tropisetron-AFT

## Antipsychotic Agents

### General

<b>AMISULPRIDE</b>			
Tab 100 mg – 1% DV Jul-13 to 2016 .....	6.22	30	Solian
Tab 200 mg – 1% DV Jul-13 to 2016 .....	21.92	60	Solian
Tab 400 mg – 1% DV Jul-13 to 2016 .....	44.52	60	Solian
Oral liq 100 mg per ml – 1% DV Jul-13 to 2016 .....	52.50	60 ml	Solian
<b>ARIPRAZOLE – Restricted</b> see terms on the next page			
⚡ Tab 10 mg .....	123.54	30	Abilify
⚡ Tab 15 mg .....	175.28	30	Abilify
⚡ Tab 20 mg .....	213.42	30	Abilify
⚡ Tab 30 mg .....	260.07	30	Abilify

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>➔Restricted</b>			
Both:			
1 Patient is suffering from schizophrenia or related psychoses; and			
2 Either:			
2.1 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of unacceptable side effects; or			
2.2 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of inadequate clinical response.			
<b>CHLORPROMAZINE HYDROCHLORIDE</b>			
Tab 10 mg			
Tab 25 mg			
Tab 100 mg			
Oral liq 10 mg per ml			
Inj 25 mg per ml, 2 ml ampoule			
<b>CLOZAPINE</b>			
Tab 25 mg .....	5.69	50	Clozaril
	11.36	100	Clozaril
	6.69	50	Clopine
	13.37	100	Clopine
Tab 50 mg .....	8.67	50	Clopine
	17.33	100	Clopine
Tab 100 mg .....	14.73	50	Clozaril
	29.45	100	Clozaril
	17.33	50	Clopine
	34.65	100	Clopine
Tab 200 mg .....	34.65	50	Clopine
	69.30	100	Clopine
Oral liq 50 mg per ml .....	17.33	100 ml	Clopine
<b>HALOPERIDOL</b>			
Tab 500 mcg – 1% DV Oct-13 to 2016 .....	6.23	100	Serenace
Tab 1.5 mg – 1% DV Oct-13 to 2016 .....	9.43	100	Serenace
Tab 5 mg – 1% DV Oct-13 to 2016 .....	29.72	100	Serenace
Oral liq 2 mg per ml – 1% DV Oct-13 to 2016.....	23.84	100 ml	Serenace
Inj 5 mg per ml, 1ml ampoule – 1% DV Oct-13 to 2016 .....	21.55	10	Serenace
<b>LEVOMEPRMAZINE</b>			
Tab 25 mg			
Tab 100 mg			
Inj 25 mg per ml, 1 ml ampoule			
<b>LITHIUM CARBONATE</b>			
Tab long-acting 400 mg			
Tab 250 mg – 1% DV Sep-12 to 2015 .....	34.30	500	Lithicarb FC
Tab 400 mg – 1% DV Sep-12 to 2015 .....	12.83	100	Lithicarb FC
Cap 250 mg – 1% DV Sep-14 to 2017 .....	9.42	100	Douglas
<b>OLANZAPINE</b>			
Tab 2.5 mg – 1% DV Sep-14 to 2017 .....	0.75	28	Zypine
Tab 5 mg – 1% DV Sep-14 to 2017 .....	1.65	28	Zypine
Tab orodispersible 5 mg – 1% DV Sep-14 to 2017 .....	1.75	28	Zypine ODT
Tab 10 mg – 1% DV Sep-14 to 2017 .....	2.55	28	Zypine
Tab orodispersible 10 mg – 1% DV Sep-14 to 2017 .....	3.05	28	Zypine ODT
Inj 10 mg vial			

# NERVOUS SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>PERICYAZINE</b>			
Tab 2.5 mg			
Tab 10 mg			
<b>QUETIAPINE</b>			
Tab 25 mg – 1% DV Sep-14 to 2017 .....	2.10	90	Quetapel
Tab 100 mg – 1% DV Sep-14 to 2017 .....	4.20	90	Quetapel
Tab 200 mg – 1% DV Sep-14 to 2017 .....	7.20	90	Quetapel
Tab 300 mg – 1% DV Sep-14 to 2017 .....	12.00	90	Quetapel
<b>RISPERIDONE – Some items restricted see terms below</b>			
Tab 0.5 mg – 1% DV Feb-15 to 2017 .....	1.90	60	Actavis
⚡ Tab orodispersible 0.5 mg .....	21.42	28	Risperdal Quicklet
Tab 1 mg – 1% DV Feb-15 to 30 Sep 2017 .....	2.10	60	Actavis
⚡ Tab orodispersible 1 mg .....	42.84	28	Risperdal Quicklet
Tab 2 mg – 1% DV Feb-15 to 2017 .....	2.34	60	Actavis
⚡ Tab orodispersible 2 mg .....	85.71	28	Risperdal Quicklet
Tab 3 mg – 1% DV Feb-15 to 2017 .....	2.55	60	Actavis
Tab 4 mg – 1% DV Feb-15 to 2017 .....	3.50	60	Actavis
Oral liq 1 mg per ml – 1% DV Sep-14 to 2017 .....	9.75	30 ml	Risperon
<b>➡Restricted</b>			
<b>Acute situations</b>			
Both:			
1 For a non-adherent patient on oral therapy with standard risperidone tablets or risperidone oral liquid; and			
2 The patient is under direct supervision for administration of medicine.			
<b>Chronic situations</b>			
Both:			
1 The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid; and			
2 The patient is under direct supervision for administration of medicine.			
<b>TRIFLUOPERAZINE HYDROCHLORIDE</b>			
Tab 1 mg			
Tab 2 mg			
Tab 5 mg			
<b>ZIPRASIDONE – Some items restricted see terms below</b>			
⚡ Cap 20 mg .....	87.88	60	Zeldox
⚡ Cap 40 mg .....	164.78	60	Zeldox
⚡ Cap 60 mg .....	247.17	60	Zeldox
⚡ Cap 80 mg .....	329.56	60	Zeldox
Inj 20 mg			
Inj 100 mg			
<b>➡Restricted</b>			
1 Patient is suffering from schizophrenia or related psychoses; and			
2 Either:			
2.1 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of unacceptable side effects; or			
2.2 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of inadequate clinical response.			
<b>ZUCLOPENTHIXOL ACETATE</b>			
Inj 50 mg per ml, 1 ml ampoule			
Inj 50 mg per ml, 2 ml ampoule			

⚡ Item restricted (see ➡ above); ⚡ Item restricted (see ➡ below)

e.g. Brand indicates brand example only. It is not a contracted product.



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
ZUCLOPENTHIXOL HYDROCHLORIDE			
Tab 10 mg .....	31.45	100	Clopixol

## Depot Injections

FLUPENTHIXOL DECANOATE			
Inj 20 mg per ml, 1 ml ampoule .....	13.14	5	Fluanxol
Inj 20 mg per ml, 2 ml ampoule .....	20.90	5	Fluanxol
Inj 100 mg per ml, 1 ml ampoule .....	40.87	5	Fluanxol
FLUPHENAZINE DECANOATE			
Inj 12.5 mg per 0.5 ml ampoule .....	17.60	5	Modecate
Inj 25 mg per ml, 1 ml ampoule .....	27.90	5	Modecate
Inj 100 mg per ml, 1 ml ampoule .....	154.50	5	Modecate
HALOPERIDOL DECANOATE			
Inj 50 mg per ml, 1 ml ampoule .....	28.39	5	Haldol
Inj 100 mg per ml, 1 ml ampoule .....	55.90	5	Haldol Concentrate
OLANZAPINE – <b>Restricted</b> see terms below			
⚡ Inj 210 mg vial .....	280.00	1	Zyprexa Relprevv
⚡ Inj 300 mg vial .....	460.00	1	Zyprexa Relprevv
⚡ Inj 405 mg vial .....	560.00	1	Zyprexa Relprevv

### ➡Restricted

#### Initiation

*Re-assessment required after 12 months*

Either:

- 1 The patient has had an initial Special Authority approval for risperidone depot injection or paliperidone depot injection; or
- 2 All of the following:
  - 2.1 The patient has schizophrenia; and
  - 2.2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
  - 2.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

#### Continuation

*Re-assessment required after 12 months*

The initiation of olanzapine depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

PALIPERIDONE – **Restricted** see terms below

⚡ Inj 25 mg syringe .....	194.25	1	Invega Sustenna
⚡ Inj 50 mg syringe .....	271.95	1	Invega Sustenna
⚡ Inj 75 mg syringe .....	357.42	1	Invega Sustenna
⚡ Inj 100 mg syringe .....	435.12	1	Invega Sustenna
⚡ Inj 150 mg syringe .....	435.12	1	Invega Sustenna

### ➡Restricted

#### Initiation

*Re-assessment required after 12 months*

Either:

- 1 The patient has had an initial Special Authority approval for risperidone depot injection or olanzapine depot injection; or
- 2 All of the following:
  - 2.1 The patient has schizophrenia or other psychotic disorder; and
  - 2.2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and

continued...

continued...

- 2.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

## Continuation

### Re-assessment required after 12 months

The initiation of paliperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

PIPTHIAZINE PALMITATE – **Restricted:** For continuation only

➔ Inj 50 mg per ml, 1 ml ampoule

➔ Inj 50 mg per ml, 2 ml ampoule

RISPERIDONE – **Restricted** see terms below

⚡ Inj 25 mg vial .....	135.98	1	Risperdal Consta
⚡ Inj 37.5 mg vial .....	178.71	1	Risperdal Consta
⚡ Inj 50 mg vial .....	217.56	1	Risperdal Consta

➔**Restricted**

## Initiation

### Re-assessment required after 12 months

Either:

- 1 The patient has had an initial Special Authority approval for paliperidone depot injection or olanzapine depot injection; or
- 2 All of the following:
  - 2.1 The patient has schizophrenia or other psychotic disorder; and
  - 2.2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
  - 2.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

## Continuation

### Re-assessment required after 12 months

The initiation of risperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

ZUCLOPENTHIXOL DECANOATE

Inj 200 mg per ml, 1 ml ampoule .....	19.80	5	Clopixol
---------------------------------------	-------	---	----------

## Anxiolytics

### ALPRAZOLAM

Tab 1 mg  
Tab 250 mcg  
Tab 500 mcg

### BUSPIRONE HYDROCHLORIDE

Tab 5 mg .....	28.00	100	Pacific Buspirone
Tab 10 mg .....	17.00	100	Pacific Buspirone

### CLONAZEPAM

Tab 500 mcg .....	6.68	100	Paxam
Tab 2 mg .....	12.75	100	Paxam

### DIAZEPAM

Tab 2 mg .....	11.44	500	Arrow-Diazepam
Tab 5 mg .....	13.71	500	Arrow-Diazepam

### LORAZEPAM

Tab 1 mg .....	19.82	250	Ativan
Tab 2.5 mg .....	13.49	100	Ativan

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>OXAZEPAM</b>			
Tab 10 mg – 1% DV Dec-14 to 2017 .....	6.17	100	<b>Ox-Pam</b>
Tab 15 mg – 1% DV Dec-14 to 2017 .....	8.53	100	<b>Ox-Pam</b>

## Multiple Sclerosis Treatments

**FINGOLIMOD – Restricted** see terms below

☞ Cap 0.5 mg .....2,650.00 28 Gilenya

☞ **Restricted**

Only for use in patients with approval by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (set out in Section B of the Pharmaceutical Schedule).

**NATALIZUMAB – Restricted** see terms below

☞ Inj 20 mg per ml, 15 ml vial .....1,750.00 1 Tysabri

☞ **Restricted**

Only for use in patients with approval by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (set out in Section B of the Pharmaceutical Schedule).

Natalizumab can only be dispensed from a pharmacy registered in the Tysabri Australasian Prescribing Programme operated by the supplier.

## Other Multiple Sclerosis Treatments

☞ **Restricted**

Only for use in patients with approval by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (set out in Section B of the Pharmaceutical Schedule).

**GLATIRAMER ACETATE – Restricted** see terms above

☞ Inj 20 mg per ml, 1 ml syringe

**INTERFERON BETA-1-ALPHA – Restricted** see terms above

☞ Inj 6 million iu in 0.5 ml pen injector .....1,170.00 4 Avonex Pen

☞ Inj 6 million iu in 0.5 ml syringe .....1,170.00 4 Avonex

☞ Inj 6 million iu vial .....1,170.00 4 Avonex

**INTERFERON BETA-1-BETA – Restricted** see terms above

☞ Inj 8 million iu per ml, 1 ml vial

## Sedatives and Hypnotics

**CHLORAL HYDRATE**

Oral liq 100 mg per ml

Oral liq 200 mg per ml

**LORMETAZEPAM – Restricted:** For continuation only

☞ Tab 1 mg

**MELATONIN – Restricted** see terms below

☞ Tab modified-release 2 mg *e.g. Circadin*

☞ Tab 1 mg

☞ Tab 2 mg

☞ Tab 3 mg

☞ Cap 2 mg

☞ Cap 3 mg

☞ **Restricted**

For in hospital use only. For the treatment of insomnia where benzodiazepines and zopiclone are contraindicated.

## NERVOUS SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>MIDAZOLAM</b>			
Tab 7.5 mg .....	40.00	100	Hypnovel
Oral liq 2 mg per ml			
Inj 1 mg per ml, 5 ml ampoule .....	10.00	10	Pfizer
	10.75		Hypnovel
Inj 5 mg per ml, 3 ml ampoule .....	11.90	5	Hypnovel Pfizer
<b>NITRAZEPAM</b>			
Tab 5 mg – 1% DV Dec-14 to 2017 .....	5.22	100	Nitrados
<b>PHENOBARBITONE</b>			
Inj 200 mg per ml, 1 ml ampoule			
<b>TEMAZEPAM</b>			
Tab 10 mg – 1% DV Sep-14 to 2017 .....	1.27	25	Normison
<b>TRIAZOLAM – Restricted:</b> For continuation only			
➡ Tab 125 mcg			
➡ Tab 250 mcg			
<b>ZOPICLONE</b>			
Tab 7.5 mg .....	1.90	30	Apo-Zopiclone

### Stimulants / ADHD Treatments

**ATOMOXETINE – Restricted** see terms below

⚡ Cap 10 mg .....	107.03	28	Strattera
⚡ Cap 18 mg .....	107.03	28	Strattera
⚡ Cap 25 mg .....	107.03	28	Strattera
⚡ Cap 40 mg .....	107.03	28	Strattera
⚡ Cap 60 mg .....	107.03	28	Strattera
⚡ Cap 80 mg .....	139.11	28	Strattera
⚡ Cap 100 mg .....	139.11	28	Strattera

➡ **Restricted**

All of the following:

- 1 Patient has ADHD (Attention Deficit and Hyperactivity Disorder) diagnosed according to DSM-IV or ICD 10 criteria; and
- 2 Once-daily dosing; and
- 3 Any of the following:
  - 3.1 Treatment with a subsidised formulation of a stimulant has resulted in the development or worsening of serious adverse reactions or where the combination of subsidised stimulant treatment with another agent would pose an unacceptable medical risk; or
  - 3.2 Treatment with a subsidised formulation of a stimulant has resulted in worsening of co-morbid substance abuse or there is a significant risk of diversion with subsidised stimulant therapy; or
  - 3.3 An effective dose of a subsidised formulation of a stimulant has been trialled and has been discontinued because of inadequate clinical response; or
  - 3.4 Treatment with a subsidised formulation of a stimulant is considered inappropriate because the patient has a history of psychoses or has a first-degree relative with schizophrenia; and
- 4 The patient will not be receiving treatment with atomoxetine in combination with a subsidised formulation of a stimulant, except for the purposes of transitioning from subsidised stimulant therapy to atomoxetine.

Note: A "subsidised formulation of a stimulant" refers to currently listed methylphenidate hydrochloride tablet formulations (immediate-release, sustained-release and extended-release) or dexamphetamine sulphate tablets.

**CAFFEINE**

Tab 100 mg

⚡ Item restricted (see ➡ above); ⚡ Item restricted (see ➡ below)

e.g. Brand indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
DEXAMFETAMINE SULFATE – <b>Restricted</b> see terms below			
⚡ Tab 5 mg – 1% DV Mar-13 to 2015.....	16.50	100	<b>PSM</b>

➡ **Restricted**

**ADHD**

Paediatrician or psychiatrist

Patient has ADHD (Attention Deficit and Hyperactivity Disorder), diagnosed according to DSM-IV or ICD 10 criteria

**Narcolepsy**

Neurologist or respiratory specialist

Patient suffers from narcolepsy

METHYLPHENIDATE HYDROCHLORIDE – **Restricted** see terms below

⚡ Tab extended-release 18 mg .....	58.96	30	Concerta
⚡ Tab extended-release 27 mg .....	65.44	30	Concerta
⚡ Tab extended-release 36 mg .....	71.93	30	Concerta
⚡ Tab extended-release 54 mg .....	86.24	30	Concerta
⚡ Tab immediate-release 5 mg .....	3.20	30	Rubifen
⚡ Tab immediate-release 10 mg .....	3.00	30	Ritalin
			Rubifen
⚡ Tab immediate-release 20 mg .....	7.85	30	Rubifen
⚡ Tab sustained-release 20 mg .....	10.95	30	Rubifen SR
	50.00	100	Ritalin SR
⚡ Cap modified-release 10 mg .....	15.60	30	Ritalin LA
⚡ Cap modified-release 20 mg .....	20.40	30	Ritalin LA
⚡ Cap modified-release 30 mg .....	25.52	30	Ritalin LA
⚡ Cap modified-release 40 mg .....	30.60	30	Ritalin LA

➡ **Restricted**

**ADHD (immediate-release and sustained-release formulations)**

Paediatrician or psychiatrist

Patient has ADHD (Attention Deficit and Hyperactivity Disorder), diagnosed according to DSM-IV or ICD 10 criteria

**Narcolepsy (immediate-release and sustained-release formulations)**

Neurologist or respiratory specialist

Patient suffers from narcolepsy

**Extended-release and modified-release formulations**

Paediatrician or psychiatrist

Both:

- 1 Patient has ADHD (Attention Deficit and Hyperactivity Disorder), diagnosed according to DSM-IV or ICD 10 criteria; and
- 2 Either:
  - 2.1 Patient is taking a currently listed formulation of methylphenidate hydrochloride (immediate-release or sustained-release) which has not been effective due to significant administration and/or compliance difficulties; or
  - 2.2 There is significant concern regarding the risk of diversion or abuse of immediate-release methylphenidate hydrochloride.

MODAFINIL – **Restricted** see terms on the next page

⚡ Tab 100 mg

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>➔Restricted</b>			
Neurologist or respiratory specialist			
All of the following:			
1	The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more; and		
2	Either:		
2.1	The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods; or		
2.2	The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations; and		
3	Either:		
3.1	An effective dose of a listed formulation of methylphenidate or dexamphetamine has been trialled and discontinued because of intolerable side effects; or		
3.2	Methylphenidate and dexamphetamine are contraindicated.		

## Treatments for Dementia

### DONEPEZIL HYDROCHLORIDE

Tab 5 mg – 1% DV Feb-15 to 2017.....	5.48	90	Donepezil-Rex
Tab 10 mg – 1% DV Feb-15 to 2017.....	10.51	90	Donepezil-Rex

### RIVASTIGMINE – Restricted see terms below

⚡ Patch 4.6 mg per 24 hour .....	90.00	30	Exelon
⚡ Patch 9.5 mg per 24 hour .....	90.00	30	Exelon

### ➔Restricted

#### Initiation

*Re-assessment required after 6 months*

Both:

- 1 The patient has been diagnosed with dementia; and
- 2 The patient has experienced intolerable nausea and/or vomiting from donepezil tablets.

#### Continuation

*Re-assessment required after 12 months*

Both:

- 1 The treatment remains appropriate; and
- 2 The patient has demonstrated a significant and sustained benefit from treatment.

## Treatments for Substance Dependence

### BUPRENORPHINE WITH NALOXONE – Restricted see terms below

⚡ Tab 2 mg with naloxone 0.5 mg .....	57.40	28	Suboxone
⚡ Tab 8 mg with naloxone 2 mg .....	166.00	28	Suboxone

### ➔Restricted

#### Detoxification

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and
- 3 Prescriber works in an opioid treatment service approved by the Ministry of Health.

#### Maintenance treatment

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient will not be receiving methadone; and
- 3 Patient is currently enrolled in an opioid substitution treatment program in a service approved by the Ministry of Health; and
- 4 Prescriber works in an opioid treatment service approved by the Ministry of Health.

### BUPROPION HYDROCHLORIDE

Tab modified-release 150 mg – 1% DV Oct-13 to 2016.....	4.97	30	Zyban
---	------	----	-------

⚡ Item restricted (see ➔ above); ⚡ Item restricted (see ➔ below)

e.g. Brand indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>DISULFIRAM</b>			
Tab 200 mg .....	24.30	100	Antabuse
<b>NALTREXONE HYDROCHLORIDE – Restricted</b> see terms below			
⚡ Tab 50 mg – 1% DV Sep-13 to 2016 .....	76.00	30	<b>Naltraccord</b>
➡ <b>Restricted</b>			
<b>Alcohol dependence</b>			
Both:			
1 Patient is currently enrolled, or is planned to be enrolled, in a recognised comprehensive treatment programme for alcohol dependence; and			
2 Naltrexone is to be prescribed by, or on the recommendation of, a physician working in an Alcohol and Drug Service.			
<b>Constipation</b>			
For the treatment of opioid-induced constipation			
<b>NICOTINE – Some items restricted</b> see terms below			
Gum 2 mg – 1% DV Apr-14 to 2017 .....	26.13	384	<b>Habitrol (Classic)</b> <b>Habitrol (Fruit)</b> <b>Habitrol (Mint)</b>
Gum 4 mg – 1% DV Apr-14 to 2017 .....	30.12	384	<b>Habitrol (Classic)</b> <b>Habitrol (Fruit)</b> <b>Habitrol (Mint)</b>
Patch 7 mg per 24 hours – 1% DV Apr-14 to 2017 .....	12.40	28	<b>Habitrol</b>
Patch 14 mg per 24 hours – 1% DV Apr-14 to 2017 .....	13.27	28	<b>Habitrol</b>
Patch 21 mg per 24 hours – 1% DV Apr-14 to 2017 .....	14.02	28	<b>Habitrol</b>
Lozenge 1 mg – 1% DV Apr-14 to 2017 .....	15.15	216	<b>Habitrol</b>
Lozenge 2 mg – 1% DV Apr-14 to 2017 .....	16.60	216	<b>Habitrol</b>
⚡ Soln for inhalation 15 mg cartridge			<i>e.g. Nicorette Inhalator</i>
➡ <b>Restricted</b>			
Any of the following:			
1 For perioperative use in patients who have a 'nil by mouth' instruction; or			
2 For use within mental health inpatient units; or			
3 For acute use in agitated patients who are unable to leave the hospital facilities.			
<b>VARENICLINE – Restricted</b> see terms below			
⚡ Tab 0.5 mg × 11 and 1 mg × 14 .....	60.48	25	Champix
⚡ Tab 1 mg .....	67.74	28	Champix
	135.48	56	Champix
➡ <b>Restricted</b>			
All of the following:			
1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and			
2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and			
3 Either:			
3.1 The patient has tried but failed to quit smoking after at least two separate trials of nicotine replacement therapy, at least one of which included the patient receiving comprehensive advice on the optimal use of nicotine replacement therapy; or			
3.2 The patient has tried but failed to quit smoking using bupropion or nortriptyline; and			
4 The patient has not used funded varenicline in the last 12 months; and			
5 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and			
6 The patient is not pregnant; and			
7 The patient will not be prescribed more than 3 months' funded varenicline in a 12 month period.			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Chemotherapeutic Agents</b>			
<b>Alkylating Agents</b>			
BUSULFAN			
Tab 2 mg .....	59.50	100	Myleran
Inj 6 mg per ml, 10 ml ampoule			
CARMUSTINE			
Inj 100 mg vial			
CHLORAMBUCIL			
Tab 2 mg			
CYCLOPHOSPHAMIDE			
Tab 50 mg .....	79.00	50	Endoxan
	158.00	100	Procytox
Inj 1 g vial .....	35.03	1	Endoxan
Inj 2 g vial .....	70.06	1	Endoxan
IFOSFAMIDE			
Inj 1 g vial .....	96.00	1	Holoxan
Inj 2 g vial .....	180.00	1	Holoxan
LOMUSTINE			
Cap 10 mg .....	132.59	20	Ceenu
Cap 40 mg .....	399.15	20	Ceenu
MELPHALAN			
Tab 2 mg			
Inj 50 mg vial			
THIOTEPA			
Inj 15 mg vial			
<b>Anthracyclines and Other Cytotoxic Antibiotics</b>			
BLEOMYCIN SULPHATE			
Inj 15,000 iu (10 mg) vial			
DACTINOMYCIN [ACTINOMYCIN D]			
Inj 0.5 mg vial			
DAUNORUBICIN			
Inj 2 mg per ml, 10 ml vial – 1% DV Aug-13 to 2016 .....	118.72	1	Pfizer
DOXORUBICIN HYDROCHLORIDE			
Note: DV limit applies to all 50 mg presentations of doxorubicin hydrochloride.			
Inj 2 mg per ml, 5 ml vial			
Inj 2 mg per ml, 25 ml vial – 1% DV Mar-13 to 2015 .....	17.00	1	Arrow-Doxorubicin
Inj 50 mg vial			
Inj 2 mg per ml, 50 ml vial			
Inj 2 mg per ml, 100 ml vial – 1% DV Mar-13 to 2015 .....	65.00	1	Arrow-Doxorubicin



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>EPIRUBICIN HYDROCHLORIDE</b>			
Inj 2 mg per ml, 5 ml vial .....	25.00	1	Epirubicin Ebewe
Inj 2 mg per ml, 25 ml vial – 1% DV Aug-12 to 2015 .....	39.38	1	<b>DBL Epirubicin Hydrochloride</b>
Inj 2 mg per ml, 50 ml vial – 1% DV Aug-12 to 2015 .....	58.20	1	<b>DBL Epirubicin Hydrochloride</b>
Inj 2 mg per ml, 100 ml vial – 1% DV Aug-12 to 2015 .....	94.50	1	<b>DBL Epirubicin Hydrochloride</b>
<b>IDARUBICIN HYDROCHLORIDE</b>			
Inj 5 mg vial – 1% DV Sep-12 to 2015 .....	100.00	1	<b>Zavedos</b>
Inj 10 mg vial – 1% DV Sep-12 to 2015 .....	200.00	1	<b>Zavedos</b>
<b>MITOMYCIN C</b>			
Inj 5 mg vial – 1% DV Oct-13 to 2016 .....	79.75	1	<b>Arrow</b>
<b>MITOZANTRONE</b>			
Inj 2 mg per ml, 5 ml vial .....	110.00	1	Mitozantrone Ebewe
Inj 2 mg per ml, 10 ml vial .....	100.00	1	Mitozantrone Ebewe
Inj 2 mg per ml, 12.5 ml vial .....	413.21	1	Onkotrone

## Antimetabolites

**AZACITIDINE – Restricted** see terms below

⚡ Inj 100 mg vial .....605.00 1 Vidaza

### ➡Restricted

#### Initiation

Haematologist

*Re-assessment required after 12 months*

All of the following:

- 1 Any of the following:
  - 1.1 The patient has International Prognostic Scoring System (IPSS) intermediate-2 or high risk myelodysplastic syndrome; or
  - 1.2 The patient has chronic myelomonocytic leukaemia (10%-29% marrow blasts without myeloproliferative disorder); or
  - 1.3 The patient has acute myeloid leukaemia with 20-30% blasts and multi-lineage dysplasia, according to World Health Organisation Classification (WHO); and
- 2 The patient has performance status (WHO/ECOG) grade 0-2; and
- 3 The patient does not have secondary myelodysplastic syndrome resulting from chemical injury or prior treatment with chemotherapy and/or radiation for other diseases; and
- 4 The patient has an estimated life expectancy of at least 3 months.

Notes: Indication marked with a \* is an Unapproved Indication. Studies of temozolomide show that its benefit is predominantly in those patients with a good performance status (WHO grade 0 or 1 or Karnofsky score >80), and in patients who have had at least a partial resection of the tumour.

#### Continuation

Haematologist

*Re-assessment required after 12 months*

Both:

- 1 No evidence of disease progression, and
- 2 The treatment remains appropriate and patient is benefitting from treatment.

#### CAPECITABINE

Tab 150 mg – 1% DV Sep-14 to 2016 .....	30.00	60	<b>Capecitabine Winthrop</b>
Tab 500 mg – 1% DV Sep-14 to 2016 .....	120.00	120	<b>Capecitabine Winthrop</b>

# ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>CLADRIBINE</b>			
Inj 2 mg per ml, 5 ml vial			
Inj 1 mg per ml, 10 ml vial .....	5,249.72	7	Leustatin
<b>CYTARABINE</b>			
Inj 20 mg per ml, 5 ml vial – 1% DV Nov-13 to 2016 .....	55.00	5	<b>Pfizer</b>
Inj 20 mg per ml, 25 ml vial .....	18.15	1	Pfizer
Inj 100 mg per ml, 10 ml vial – 1% DV Nov-13 to 2016 .....	8.83	1	<b>Pfizer</b>
Inj 100 mg per ml, 20 ml vial – 1% DV Nov-13 to 2016 .....	17.65	1	<b>Pfizer</b>
<b>FLUDARABINE PHOSPHATE</b>			
Tab 10 mg – 1% DV Jun-12 to 2015 .....	433.50	20	<b>Fludara Oral</b>
Inj 50 mg vial .....	525.00	5	Fludarabine Ebewe
<b>FLUOROURACIL</b>			
Inj 25 mg per ml, 100 ml vial .....	13.55	1	Hospira
Inj 50 mg per ml, 10 ml vial .....	26.25	5	Fluorouracil Ebewe
Inj 50 mg per ml, 20 ml vial .....	7.50	1	Fluorouracil Ebewe
Inj 50 mg per ml, 50 ml vial .....	18.00	1	Fluorouracil Ebewe
Inj 50 mg per ml, 100 ml vial .....	34.50	1	Fluorouracil Ebewe
<b>GEMCITABINE</b>			
Inj 10 mg per ml, 20 ml vial – 1% DV Oct-14 to 2017 .....	8.36	1	<b>Gemcitabine Ebewe</b>
Inj 10 mg per ml, 100 ml vial – 1% DV Oct-14 to 2017 .....	15.89	1	<b>Gemcitabine Ebewe</b>
<b>MERCAPTOPURINE</b>			
Tab 50 mg – 1% DV Oct-13 to 2016 .....	49.41	25	<b>Puri-nethol</b>
<b>METHOTREXATE</b>			
Tab 2.5 mg – 1% DV Jun-14 to 2015 .....	3.82	30	<b>Trexate</b>
Tab 10 mg – 1% DV Jun-14 to 2015 .....	26.25	50	<b>Trexate</b>
Inj 2.5 mg per ml, 2 ml vial			
Inj 7.5 mg prefilled syringe – 1% DV Jan-14 to 2016 .....	17.19	1	<b>Methotrexate Sandoz</b>
Inj 10 mg prefilled syringe – 1% DV Jan-14 to 2016 .....	17.25	1	<b>Methotrexate Sandoz</b>
Inj 15 mg prefilled syringe – 1% DV Jan-14 to 2016 .....	17.38	1	<b>Methotrexate Sandoz</b>
Inj 20 mg prefilled syringe – 1% DV Jan-14 to 2016 .....	17.50	1	<b>Methotrexate Sandoz</b>
Inj 25 mg prefilled syringe – 1% DV Jan-14 to 2016 .....	17.63	1	<b>Methotrexate Sandoz</b>
Inj 30 mg prefilled syringe – 1% DV Jan-14 to 2016 .....	17.75	1	<b>Methotrexate Sandoz</b>
Inj 25 mg per ml, 2 ml vial – 1% DV Sep-13 to 2016 .....	20.20	5	<b>Hospira</b>
Inj 25 mg per ml, 20 ml vial – 1% DV Sep-13 to 2016 .....	27.78	1	<b>Hospira</b>
Inj 100 mg per ml, 10 ml vial .....	25.00	1	Methotrexate Ebewe
Inj 100 mg per ml, 50 ml vial – 1% DV Oct-14 to 2017 .....	99.99	1	<b>Methotrexate Ebewe</b>
<b>THIOGUANINE</b>			
Tab 40 mg			

## Other Cytotoxic Agents

<b>AMSACRINE</b>			
Inj 50 mg per ml, 1.5 ml ampoule			
Inj 75 mg			
<b>ANAGRELIDE HYDROCHLORIDE</b>			
Cap 0.5 mg			
<b>ARSENIC TRIOXIDE</b>			
Inj 1 mg per ml, 10 ml vial .....	4,817.00	10	AFT

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)

e.g. Brand indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>BORTEZOMIB – Restricted</b> see terms below			
⚡ Inj 1 mg vial .....	540.70	1	Velcade
⚡ Inj 3.5 mg vial .....	1,892.50	1	Velcade
<b>➡Restricted</b>			
<b>Initiation - treatment naive multiple myeloma/amyloidosis</b>			
Both:			
1 Either:			
1.1 The patient has treatment-naive symptomatic multiple myeloma; or			
1.2 The patient has treatment-naive symptomatic systemic AL amyloidosis *; and			
2 Maximum of 9 treatment cycles.			
Note: Indications marked with * are Unapproved Indications.			
<b>Initiation - relapsed/refractory multiple myeloma/amyloidosis</b>			
All of the following:			
1 Either:			
1.1 The patient has relapsed or refractory multiple myeloma; or			
1.2 The patient has relapsed or refractory systemic AL amyloidosis *; and			
2 The patient has received only one prior front line chemotherapy for multiple myeloma or amyloidosis; and			
3 The patient has not had prior publicly funded treatment with bortezomib; and			
4 Maximum of 4 treatment cycles.			
Note: Indications marked with * are Unapproved Indications.			
<b>Continuation - relapsed/refractory multiple myeloma/amyloidosis</b>			
Both:			
1 The patient's disease obtained at least a partial response from treatment with bortezomib at the completion of cycle 4; and			
2 Maximum of 4 further treatment cycles (making a total maximum of 8 consecutive treatment cycles).			
Notes: Responding relapsed/refractory multiple myeloma patients should receive no more than 2 additional cycles of treatment beyond the cycle at which a confirmed complete response was first achieved. A line of therapy is considered to comprise either:			
1 A known therapeutic chemotherapy regimen and supportive treatments; or			
2 A transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments.			
Refer to datasheet for recommended dosage and number of doses of bortezomib per treatment cycle.			
<b>COLASPASE [L-ASPARAGINASE]</b>			
Inj 10,000 iu vial .....	102.32	1	Leunase
<b>DACARBAZINE</b>			
Inj 200 mg vial – 1% DV Oct-13 to 2016 .....	51.84	1	Hospira
<b>ETOPOSIDE</b>			
Cap 50 mg .....	340.73	20	Vepesid
Cap 100 mg .....	340.73	10	Vepesid
Inj 20 mg per ml, 5 ml vial .....	25.00	1	Hospira
<b>ETOPOSIDE (AS PHOSPHATE)</b>			
Inj 100 mg vial .....	40.00	1	Etopophos
<b>HYDROXYUREA</b>			
Cap 500 mg .....	31.76	100	Hydrea
<b>IRINOTECAN HYDROCHLORIDE</b>			
Inj 20 mg per ml, 2 ml vial – 1% DV Nov-12 to 2015 .....	9.34	1	Irinotecan Actavis 40
Inj 20 mg per ml, 5 ml vial – 1% DV Nov-12 to 2015 .....	23.34	1	Irinotecan Actavis 100
<b>LENALIDOMIDE – Restricted</b> see terms on the next page			
⚡ Cap 10 mg .....	6,207.00	21	Revlimid
⚡ Cap 25 mg .....	7,627.00	21	Revlimid

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>➔Restricted</b>			
<b>Initiation</b>			
Haematologist			
<i>Re-assessment required after 6 months</i>			
All of the following:			
1 Patient has relapsed or refractory multiple myeloma with progressive disease; and			
2 Either:			
2.1 Lenalidomide to be used as third line* treatment for multiple myeloma; or			
2.2 Both:			
2.2.1 Lenalidomide to be used as second line treatment for multiple myeloma; and			
2.2.2 The patient has experienced severe (grade $\geq 3$ ), dose limiting, peripheral neuropathy with either bortezomib or thalidomide that precludes further treatment with either of these treatments; and			
3 Lenalidomide to be administered at a maximum dose of 25 mg/day in combination with dexamethasone.			
<b>Continuation</b>			
Haematologist			
<i>Re-assessment required after 6 months</i>			
Both:			
1 No evidence of disease progression; and			
2 The treatment remains appropriate and patient is benefitting from treatment.			
Notes: Indication marked with * is an Unapproved Indication (refer to Interpretations and Definitions). A line of treatment is considered to comprise either: a) a known therapeutic chemotherapy regimen and supportive treatments or b) a transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments. Prescriptions must be written by a registered prescriber in the lenalidomide risk management programme operated by the supplier.			
PEGASPARGASE – <b>Restricted</b> see terms below			
⚡ Inj 750 iu per ml, 5 ml vial .....	3,005.00	1	Oncaspar
<b>➔Restricted</b>			
<b>Newly diagnosed ALL</b>			
<i>Limited to 12 months' treatment</i>			
All of the following:			
1 The patient has newly diagnosed acute lymphoblastic leukaemia; and			
2 Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol; and			
3 Treatment is with curative intent.			
<b>Relapsed ALL</b>			
<i>Limited to 12 months' treatment</i>			
All of the following:			
1 The patient has relapsed acute lymphoblastic leukaemia; and			
2 Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol; and			
3 Treatment is with curative intent.			
<b>PENTOSTATIN [DEOXYCOFORMYCIN]</b>			
Inj 10 mg vial			
<b>PROCARBAZINE HYDROCHLORIDE</b>			
Cap 50 mg .....	498.00	50	Natulan
<b>TEMOZOLOMIDE – Restricted</b> see terms on the next page			
⚡ Cap 5 mg – 1% DV Sep-13 to 2016 .....	8.00	5	Temaccord
⚡ Cap 20 mg – 1% DV Sep-13 to 2016 .....	36.00	5	Temaccord
⚡ Cap 100 mg – 1% DV Sep-13 to 2016 .....	175.00	5	Temaccord
⚡ Cap 250 mg – 1% DV Sep-13 to 2016 .....	410.00	5	Temaccord

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➔ **Restricted**

All of the following:

- 1 Either:
  - 1.1 Patient has newly diagnosed glioblastoma multiforme; or
  - 1.2 Patient has newly diagnosed anaplastic astrocytoma\*; and
- 2 Temozolomide is to be (or has been) given concomitantly with radiotherapy; and
- 3 Following concomitant treatment temozolomide is to be used for a maximum of six cycles of 5 days treatment, at a maximum dose of 200 mg/m<sup>2</sup>.

Notes: Indication marked with a \* is an Unapproved Indication. Studies of temozolomide show that its benefit is predominantly in those patients with a good performance status (WHO grade 0 or 1 or Karnofsky score >80), and in patients who have had at least a partial resection of the tumour.

THALIDOMIDE – **Restricted** see terms below

⚡ Cap 50 mg .....	378.00	28	Thalomid
⚡ Cap 100 mg .....	756.00	28	Thalomid

➔ **Restricted**

**Initiation**

Either:

- 1 The patient has multiple myeloma; or
- 2 The patient has systemic AL amyloidosis\*; or
- 3 The patient has erythema nodosum leprosum.

**Continuation**

Patient has obtained a response from treatment during the initial approval period.

Notes: Prescription must be written by a registered prescriber in the thalidomide risk management programme operated by the supplier.

Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen.

Indication marked with \* is an Unapproved Indication

TRETINOIN

Cap 10 mg .....	479.50	100	Vesanoid
-----------------	--------	-----	----------

**Platinum Compounds**

CARBOPLATIN

Inj 10 mg per ml, 5 ml vial .....	20.00	1	Carboplatin Ebewe
Inj 10 mg per ml, 15 ml vial – 1% DV Jan-13 to 2015 .....	19.50	1	<b>Carbaccord</b>
Inj 10 mg per ml, 45 ml vial – 1% DV Jan-13 to 2015 .....	48.50	1	<b>Carbaccord</b>
Inj 10 mg per ml, 100 ml vial .....	105.00	1	Carboplatin Ebewe

CISPLATIN

Inj 1 mg per ml, 50 ml vial .....	15.00	1	Cisplatin Ebewe
Inj 1 mg per ml, 100 ml vial .....	21.00	1	Cisplatin Ebewe

OXALIPLATIN

Inj 50 mg vial – 1% DV Aug-12 to 2015 .....	15.32	1	<b>Oxaliplatin Actavis 50</b>
Inj 100 mg vial – 1% DV Aug-12 to 2015 .....	25.01	1	<b>Oxaliplatin Actavis 100</b>

**Protein-Tyrosine Kinase Inhibitors**

DASATINIB – **Restricted** see terms below

⚡ Tab 20 mg .....	3,774.06	60	Sprycel
⚡ Tab 50 mg .....	6,214.20	60	Sprycel
⚡ Tab 70 mg .....	7,692.58	60	Sprycel
⚡ Tab 100 mg .....	6,214.20	30	Sprycel

➔ **Restricted**

For use in patients with approval from the CML/GIST Co-ordinator

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>ERLOTINIB – Restricted</b> see terms below			
☞ Tab 100 mg .....	1,133.00	30	Tarceva
☞ Tab 150 mg .....	1,700.00	30	Tarceva

**☞Restricted**
**Initiation**

*Re-assessment required after 3 months*

Either:

- 1 All of the following:
  - 1.1 Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
  - 1.2 There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase; and
  - 1.3 Either:
    - 1.3.1 Patient is treatment naive; or
    - 1.3.2 Both:
      - 1.3.2.1 Patient has documented disease progression following treatment with first line platinum based chemotherapy; and
      - 1.3.2.2 Patient has not received prior treatment with gefitinib; and
  - 1.4 Erlotinib is to be given for a maximum of 3 months, or
- 2 The patient received funded erlotinib prior to 31 December 2013 and radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

**Continuation**

*Re-assessment required after 6 months*

Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

**GEFITINIB – Restricted** see terms below

☞ Tab 250 mg .....	1,700.00	30	Iressa
--------------------	----------	----	--------

**☞Restricted**
**Initiation**

*Re-assessment required after 3 months*

Both

- 1 Patient has treatment naive locally advanced, or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
- 2 There is documentation confirming that disease expresses activating mutations of EGFR tyrosine kinase.

**Continuation**

*Re-assessment required after 6 months*

Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

**IMATINIB MESILATE**

Note: Imatinib-AFT is not a registered for the treatment of Gastro Intestinal Stromal Tumours (GIST). The Glivec brand of imatinib mesilate (supplied by Novartis) remains fully subsidised under Special Authority for patients with unresectable and/or metastatic malignant GIST, see SA1460 in Section B of the Pharmaceutical Schedule.

☞ Tab 100 mg .....	2,400.00	60	Glivec
--------------------	----------	----	--------

**☞Restricted**
**Initiation**

*Re-assessment required after 12 months*

Both:

- 1 Patient has diagnosis (confirmed by an oncologist) of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST); and
- 2 Maximum dose of 400 mg/day.

**Continuation**

*Re-assessment required after 12 months*

Adequate clinical response to treatment with imatinib (prescriber determined).

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Cap 100 mg – <b>1% DV Jul-14 to 2017</b> .....	298.90	60	<b>Imatinib-AFT</b>
Cap 400 mg .....	597.80	30	Imatinib-AFT

LAPATINIB – **Restricted** see terms below

⚡ Tab 250 mg ..... 1,899.00 70 Tykerb

➡ **Restricted**

**Initiation**

*Re-assessment required after 12 months*

Either:

- 1 All of the following:
  - 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
  - 1.2 The patient has not previously received trastuzumab treatment for HER 2 positive metastatic breast cancer; and
  - 1.3 Lapatinib not to be given in combination with trastuzumab; and
  - 1.4 Lapatinib to be discontinued at disease progression; or
- 2 All of the following:
  - 2.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
  - 2.2 The patient started trastuzumab for metastatic breast cancer but discontinued trastuzumab within 3 months of starting treatment due to intolerance; and
  - 2.3 The cancer did not progress whilst on trastuzumab; and
  - 2.4 Lapatinib not to be given in combination with trastuzumab; and
  - 2.5 Lapatinib to be discontinued at disease progression.

**Continuation**

*Re-assessment required after 12 months*

All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The cancer has not progressed at any time point during the previous 12 months whilst on lapatinib; and
- 3 Lapatinib not to be given in combination with trastuzumab; and
- 4 Lapatinib to be discontinued at disease progression.

NILOTINIB – **Restricted** see terms below

⚡ Cap 150 mg ..... 4,680.00 120 Tasigna  
 ⚡ Cap 200 mg ..... 6,532.00 120 Tasigna

➡ **Restricted**

**Initiation**

Haematologist

*Re-assessment required after 6 months*

All of the following:

- 1 Patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis, accelerated phase, or in chronic phase; and
- 2 Either:
  - 2.1 Patient has documented CML treatment failure\* with imatinib; or
  - 2.2 Patient has experienced treatment limiting toxicity with imatinib precluding further treatment with imatinib; and
- 3 Maximum nilotinib dose of 800 mg/day; and
- 4 Subsidised for use as monotherapy only.

Note: \*treatment failure as defined by Leukaemia Net Guidelines.

**Continuation**

Haematologist

*Re-assessment required after 6 months*

All of the following:

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
continued...			
<ol style="list-style-type: none"> <li>1 Lack of treatment failure while on nilotinib as defined by Leukaemia Net Guidelines; and</li> <li>2 Nilotinib treatment remains appropriate and the patient is benefiting from treatment; and</li> <li>3 Maximum nilotinib dose of 800 mg/day; and</li> <li>4 Subsidised for use as monotherapy only.</li> </ol>			
PAZOPANIB – <b>Restricted</b> see terms below			
☞ Tab 200 mg .....	1,334.70	30	Votrient
☞ Tab 400 mg .....	2,669.40	30	Votrient
☞ <b>Restricted</b>			
<b>Initiation</b>			
<i>Re-assessment required after 3 months</i>			
All of the following:			
<ol style="list-style-type: none"> <li>1 The patient has metastatic renal cell carcinoma; and</li> <li>2 Any of the following: <ol style="list-style-type: none"> <li>2.1 The patient is treatment naive; or</li> <li>2.2 The patient has only received prior cytokine treatment; or</li> <li>2.3 Both: <ol style="list-style-type: none"> <li>2.3.1 The patient has discontinued sunitinib within 3 months of starting treatment due to intolerance; and</li> <li>2.3.2 The cancer did not progress whilst on sunitinib; and</li> </ol> </li> </ol> </li> <li>3 The patient has good performance status (WHO/ECOG grade 0-2); and</li> <li>4 The disease is of predominant clear cell histology; and</li> <li>5 The patient has intermediate or poor prognosis defined as any of the following: <ol style="list-style-type: none"> <li>5.1 Lactate dehydrogenase level &gt; 1.5 times upper limit of normal; or</li> <li>5.2 Haemoglobin level &lt; lower limit of normal; or</li> <li>5.3 Corrected serum calcium level &gt; 10 mg/dL (2.5 mmol/L); or</li> <li>5.4 Interval of &lt; 1 year from original diagnosis to the start of systemic therapy; or</li> <li>5.5 Karnofsky performance score of ≤ 70; or</li> <li>5.6 ≥ 2 sites of organ metastasis.</li> </ol> </li> </ol>			
<b>Continuation</b>			
<i>Re-assessment required after 3 months</i>			
Both:			
<ol style="list-style-type: none"> <li>1 No evidence of disease progression; and</li> <li>2 The treatment remains appropriate and the patient is benefiting from treatment.</li> </ol>			
Notes: Pazopanib treatment should be stopped if disease progresses.			
Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.			
SUNITINIB – <b>Restricted</b> see terms below			
☞ Cap 12.5 mg .....	2,315.38	28	Sutent
☞ Cap 25 mg .....	4,630.77	28	Sutent
☞ Cap 50 mg .....	9,261.54	28	Sutent
☞ <b>Restricted</b>			
<i>Re-assessment required after 3 months</i>			
<b>Initiation - RCC</b>			
<ol style="list-style-type: none"> <li>1 The patient has metastatic renal cell carcinoma; and</li> <li>2 Any of the following: <ol style="list-style-type: none"> <li>2.1 The patient is treatment naive; or</li> <li>2.2 The patient has only received prior cytokine treatment; or</li> <li>2.3 The patient has only received prior treatment with an investigational agent within the confines of a bona fide clinical trial which has Ethics Committee approval; or</li> </ol> </li> </ol>			
continued...			



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
continued...			
2.4 Both:			
2.4.1 The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance; and			
2.4.2 The cancer did not progress whilst on pazopanib; and			
3 The patient has good performance status (WHO/ECOG grade 0-2); and			
4 The disease is of predominant clear cell histology; and			
5 The patient has intermediate or poor prognosis defined as any of the following:			
5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; or			
5.2 Haemoglobin level < lower limit of normal; or			
5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); or			
5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; or			
5.5 Karnofsky performance score of ≤ 70; or			
5.6 ≥ 2 sites of organ metastasis; and			
6 Sunitinib to be used for a maximum of 2 cycles.			
<b>Continuation - RCC</b>			
<i>Re-assessment required after 3 months</i>			
Both:			
1 No evidence of disease progression; and			
2 The treatment remains appropriate and the patient is benefiting from treatment.			
<b>Initiation - GIST</b>			
<i>Re-assessment required after 3 months</i>			
Both:			
1 The patient has unresectable or metastatic malignant gastrointestinal stromal tumour (GIST); and			
2 Either:			
2.1 The patient's disease has progressed following treatment with imatinib; or			
2.2 The patient has documented treatment-limiting intolerance, or toxicity to, imatinib.			
<b>Continuation - GIST</b>			
<i>Re-assessment required after 6 months</i>			
Both:			
The patient has responded to treatment or has stable disease as determined by Choi's modified CT response evaluation criteria as follows:			
1 Any of the following:			
1.1 The patient has had a complete response (disappearance of all lesions and no new lesions); or			
1.2 The patient has had a partial response (a decrease in size of ≥ 10% or decrease in tumour density in Hounsfield Units (HU) of ≥ 15% on CT and no new lesions and no obvious progression of non-measurable disease); or			
1.3 The patient has stable disease (does not meet criteria the two above) and does not have progressive disease and no symptomatic deterioration attributed to tumour progression; and			
2 The treatment remains appropriate and the patient is benefiting from treatment.			
Notes: RCC - Sunitinib treatment should be stopped if disease progresses.			
Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.			
GIST - It is recommended that response to treatment be assessed using Choi's modified CT response evaluation criteria (J Clin Oncol, 2007, 25:1753-1759). Progressive disease is defined as either: an increase in tumour size of ≥ 10% and not meeting criteria of partial response (PR) by tumour density (HU) on CT; or: new lesions, or new intratumoral nodules, or increase in the size of the existing intratumoral nodules.			
<b>Taxanes</b>			
<b>DOCETAXEL</b>			
Inj 10 mg per ml, 2 ml vial – 1% DV Dec-14 to 2017 .....	13.70	1	<b>DBL Docetaxel</b>
Inj 10 mg per ml, 8 ml vial – 1% DV Dec-14 to 2017 .....	29.99	1	<b>DBL Docetaxel</b>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>PACLITAXEL</b>			
Inj 6 mg per ml, 5 ml vial – 1% DV Sep-14 to 2017 .....	45.00	5	<b>Paclitaxel Ebewe</b>
Inj 6 mg per ml, 16.7 ml vial – 1% DV Sep-14 to 2017 .....	19.02	1	<b>Paclitaxel Ebewe</b>
Inj 6 mg per ml, 25 ml vial – 1% DV Sep-14 to 2017 .....	26.69	1	<b>Paclitaxel Ebewe</b>
Inj 6 mg per ml, 50 ml vial – 1% DV Sep-14 to 2017 .....	36.53	1	<b>Paclitaxel Ebewe</b>
Inj 6 mg per ml, 100 ml vial – 1% DV Sep-14 to 2017 .....	73.06	1	<b>Paclitaxel Ebewe</b>

### Treatment of Cytotoxic-Induced Side Effects

<b>CALCIUM FOLINATE</b>			
Tab 15 mg .....	82.45	10	<b>DBL Leucovorin Calcium</b>
Inj 3 mg per ml, 1 ml ampoule			
Inj 10 mg per ml, 5 ml ampoule – 1% DV Oct-14 to 2017 .....	18.25	5	<b>Calcium Folate Ebewe</b>
Inj 10 mg per ml, 10 ml vial – 1% DV Oct-14 to 2017 .....	7.33	1	<b>Calcium Folate Ebewe</b>
Inj 10 mg per ml, 30 ml vial – 1% DV Oct-14 to 2017 .....	22.51	1	<b>Calcium Folate Ebewe</b>
Inj 10 mg per ml, 100 ml vial – 1% DV Oct-14 to 2017 .....	67.51	1	<b>Calcium Folate Ebewe</b>

<b>MESNA</b>			
Tab 400 mg – 1% DV Oct-13 to 2016 .....	227.50	50	<b>Uromitexan</b>
Tab 600 mg – 1% DV Oct-13 to 2016 .....	339.50	50	<b>Uromitexan</b>
Inj 100 mg per ml, 4 ml ampoule – 1% DV Oct-13 to 2016 .....	148.05	15	<b>Uromitexan</b>
Inj 100 mg per ml, 10 ml ampoule – 1% DV Oct-13 to 2016 .....	339.90	15	<b>Uromitexan</b>

### Vinca Alkaloids

<b>VINBLASTINE SULPHATE</b>			
Inj 1 mg per ml, 10 ml vial .....	137.50	5	<b>Hospira</b>
<b>VINCISTINE SULPHATE</b>			
Inj 1 mg per ml, 1 ml vial – 1% DV Sep-13 to 2016 .....	64.80	5	<b>Hospira</b>
Inj 1 mg per ml, 2 ml vial – 1% DV Sep-13 to 2016 .....	69.60	5	<b>Hospira</b>
<b>VINOELBINE</b>			
Inj 10 mg per ml, 1 ml vial – 1% DV Sep-12 to 2015 .....	12.85	1	<b>Navelbine</b>
Inj 10 mg per ml, 5 ml vial – 1% DV Sep-12 to 2015 .....	64.25	1	<b>Navelbine</b>

### Endocrine Therapy

<b>BICALUTAMIDE</b>			
Tab 50 mg – 1% DV Sep-14 to 2017 .....	4.90	28	<b>Bicalaccord</b>
<b>FLUTAMIDE</b>			
Tab 250 mg .....	55.00	100	<b>Flutamin</b>
<b>MEGESTROL ACETATE</b>			
Tab 160 mg – 1% DV Jan-13 to 2015 .....	51.55	30	<b>Apo-Megestrol</b>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>OCTREOTIDE – Some items restricted</b> see terms below			
Inj 50 mcg per ml, 1 ml ampoule – <b>1% DV Sep-14 to 2017</b> .....	13.50	5	<b>DBL</b>
Inj 100 mcg per ml, 1 ml ampoule – <b>1% DV Sep-14 to 2017</b> .....	22.40	5	<b>DBL</b>
Inj 500 mcg per ml, 1 ml ampoule – <b>1% DV Sep-14 to 2017</b> .....	89.40	5	<b>DBL</b>
⚡ Inj 10 mg vial .....	1,772.50	1	Sandostatin LAR
⚡ Inj 20 mg vial .....	2,358.75	1	Sandostatin LAR
⚡ Inj 30 mg vial .....	2,951.25	1	Sandostatin LAR

➡ **Restricted**

Note: restriction applies only to the long-acting formulations of octreotide

**Malignant bowel obstruction**

All of the following:

- 1 The patient has nausea\* and vomiting\* due to malignant bowel obstruction\*; and
- 2 Treatment with antiemetics, rehydration, antimuscarinic agents, corticosteroids and analgesics for at least 48 hours has failed; and
- 3 Octreotide to be given at a maximum dose 1500 mcg daily for up to 4 weeks.

Note: Indications marked with \* are Unapproved Indications

**Initiation - acromegaly**

*Re-assessment required after 3 months*

Both:

- 1 The patient has acromegaly; and
- 2 Any of the following:
  - 2.1 Treatment with surgery, radiotherapy and a dopamine agonist has failed; or
  - 2.2 Treatment with octreotide is for an interim period while awaiting the effects of radiotherapy and a dopamine agonist has failed; or
  - 2.3 The patient is unwilling, or unable, to undergo surgery and/or radiotherapy.

**Continuation - acromegaly**

Both:

- 1 IGF1 levels have decreased since starting octreotide; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Note: In patients with acromegaly octreotide treatment should be discontinued if IGF1 levels have not decreased after 3 months treatment. In patients treated with radiotherapy octreotide treatment should be withdrawn every 2 years, for 1 month, for assessment of remission. Octreotide treatment should be stopped where there is biochemical evidence of remission (normal IGF1 levels) following octreotide treatment withdrawal for at least 4 weeks.

**Other indications**

Any of the following:

- 1 VIPomas and glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or
- 2 Both:
  - 2.1 Gastrinoma; and
  - 2.2 Either:
    - 2.2.1 Patient has failed surgery; or
    - 2.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed; or
- 3 Both:
  - 3.1 Insulinomas; and
  - 3.2 Surgery is contraindicated or has failed; or
- 4 For pre-operative control of hypoglycaemia and for maintenance therapy; or
- 5 Both:
  - 5.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and
  - 5.2 Disabling symptoms not controlled by maximal medical therapy.

## ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>TAMOXIFEN CITRATE</b>			
Tab 10 mg .....	2.63	60	Genox
	17.50	100	Genox
Tab 20 mg .....	2.63	30	Genox
	8.75	100	Genox

### Aromatase Inhibitors

<b>ANASTROZOLE</b>			
Tab 1 mg .....	26.55	30	Aremed DP-Anastrozole
<b>EXEMESTANE</b>			
Tab 25 mg – 1% DV Sep-14 to 2017 .....	14.50	30	<b>Aromasin</b>
<b>LETROZOLE</b>			
Tab 2.5 mg – 1% DV Oct-12 to 2015 .....	4.85	30	<b>Letraccord</b>

### Immunosuppressants

#### Calcineurin Inhibitors

<b>CICLOSPORIN</b>			
Cap 25 mg .....	44.63	50	Neoral
Cap 50 mg .....	88.91	50	Neoral
Cap 100 mg .....	177.81	50	Neoral
Oral liq 100 mg per ml – 1% DV Oct-12 to 2015 .....	198.13	50 ml	<b>Neoral</b>
Inj 50 mg per ml, 5 ml ampoule – 1% DV Oct-12 to 2015 .....	276.30	10	<b>Sandimmun</b>
<b>TACROLIMUS – Restricted</b> see terms below			
⚡ Cap 0.5 mg – 1% DV Nov-14 to 31 Oct 2018 .....	85.60	100	<b>Tacrolimus Sandoz</b>
⚡ Cap 1 mg – 1% DV Nov-14 to 31 Oct 2018 .....	171.20	100	<b>Tacrolimus Sandoz</b>
⚡ Cap 5 mg – 1% DV Nov-14 to 31 Oct 2018 .....	428.00	50	<b>Tacrolimus Sandoz</b>
⚡ Inj 5 mg per ml, 1 ml ampoule			

➡ **Restricted**

For use in organ transplant recipients

#### Fusion Proteins

<b>ETANERCEPT – Restricted</b> see terms below			
⚡ Inj 25 mg vial .....	949.96	4	Enbrel
⚡ Inj 50 mg autoinjector .....	1,899.92	4	Enbrel
⚡ Inj 50 mg syringe .....	1,899.92	4	Enbrel

➡ **Restricted**

#### Initiation - juvenile idiopathic arthritis

Rheumatologist or named specialist

*Re-assessment required after 4 months*

Either:

1 Both:

1.1 The patient has had an initial Special Authority approval for adalimumab for juvenile idiopathic arthritis (JIA); and

1.2 Either:

1.2.1 The patient has experienced intolerable side effects from adalimumab; or

1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for JIA; or

continued...

⚡ Item restricted (see ➡ above); ⚡ Item restricted (see ➡ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

continued...

2 All of the following:

- 2.1 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and
- 2.2 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2.3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
- 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m<sup>2</sup> weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and
- 2.5 Both:
  - 2.5.1 Either:
    - 2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
    - 2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and
  - 2.5.2 Physician's global assessment indicating severe disease.

**Continuation - juvenile idiopathic arthritis**

Rheumatologist or named specialist

*Re-assessment required after 6 months*

All of the following:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
  - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
  - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

**Initiation - rheumatoid arthritis**

Rheumatologist

*Re-assessment required after 6 months*

Either:

- 1 Both:
  - 1.1 The patient has had an initial Special Authority approval for adalimumab for rheumatoid arthritis; and
  - 1.2 Either:
    - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
    - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for rheumatoid arthritis; or
- 2 All of the following:
  - 2.1 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and
  - 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
  - 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
  - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
  - 2.5 Any of the following:
    - 2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of ciclosporin; or

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
- 2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
- 2.6 Either:
  - 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
  - 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 2.7 Either:
  - 2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
  - 2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

## Continuation - rheumatoid arthritis

Rheumatologist

*Re-assessment required after 6 months*

All of the following:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
  - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
  - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

## Initiation - ankylosing spondylitis

Rheumatologist

*Re-assessment required after 6 months*

Either:

- 1 Both:
  - 1.1 The patient has had an initial Special Authority approval for adalimumab for ankylosing spondylitis; and
  - 1.2 Either:
    - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
    - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for ankylosing spondylitis; or
- 2 All of the following:
  - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
  - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
  - 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
  - 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of an exercise regime supervised by a physiotherapist; and
  - 2.5 Either:
    - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or

continued...

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

continued...

2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and

2.6 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of starting treatment.

Average normal chest expansion corrected for age and gender:

Age	Male	Female
18-24	7.0 cm	5.5 cm
25-34	7.5 cm	5.5 cm
35-44	6.5 cm	4.5 cm
45-54	6.0 cm	5.0 cm
55-64	5.5 cm	4.0 cm
65-74	4.0 cm	4.0 cm
75+	3.0 cm	2.5 cm

### Continuation - ankylosing spondylitis

Rheumatologist

*Re-assessment required after 6 months*

All of the following:

- 1 Following 12 weeks of etanercept treatment, BASDAI has improved by 4 or more points from pre-treatment baseline on a 10 point scale, or by 50%, whichever is less; and
- 2 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

### Initiation - psoriatic arthritis

Rheumatologist

*Re-assessment required after 6 months*

Either:

- 1 Both:
  - 1.1 The patient has had an initial Special Authority approval for adalimumab for psoriatic arthritis; and
  - 1.2 Either:
    - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
    - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for psoriatic arthritis; or
- 2 All of the following:
  - 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
  - 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
  - 2.3 Patient has tried and not responded to at least three months of sulphasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
  - 2.4 Either:
    - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
    - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
  - 2.5 Any of the following:
    - 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
    - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or

continued...

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

continued...

- 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

## Continuation - psoriatic arthritis

Rheumatologist

*Re-assessment required after 6 months*

All of the following:

- 1 Either:
  - 1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
  - 1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician; and
- 2 Etanercept to be administered at doses no greater than 50 mg every 7 days.

## Initiation - plaque psoriasis, prior TNF use

Dermatologist

*Re-assessment required after 4 months*

Both:

- 1 The patient has had an initial Special Authority approval for adalimumab for severe chronic plaque psoriasis; and
 

Either:

  - 1.1 The patient has experienced intolerable side effects from adalimumab; or
  - 1.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe chronic plaque psoriasis; and
- 2 Patient must be reassessed for continuation after 3 doses.

## Initiation - plaque psoriasis, treatment-naïve

Dermatologist

*Re-assessment required after 4 months*

All of the following:

- 1 Either:
  - 1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
  - 1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
- 2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
- 3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 4 The most recent PASI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

## Continuation - plaque psoriasis

Dermatologist

*Re-assessment required after 6 months*

Both:

- 1 Either:
  - 1.1 Both:

continued...



Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

continued...

- 1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
- 1.1.2 Following each prior etanercept treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-etanercept treatment baseline value; or
- 1.2 Both:
  - 1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
  - 1.2.2 Either:
    - 1.2.2.1 Following each prior etanercept treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
    - 1.2.2.2 Following each prior etanercept treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-etanercept treatment baseline value; and
- 2 Etanercept to be administered at doses no greater than 50 mg every 7 days.

### Indication - pyoderma gangrenosum

Dermatologist

All of the following:

- 1 Patient has pyoderma gangrenosum\*; and
- 2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response; and
- 3 A maximum of 4 doses.

Note: Indications marked with \* are Unapproved Indications (refer to Section A: General Rules, Part I (Interpretations and Definitions) and Part V (Miscellaneous Provisions) rule 5.5).

### Renewal - pyoderma gangrenosum

Dermatologist

All of the following:

- 1 Patient has shown clinical improvement; and
- 2 Patient continues to require treatment; and
- 3 A maximum of 4 doses

### Initiation - adult-onset Still's disease

Rheumatologist

*Re-assessment required after 6 months*

Either:

- 1 Both:
  - 1.1 Either:
    - 1.1.1 The patient has had an initial Special Authority approval for etanercept for adult-onset Still's disease (AOSD); or
    - 1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the HML rules; and
  - 1.2 Either:
    - 1.2.1 The patient has experienced intolerable side effects from etanercept and/or tocilizumab; or
    - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or tocilizumab such that they do not meet the renewal criteria for AOSD; or
- 2 All of the following:
  - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
  - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and
  - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

### Continuation - adult-onset Still's disease

Paediatric rheumatologist

*Re-assessment required after 6 months*

The patient has a sustained improvement in inflammatory markers and functional status.

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Monoclonal Antibodies

ABCIXIMAB – **Restricted** see terms below

⚡ Inj 2 mg per ml, 5 ml vial .....	579.53	1	ReoPro
------------------------------------	--------	---	--------

➡ **Restricted**

Either:

- 1 For use in patients with acute coronary syndromes undergoing percutaneous coronary intervention; or
- 2 For use in patients undergoing intra-cranial intervention.

ADALIMUMAB – **Restricted** see terms below

⚡ Inj 20 mg per 0.4 ml syringe .....	1,799.92	2	Humira
⚡ Inj 40 mg per 0.8 ml pen .....	1,799.92	2	HumiraPen
⚡ Inj 40 mg per 0.8 ml syringe .....	1,799.92	2	Humira

➡ **Restricted**

**Initiation - juvenile idiopathic arthritis**

Rheumatologist or named specialist

*Re-assessment required after 4 months*

Either:

- 1 Either:
  - 1.1 Both:
    - 1.1.1 The patient has had an initial Special Authority approval for etanercept for juvenile idiopathic arthritis (JIA); and
  - 1.1.2 Either:
    - 1.1.2.1 The patient has experienced intolerable side effects from etanercept; or
    - 1.1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for JIA; or
- 2 All of the following:
  - 2.1 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and
  - 2.2 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
  - 2.3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
  - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m<sup>2</sup> weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and
  - 2.5 Both:
    - 2.5.1 Either:
      - 2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
      - 2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and
    - 2.5.2 Physician's global assessment indicating severe disease.

**Continuation - juvenile idiopathic arthritis**

Rheumatologist or named specialist

*Re-assessment required after 6 months*

All of the following:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
  - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or

continued...

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

continued...

- 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

### Initiation - fistulising Crohn's disease

Gastroenterologist

*Re-assessment required after 4 months*

All of the following

- 1 Patient has confirmed Crohn's disease; and
- 2 Either:
  - 2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
  - 2.2 Patient has one or more rectovaginal fistula(e); and
- 3 A Baseline Fistula Assessment (a copy of which is available at [www.pharmac.govt.nz/latest/BaselineFistulaAssessment.pdf](http://www.pharmac.govt.nz/latest/BaselineFistulaAssessment.pdf)) has been completed and is no more than 1 month old at the time of application.

### Continuation - fistulising Crohn's disease

Gastroenterologist

*Re-assessment required after 6 months*

Either:

- 1 The number of open draining fistulae have decreased from baseline by at least 50%; or
- 2 There has been a marked reduction in drainage of all fistula(e) from baseline as demonstrated by a reduction in the Fistula Assessment score, together with less induration and patient-reported pain.

### Initiation - Crohn's disease

Gastroenterologist

*Re-assessment required after 3 months*

All of the following:

- 1 Patient has severe active Crohn's disease; and
- 2 Any of the following:
  - 2.1 Patient has a Crohn's Disease Activity Index (CDAI) score of greater than or equal to 300; or
  - 2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
  - 2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
  - 2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate.

### Continuation - Crohn's disease

Gastroenterologist

*Re-assessment required after 3 months*

Both:

- 1 Either:
  - 1.1 Either:
    - 1.1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on adalimumab; or
    - 1.1.2 CDAI score is 150 or less; or
  - 1.2 Both:
    - 1.2.1 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
    - 1.2.2 Applicant to indicate the reason that CDAI score cannot be assessed; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

## Initiation - rheumatoid arthritis

Rheumatologist

*Re-assessment required after 6 months*

Either:

- 1 Both:
  - 1.1 The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis; and
  - 1.2 Either:
    - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
    - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for rheumatoid arthritis; or
- 2 All of the following:
  - 2.1 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and
  - 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
  - 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
  - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
  - 2.5 Any of the following:
    - 2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of ciclosporin; or
    - 2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
    - 2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
  - 2.6 Either:
    - 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
    - 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
  - 2.7 Either:
    - 2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
    - 2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

## Continuation - rheumatoid arthritis

Rheumatologist

*Re-assessment required after 6 months*

All of the following:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
  - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
  - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 3 Adalimumab to be administered at doses no greater than 50 mg every 7 days.

continued...

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

continued...

### Initiation - ankylosing spondylitis

Rheumatologist

*Re-assessment required after 6 months*

Either:

- 1 Both:
  - 1.1 The patient has had an initial Special Authority approval for etanercept for ankylosing spondylitis; and
  - 1.2 Either:
    - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
    - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for ankylosing spondylitis; or
- 2 All of the following:
  - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
  - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
  - 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
  - 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of an exercise regime supervised by a physiotherapist; and
  - 2.5 Either:
    - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
    - 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and
  - 2.6 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of starting treatment.

Average normal chest expansion corrected for age and gender:

Age	Male	Female
18-24	7.0 cm	5.5 cm
25-34	7.5 cm	5.5 cm
35-44	6.5 cm	4.5 cm
45-54	6.0 cm	5.0 cm
55-64	5.5 cm	4.0 cm
65-74	4.0 cm	4.0 cm
75+	3.0 cm	2.5 cm

### Continuation - ankylosing spondylitis

Rheumatologist

*Re-assessment required after 6 months*

All of the following:

- 1 Following 12 weeks of adalimumab treatment, BASDAI has improved by 4 or more points from pre-treatment baseline on a 10 point scale, or by 50%, whichever is less; and
- 2 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

### Initiation - psoriatic arthritis

Rheumatologist

*Re-assessment required after 6 months*

Either:

- 1 Both:

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 1.1 The patient has had an initial Special Authority approval for etanercept for psoriatic arthritis; and
- 1.2 Either:
  - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
  - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for psoriatic arthritis; or
- 2 All of the following:
  - 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
  - 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
  - 2.3 Patient has tried and not responded to at least three months of sulphasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
  - 2.4 Either:
    - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
    - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
  - 2.5 Any of the following:
    - 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
    - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
    - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

## Continuation - psoriatic arthritis

Rheumatologist

*Re-assessment required after 6 months*

Both:

- 1 Either:
  - 1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
  - 1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

## Initiation - plaque psoriasis, prior TNF use

Dermatologist

*Re-assessment required after 4 months*

Both:

- 1 The patient has had an initial Special Authority approval for etanercept for severe chronic plaque psoriasis; and
- 2 Either:
  - 2.1 The patient has experienced intolerable side effects from etanercept; or
  - 2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for severe chronic plaque psoriasis; and

## Initiation - plaque psoriasis, treatment-naïve

Dermatologist

*Re-assessment required after 4 months*

All of the following:

- 1 Either:
  - 1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or

continued...

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

continued...

- 1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
- 2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
- 3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 4 The most recent PASI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

### **Continuation - plaque psoriasis**

Dermatologist

*Re-assessment required after 6 months*

Both:

- 1 Either:
  - 1.1 Both:
    - 1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
    - 1.1.2 Following each prior adalimumab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-adalimumab treatment baseline value; or
  - 1.2 Both:
    - 1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
    - 1.2.2 Either:
      - 1.2.2.1 Following each prior adalimumab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
      - 1.2.2.2 Following each prior adalimumab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-etanercept treatment baseline value; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

### **Indication - pyoderma gangrenosum**

Dermatologist

All of the following:

- 1 Patient has pyoderma gangrenosum\*; and
- 2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response; and
- 3 A maximum of 4 doses.

Note: Indications marked with \* are Unapproved Indications (refer to Section A: General Rules, Part I (Interpretations and Definitions) and Part V (Miscellaneous Provisions) rule 5.5).

### **Renewal - pyoderma gangrenosum**

Dermatologist

All of the following:

- 1 Patient has shown clinical improvement; and
- 2 Patient continues to require treatment; and
- 3 A maximum of 4 doses

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
continued...			
<b>Initiation - adult-onset Still's disease</b>			
Rheumatologist			
<i>Re-assessment required after 6 months</i>			
Either:			
1 Both:			
1.1 Either:			
1.1.1 The patient has had an initial Special Authority approval for etanercept for adult-onset Still's disease (AOSD); or			
1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the HML rules; and			
1.2 Either:			
1.2.1 The patient has experienced intolerable side effects from etanercept and/or tocilizumab; or			
1.2.2 The patient has received insufficient benefit from at least a three-month trial of etanercept and/or tocilizumab such that they do not meet the renewal criteria for AOSD; or			
2 All of the following:			
2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and			
2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and			
2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.			
<b>Continuation - adult-onset Still's disease</b>			
Rheumatologist			
<i>Re-assessment required after 6 months</i>			
The patient has a sustained improvement in inflammatory markers and functional status.			
<b>BASILIXIMAB – Restricted</b> see terms below			
⌄ Inj 20 mg vial .....	3,200.00	1	Simulect
➡ <b>Restricted</b>			
For use in solid organ transplants			
<b>BEVACIZUMAB – Restricted</b> see terms below			
⌄ Inj 25 mg per ml, 16 ml vial			
⌄ Inj 25 mg per ml, 4 ml vial			
➡ <b>Restricted</b>			
Either:			
1 Ocular neovascularisation; or			
2 Exudative ocular angiopathy.			
<b>INFLIXIMAB – Restricted</b> see terms below			
⌄ Inj 100 mg – 10% DV Mar-15 to 29 Feb 2020 .....	806.00	1	Remicade
➡ <b>Restricted</b>			
<b>Graft vs host disease</b>			
Patient has steroid-refractory acute graft vs. host disease of the gut			
<b>Initiation - rheumatoid arthritis</b>			
Rheumatologist			
<i>Re-assessment required after 3-4 months</i>			
All of the following:			
1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and			
2 Either:			
2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or			
2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept; and			
continued...			
⌄ Item restricted (see ➡ above); ⌄ Item restricted (see ➡ below) e.g. Brand indicates brand example only. It is not a contracted product.			



Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

continued...

- Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance

**Continuation - rheumatoid arthritis**

Rheumatologist

*Re-assessment required after 6 months*

All of the following:

- Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- Either:
  - Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
  - The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- Infliximab to be administered at doses no greater than 3 mg/kg every 8 weeks.

**Initiation - ankylosing spondylitis**

Rheumatologist

*Re-assessment required after 3 months*

Both:

- The patient has had an initial Special Authority approval for adalimumab and/or etanercept for ankylosing spondylitis; and
- Either:
  - The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
  - Following 12 weeks of adalimumab and/or etanercept treatment, the patient did not meet the renewal criteria for adalimumab and/or etanercept for ankylosing spondylitis.

**Continuation - ankylosing spondylitis**

Rheumatologist

*Re-assessment required after 6 months*

All of the following:

- Following 12 weeks of infliximab treatment, BASDAI has improved by 4 or more points from pre-infliximab baseline on a 10 point scale, or by 50%, whichever is less; and
- Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- Infliximab to be administered at doses no greater than 5 mg/kg every 6-8 weeks.

**Initiation - psoriatic arthritis**

Rheumatologist

*Re-assessment required after 3-4 months*

Both:

- The patient has had an initial Special Authority approval for adalimumab and/or etanercept for psoriatic arthritis; and
- Either:
  - The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
  - Following 3-4 months' initial treatment with adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for psoriatic arthritis.

**Continuation - psoriatic arthritis**

Rheumatologist

*Re-assessment required after 6 months*

Both:

- Either:
  - Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior infliximab treatment in the opinion of the treating physician; and
- 2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

## **Initiation - severe ocular inflammation**

*Re-assessment required after 3 doses*

Both:

- 1 Patient has severe, vision-threatening ocular inflammation requiring rapid control; and
- 2 Either:
  - 2.1 Patient has failed to achieve control of severe vision-threatening ocular inflammation following high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids; or
  - 2.2 Patient developed new inflammatory symptoms while receiving high dose steroids.

## **Initiation - chronic ocular inflammation**

*Re-assessment required after 3 doses*

Both:

- 1 Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision loss; and
- 2 Patient has tried at least two other immunomodulatory agents.

## **Continuation - ocular inflammation**

Both:

- 1 Patient had a good clinical response to initial treatment; and
- 2 Either:
  - 2.1 A withdrawal of infliximab has been trialled and patient has relapsed after trial withdrawal; or
  - 2.2 Patient has Behcet's disease.

## **Pulmonary sarcoidosis**

Both:

- 1 Patient has life-threatening pulmonary sarcoidosis that is refractory to other treatments; and
- 2 Treatment is to be prescribed by, or has been recommended by, a physician with expertise in the treatment of pulmonary sarcoidosis.

## **Initiation - Crohn's disease (adults)**

Gastroenterologist

*Re-assessment required after 3 months*

All of the following:

- 1 Patient has severe active Crohn's disease; and
- 2 Any of the following:
  - 2.1 Patient has a Crohn's Disease Activity Index (CDAI) score of greater than or equal to 300; or
  - 2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
  - 2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
  - 2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate; and
- 5 Patient must be reassessed for continuation after 3 months of therapy.

## **Continuation - Crohn's disease (adults)**

Gastroenterologist

*Re-assessment required after 6 months*

All of the following:

- 1 One of the following:

continued...

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

continued...

- 1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on infliximab; or
- 1.2 CDAI score is 150 or less; or
- 1.3 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle; and
- 3 Patient must be reassessed for continuation after further 6 months.

#### **Initiation - Crohn's disease (children)**

Gastroenterologist

*Re-assessment required after 3 months*

All of the following:

- 1 Paediatric patient has severe active Crohn's disease; and
- 2 Any of the following:
  - 2.1 Patient has a Paediatric Crohn's Disease Activity Index (PCDAI) score of greater than or equal to 30; or
  - 2.2 Patient has extensive small intestine disease; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate; and
- 5 Patient must be reassessed for continuation after 3 months of therapy.

#### **Continuation - Crohn's disease (children)**

Gastroenterologist

*Re-assessment required after 6 months*

All of the following:

- 1 One of the following:
  - 1.1 PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on infliximab; or
  - 1.2 PCDAI score is 15 or less; or
  - 1.3 The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle; and
- 3 Patient must be reassessed for continuation after further 6 months.

#### **Initiation - fistulising Crohn's disease**

Gastroenterologist

All of the following:

- 1 Patient has confirmed Crohn's disease; and
- 2 Either:
  - 2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
  - 2.2 Patient has one or more rectovaginal fistula(e); and
- 3 Patient must be reassessed for continuation after 4 months of therapy.

#### **Continuation - fistulising Crohn's disease**

Gastroenterologist

All of the following:

- 1 Either:
  - 1.1 The number of open draining fistulae have decreased from baseline by at least 50%; or
  - 1.2 There has been a marked reduction in drainage of all fistula(e) from baseline (in the case of adult patients, as demonstrated by a reduction in the Fistula Assessment score), together with less induration and patient reported pain; and

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle; and
- Patient must be reassessed for continuation after further 6 months.

## **Initiation - acute severe fulminant ulcerative colitis**

Gastroenterologist

All of the following:

- Patient has acute, severe fulminant ulcerative colitis; and
- Treatment with intravenous or high dose oral corticosteroids has not been successful; and
- Patient must be reassessed for continuation after 6 weeks of therapy.

## **Continuation - severe fulminant ulcerative colitis**

Gastroenterologist

All of the following:

- Where maintenance treatment is considered appropriate, infliximab should be used in combination with immunomodulators and reassessed every 6 months; and
- Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle; and
- Patient must be reassessed for continuation after further 6 months.

## **Initiation - severe ulcerative colitis**

Gastroenterologist

All of the following:

- Patient has histologically confirmed ulcerative colitis; and
- The Simple Clinical Colitis Activity Index (SCCAI) is  $\geq 4$
- Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses for an adequate duration (unless contraindicated) and corticosteroids; and
- Surgery (or further surgery) is considered to be clinically inappropriate; and
- Patient must be reassessed for continuation after 3 months of therapy.

## **Continuation - severe ulcerative colitis**

Gastroenterologist

All of the following:

- Patient is continuing to maintain remission and the benefit of continuing infliximab outweighs the risks; and
- SCCAI score has reduced by  $\geq 2$  points from the SCCAI score when the patient was initiated on infliximab; and
- Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

## **Initiation - plaque psoriasis, prior TNF use**

Dermatologist

*Re-assessment required after 3 doses*

Both:

- The patient has had an initial Special Authority approval for adalimumab or etanercept for severe chronic plaque psoriasis; and
- Either:
  - The patient has experienced intolerable side effects from adalimumab or etanercept; or
  - The patient has received insufficient benefit from adalimumab or etanercept to meet the renewal criteria for adalimumab or etanercept for severe chronic plaque psoriasis.

continued...

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

continued...

**Initiation - plaque psoriasis, treatment-naïve**

Dermatologist

*Re-assessment required after 3 doses*

All of the following:

- 1 Either:
  - 1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
  - 1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
- 2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, thotrexate, cyclosporin, or acitretin; and
- 3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 4 The most recent PASI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

**Continuation - plaque psoriasis**

Dermatologist

*Re-assessment required after 3 doses*

Both:

- 1 Either:
  - 1.1 Both:
    - 1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
    - 1.1.2 Following each prior infliximab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-infliximab treatment baseline value; or
  - 1.2 Both:
    - 1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
    - 1.2.2 Either:
      - 1.2.2.1 Following each prior infliximab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
      - 1.2.2.2 Following each prior infliximab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-infliximab treatment baseline value; and
- 2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

OMALIZUMAB – **Restricted** see terms on the next page

¶ Inj 150 mg vial ..... 500.00 1 Xolair

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>➔Restricted</b>			
<b>Initiation</b>			
Respiratory physician			
<i>Re-assessment required after 6 months</i>			
All of the following:			
1 Patient is over the age of 6; and			
2 Patient has a diagnosis of severe, life threatening asthma; and			
3 Past or current evidence of atopy, documented by skin prick testing or RAST; and			
4 Total serum human immunoglobulin E (IgE) between 76 IU/mL and 1300 IU/ml at baseline; and			
5 Proven compliance with optimal inhaled therapy including high dose inhaled corticosteroid (budesonide 1600 micrograms per day or fluticasone propionate 1000 micrograms per day or equivalent), plus long-acting beta-2 agonist therapy (at least salmeterol 50 micrograms bd or eformoterol 12 micrograms bd) for at least 12 months, unless contraindicated or not tolerated; and			
6 Patient has received courses of systemic corticosteroids equivalent to at least 28 days treatment in the past 12 months, unless contraindicated or not tolerated; and			
7 At least four admissions to hospital for a severe asthma exacerbation over the previous 24 months with at least one of those being in the previous 12 months; and			
8 An Asthma Control Questionnaire (ACQ-5) score of at least 3.0 as assessed in the previous month.			
<b>Continuation</b>			
Respiratory physician			
<i>Re-assessment required after 6 months</i>			
All of the following:			
1 Hospital admissions have been reduced as a result of treatment; and			
2 A reduction in the Asthma Control Questionnaire (ACQ-5) score of at least 1.0 from baseline; and			
3 A reduction in the maintenance oral corticosteroid dose of at least 50% from baseline.			
<b>RANIBIZUMAB – Restricted</b> see terms below			
⚡ Inj 10 mg per ml, 0.23 ml vial			
⚡ Inj 10 mg per ml, 0.3 ml vial			
<b>➔Restricted</b>			
<b>Initiation</b>			
<i>Re-assessment required after 3 doses</i>			
Both:			
1 Either			
1.1 Age-related macular degeneration; or			
1.2 Choroidal neovascular membrane; and			
2 Any of the following:			
2.1 The patient has had a severe ophthalmic inflammatory response following bevacizumab; or			
2.2 The patient has had a myocardial infarction or stroke within the last three months; or			
2.3 The patient has failed to respond to bevacizumab following three intraocular injections; or			
2.4 The patient is of child-bearing potential and has not completed a family.			
<b>Continuation</b>			
Both:			
1 Documented benefit after three doses must be demonstrated to continue; and			
2 In the case of but previous non-response to bevacizumab, a retrial of bevacizumab is required to confirm non-response before continuing with ranibizumab.			
<b>RITUXIMAB – Restricted</b> see terms on the next page			
⚡ Inj 10 mg per ml, 10 ml vial ..... 1,075.50 2 Mabthera			
⚡ Inj 10 mg per ml, 50 ml vial ..... 2,688.30 1 Mabthera			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>➔Restricted</b>			
<b>Initiation - haemophilia with inhibitors</b>			
Haematologist			
Any of the following:			
1 Patient has mild congenital haemophilia complicated by inhibitors; or			
2 Patient has severe congenital haemophilia complicated by inhibitors and has failed immune tolerance therapy; or			
3 Patient has acquired haemophilia.			
<b>Continuation - haemophilia with inhibitors</b>			
Haematologist			
All of the following:			
1 Patient was previously treated with rituximab for haemophilia with inhibitors; and			
2 An initial response lasting at least 12 months was demonstrated; and			
3 Patient now requires repeat treatment.			
<b>Initiation - post-transplant</b>			
Both:			
1 The patient has B-cell post-transplant lymphoproliferative disorder*; and			
2 To be used for a maximum of 8 treatment cycles.			
Note: Indications marked with * are Unapproved Indications.			
<b>Continuation - post-transplant</b>			
All of the following:			
1 The patient has had a rituximab treatment-free interval of 12 months or more; and			
2 The patient has B-cell post-transplant lymphoproliferative disorder*; and			
3 To be used for no more than 6 treatment cycles.			
Note: Indications marked with * are Unapproved Indications			
<b>Initiation - indolent, low-grade lymphomas</b>			
Either:			
1 Both:			
1.1 The patient has indolent low grade NHL with relapsed disease following prior chemotherapy; and			
1.2 To be used for a maximum of 6 treatment cycles; or			
2 Both:			
2.1 The patient has indolent, low grade lymphoma requiring first-line systemic chemotherapy; and			
2.2 To be used for a maximum of 6 treatment cycles.			
Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia.			
<b>Continuation - indolent, low-grade lymphomas</b>			
All of the following:			
1 The patient has had a rituximab treatment-free interval of 12 months or more; and			
2 The patient has indolent, low-grade NHL with relapsed disease following prior chemotherapy; and			
3 To be used for no more than 6 treatment cycles.			
Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia.			
<b>Initiation - aggressive CD20 positive NHL</b>			
Either:			
1 All of the following:			
1.1 The patient has treatment naive aggressive CD20 positive NHL; and			
1.2 To be used with a multi-agent chemotherapy regimen given with curative intent; and			
1.3 To be used for a maximum of 8 treatment cycles; or			
2 Both:			
2.1 The patient has aggressive CD20 positive NHL with relapsed disease following prior chemotherapy; and			
2.2 To be used for a maximum of 6 treatment cycles.			

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia.

## Continuation - aggressive CD20 positive NHL

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has relapsed refractory/aggressive CD20 positive NHL; and
- 3 To be used with a multi-agent chemotherapy regimen given with curative intent; and
- 4 To be used for a maximum of 4 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia.

## Chronic lymphocytic leukaemia

All of the following:

- 1 The patient has progressive Binet stage A, B or C chronic lymphocytic leukaemia (CLL) requiring treatment; and
- 2 The patient is rituximab treatment naive; and
- 3 Either:
  - 3.1 The patient is chemotherapy treatment naive; or
  - 3.2 Both:
    - 3.2.1 The patient's disease has relapsed following no more than three prior lines of chemotherapy treatment; and
    - 3.2.2 The patient has had a treatment-free interval of 12 months or more if previously treated with fludarabine and cyclophosphamide chemotherapy; and
- 4 The patient has good performance status; and
- 5 The patient has good renal function (creatinine clearance  $\geq$  30 ml/min); and
- 6 The patient does not have chromosome 17p deletion CLL; and
- 7 Rituximab to be administered in combination with fludarabine and cyclophosphamide for a maximum of 6 treatment cycles; and
- 8 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration).

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with rituximab is expected to improve symptoms and improve ECOG score to  $<2$ .

## Initiation - rheumatoid arthritis - prior TNF inhibitor use

Rheumatologist

*Re-assessment required after 2 doses*

All of the following:

- 1 Both:
  - 1.1 The patient has had an initial community Special Authority approval for at least one of etanercept and/or adalimumab for rheumatoid arthritis; and
  - 1.2 Either:
    - 1.2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
    - 1.2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for rheumatoid arthritis; and
- 2 Either:
  - 2.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
  - 2.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 3 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

continued...



Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

continued...

# Initiation - rheumatoid arthritis - TNF inhibitors contraindicated

Rheumatologist

*Re-assessment required after 2 doses*

All of the following:

- 1 Treatment with a Tumour Necrosis Factor alpha inhibitor is contraindicated; and
- 2 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and
- 3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
- 4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
- 5 Any of the following:
  - 5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of cyclosporin; or
  - 5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
  - 5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
- 6 Either:
  - 6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
  - 6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 7 Either:
  - 7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
  - 7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months; and
- 8 Either:
  - 8.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
  - 8.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 9 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

# Continuation - rheumatoid arthritis - re-treatment in 'partial responders' to rituximab

Rheumatologist

*Re-assessment required after 2 doses*

All of the following:

- 1 Either:
  - 1.1 At 4 months following the initial course of rituximab infusions the patient had between a 30% and 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
  - 1.2 At 4 months following the second course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
  - 1.3 At 4 months following the third and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and
- 3 Either:
  - 3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
  - 3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

## Continuation - rheumatoid arthritis - re-treatment in 'responders' to rituximab

Rheumatologist

*Re-assessment required after 2 doses*

All of the following:

- 1 Either:
  - 1.1 At 4 months following the initial course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
  - 1.2 At 4 months following the second and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and
- 3 Either:
  - 3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
  - 3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

## Initiation – severe cold haemagglutinin disease (CHAD)

Haematologist

*Limited to 4 weeks' treatment*

Both:

- 1 Patient has cold haemagglutinin disease\*; and
- 2 Patient has severe disease which is characterized by symptomatic anaemia, transfusion dependence or disabling circulatory symptoms.

Note: Indications marked with \* are Unapproved Indications.

## Continuation – severe cold haemagglutinin disease (CHAD)

Haematologist

*Limited to 4 weeks' treatment*

Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m<sup>2</sup> weekly for 4 weeks) is now planned; or
- 2 All of the following:
  - 2.1 Patient was previously treated with rituximab for severe cold haemagglutinin disease\*; and
  - 2.2 An initial response lasting at least 12 months was demonstrated; and
  - 2.3 Patient now requires repeat treatment.

Note: Indications marked with \* are Unapproved Indications.

## Initiation – warm autoimmune haemolytic anaemia (warm AIHA)

Haematologist

*Limited to 4 weeks' treatment*

Both:

- 1 Patient has warm autoimmune haemolytic anaemia\*; and
- 2 One of the following treatments has been ineffective: steroids (including if patient requires ongoing steroids at doses equivalent to >5 mg prednisone daily), cytotoxic agents (e.g. cyclophosphamide monotherapy or in combination), intravenous immunoglobulin.

Note: Indications marked with \* are Unapproved Indications.

## Continuation – warm autoimmune haemolytic anaemia (warm AIHA)

Haematologist

*Limited to 4 weeks' treatment*

Either:

continued...

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

continued...

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m<sup>2</sup> weekly for 4 weeks) is now planned; or
- 2 All of the following:
  - 2.1 Patient was previously treated with rituximab for warm autoimmune haemolytic anaemia\*; and
  - 2.2 An initial response lasting at least 12 months was demonstrated; and
  - 2.3 Patient now requires repeat treatment.

Note: Indications marked with \* are Unapproved Indications.

**Initiation – immune thrombocytopenic purpura (ITP)**

Haematologist

*Limited to 4 weeks' treatment*

Both:

- 1 Either:
  - 1.1 Patient has immune thrombocytopenic purpura\* with a platelet count of  $\leq$  20,000 platelets per microlitre; or
  - 1.2 Patient has immune thrombocytopenic purpura\* with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding; and
- 2 Any of the following:
  - 2.1 Treatment with steroids and splenectomy have been ineffective; or
  - 2.2 Treatment with steroids has been ineffective and splenectomy is an absolute contraindication; or
  - 2.3 Other treatments including steroids have been ineffective and patient is being prepared for elective surgery (e.g. splenectomy).

Note: Indications marked with \* are Unapproved Indications.

**Continuation – immune thrombocytopenic purpura (ITP)**

Haematologist

*Limited to 4 weeks' treatment*

Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m<sup>2</sup> weekly for 4 weeks) is now planned; or
- 2 All of the following:
  - 2.1 Patient was previously treated with rituximab for immune thrombocytopenic purpura\*; and
  - 2.2 An initial response lasting at least 12 months was demonstrated; and
  - 2.3 Patient now requires repeat treatment.

Note: Indications marked with \* are Unapproved Indications.

**Initiation – thrombotic thrombocytopenic purpura (TTP)**

Haematologist

*Limited to 4 weeks' treatment*

Either:

- 1 Patient has thrombotic thrombocytopenic purpura\* and has experienced progression of clinical symptoms or persistent thrombocytopenia despite plasma exchange; or
- 2 Patient has acute idiopathic thrombotic thrombocytopenic purpura\* with neurological or cardiovascular pathology.

Note: Indications marked with \* are Unapproved Indications.

**Continuation – thrombotic thrombocytopenic purpura (TTP)**

Haematologist

*Limited to 4 weeks' treatment*

All of the following:

- 1 Patient was previously treated with rituximab for thrombotic thrombocytopenic purpura\*; and
- 2 An initial response lasting at least 12 months was demonstrated; and
- 3 Patient now requires repeat treatment.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

Note: Indications marked with \* are Unapproved Indications.

## **Initiation – pure red cell aplasia (PRCA)**

Haematologist

*Limited to 6 weeks' treatment*

Patient has autoimmune pure red cell aplasia\* associated with a demonstrable B-cell lymphoproliferative disorder.

Note: Indications marked with \* are Unapproved Indications.

## **Continuation – pure red cell aplasia (PRCA)**

Haematologist

*Limited to 6 weeks' treatment*

Patient was previously treated with rituximab for pure red cell aplasia\* associated with a demonstrable B-cell lymphoproliferative disorder and demonstrated an initial response lasting at least 12 months.

Note: Indications marked with \* are Unapproved Indications.

## **Initiation – ANCA associated vasculitis**

*Limited to 4 weeks' treatment*

All of the following:

- 1 Patient has been diagnosed with ANCA associated vasculitis\*; and
- 2 Either:
  - 2.1 Patient does not have MPO-ANCA positive vasculitis\*; or
  - 2.2 Mycophenolate mofetil has not been effective in those patients who have MPO-ANCA positive vasculitis\*; and
- 3 The total rituximab dose would not exceed the equivalent of 375 mg/m<sup>2</sup> of body-surface area per week for a total of 4 weeks; and
- 4 Any of the following:
  - 4.1 Induction therapy with daily oral or pulse intravenous cyclophosphamide has failed to achieve complete absence of disease after at least 3 months; or
  - 4.2 Patient has previously had a cumulative dose of cyclophosphamide >15 g or a further repeat 3 month induction course of cyclophosphamide would result in a cumulative dose >15 g; or
  - 4.3 Cyclophosphamide and methotrexate are contraindicated; or
  - 4.4 Patient is a female of child-bearing potential; or
  - 4.5 Patient has a previous history of haemorrhagic cystitis, urological malignancy or haematological malignancy.

Note: Indications marked with \* are Unapproved Indications.

## **Continuation – ANCA associated vasculitis**

*Limited to 4 weeks' treatment*

All of the following:

- 1 Patient has been diagnosed with ANCA associated vasculitis\*; and
- 2 Patient has previously responded to treatment with rituximab but is now experiencing an acute flare of vasculitis; and
- 3 The total rituximab dose would not exceed the equivalent of 375 mg/m<sup>2</sup> of body-surface area per week for a total of 4 weeks.

Note: Indications marked with \* are Unapproved Indications.

## **Initiation – treatment refractory systemic lupus erythematosus (SLE)**

Rheumatologist or nephrologist

All of the following:

- 1 The patient has severe, immediately life- or organ-threatening SLE\*; and
- 2 The disease has proved refractory to treatment with steroids at a dose of at least 1 mg/kg; and
- 3 The disease has relapsed following prior treatment for at least 6 months with maximal tolerated doses of azathioprine, mycophenolate mofetil and high dose cyclophosphamide, or cyclophosphamide is contraindicated; and
- 4 Maximum of four 1000 mg infusions of rituximab.

continued...

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

continued. . .

Note: Indications marked with \* are Unapproved Indications.

**Continuation – treatment refractory systemic lupus erythematosus (SLE)**

Rheumatologist or nephrologist

All of the following:

- 1 Patient's SLE\* achieved at least a partial response to the previous round of prior rituximab treatment; and
- 2 The disease has subsequently relapsed; and
- 3 Maximum of two 1000 mg infusions of rituximab.

Note: Indications marked with \* are Unapproved Indications.

**Antibody-mediated renal transplant rejection**

Nephrologist

Patient has been diagnosed with antibody-mediated renal transplant rejection\*.

Note: Indications marked with \* are Unapproved Indications.

**ABO-incompatible renal transplant**

Nephrologist

Patient is to undergo an ABO-incompatible renal transplant\*.

Note: Indications marked with \* are Unapproved Indications.

TOCILIZUMAB – **Restricted** see terms below

⚡ Inj 20 mg per ml, 4 ml vial .....	220.00	1	Actemra
⚡ Inj 20 mg per ml, 10 ml vial .....	550.00	1	Actemra
⚡ Inj 20 mg per ml, 20 ml vial .....	1,100.00	1	Actemra

➡ **Restricted**

**Initiation -Rheumatoid Arthritis**

Rheumatologist

*Re-assessment required after 6 months*

Either:

- 1 All of the following:
  - 1.1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and
  - 1.2 Either:
    - 1.2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
    - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for rheumatoid arthritis; and
  - 1.3 The patient has been started on rituximab for rheumatoid arthritis in a DHB hospital in accordance with the HML rules; and
  - 1.4 Either:
    - 1.4.1 The patient has experienced intolerable side effects from rituximab; or
    - 1.4.2 At four months following the initial course of rituximab the patient has received insufficient benefit such that they do not meet the renewal criteria for rheumatoid arthritis; or
- 2 All of the following:
  - 2.1 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and
  - 2.2 Tocilizumab is to be used as monotherapy; and
  - 2.3 Either:
    - 2.3.1 Treatment with methotrexate is contraindicated; or
    - 2.3.2 Patient has tried and did not tolerate oral and/or parenteral methotrexate; and
  - 2.4 Either:
    - 2.4.1 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of cyclosporin alone or in combination with another agent; or

continued. . .

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 2.4.2 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of leflunomide alone or in combination with another agent; and
- 2.5 Either:
  - 2.5.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 active, swollen, tender joints; or
  - 2.5.2 Patient has persistent symptoms of poorly controlled and active disease in at least four active joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 2.6 Either:
  - 2.6.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
  - 2.6.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

## Continuation - Rheumatoid Arthritis

Rheumatologist

*Re-assessment required after 6 months*

Either:

- 1 Following 6 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician.

## Initiation - systemic juvenile idiopathic arthritis

Rheumatologist

*Re-assessment required after 6 months*

Both:

- 1 Patient diagnosed with systemic juvenile idiopathic arthritis; and
- 2 Patient has tried and not responded to a reasonable trial of all of the following, either alone or in combination: oral or parenteral methotrexate; non-steroidal anti-inflammatory drugs (NSAIDs); and systemic corticosteroids.

## Continuation - systemic juvenile idiopathic arthritis

Rheumatologist

*Re-assessment required after 6 months*

Either:

- 1 Following up to 6 months' initial treatment, the patient has achieved at least an American College of Rheumatology paediatric 30% improvement criteria (ACR Pedi 30) response from baseline; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing ACR Pedi 30 response from baseline.

## Initiation - adult-onset Still's disease

Rheumatologist

*Re-assessment required after 6 months*

Either:

- 1 Both:
  - 1.1 Either:
    - 1.1.1 The patient has had an initial Special Authority approval for etanercept for adult-onset Still's disease (AOSD); or
    - 1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the HML rules; and
  - 1.2 Either:
    - 1.2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
    - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for AOSD; or

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

2 All of the following:

- 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
- 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and
- 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

**Continuation - adult-onset Still's disease**

Rheumatologist

*Re-assessment required after 6 months*

The patient has a sustained improvement in inflammatory markers and functional status.

TRASTUZUMAB – **Restricted** see terms below

¶ Inj 150 mg vial .....	1,350.00	1	Herceptin
¶ Inj 440 mg vial .....	3,875.00	1	Herceptin

➔ **Restricted**

**Early breast cancer**

Limited to 12 months' treatment

All of the following:

- 1 The patient has early breast cancer expressing HER 2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 Maximum cumulative dose of 106 mg/kg (12 months' treatment); and
- 3 Any of the following:
  - 3.1 9 weeks' concurrent treatment with adjuvant chemotherapy is planned; or
  - 3.2 12 months' concurrent treatment with adjuvant chemotherapy is planned; or
  - 3.3 12 months' sequential treatment following adjuvant chemotherapy is planned; or
  - 3.4 Other treatment regimen, in association with adjuvant chemotherapy, is planned.

**Initiation - metastatic breast cancer (trastuzumab-naïve patients)**

*Re-assessment required after 12 months*

Either:

- 1 All of the following:
  - 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
  - 1.2 The patient has not previously received lapatinib treatment for HER 2 positive metastatic breast cancer; and
  - 1.3 Trastuzumab not to be given in combination with lapatinib; and
  - 1.4 Trastuzumab to be discontinued at disease progression; or
- 2 All of the following:
  - 2.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
  - 2.2 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
  - 2.3 The cancer did not progress whilst on lapatinib; and
  - 2.4 Trastuzumab not to be given in combination with lapatinib; and
  - 2.5 Trastuzumab to be discontinued at disease progression.

**Initiation - metastatic breast cancer (patients previously treated with trastuzumab)**

*Re-assessment required after 12 months*

All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The patient received prior adjuvant trastuzumab treatment for early breast cancer; and
- 3 Any of the following:
  - 3.1 All of the following:

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 3.1.1 The patient has not previously received lapatinib treatment for metastatic breast cancer; and
- 3.1.2 Trastuzumab not to be given in combination with lapatinib; and
- 3.1.3 Trastuzumab to be discontinued at disease progression; or
- 3.2 All of the following:
  - 3.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
  - 3.2.2 The cancer did not progress whilst on lapatinib; and
  - 3.2.3 Trastuzumab not to be given in combination with lapatinib; and
  - 3.2.4 Trastuzumab to be discontinued at disease progression; or
- 3.3 All of the following:
  - 3.3.1 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
  - 3.3.2 Trastuzumab not to be given in combination with lapatinib; and
  - 3.3.3 Trastuzumab to be discontinued at disease progression.

#### Continuation - metastatic breast cancer

Re-assessment required after 12 months

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
- 3 Trastuzumab not to be given in combination with lapatinib; and
- 4 Trastuzumab to be discontinued at disease progression.

#### Other Immunosuppressants

##### ANTITHYMOCYTE GLOBULIN (EQUINE)

Inj 50 mg per ml, 5 ml ampoule .....	2,351.25	5	ATGAM
--------------------------------------	----------	---	-------

##### ANTITHYMOCYTE GLOBULIN (RABBIT)

Inj 25 mg vial

##### AZATHIOPRINE

Tab 25 mg .....	8.28	60	Azamun
Tab 50 mg – 1% DV Jun-14 to 2016 .....	13.22	100	<b>Azamun</b>
Inj 50 mg vial .....	126.00	1	Imuran

##### BACILLUS CALMETTE-GUERIN (BCG) – **Restricted** see terms below

☞ Inj 2-8 × 10 <sup>8</sup> CFU vial – 1% DV Sep-13 to 2016 .....	149.37	1	<b>OncoTICE</b>
☞ Inj 40 mg per ml, vial .....	149.37	3	SII-Onco-BCG

☞ **Restricted**

For use in bladder cancer

##### EVEROLIMUS – **Restricted** see terms below

☞ Tab 5 mg .....	4,555.76	30	Afinitor
☞ Tab 10 mg .....	6,512.29	30	Afinitor

☞ **Restricted**

##### Initiation

Neurologist or oncologist

Re-assessment required after 3 months

Both:

- 1 Patient has tuberous sclerosis; and
- 2 Patient has progressively enlarging sub-ependymal giant cell astrocytomas (SEGAs) that require treatment.

continued...



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

### Continuation

Neurologist or oncologist

*Re-assessment required after 12 months*

All of the following:

- 1 Documented evidence of SEGA reduction or stabilisation by MRI within the last 3 months; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment; and
- 3 Everolimus to be discontinued at progression of SEGAs.

Note: MRI should be performed at minimum once every 12 months, more frequent scanning should be performed with new onset of symptoms such as headaches, visual complaints, nausea or vomiting, or increase in seizure activity.

### MYCOPHENOLATE MOFETIL

Tab 500 mg – 1% DV Nov-13 to 2016 .....	25.00	50	CellCept
Cap 250 mg – 1% DV Nov-13 to 2016 .....	25.00	100	CellCept
Powder for oral liq 1 g per 5 ml – 1% DV Nov-13 to 2016 .....	187.25	165 ml	CellCept
Inj 500 mg vial – 1% DV Nov-13 to 2016 .....	133.33	4	CellCept

### PICIBANIL

Inj 100 mg vial

### SIROLIMUS – **Restricted** see terms below

⚡ Tab 1 mg .....	813.00	100	Rapamune
⚡ Tab 2 mg .....	1,626.00	100	Rapamune
⚡ Oral liq 1 mg per ml .....	487.80	60 ml	Rapamune

### ➡ **Restricted**

For rescue therapy for an organ transplant recipient

Notes: Rescue therapy defined as unresponsive to calcineurin inhibitor treatment as defined by refractory rejection; or intolerant to calcineurin inhibitor treatment due to any of the following:

- GFR < 30 ml/min; or
- Rapidly progressive transplant vasculopathy; or
- Rapidly progressive obstructive bronchiolitis; or
- HUS or TTP; or
- Leukoencephalopathy; or
- Significant malignant disease

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Antiallergy Preparations</b>			
<b>Allergy Desensitisation</b>			
BEE VENOM – <b>Restricted</b> see terms below			
☞ Inj 120 mcg vial with diluent, 6 vial			
☞ Inj 550 mcg vial with diluent			
☞ <b>Restricted</b>			
Both:			
1 RAST or skin test positive; and			
2 Patient has had severe generalised reaction to the sensitising agent.			
PAPER WASP VENOM – <b>Restricted</b> see terms below			
☞ Inj 550 mcg vial with diluent			
☞ <b>Restricted</b>			
Both:			
1 RAST or skin test positive; and			
2 Patient has had severe generalised reaction to the sensitising agent.			
YELLOW JACKET WASP VENOM – <b>Restricted</b> see terms below			
☞ Inj 550 mcg vial with diluent			
☞ <b>Restricted</b>			
Both:			
1 RAST or skin test positive; and			
2 Patient has had severe generalised reaction to the sensitising agent.			
<b>Allergy Prophylactics</b>			
BECLOMETHASONE DIPROPIONATE			
Nasal spray 50 mcg per dose .....	4.85	200 dose	Alanase
Nasal spray 100 mcg per dose .....	5.75	200 dose	Alanase
BUDESONIDE			
Nasal spray 50 mcg per dose .....	4.85	200 dose	Butacort Aqueous
Nasal spray 100 mcg per dose .....	5.75	200 dose	Butacort Aqueous
FLUTICASONE PROPIONATE			
Nasal spray 50 mcg per dose – 1% DV Apr-13 to 2015 .....	2.30	120 dose	Flixonase Hayfever & Allergy
IPRATROPIUM BROMIDE			
Aqueous nasal spray 0.03% – 1% DV Jan-15 to 2017 .....	3.95	15 ml	Univent
SODIUM CROMOGLYCATE			
Nasal spray 4%			
<b>Antihistamines</b>			
CETIRIZINE HYDROCHLORIDE			
Tab 10 mg .....	1.59	100	Zetop
Oral liq 1 mg per ml – 1% DV Feb-15 to 2017 .....	2.99	200 ml	Histaclear
CHLORPHENIRAMINE MALEATE			
Oral liq 0.4 mg per ml			
Inj 10 mg per ml, 1 ml ampoule			
CYPROHEPTADINE HYDROCHLORIDE			
Tab 4 mg			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>FEXOFENADINE HYDROCHLORIDE</b>			
Tab 60 mg			
Tab 120 mg			
Tab 180 mg			
<b>LORATADINE</b>			
Tab 10 mg – 1% DV Dec-13 to 2016 .....	1.30	100	<b>Lorafix</b>
Oral liq 1 mg per ml – 1% DV Nov-14 to 2016 .....	4.25	200 ml	<b>LoraPaed</b>
<b>PROMETHAZINE HYDROCHLORIDE</b>			
Tab 10 mg – 1% DV Sep-12 to 2015 .....	1.99	50	<b>Allersoothe</b>
Tab 25 mg – 1% DV Sep-12 to 2015 .....	2.99	50	<b>Allersoothe</b>
Oral liq 1 mg per ml – 1% DV Feb-13 to 2015 .....	2.79	100 ml	<b>Allersoothe</b>
Inj 25 mg per ml, 2 ml ampoule .....	11.99	5	<b>Hospira</b>
<b>TRIMEPAZINE TARTRATE</b>			
Oral liq 6 mg per ml			

## Anticholinergic Agents

<b>IPRATROPIUM BROMIDE</b>			
Aerosol inhaler 20 mcg per dose			
Nebuliser soln 250 mcg per ml, 1 ml ampoule – 1% DV Sep-13 to 2016 .....	3.26	20	<b>Univent</b>
Nebuliser soln 250 mcg per ml, 2 ml ampoule – 1% DV Sep-13 to 2016 .....	3.37	20	<b>Univent</b>

## Anticholinergic Agents with Beta-Adrenoceptor Agonists

<b>SALBUTAMOL WITH IPRATROPIUM BROMIDE</b>			
Aerosol inhaler 100 mcg with ipratropium bromide 20 mcg per dose			
Nebuliser soln 2.5 mg with ipratropium bromide 0.5 mg per 2.5 ml ampoule – 1% DV Nov-12 to 2015 .....	3.75	20	<b>Duolin</b>

## Long-Acting Muscarinic Agents

### ➔ Restricted

#### Initiation

All of the following:

- 1 To be used for the long-term maintenance treatment of bronchospasm and dyspnoea associated with COPD; and
- 2 In addition to standard treatment, the patient has trialled a short acting bronchodilator dose of at least 40 µg ipratropium q.i.d for one month; and
- 3 Either the patient's breathlessness according to the Medical Research Council (UK) dyspnoea scale is:
  - 3.1 Grade 4 (stops for breath after walking about 100 meters or after a few minutes on the level); or
  - 3.2 Grade 5 (too breathless to leave the house, or breathless when dressing or undressing); and
- 4 Actual FEV<sub>1</sub> as a % of predicted, must be below 60%.
- 5 Either:
  - 5.1 Patient is not a smoker (for reporting purposes only); or
  - 5.2 Patient is a smoker and has been offered smoking cessation counselling; and
- 6 The patient has been offered annual influenza immunization.

**GLYCOPYRRONIUM – Restricted** see terms above

Note: glycopyrronium treatment must not be used if the patient is also receiving treatment with subsidised tiotropium.

⬆ Powder for inhalation 50 mcg per dose .....	61.00	30 dose	<b>Seebri Breezhaler</b>
---	-------	---------	--------------------------

**TIOTROPIUM BROMIDE – Restricted** see terms above

Note: tiotropium treatment must not be used if the patient is also receiving treatment with subsidised glycopyrronium.

⬆ Powder for inhalation 18 mcg per dose .....	70.00	30 dose	<b>Spiriva</b>
---	-------	---------	----------------

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Beta-Adrenoceptor Agonists</b>			
<b>SALBUTAMOL</b>			
Oral liq 400 mcg per ml – 1% DV Jan-14 to 2016.....	2.06	150 ml	<b>Ventolin</b>
Inj 500 mcg per ml, 1 ml ampoule			
Inj 1 mg per ml, 5 ml ampoule			
Aerosol inhaler, 100 mcg per dose .....	4.00	200 dose	<b>Salamol</b>
	6.00		<b>Ventolin</b>
Nebuliser soln 1 mg per ml, 2.5 ml ampoule – 1% DV Nov-12 to 2015.....	3.25	20	<b>Asthalin</b>
Nebuliser soln 2 mg per ml, 2.5 ml ampoule – 1% DV Nov-12 to 2015.....	3.44	20	<b>Asthalin</b>
<b>TERBUTALINE SULPHATE</b>			
Powder for inhalation 250 mcg per dose			
Inj 0.5 mg per ml, 1 ml ampoule			
<b>Cough Suppressants</b>			
<b>PHOLCODINE</b>			
Oral liq 1 mg per ml			
<b>Decongestants</b>			
<b>OXYMETAZOLINE HYDROCHLORIDE</b>			
Aqueous nasal spray 0.25 mg per ml			
Aqueous nasal spray 0.5 mg per ml			
<b>PSEUDOEPHEDRINE HYDROCHLORIDE</b>			
Tab 60 mg			
<b>SODIUM CHLORIDE</b>			
Aqueous nasal spray 7.4 mg per ml			
<b>SODIUM CHLORIDE WITH SODIUM BICARBONATE</b>			
Soln for nasal irrigation			
<b>XYLOMETAZOLINE HYDROCHLORIDE</b>			
Aqueous nasal spray 0.05%			
Aqueous nasal spray 0.1%			
Nasal drops 0.05%			
Nasal drops 0.1%			
<b>Inhaled Corticosteroids</b>			
<b>BECLOMETHASONE DIPROPIONATE</b>			
Aerosol inhaler 50 mcg per dose .....	8.54	200 dose	<b>Beclazone 50</b>
	9.30		<b>Qvar</b>
Aerosol inhaler 100 mcg per dose .....	12.50	200 dose	<b>Beclazone 100</b>
	15.50		<b>Qvar</b>
Aerosol inhaler 250 mcg per dose .....	22.67	200 dose	<b>Beclazone 250</b>
<b>BUDESONIDE</b>			
Nebuliser soln 250 mcg per ml, 2 ml ampoule			
Nebuliser soln 500 mcg per ml, 2 ml ampoule			
Powder for inhalation 100 mcg per dose			
Powder for inhalation 200 mcg per dose			
Powder for inhalation 400 mcg per dose			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>FLUTICASONE</b>			
Aerosol inhaler 50 mcg per dose .....	7.50	120 dose	Flixotide
Powder for inhalation 50 mcg per dose .....	8.67	60 dose	Flixotide Accuhaler
Powder for inhalation 100 mcg per dose .....	13.87	60 dose	Flixotide Accuhaler
Aerosol inhaler 125 mcg per dose .....	13.60	120 dose	Flixotide
Aerosol inhaler 250 mcg per dose .....	27.20	120 dose	Flixotide
Powder for inhalation 250 mcg per dose .....	24.51	60 dose	Flixotide Accuhaler

## Leukotriene Receptor Antagonists

**MONTELUKAST – Restricted** see terms below

⚡ Tab 4 mg .....	18.48	28	Singulair
⚡ Tab 5 mg .....	18.48	28	Singulair
⚡ Tab 10 mg .....	18.48	28	Singulair

➡ **Restricted**

**Pre-school wheeze**

Both:

- 1 To be used for the treatment of intermittent severe wheezing (possibly viral); and
- 2 The patient has had at least three episodes in the previous 12 months of acute wheeze severe enough to seek medical attention.

**Exercise-induced asthma**

All of the following:

- 1 Patient has been trialed with maximal asthma therapy, including inhaled corticosteroids and long-acting beta-adrenoceptor agonists; and
- 2 Patient continues to receive optimal inhaled corticosteroid therapy; and
- 3 Patient continues to experience frequent episodes of exercise-induced bronchoconstriction.

**Aspirin desensitisation**

Clinical immunologist or allergist

All of the following:

- 1 Patient is undergoing aspirin desensitisation therapy under the supervision of a clinical immunologist or allergist; and
- 2 Patient has moderate to severe aspirin-exacerbated respiratory disease or Samter's triad; and
- 3 Nasal polyposis, confirmed radiologically or surgically; and
- 4 Documented aspirin or NSAID allergy confirmed by aspirin challenge or a clinical history of severe reaction to aspirin or NSAID where challenge would be considered dangerous.

## Long-Acting Beta-Adrenoceptor Agonists

**EFORMOTEROL FUMARATE**

Powder for inhalation 6 mcg per dose  
Powder for inhalation 12 mcg per dose

**INDACATEROL**

Powder for inhalation 150 mcg per dose .....	61.00	30 dose	Onbrez Breezhaler
Powder for inhalation 300 mcg per dose .....	61.00	30 dose	Onbrez Breezhaler

**SALMETEROL**

Aerosol inhaler 25 mcg per dose .....	26.46	120 dose	Serevent
Powder for inhalation 50 mcg per dose .....	26.46	60 dose	Serevent Accuhaler

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

## Inhaled Corticosteroids with Long-Acting Beta-Adrenoceptor Agonists

BUDESONIDE WITH EFORMOTEROL – **Restricted** see terms below

- ☞ Powder for inhalation 100 mcg with eformoterol fumarate 6 mcg
- ☞ Powder for inhalation 200 mcg with eformoterol fumarate 6 mcg
- ☞ Powder for inhalation 400 mcg with eformoterol fumarate 12 mcg
- ☞ Aerosol inhaler 100 mcg with eformoterol fumarate 6 mcg
- ☞ Aerosol inhaler 200 mcg with eformoterol fumarate 6 mcg

### ☞Restricted

Either:

- 1 All of the following:
  - 1.1 Patient is a child under the age of 12; and
  - 1.2 Has been treated with inhaled corticosteroids of at least 400 mcg per day beclomethasone or budesonide, or 200 mcg per day fluticasone; and
  - 1.3 The prescriber considers that the patient would receive additional clinical benefit from switching to a combination product; or
- 2 All of the following:
  - 2.1 Patient is over the age of 12; and
  - 2.2 Has been treated with inhaled corticosteroids of at least 800 mcg per day beclomethasone or budesonide, or 500 mcg per day fluticasone; and
  - 2.3 The prescriber considers that the patient would receive additional clinical benefit from switching to a combination product.

FLUTICASONE WITH SALMETEROL

Aerosol inhaler 50 mcg with salmeterol 25 mcg .....	37.48	120 dose	Seretide
Powder for inhalation 100 mcg with salmeterol 50 mcg .....	37.48	60 dose	Seretide Accuhaler
Aerosol inhaler 125 mcg with salmeterol 25 mcg .....	49.69	120 dose	Seretide
Powder for inhalation 250 mcg with salmeterol 50 mcg .....	49.69	60 dose	Seretide Accuhaler

## Mast Cell Stabilisers

NEDOCROMIL

Aerosol inhaler 2 mg per dose

SODIUM CROMOGLYCATE

Powder for inhalation 20 mg per dose

Aerosol inhaler 5 mg per dose

## Methylxanthines

AMINOPHYLLINE

Inj 25 mg per ml, 10 ml ampoule – 1% DV Oct-14 to 2017 .....	118.25	5	DBL Aminophylline
--	--------	---	-------------------

CAFFEINE CITRATE

Oral liq 20 mg per ml (caffeine 10 mg per ml) .....	14.85	25 ml	Biomed
Inj 20 mg per ml (caffeine 10 mg per ml), 2.5 ml ampoule .....	55.75	5	Biomed

THEOPHYLLINE

Tab long-acting 250 mg

Oral liq 80 mg per 15 ml

## Mucolytics and Expectorants

DORNASE ALFA – **Restricted** see terms on the next page

☞ Nebuliser soln 2.5 mg per 2.5 ml ampoule .....	250.00	6	Pulmozyme
--	--------	---	-----------

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

### ➔ Restricted

Any of the following:

- 1 Cystic fibrosis and the patient has been approved by the Cystic Fibrosis Panel; and/or
- 2 Significant mucus production and meets the following criteria
- 3 Treatment for up to four weeks for patients meeting the following:
  - 3.1 Patient is an in-patient; and
  - 3.2 The mucus production cannot be cleared by first line chest techniques; or
- 4 Treatment for up to three days for patients diagnosed with empyema.

#### SODIUM CHLORIDE

Nebuliser soln 7%, 90 ml bottle .....	23.50	90 ml	Biomed
---------------------------------------	-------	-------	--------

### Pulmonary Surfactants

#### BERACTANT

Soln 200 mg per 8 ml vial .....	550.00	1	Survanta
---------------------------------	--------	---	----------

#### PORACTANT ALFA

Soln 120 mg per 1.5 ml vial .....	425.00	1	Curosurf
Soln 240 mg per 3 ml vial .....	695.00	1	Curosurf

### Respiratory Stimulants

#### DOXAPRAM

Inj 20 mg per ml, 5 ml vial

### Sclerosing Agents

#### TALC

Powder

Soln (slurry) 100 mg per ml, 50 ml

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Anti-Infective Preparations</b>			
<b>Antibacterials</b>			
CHLORAMPHENICOL			
Eye oint 1% – 1% DV Jan-13 to 2015.....	2.76	4 g	Chlorsig
Ear drops 0.5%			
Eye drops 0.5% – 1% DV Sep-12 to 2015.....	1.20	10 ml	Chlorafast
Eye drops 0.5%, single dose			
CIPROFLOXACIN			
Eye drops 0.3%			
FRAMYCETIN SULPHATE			
Ear/eye drops 0.5%			
FUSIDIC ACID			
Eye drops 1% .....	4.50	5 g	Fucithalmic
GENTAMICIN SULPHATE			
Eye drops 0.3% .....	11.40	5 ml	Genoptic
PROPAMIDINE ISETHIONATE			
Eye drops 0.1%			
SULPHACETAMIDE SODIUM			
Eye drops 10%			
TOBRAMYCIN			
Eye oint 0.3% – 1% DV Sep-14 to 2017 .....	10.45	3.5 g	Tobrex
Eye drops 0.3% – 1% DV Sep-14 to 2017 .....	11.48	5 ml	Tobrex
<b>Antifungals</b>			
NATAMYCIN			
Eye drops 5%			
<b>Antivirals</b>			
ACICLOVIR			
Eye oint 3%			
GANCICLOVIR			
Eye gel 0.15%			<i>e.g. Virgan</i>
<b>Combination Preparations</b>			
CIPROFLOXACIN WITH HYDROCORTISONE			
Ear drops ciprofloxacin 0.2% with 1% hydrocortisone – 1% DV Mar-15 to 2017 .....	16.30	10 ml	Ciproxin HC Otic
DEXAMETHASONE WITH FRAMYCETIN AND GRAMICIDIN			
Ear/eye drops 500 mcg with framycetin sulphate 5 mg and gramicidin 50 mcg per ml			



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>DEXAMETHASONE WITH NEOMYCIN SULPHATE AND POLYMYXIN B SULPHATE</b>			
Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin b sulphate 6,000 u per g – <b>1% DV Sep-14 to 2017</b> .....	5.39	3.5 g	<b>Maxitrol</b>
Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin b sulphate 6,000 u per ml – <b>1% DV Sep-14 to 2017</b> .....	4.50	5 ml	<b>Maxitrol</b>
<b>DEXAMETHASONE WITH TOBRAMYCIN</b>			
Eye drops 0.1% with tobramycin 0.3% – <b>1% DV Mar-15 to 2017</b> .....	12.64	5 ml	<b>Tobradex</b>
<b>FLUMETASONE PIVALATE WITH CLIOQUINOL</b>			
Ear drops 0.02% with clioquinol 1%			
<b>TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCIN AND NYSTATIN</b>			
Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g .....	5.16	7.5 ml	<b>Kenacomb</b>

## Anti-Inflammatory Preparations

### Corticosteroids

<b>DEXAMETHASONE</b>			
Eye oint 0.1% – <b>1% DV Oct-14 to 2017</b> .....	5.86	3.5 g	<b>Maxidex</b>
Eye drops 0.1% – <b>1% DV Oct-14 to 2017</b> .....	4.50	5 ml	<b>Maxidex</b>
<b>FLUOROMETHOLONE</b>			
Eye drops 0.1% – <b>1% DV Dec-12 to 2015</b> .....	3.80	5 ml	<b>Flucon</b>
<b>PREDNISOLONE ACETATE</b>			
Eye drops 0.12%			
Eye drops 1%			
<b>PREDNISOLONE SODIUM PHOSPHATE</b>			
Eye drops 0.5%, single dose			

### Non-Steroidal Anti-Inflammatory Drugs

<b>DICLOFENAC SODIUM</b>			
Eye drops 0.1% – <b>1% DV Sep-14 to 2017</b> .....	13.80	5 ml	<b>Voltaren Ophtha</b>
Eye drops 0.1%, single dose			
<b>KETOROLAC TROMETAMOL</b>			
Eye drops 0.5%			

## Decongestants and Antiallergics

### Antiallergic Preparations

<b>LEVOCABASTINE</b>			
Eye drops 0.05%			
<b>LODOXAMIDE</b>			
Eye drops 0.1% – <b>1% DV Sep-14 to 2017</b> .....	8.71	10 ml	<b>Lomide</b>
<b>OLOPATADINE</b>			
Eye drops 0.1%			
<b>SODIUM CROMOGLYCATE</b>			
Eye drops 2%			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Decongestants</b>			
NAPHAZOLINE HYDROCHLORIDE			
Eye drops 0.1% – 1% DV Sep-14 to 2017 .....	4.15	15 ml	Naphcon Forte
<b>Diagnostic and Surgical Preparations</b>			
<b>Diagnostic Dyes</b>			
FLUORESCEIN SODIUM			
Eye drops 2%, single dose			
Inj 10%, 5 ml vial .....	125.00	12	Fluorescite
Ophthalmic strips 1 mg			
FLUORESCEIN SODIUM WITH LIGNOCAINE HYDROCHLORIDE			
Eye drops 0.25% with lignocaine hydrochloride 4%, single dose			
LISSAMINE GREEN			
Ophthalmic strips 1.5 mg			
ROSE BENGAL SODIUM			
Ophthalmic strips 1%			
<b>Irrigation Solutions</b>			
CALCIUM CHLORIDE WITH MAGNESIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ACETATE, SODIUM CHLORIDE AND SODIUM CITRATE			
Eye drops 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium citrate 0.17%, 15 ml			<i>e.g. Balanced Salt Solution</i>
Eye drops 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium citrate 0.17%, 250 ml			<i>e.g. Balanced Salt Solution</i>
Eye drops 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium citrate 0.17%, 500 ml			<i>e.g. Balanced Salt Solution</i>
<b>Ocular Anaesthetics</b>			
OXYBUPROCAINE HYDROCHLORIDE			
Eye drops 0.4%, single dose			
PROXYMETACAINE HYDROCHLORIDE			
Eye drops 0.5%			
TETRACAINE [AMETHOCAINE] HYDROCHLORIDE			
Eye drops 0.5%, single dose			
Eye drops 1%, single dose			
<b>Viscoelastic Substances</b>			
HYPROMELLOSE			
Inj 2%, 1 ml syringe			
Inj 2%, 2 ml syringe			

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)

*e.g. Brand* indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>SODIUM HYALURONATE</b>			
Inj 14 mg per ml, 0.85 ml syringe – <b>1% DV Oct-12 to 2015</b> .....	50.00	1	<b>Healon GV</b>
Inj 14 mg per ml, 0.55 ml syringe – <b>1% DV Oct-12 to 2015</b> .....	50.00	1	<b>Healon GV</b>
Inj 23 mg per ml, 0.6 ml syringe			
Inj 10 mg per ml, 0.85 ml syringe – <b>1% DV Oct-12 to 2015</b> .....	30.00	1	<b>Provisc</b>
<b>SODIUM HYALURONATE WITH CHONDROITIN SULPHATE</b>			
Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.35 ml syringe and inj 10 mg sodium hyaluronate per ml, 0.4 ml syringe .....	64.00	1	Duovisc
Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.5 ml syringe and inj 10 mg sodium hyaluronate per ml, 0.55 ml syringe .....	74.00	1	Duovisc
Inj 30 mg with chondroitin sulphate 40 mg per ml, 0.75 ml syringe			
<b>Other</b>			
<b>DISODIUM EDETATE</b>			
Inj 150 mg per ml, 20 ml ampoule			
Inj 150 mg per ml, 20 ml vial			
Inj 150 mg per ml, 100 ml vial			
<b>RIBOFLAVIN 5-PHOSPHATE</b>			
Soln trans epithelial riboflavin			
Inj 0.1%			
Inj 0.1% plus 20% dextran T500			
<b>Glaucoma Preparations</b>			
<b>Beta Blockers</b>			
<b>BETAXOLOL</b>			
Eye drops 0.25% – <b>1% DV Sep-14 to 2017</b> .....	11.80	5 ml	<b>Betoptic S</b>
Eye drops 0.5% – <b>1% DV Sep-14 to 2017</b> .....	7.50	5 ml	<b>Betoptic</b>
<b>LEVOBUNOLOL HYDROCHLORIDE</b>			
Eye drops 0.25% .....	7.00	5 ml	Betagan
Eye drops 0.5% .....	7.00	5 ml	Betagan
<i>(Betagan Eye drops 0.25% to be delisted 1 July 2015)</i>			
<b>TIMOLOL</b>			
Eye drops 0.25% – <b>1% DV Sep-14 to 2017</b> .....	1.45	5 ml	<b>Arrow-Timolol</b>
Eye drops 0.25%, gel forming – <b>1% DV Mar-14 to 2016</b> .....	3.30	2.5 ml	<b>Timoptol XE</b>
Eye drops 0.5% – <b>1% DV Sep-14 to 2017</b> .....	1.45	5 ml	<b>Arrow-Timolol</b>
Eye drops 0.5%, gel forming – <b>1% DV Mar-14 to 2016</b> .....	3.78	2.5 ml	<b>Timoptol XE</b>
<b>Carbonic Anhydrase Inhibitors</b>			
<b>ACETAZOLAMIDE</b>			
Tab 250 mg – <b>1% DV Sep-14 to 2017</b> .....	17.03	100	<b>Diamox</b>
Inj 500 mg			
<b>BRINZOLAMIDE</b>			
Eye drops 1%			
<b>DORZOLAMIDE</b>			
Eye drops 2%			
<b>DORZOLAMIDE WITH TIMOLOL</b>			
Eye drops 2% with timolol 0.5% .....	15.50	5 ml	Cosopt

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Miotics</b>			
ACETYLCHOLINE CHLORIDE			
Inj 20 mg vial with diluent			
PILOCARPINE HYDROCHLORIDE			
Eye drops 1% – 1% DV Sep-14 to 2017 .....	4.26	15 ml	Isopto Carpine
Eye drops 2% – 1% DV Sep-14 to 2017 .....	5.35	15 ml	Isopto Carpine
Eye drops 2%, single dose			
Eye drops 4% – 1% DV Sep-14 to 2017 .....	7.99	15 ml	Isopto Carpine
<b>Prostaglandin Analogues</b>			
BIMATOPROST			
Eye drops 0.03%			
LATANOPROST			
Eye drops 0.005% – 1% DV Sep-12 to 2015 .....	1.99	2.5 ml	Hysite
TRAVOPROST			
Eye drops 0.004%			
<b>Sympathomimetics</b>			
APRACLONIDINE			
Eye drops 0.5% – 1% DV Mar-15 to 2017 .....	19.77	5 ml	Iopidine
BRIMONIDINE TARTRATE			
Eye drops 0.2% – 1% DV Sep-14 to 2017 .....	4.32	5 ml	Arrow-Brimonidine
BRIMONIDINE TARTRATE WITH TIMOLOL			
Eye drops 0.2% with timolol 0.5%			
<b>Mydriatics and Cycloplegics</b>			
<b>Anticholinergic Agents</b>			
ATROPINE SULPHATE			
Eye drops 0.5%			
Eye drops 1%, single dose			
Eye drops 1% – 1% DV Jul-14 to 2017 .....	17.36	15 ml	Atropt
CYCLOPENTOLATE HYDROCHLORIDE			
Eye drops 0.5%, single dose			
Eye drops 1% – 1% DV Sep-14 to 2017 .....	8.76	15 ml	Cyclogyl
Eye drops 1%, single dose			
TROPICAMIDE			
Eye drops 0.5% – 1% DV Oct-14 to 2017 .....	7.15	15 ml	Mydriacyl
Eye drops 0.5%, single dose			
Eye drops 1% – 1% DV Oct-14 to 2017 .....	8.66	15 ml	Mydriacyl
Eye drops 1%, single dose			
<b>Sympathomimetics</b>			
PHENYLEPHRINE HYDROCHLORIDE			
Eye drops 2.5%, single dose			
Eye drops 10%, single dose			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Ocular Lubricants</b>			
<b>CARBOMER</b>			
Ophthalmic gel 0.3%, single dose .....	8.25	30	Poly Gel
Ophthalmic gel 0.2%			
<b>CARMELLOSE SODIUM</b>			
Eye drops 0.5%			
Eye drops 0.5%, single dose			
Eye drops 1%			
Eye drops 1%, single dose			
<b>HYPROMELLOSE</b>			
Eye drops 0.5% .....	3.92	15 ml	Methopt
<b>HYPROMELLOSE WITH DEXTRAN</b>			
Eye drops 0.3% with dextran 0.1% .....	2.30	15 ml	Poly-Tears
Eye drops 0.3% with dextran 0.1%, single dose			
<b>MACROGOL 400 AND PROPYLENE GLYCOL</b>			
Eye drops 0.4% with propylene glycol 0.3% preservative free, single dose .....	4.30	24	Systane Unit Dose
<b>PARAFFIN LIQUID WITH SOFT WHITE PARAFFIN</b>			
Eye oint 42.5% with soft white paraffin 57.3%			
<b>PARAFFIN LIQUID WITH WOOL FAT</b>			
Eye oint 3% with wool fat 3% – <b>1% DV Jul-14 to 2017</b> .....	3.63	3.5 g	<b>Poly-Visc</b>
<b>POLYVINYL ALCOHOL</b>			
Eye drops 1.4% .....	2.95	15 ml	Vistil
	3.62		Liquifilm Tears
Eye drops 3% .....	3.80	15 ml	Vistil Forte
	3.88		Liquifilm Forte
<b>POLYVINYL ALCOHOL WITH POVIDONE</b>			
Eye drops 1.4% with povidone 0.6%, single dose			
<b>RETINOL PALMITATE</b>			
Oint 138 mcg per g .....	3.80	5 g	VitA-POS
<b>SODIUM HYALURONATE</b>			
Eye drops 1 mg per ml .....	22.00	10 ml	Hylo-Fresh

### Other Otological Preparations

<b>ACETIC ACID WITH PROPYLENE GLYCOL</b>			
Ear drops 2.3% with propylene glycol 2.8%			
<b>DOCUSATE SODIUM</b>			
Ear drops 0.5%			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Agents Used in the Treatment of Poisonings</b>			
<b>Antidotes</b>			
ACETYLCYSTEINE			
Tab eff 200 mg			
Inj 200 mg per ml, 10 ml ampoule – 1% DV Jul-12 to 2015 .....	178.00	10	<b>Martindale</b>
			<b>Acetylcysteine</b>
Inj 200 mg per ml, 30 ml vial .....	219.00	4	Acetadote
DIGOXIN IMMUNE FAB			
Inj 38 mg vial			
Inj 40 mg vial			
ETHANOL			
Liq 96%			
ETHANOL WITH GLUCOSE			
Inj 10% with glucose 5%, 500 ml bottle			
ETHANOL, DEHYDRATED			
Inj 100%, 5 ml ampoule			
Inj 96%			
FLUMAZENIL			
Inj 0.1 mg per ml, 5 ml ampoule .....	170.10	5	Anexate
HYDROXOCOBALAMIN			
Inj 5 g vial			
Inj 2.5 g vial			
NALOXONE HYDROCHLORIDE			
Inj 400 mcg per ml, 1 ml ampoule .....	48.84	5	Hospira
PRALDOXIME IODIDE			
Inj 25 mg per ml, 20 ml ampoule			
SODIUM NITRITE			
Inj 30 mg per ml, 10 ml ampoule			
SODIUM THIOSULFATE			
Inj 500 mg per ml, 20 ml ampoule			
Inj 250 mg per ml, 10 ml vial			
Inj 500 mg per ml, 10 ml vial			
SOYA OIL			
Inj 20%, 500 ml bag			
Inj 20%, 500 ml bottle			
<b>Antitoxins</b>			
BOTULISM ANTITOXIN			
Inj 250 ml vial			
DIPHTHERIA ANTITOXIN			
Inj 10,000 iu vial			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Antivenoms</b>			
RED BACK SPIDER ANTIVENOM			
Inj 500 u vial			
SNAKE ANTIVENOM			
Inj 50 ml vial			
<b>Removal and Elimination</b>			
CHARCOAL			
Oral liq 200 mg per ml .....	43.50	250 ml	Carbasorb-X
DEFERASIROX – <b>Restricted</b> see terms below			
⚡ Tab 125 mg dispersible .....	276.00	28	Exjade
⚡ Tab 250 mg dispersible .....	552.00	28	Exjade
⚡ Tab 500 mg dispersible .....	1,105.00	28	Exjade
➡ <b>Restricted</b>			
<b>Initiation</b>			
Haematologist			
<i>Re-assessment required after 2 years</i>			
All of the following:			
1 The patient has been diagnosed with chronic iron overload due to congenital inherited anaemia; and			
2 Deferasirox is to be given at a daily dose not exceeding 40 mg/kg/day; and			
3 Any of the following:			
3.1 Treatment with maximum tolerated doses of deferiprone monotherapy or deferiprone and desferrioxamine combination therapy have proven ineffective as measured by serum ferritin levels, liver or cardiac MRI T2*; or			
3.2 Treatment with deferiprone has resulted in severe persistent vomiting or diarrhoea; or			
3.3 Treatment with deferiprone has resulted in arthritis; or			
3.4 Treatment with deferiprone is contraindicated due to a history of agranulocytosis (defined as an absolute neutrophil count (ANC) of < 0.5 cells per $\mu\text{L}$ ) or recurrent episodes (greater than 2 episodes) of moderate neutropenia (ANC 0.5 - 1.0 cells per $\mu\text{L}$ )			
<b>Continuation</b>			
Haematologist			
<i>Re-assessment required after 2 years</i>			
Either:			
1 For the first renewal following 2 years of therapy, the treatment has been tolerated and has resulted in clinical improvement in all three parameters namely serum ferritin, cardiac MRI T2* and liver MRI T2* levels; or			
2 For subsequent renewals, the treatment has been tolerated and has resulted in clinical stability or continued improvement in all three parameters namely serum ferritin, cardiac MRI T2* and liver MRI T2* levels.			
DEFERIPRONE – <b>Restricted</b> see terms below			
⚡ Tab 500 mg .....	533.17	100	Ferriprox
⚡ Oral liq 100 mg per ml .....	266.59	250 ml	Ferriprox
➡ <b>Restricted</b>			
Patient has been diagnosed with chronic iron overload due to congenital inherited anaemia or acquired red cell aplasia.			
DEFERRIOXAMINE MESILATE			
Inj 500 mg vial .....	109.89	10	Hospira
DICOBALT EDETATE			
Inj 15 mg per ml, 20 ml ampoule			
DIMERCAPROL			
Inj 50 mg per ml, 2 ml ampoule			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
DIMERCAPTOSUCCINIC ACID Cap 100 mg			
SODIUM CALCIUM EDETATE Inj 200 mg per ml, 2.5 ml ampoule Inj 200 mg per ml, 5 ml ampoule			
<b>Antiseptics and Disinfectants</b>			
CHLORHEXIDINE Soln 4% ..... Soln 5% .....	1.86 15.50	50 ml 500 ml	healthE healthE
CHLORHEXIDINE WITH CETRIMIDE Crm 0.1% with cetrimide 0.5% Foaming soln 0.5% with cetrimide 0.5%			
CHLORHEXIDINE WITH ETHANOL Soln 0.5% with ethanol 70%, non-staining (pink) 100 ml ..... Soln 2% with ethanol 70%, non-staining (pink) 100 ml ..... Soln 0.5% with ethanol 70%, non-staining (pink) 25 ml ..... Soln 0.5% with ethanol 70%, staining (red) 100 ml ..... Soln 2% with ethanol 70%, staining (red) 100 ml ..... Soln 0.5% with ethanol 70%, non-staining (pink) 500 ml ..... Soln 0.5% with ethanol 70%, staining (red) 500 ml ..... Soln 2% with ethanol 70%, staining (red) 500 ml .....	2.65 3.54 1.55 2.90 3.86 5.45 5.90 9.56	1 1 1 1 1 1 1 1	healthE healthE healthE healthE healthE healthE healthE healthE
IODINE WITH ETHANOL Soln 1% with ethanol 70%, 100 ml .....	9.30	1	healthE
ISOPROPYL ALCOHOL Soln 70%, 500 ml .....	5.00 5.65	1	PSM healthE
POVIDONE-IODINE Vaginal tab 200 mg			
➡ <b>Restricted</b> Rectal administration pre-prostate biopsy.			
Oint 10% ..... Soln 10% .....  Soln 5% Soln 7.5% Pad 10% Swab set 10%	3.27 2.95 6.20	25 g 100 ml 500 ml	Betadine Riodine Riodine Betadine
POVIDONE-IODINE WITH ETHANOL Soln 10% with ethanol 30% ..... Soln 10% with ethanol 70%	10.00	500 ml	Betadine Skin Prep
SODIUM HYPOCHLORITE Soln			



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Contrast Media</b>			
<b>Iodinated X-ray Contrast Media</b>			
DIATRIZOATE MEGLUMINE WITH SODIUM AMIDOTRIZOATE			
Oral liq 660 mg per ml with sodium amidotrizoate 100 mg per ml, 100 ml bottle .....	22.50	100 ml	Gastrografin
Inj 260 mg with sodium amidotrizoate 40 mg per ml, 250 ml bottle .....	80.00	1	Urografin
DIATRIZOATE SODIUM			
Oral liq 370 mg per ml, 10 ml sachet .....	156.12	50	Ioscan
IODISED OIL			
Inj 38% w/w (480 mg per ml), 10 ml ampoule .....	143.00	1	Lipiodol Ultra Fluid
IODIXANOL			
Inj 270 mg per ml (iodine equivalent), 50 ml bottle – <b>5% DV Sep-14 to 2017</b> .....	220.00	10	Visipaque
Inj 270 mg per ml (iodine equivalent), 100 ml bottle – <b>5% DV Sep-14 to 2017</b> .....	430.00	10	Visipaque
Inj 320 mg per ml (iodine equivalent), 50 ml bottle – <b>5% DV Sep-14 to 2017</b> .....	220.00	10	Visipaque
Inj 320 mg per ml (iodine equivalent), 100 ml bottle – <b>5% DV Sep-14 to 2017</b> .....	430.00	10	Visipaque
Inj 320 mg per ml (iodine equivalent), 200 ml bottle – <b>5% DV Sep-14 to 2017</b> .....	850.00	10	Visipaque
IOHEXOL			
Inj 240 mg per ml (iodine equivalent), 50 ml bottle – <b>5% DV Sep-14 to 2017</b> .....	75.00	10	Omnipaque
Inj 300 mg per ml (iodine equivalent), 20 ml bottle – <b>5% DV Sep-14 to 2017</b> .....	57.00	10	Omnipaque
Inj 300 mg per ml (iodine equivalent), 50 ml bottle – <b>5% DV Sep-14 to 2017</b> .....	75.00	10	Omnipaque
Inj 300 mg per ml (iodine equivalent), 100 ml bottle – <b>5% DV Sep-14 to 2017</b> .....	150.00	10	Omnipaque
Inj 350 mg per ml (iodine equivalent), 20 ml bottle – <b>5% DV Sep-14 to 2017</b> .....	59.00	10	Omnipaque
Inj 350 mg per ml (iodine equivalent), 50 ml bottle – <b>5% DV Sep-14 to 2017</b> .....	75.00	10	Omnipaque
Inj 350 mg per ml (iodine equivalent), 75 ml bottle – <b>5% DV Sep-14 to 2017</b> .....	114.00	10	Omnipaque
Inj 350 mg per ml (iodine equivalent), 100 ml bottle – <b>5% DV Sep-14 to 2017</b> .....	150.00	10	Omnipaque
Inj 350 mg per ml (iodine equivalent), 200 ml bottle – <b>5% DV Sep-14 to 2017</b> .....	290.00	10	Omnipaque

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Non-iodinated X-ray Contrast Media</b>			
<b>BARIUM SULPHATE</b>			
Powder for oral liq 20 mg per g (2% w/w), 22.1 g sachet .....	507.50	50	E-Z-Cat Dry
Oral liq 400 mg per ml (40% w/v, 30% w/w), bottle .....	17.39	148 g	Varibar - Thin Liquid
Oral liq 600 mg per g (60% w/w), tube .....	36.51	454 g	E-Z-Paste
Oral liq 400 mg per ml (40% w/v), bottle .....	38.40	240 ml	Varibar - Nectar
.....	145.04	230 ml	Varibar - Pudding
.....	155.35	250 ml	Varibar - Honey
Enema 1,250 mg per ml (125% w/v), 500 ml bag .....	282.30	12	Liquibar
Oral liq 22 mg per g (2.2% w/w), 250 ml bottle .....	175.00	24	CT Plus+
Oral liq 22 mg per g (2.2% w/w), 450 ml bottle .....	220.00	24	CT Plus+
Oral liq 1 mg per ml (0.1% w/v, 0.1% w/w), 450 ml bottle .....	441.12	24	VoLumen
Oral liq 20.9 mg per ml (2.1% w/v, 2% w/w), 250 ml bottle .....	140.94	24	Readi-CAT 2
Powder for oral soln 97.65% w/w, 300 g bottle .....	237.76	24	X-Opaque-HD
Oral liq 400 mg per ml (40% w/v, 30% w/w), 20 ml bottle .....	52.35	3	Tagitol V
Oral liq 1,250 mg per ml (125% w/v), 2,000 ml bottle .....	91.77	1	Liquibar
<b>BARIUM SULPHATE WITH SODIUM BICARBONATE</b>			
Grans eff 382.2 mg per g with sodium bicarbonate 551.3 mg per g, 4 g sachet .....	102.93	50	E-Z-Gas II
<b>CITRIC ACID WITH SODIUM BICARBONATE</b>			
Powder 382.2 mg per g with sodium bicarbonate 551.3 mg per g, 4 g sachet .....			<i>e.g. E-Z-GAS II</i>
<b>Paramagnetic Contrast Media</b>			
<b>GADOBENIC ACID</b>			
Inj 334 mg per ml, 10 ml vial .....	324.74	10	Multihance
Inj 334 mg per ml, 20 ml vial .....	636.28	10	Multihance
<b>GADOBUTROL</b>			
Inj 1 mmol per ml, 15 ml vial .....			
Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 7.5 ml prefilled syringe .....	180.00	5	Gadovist
Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 15 ml prefilled syringe .....	700.00	10	Gadovist
<b>GADODIAMIDE</b>			
Inj 287 mg per ml, 10 ml prefilled syringe .....	200.00	10	Omniscan
Inj 287 mg per ml, 10 ml vial .....	170.00	10	Omniscan
Inj 287 mg per ml, 5 ml vial .....	120.00	10	Omniscan
Inj 287 mg per ml, 15 ml prefilled syringe .....	320.00	10	Omniscan
<b>GADOTERIC ACID</b>			
Inj 279.32 mg per ml (0.5 mmol per ml), 10 ml prefilled syringe .....	24.50	1	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 15 ml bottle .....	34.50	1	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 15 ml prefilled syringe .....	41.00	1	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 20 ml prefilled syringe .....	55.00	1	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 10 ml bottle .....	23.20	1	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 20 ml bottle .....	46.30	1	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 5 ml bottle .....	12.30	1	Dotarem

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>GADOXETATE DISODIUM</b>			
Inj 181.43 mg per ml (equivalent to 0.25 mmol per ml), 10 ml prefilled syringe .....	300.00	1	Primovist
<b>MEGLUMINE GADOPENTETATE</b>			
Inj 469 mg per ml, 10 ml prefilled syringe .....	95.00	5	Magnevist
Inj 469 mg per ml, 10 ml vial .....	185.00	10	Magnevist
<b>MEGLUMINE IOTROXATE</b>			
Inj 105 mg per ml, 100 ml bottle .....	150.00	100 ml	Biliscopin
<b>Ultrasound Contrast Media</b>			
<b>PERFLUTREN</b>			
Inj 1.1 mg per ml, 1.5 ml vial – <b>5% DV Sep-14 to 2017</b> .....	180.00	1	<b>Definity</b>
	720.00	4	<b>Definity</b>
<b>Diagnostic Agents</b>			
<b>ARGININE</b>			
Inj 50 mg per ml, 500 ml bottle			
Inj 100 mg per ml, 300 ml bottle			
<b>HISTAMINE ACID PHOSPHATE</b>			
Nebuliser soln 0.6%, 10 ml vial			
Nebuliser soln 2.5%, 10 ml vial			
Nebuliser soln 5%, 10 ml vial			
<b>METHACHOLINE CHLORIDE</b>			
Powder 100 mg			
<b>SECRETIN PENTAHYDROCHLORIDE</b>			
Inj 100 u ampoule			
<b>SINCALIDE</b>			
Inj 5 mcg per vial			
<b>TUBERCULIN, PURIFIED PROTEIN DERIVATIVE</b>			
Inj 5 TU per 0.1 ml, 1 ml vial			
<b>Diagnostic Dyes</b>			
<b>BONNEY'S BLUE DYE</b>			
Soln			
<b>INDIGO CARMINE</b>			
Inj 4 mg per ml, 5 ml ampoule			
Inj 8 mg per ml, 5 ml ampoule			
<b>INDOCYANINE GREEN</b>			
Inj 25 mg vial			
<b>METHYLTHIONINIUM CHLORIDE [METHYLENE BLUE]</b>			
Inj 10 mg per ml, 10 ml ampoule			
Inj 10 mg per ml, 5 ml ampoule			
<b>PATENT BLUE V</b>			
Inj 2.5%, 2 ml ampoule .....	440.00	5	Obex Medical

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Irrigation Solutions</b>			
<b>CHLORHEXIDINE</b>			
Irrigation soln 0.02%, bottle .....	2.92	100 ml	Baxter
Irrigation soln 0.05%, bottle .....	3.02	100 ml	Baxter
	3.63	500 ml	Baxter
Irrigation soln 0.1%, bottle .....	3.10	100 ml	Baxter
Irrigation soln 0.5%, bottle .....	4.69	500 ml	Baxter
Irrigation soln 0.02%, 500 ml bottle			
Irrigation soln 0.1%, 30 ml ampoule			
<b>CHLORHEXIDINE WITH CETRIMIDE</b>			
Irrigation soln 0.015% with cetrimide 0.15%, 30 ml ampoule			
Irrigation soln 0.015% with cetrimide 0.15%, bottle .....	3.21	100 ml	Baxter
	3.47	500 ml	Baxter
	4.17	1,000 ml	Baxter
Irrigation soln 0.05% with cetrimide 0.5%, bottle .....	4.20	100 ml	Baxter
	3.87	500 ml	Baxter
Irrigation soln 0.1% with cetrimide 1%, bottle .....	4.38	100 ml	Baxter
	5.81	500 ml	Baxter
<b>GLYCINE</b>			
Irrigation soln 1.5%, bottle .....	11.38	2,000 ml	Baxter
	14.44	3,000 ml	Baxter
<b>SODIUM CHLORIDE</b>			
Irrigation soln 0.9%, 30 ml ampoule .....	19.50	30 ml	Pfizer
Irrigation soln 0.9%, bottle .....	2.49	100 ml	Baxter
	2.88	500 ml	Baxter
	2.96	1,000 ml	Baxter
	10.00	2,000 ml	Baxter
	12.67	3,000 ml	Baxter
<b>WATER</b>			
Irrigation soln, bottle .....	2.68	100 ml	Baxter
	2.61	500 ml	Baxter
	2.75	1,000 ml	Baxter
	9.71	2,000 ml	Baxter
	15.80	3,000 ml	Baxter
<b>Surgical Preparations</b>			
<b>BISMUTH SUBNITRATE AND IODOFORM PARAFFIN</b>			
Paste			
<b>DIMETHYL SULFOXIDE</b>			
Soln 50%			
Soln 99%			
<b>PHENOL</b>			
Inj 6%, 10 ml ampoule			
<b>PHENOL WITH IOXAGLIC ACID</b>			
Inj 12%, 10 ml ampoule			
<b>TROMETAMOL</b>			
Inj 36 mg per ml, 500 ml bottle			

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

## Cardioplegia Solutions

### ELECTROLYTES

Inj aspartic acid 10.43 mg per ml, citric acid 0.22476 mg per ml, glutamic acid 11.53 mg per ml, sodium phosphate 0.1725 mg per ml, potassium chloride 2.15211 mg per ml, sodium citrate 1.80768 mg per ml, sodium hydroxide 6.31 mg per ml and trometamol 11.2369 mg per ml, 364 ml bag

*e.g. Cardioplegia  
Enriched Paed.  
Soln.*

Inj aspartic acid 8.481 mg per ml, citric acid 0.8188 mg per ml, glutamic acid 9.375 mg per ml, sodium phosphate 0.6285 mg per ml, potassium chloride 2.5 mg per ml, sodium citrate 6.585 mg per ml, sodium hydroxide 5.133 mg per ml and trometamol 9.097 mg per ml, 527 ml bag

*e.g. Cardioplegia  
Enriched Solution*

Inj citric acid 0.07973 mg per ml, sodium phosphate 0.06119 mg per ml, potassium chloride 2.181 mg per ml, sodium chloride 1.788 mg ml, sodium citrate 0.6412 mg per ml and trometamol 5.9 mg per ml, 523 ml bag

*e.g. Cardioplegia Base  
Solution*

Inj 110 mmol/l sodium, 16 mmol/l potassium, 1.2 mmol/l calcium, 16 mmol/l magnesium and 160 mmol/l chloride, 1,000 ml bag

*e.g. Cardioplegia  
Solution AHB7832*

Inj 143 mmol/l sodium, 16 mmol/l potassium, 16 mmol/l magnesium and 1.2 mmol/l calcium, 1,000 ml bag

*e.g. Cardioplegia  
Electrolyte Solution*

### MONOSODIUM GLUTAMATE WITH SODIUM ASPARTATE

Inj 42.68 mg with sodium aspartate 39.48 mg per ml, 250 ml bottle

### MONOSODIUM L-ASPARTATE

Inj 14 mmol per 10 ml, 10 ml

## Cold Storage Solutions

### SODIUM WITH POTASSIUM

Inj 29 mmol/l with potassium 125 mmol/l, 1,000 ml bag

# EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS

	Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
<b>Extemporaneously Compounded Preparations</b>		
ACETIC ACID Liq		
ALUM Powder BP		
ARACHIS OIL [PEANUT OIL] Liq		
ASCORBIC ACID Powder		
BENZOIN Tincture compound BP		
BISMUTH SUBGALLATE Powder		
BORIC ACID Powder		
CARBOXYMETHYLCELLULOSE Soln 1.5%		
CETRIMIDE Soln 40%		
CHLORHEXIDINE GLUCONATE Soln 20 %		
CHLOROFORM Liq BP		
CITRIC ACID Powder BP		
CLOVE OIL Liq		
COAL TAR Soln BP		
CODEINE PHOSPHATE Powder		
COLLODION FLEXIBLE Liq		
COMPOUND HYDROXYBENZOATE Soln		
CYSTEAMINE HYDROCHLORIDE Powder		
DISODIUM HYDROGEN PHOSPHATE WITH SODIUM DIHYDROGEN PHOSPHATE Inj 37.46 mg with sodium dihydrogen phosphate 47.7 mg in 1.5 ml ampoule		
DITHRANOL Powder		

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
GLUCOSE [DEXTROSE] Powder			
GLYCERIN WITH SODIUM SACCHARIN Suspension .....	35.50	473 ml	Ora-Sweet SF
GLYCERIN WITH SUCROSE Suspension .....	35.50	473 ml	Ora-Sweet
GLYCEROL Liq .....	19.80	2,000 ml	ABM
HYDROCORTISONE Powder – 1% DV Dec-14 to 2017 .....	59.50	25 g	<b>ABM</b>
LACTOSE Powder			
MAGNESIUM HYDROXIDE Paste			
MENTHOL Crystals			
METHADONE HYDROCHLORIDE Powder			
METHYL HYDROXYBENZOATE Powder			
METHYLCELLULOSE Powder			
Suspension .....	35.50	473 ml	Ora-Plus
METHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCHARIN Suspension .....	35.50	473 ml	Ora-Blend SF
METHYLCELLULOSE WITH GLYCERIN AND SUCROSE Suspension .....	35.50	473 ml	Ora-Blend
OLIVE OIL Liq			
PARAFFIN Liq			
PHENOBARBITONE SODIUM Powder			
PHENOL Liq			
PILOCARPINE NITRATE Powder			
POLYHEXAMETHYLENE BIGUANIDE Liq			
POVIDONE K30 Powder			
PROPYLENE GLYCOL Liq .....	12.00	500 ml	ABM

## EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
SALICYLIC ACID Powder			
SILVER NITRATE Crystals			
SODIUM BICARBONATE Powder BP			
SODIUM CITRATE Powder			
SODIUM METABISULFITE Powder			
STARCH Powder			
SULPHUR Precipitated Sublimed			
SYRUP Liq (pharmaceutical grade) .....	21.75	2,000 ml	Midwest
THEOBROMA OIL Oint			
TRI-SODIUM CITRATE Crystals			
TRICHLORACETIC ACID Grans			
UREA Powder BP			
WOOL FAT Oint, anhydrous			
XANTHAN Gum 1%			
ZINC OXIDE Powder			



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Food Modules

Carbohydrate

➡Restricted

Use as an additive

Any of the following:

- 1 Cystic fibrosis; or
- 2 Chronic kidney disease; or
- 3 Cancer in children; or
- 4 Cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or
- 5 Faltering growth in an infant/child; or
- 6 Bronchopulmonary dysplasia; or
- 7 Premature and post premature infant; or
- 8 Inborn errors of metabolism.

Use as a module

For use as a component in a modular formula

CARBOHYDRATE SUPPLEMENT – **Restricted** see terms above

- 📦 Powder 95 g carbohydrate per 100 g, 368 g can
- 📦 Powder 96 g carbohydrate per 100 g, 400 g can *e.g. Polycal*

Fat

➡Restricted

Use as an additive

Any of the following:

- 1 Patient has inborn errors of metabolism; or
- 2 Faltering growth in an infant/child; or
- 3 Bronchopulmonary dysplasia; or
- 4 Fat malabsorption; or
- 5 Lymphangiectasia; or
- 6 Short bowel syndrome; or
- 7 Infants with necrotising enterocolitis; or
- 8 Biliary atresia; or
- 9 For use in a ketogenic diet; or
- 10 Chyle leak; or
- 11 Ascites; or
- 12 Patient has increased energy requirements, and for whom dietary measures have not been successful.

Use as a module

For use as a component in a modular formula

LONG-CHAIN TRIGLYCERIDE SUPPLEMENT – **Restricted** see terms above

- 📦 Liquid 50 g fat per 100 ml, 200 ml bottle *e.g. Calogen*
- 📦 Liquid 50 g fat per 100 ml, 500 ml bottle *e.g. Calogen*

MEDIUM-CHAIN TRIGLYCERIDE SUPPLEMENT – **Restricted** see terms above

- 📦 Liquid 50 g fat per 100 ml, 250 ml bottle *e.g. Liquigen*
- 📦 Liquid 95 g fat per 100 ml, 500 ml bottle *e.g. MCT Oil*

WALNUT OIL – **Restricted** see terms above

- 📦 Liq

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Protein</b>			
➡ <b>Restricted</b>			
<b>Use as an additive</b>			
Either:			
1 Protein losing enteropathy; or			
2 High protein needs.			
<b>Use as a module</b>			
For use as a component in a modular formula			
PROTEIN SUPPLEMENT – <b>Restricted</b> see terms above			
⬆ Powder 5 g protein, 0.67 g carbohydrate and 0.6 g fat per 6.6 g, 275 g can			<i>e.g. Promod</i>
⬆ Powder 6 g protein per 7 g, can .....	8.95	227 g	Resource Beneprotein
⬆ Powder 89 g protein, <1.5 g carbohydrate and 2 g fat per 100 g, 225 g can			<i>e.g. Protifar</i>
<b>Other Supplements</b>			
<b>BREAST MILK FORTIFIER</b>			
Powder 0.2 g protein, 0.7 g carbohydrate and 0.02 g fat per 1 g sachet			<i>e.g. FM 85</i>
Powder 0.5 g protein, 1.2 g carbohydrate and 0.08 g fat per 2 g sachet			<i>e.g. S26 Human Milk Fortifier</i>
Powder 0.6 g protein and 1.4 g carbohydrate per 2.2 g sachet			<i>e.g. Nutricia Breast Milk Fortifier</i>
<b>CARBOHYDRATE AND FAT SUPPLEMENT – <b>Restricted</b> see terms below</b>			
⬆ Powder 72.7 g carbohydrate and 22.3 g fat per 100 g, 400 g can			<i>e.g. Super Soluble Duocal</i>
➡ <b>Restricted</b>			
Both:			
1 Infant or child aged four years or under; and			
2 Any of the following:			
2.1 Cystic fibrosis; or			
2.2 Cancer in children; or			
2.3 Faltering growth; or			
2.4 Bronchopulmonary dysplasia; or			
2.5 Premature and post premature infants.			
<b>Food/Fluid Thickeners</b>			
<b>NOTE:</b>			
While pre-thickened drinks and supplements have not been included in Section H, DHB hospitals may continue to use such products for patients with dysphagia, provided that:			
<ul style="list-style-type: none"> <li>use was established prior to 1 July 2013; and</li> <li>the product has not been specifically considered and excluded by PHARMAC; and</li> <li>use of the product conforms to any applicable indication restrictions for similar products that are listed in Section H (for example, use of thickened high protein products should be in line with the restriction for high protein oral feed in Section H).</li> </ul>			
PHARMAC intends to make a further decision in relation to pre-thickened drinks and supplements in the future, and will notify of any change to this situation.			
<b>CAROB BEAN GUM WITH MAIZE STARCH AND MALTODEXTRIN</b>			
Powder			<i>e.g. Feed Thickener Karicare Aptamil</i>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
GUAR GUM Powder			<i>e.g. Guarcol</i>
MAIZE STARCH Powder			<i>e.g. Resource Thicken Up; Nutilis</i>
MALTODEXTRIN WITH XANTHAN GUM Powder			<i>e.g. Instant Thick</i>
MALTODEXTRIN WITH XANTHAN GUM AND ASCORBIC ACID Powder			<i>e.g. Easy Thick</i>

## Metabolic Products

### ➔ Restricted

Any of the following:

- 1 For the dietary management of homocystinuria, maple syrup urine disease, phenylketonuria (PKU), glutaric aciduria, isovaleric acidemia, propionic acidemia, methylmalonic acidemia, tyrosinaemia or urea cycle disorders; or
- 2 Patient has adrenoleukodystrophy; or
- 3 For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.

## Glutaric Aciduria Type 1 Products

AMINO ACID FORMULA (WITHOUT LYSINE AND LOW TRYPTOPHAN) – **Restricted** see terms above

- ⬆ Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre  
per 100 g, 400 g can *e.g. GA1 Anamix Infant*
- ⬆ Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can *e.g. XLYS Low TRY  
Maxamaid*

## Homocystinuria Products

AMINO ACID FORMULA (WITHOUT METHIONINE) – **Restricted** see terms above

- ⬆ Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre  
per 100 g, 400 g can *e.g. HCU Anamix Infant*
- ⬆ Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can *e.g. XMET Maxamaid*
- ⬆ Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can *e.g. XMET Maxamum*
- ⬆ Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per  
100 ml, 125 ml bottle *e.g. HCU Anamix Junior  
LQ*

## Isovaleric Acidemia Products

AMINO ACID FORMULA (WITHOUT LEUCINE) – **Restricted** see terms above

- ⬆ Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre  
per 100 g, 400 g can *e.g. IVA Anamix Infant*
- ⬆ Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can *e.g. XLEU Maxamaid*
- ⬆ Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can *e.g. XLEU Maxamum*

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Maple Syrup Urine Disease Products</b>			
AMINO ACID FORMULA (WITHOUT ISOLEUCINE, LEUCINE AND VALINE) – <b>Restricted</b> see terms on the preceding page			
⚡ Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can			e.g. MSUD Anamix Infant
⚡ Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can			e.g. MSUD Maxamaid
⚡ Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can			e.g. MSUD Maxamum
⚡ Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle			e.g. MSUD Anamix Junior LQ
<b>Phenylketonuria Products</b>			
AMINO ACID FORMULA (WITHOUT PHENYLALANINE) – <b>Restricted</b> see terms on the preceding page			
⚡ Tab 8.33 mg			e.g. Phlexy-10
⚡ Powder 29 g protein, 38 g carbohydrate and 13.5 g fibre per 100 g, 29 g sachet			e.g. PKU Anamix Junior
⚡ Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can			e.g. PKU Anamix Infant
⚡ Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can			e.g. XP Maxamaid
⚡ Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can			e.g. XP Maxamum
⚡ Powder 8.33 g protein and 8.8 g carbohydrate per 20 g sachet			e.g. Phlexy-10
⚡ Liquid 10 g protein, 4.4 g carbohydrate and 0.25 g fibre per 100 ml, 62.5 ml bottle			e.g. PKU Lophlex LQ 10
⚡ Liquid 20 g protein, 8.8 g carbohydrate and 0.34 g fibre per 100 ml, 125 ml bottle			e.g. PKU Lophlex LQ 20
⚡ Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, bottle .....	13.10	125 ml	PKU Anamix Junior LQ (Berry) PKU Anamix Junior LQ (Orange) PKU Anamix Junior LQ (Unflavoured)
⚡ Liquid 16 g protein, 7 g carbohydrate and 0.27 g fibre per 100 ml, 125 ml bottle			e.g. PKU Lophlex LQ 20
⚡ Liquid 16 g protein, 7 g carbohydrate and 0.27 g fibre per 100 ml, 62.5 ml bottle			e.g. PKU Lophlex LQ 10
⚡ Liquid 16 g protein, 7 g carbohydrate and 0.4 g fibre per 100 ml, 125 ml bottle			e.g. PKU Lophlex LQ 20
⚡ Liquid 16 g protein, 7 g carbohydrate and 0.4 g fibre per 100 ml, 62.5 ml bottle			e.g. PKU Lophlex LQ 10
⚡ Liquid 6.7 g protein, 5.1 g carbohydrate and 2 g fat per 100 ml, 250 ml carton			e.g. Easiphen

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

## Propionic Acidaemia and Methylmalonic Acidaemia Products

AMINO ACID FORMULA (WITHOUT ISOLEUCINE, METHIONINE, THREONINE AND VALINE) – **Restricted** see terms on page 195

⬆ Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can	<i>e.g. MMA/PA Anamix Infant</i>
⬆ Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can	<i>e.g. XMTVI Maxamaid</i>
⬆ Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can	<i>e.g. XMTVI Maxamum</i>

## Protein Free Supplements

PROTEIN FREE SUPPLEMENT – **Restricted** see terms on page 195

⬆ Powder nil added protein and 67 g carbohydrate per 100 g, 400 g can	<i>e.g. Energivit</i>
---	-----------------------

## Tyrosinaemia Products

AMINO ACID FORMULA (WITHOUT PHENYLALANINE AND TYROSINE) – **Restricted** see terms on page 195

⬆ Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can	<i>e.g. TYR Anamix Infant</i>
⬆ Powder 25 g protein and 51 g carbohydrate per 100 g, 400 g can	<i>e.g. XPHEN, TYR Maxamaid</i>
⬆ Powder 29 g protein, 38 g carbohydrate and 13.5 g fat per 100 g, 29 g sachet	<i>e.g. TYR Anamix Junior</i>
⬆ Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle	<i>e.g. TYR Anamix Junior LQ</i>

## Urea Cycle Disorders Products

AMINO ACID SUPPLEMENT – **Restricted** see terms on page 195

⬆ Powder 25 g protein and 65 g carbohydrate per 100 g, 200 g can	<i>e.g. Dialamine</i>
⬆ Powder 79 g protein per 100 g, 200 g can	<i>e.g. Essential Amino Acid Mix</i>

## X-Linked Adrenoleukodystrophy Products

GLYCEROL TRIERUCATE – **Restricted** see terms on page 195

⬆ Liquid, 1,000 ml bottle
---------------------------

GLYCEROL TRIOLEATE – **Restricted** see terms on page 195

⬆ Liquid, 500 ml bottle
-------------------------

## Specialised Formulas

### Diabetic Products

#### ➡ **Restricted**

Any of the following:

- 1 For patients with type I or type II diabetes suffering weight loss and malnutrition that requires nutritional support; or
- 2 For patients with pancreatic insufficiency; or
- 3 For patients who have, or are expected to, eat little or nothing for 5 days;
- 4 For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism; or

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
continued...			
5 For use pre- and post-surgery; or			
6 For patients being tube-fed; or			
7 For tube-feeding as a transition from intravenous nutrition.			
LOW-GI ENTERAL FEED 1 KCAL/ML – <b>Restricted</b> see terms on the preceding page			
☞ Liquid 5 g protein, 9.6 g carbohydrate and 5.4 g fat per 100 ml, 1,000 ml bottle .....	7.50	1,000 ml	Glucerna Select RTH (Vanilla)
☞ Liquid 4.3 g protein, 11.3 g carbohydrate and 4.2 g fat per 100 ml, 1,000 ml bag .....			e.g. <i>Nutrison Advanced Diason</i>
LOW-GI ORAL FEED 1 KCAL/ML – <b>Restricted</b> see terms on the preceding page			
☞ Liquid 4.5 g protein, 9.8 g carbohydrate, 4.4 g fat and 1.9 g fibre per 100 ml, can .....	2.10	237 ml	Sustagen Diabetic (Vanilla)
☞ Liquid 5 g protein, 9.6 g carbohydrate and 5.4 g fat per 100 ml, 250 ml bottle .....	1.88	250 ml	Glucerna Select (Vanilla)
☞ Liquid 6 g protein, 9.5 g carbohydrate, 4.7 g fat and 2.6 g fibre per 100 ml, can .....	2.10	237 ml	Resource Diabetic (Vanilla)
☞ Liquid 4.9 g protein, 11.7 g carbohydrate, 3.8 g fat and 2 g fibre per 100 ml, 200 ml bottle .....			e.g. <i>Diasip</i>
<b>Elemental and Semi-Elemental Products</b>			
➡ <b>Restricted</b>			
Any of the following:			
1 Malabsorption; or			
2 Short bowel syndrome; or			
3 Enterocutaneous fistulas; or			
4 Eosinophilic enteritis (including oesophagitis); or			
5 Inflammatory bowel disease; or			
6 Acute pancreatitis where standard feeds are not tolerated; or			
7 Patients with multiple food allergies requiring enteral feeding.			
AMINO ACID ORAL FEED – <b>Restricted</b> see terms above			
☞ Powder 11.5 g protein, 61.7 g carbohydrate and 0.8 g fat per sachet .....	4.50	80.4 g	Vivonex TEN
AMINO ACID ORAL FEED 0.8 KCAL/ML – <b>Restricted</b> see terms above			
☞ Liquid 2.5 g protein, 11 g carbohydrate and 3.5 g fat per 100 ml, 250 ml carton .....			e.g. <i>Elemental 028 Extra</i>
PEPTIDE-BASED ENTERAL FEED 1 KCAL/ML – <b>Restricted</b> see terms above			
☞ Liquid 4 g protein, 17.6 g carbohydrate and 1.7 g fat per 100 ml, 1,000 ml bag .....			e.g. <i>Nutrison Advanced Peptisorb</i>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
PEPTIDE-BASED ORAL FEED – <b>Restricted</b> see terms on the preceding page			
⬆ Powder 12.5 g protein, 55.4 g carbohydrate and 3.25 g fat per sachet .....	4.40	79 g	Vital HN
⬆ Powder 13.7 g protein, 62.9 g carbohydrate and 17.5 g fat per 100 g, 400 g can			<i>e.g. Peptamen Junior</i>
⬆ Powder 13.8 g protein, 59 g carbohydrate and 18 g fat per 100 g, 400 g can			<i>e.g. MCT Pepdite; MCT Pepdite 1+</i>
⬆ Powder 15.8 g protein, 49.5 g carbohydrate and 4.65 g fat per 76 g sachet .....	7.50	76 g	Alitraq
PEPTIDE-BASED ORAL FEED 1 KCAL/ML – <b>Restricted</b> see terms on the preceding page			
⬆ Liquid 5 g protein, 16 g carbohydrate and 1.69 g fat per 100 ml, carton .....	4.95	237 ml	Peptamen OS 1.0 (Vanilla)

## Fat Modified Products

FAT-MODIFIED FEED – **Restricted** see terms below

⬆ Powder 11.4 g protein, 68 g carbohydrate and 11.8 g fat per 100 g, 400 g can			<i>e.g. Monogen</i>
---	--	--	---------------------

### ➡ Restricted

Any of the following:

- 1 Patient has metabolic disorders of fat metabolism; or
- 2 Patient has a chyle leak; or
- 3 Modified as a modular feed for adults.

## Hepatic Products

### ➡ Restricted

For children (up to 18 years) who require a liver transplant

HEPATIC ORAL FEED – **Restricted** see terms above

⬆ Powder 11 g protein, 64 g carbohydrate and 20 g fat per 100 g, can .....	78.97	400 g	Heparon Junior
--	-------	-------	----------------

## High Calorie Products

### ➡ Restricted

Any of the following:

- 1 Patient is fluid volume or rate restricted; or
- 2 Patient requires low electrolyte; or
- 3 Both:
  - 3.1 Any of the following:
    - 3.1.1 Cystic fibrosis; or
    - 3.1.2 Any condition causing malabsorption; or
    - 3.1.3 Faltering growth in an infant/child; or
    - 3.1.4 Increased nutritional requirements; and
  - 3.2 Patient has substantially increased metabolic requirements.

ENTERAL FEED 2 KCAL/ML – **Restricted** see terms above

⬆ Liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 ml, bottle .....	5.50	500 ml	Nutrison Concentrated
⬆ Liquid 8.4 g protein, 21.9 g carbohydrate, 9.1 g fat and 0.5 g fibre per 100 ml, bottle .....	11.00	1,000 ml	TwoCal HN RTH (Vanilla)

ORAL FEED 2 KCAL/ML – **Restricted** see terms above

⬆ Liquid 8.4 g protein, 22.4 g carbohydrate, 8.9 g fat and 0.8 g fibre per 100 ml, bottle .....	1.90	200 ml	Two Cal HN
--	------	--------	------------

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>High Protein Products</b>			
HIGH PROTEIN ENTERAL FEED 1.25 KCAL/ML – <b>Restricted</b> see terms below			
☞ Liquid 6.3 g protein, 14.2 g carbohydrate and 4.9 g fat per 100 ml, 1,000 ml bag			<i>e.g. Nutrison Protein Plus</i>
☞ <b>Restricted</b>			
Both:			
1 The patient has a high protein requirement; and			
2 Any of the following:			
2.1 Patient has liver disease; or			
2.2 Patient is obese (BMI > 30) and is undergoing surgery; or			
2.3 Patient is fluid restricted; or			
2.4 Patient's needs cannot be more appropriately met using high calorie product.			
HIGH PROTEIN ENTERAL FEED 1.28 KCAL/ML – <b>Restricted</b> see terms below			
☞ Liquid 6.3 g protein, 14.1 g carbohydrate, 4.9 g fat and 1.5 g fibre per 100 ml, 1,000 ml bag			<i>e.g. Nutrison Protein Plus Multi Fibre</i>
☞ <b>Restricted</b>			
Both:			
1 The patient has a high protein requirement; and			
2 Any of the following:			
2.1 Patient has liver disease; or			
2.2 Patient is obese (BMI > 30) and is undergoing surgery; or			
2.3 Patient is fluid restricted; or			
2.4 Patient's needs cannot be more appropriately met using high calorie product.			
HIGH PROTEIN ORAL FEED 1 KCAL/ML – <b>Restricted</b> see terms below			
☞ Liquid 10 g protein, 10.3 g carbohydrate and 2.1 g fat per 100 ml, 200 ml bottle			<i>e.g. Fortimel Regular</i>
<i>(e.g. Fortimel Regular Liquid 10 g protein, 10.3 g carbohydrate and 2.1 g fat per 100 ml, 200 ml bottle to be delisted 1 May 2015)</i>			
☞ <b>Restricted</b>			
Any of the following:			
1 Decompensating liver disease without encephalopathy; or			
2 Protein losing gastro-enteropathy; or			
3 Patient has increased protein requirements without increased energy requirements.			
⚡ Item restricted (see ☞ above); ☞ Item restricted (see ☞ below) <i>e.g. Brand indicates brand example only. It is not a contracted product.</i>			



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Infant Formulas</b>			
AMINO ACID FORMULA – <b>Restricted</b> see terms below			
⚡ Powder 1.95 g protein, 8.1 g carbohydrate and 3.5 g fat per 100 ml, 400 g can			<i>e.g. Neocate</i>
⚡ Powder 13 g protein, 52.5 g carbohydrate and 24.5 g fat per 100 g, 400 g can			<i>e.g. Neocate LCP</i>
⚡ Powder 13.5 g protein, 52 g carbohydrate and 24.5 g fat per 100 g, can .....53.00	400 g		Neocate Gold (Unflavoured)
⚡ Powder 14 g protein, 50 g carbohydrate and 24.3 g fat per 100 g, 400 g can			<i>e.g. Neocate Advance</i>
⚡ Powder 16 g protein, 51.4 g carbohydrate and 21 g fat per 100 g, can .....53.00	400 g		Neocate Advance (Vanilla)
⚡ Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 ml, can .....53.00	400 g		Elecare LCP (Unflavoured)
⚡ Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 ml, can .....53.00	400 g		Elecare (Unflavoured) Elecare (Vanilla)
⚡ Powder 6 g protein, 31.5 g carbohydrate and 5.88 g fat per sachet .....6.00	48.5 g		Vivonex Paediatric

#### ➡ **Restricted**

##### **Initiation**

Any of the following:

- 1 Extensively hydrolysed formula has been reasonably trialled and is inappropriate due to documented severe intolerance or allergy or malabsorption; or
- 2 History of anaphylaxis to cows' milk protein formula or dairy products; or
- 3 Eosinophilic oesophagitis.

##### **Continuation**

Both:

- 1 An assessment as to whether the infant can be transitioned to a cows' milk protein, soy, or extensively hydrolysed infant formula has been undertaken; and
- 2 The outcome of the assessment is that the infant continues to require an amino acid infant formula.

EXTENSIVELY HYDROLYSED FORMULA – **Restricted** see terms below

⚡ Powder 14 g protein, 53.4 g carbohydrate and 27.3 g fat per 100 g, 450 g can	<i>e.g. Gold Pepti Junior Karicare Aptamil</i>
--	--

#### ➡ **Restricted**

##### **Initiation - new patients**

Any of the following:

- 1 Both:
  - 1.1 Cows' milk formula is inappropriate due to severe intolerance or allergy to its protein content; and
  - 1.2 Either:
    - 1.2.1 Soy milk formula has been trialled without resolution of symptoms; or
    - 1.2.2 Soy milk formula is considered clinically inappropriate or contraindicated; or
- 2 Severe malabsorption; or
- 3 Short bowel syndrome; or
- 4 Intractable diarrhoea; or
- 5 Biliary atresia; or
- 6 Cholestatic liver diseases causing malabsorption; or
- 7 Cystic fibrosis; or

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
continued...			
8 Proven fat malabsorption; or			
9 Severe intestinal motility disorders causing significant malabsorption; or			
10 Intestinal failure.			
<b>Initiation - step down from amino acid formula</b>			
Both:			
1 The infant is currently receiving funded amino acid formula; and			
2 The infant is to be trialled on, or transitioned to, an extensively hydrolysed formula.			
<b>Continuation</b>			
Both:			
1 An assessment as to whether the infant can be transitioned to a cows' milk protein or soy infant formula has been undertaken; and			
2 The outcome of the assessment is that the infant continues to require an extensively hydrolysed infant formula.			
<b>FRUCTOSE-BASED FORMULA</b>			
Powder 14.6 g protein, 49.7 g carbohydrate and 30.8 g fat per 100 g, 400 g can			<i>e.g. Galactomin 19</i>
<b>LACTOSE-FREE FORMULA</b>			
Powder 1.3 g protein, 7.3 g carbohydrate and 3.5 g fat per 100 ml, 900 g can			<i>e.g. Karicare Aptamil Gold De-Lact</i>
Powder 1.5 g protein, 7.2 g carbohydrate and 3.6 g fat per 100 ml, 900 g can			<i>e.g. S26 Lactose Free</i>
<b>LOW-CALCIUM FORMULA</b>			
Powder 14.6 g protein, 53.7 g carbohydrate and 26.1 g fat per 100 g, 400 g can			<i>e.g. Locasol</i>
<b>PAEDIATRIC ORAL FEED 1 KCAL/ML – Restricted</b> see terms below			
☞ Liquid 2.6 g protein, 10.3 g carbohydrate, 5.4 g fat and 0.6 g fibre per 100 ml, 100 ml bottle			<i>e.g. Infatrini</i>
<b>☞Restricted</b>			
Both:			
1 Either:			
1.1 The patient is fluid restricted; or			
1.2 The patient has increased nutritional requirements due to faltering growth; and			
2 Patient is under 18 months old and weighs less than 8kg.			
<b>PRETERM FORMULA – Restricted</b> see terms below			
☞ Powder 1.9 g protein, 7.5 g carbohydrate and 3.9 g fat per 14 g, can ..... 15.25	400 g		S-26 Gold Premgro
☞ Liquid 2.2 g protein, 8.4 g carbohydrate and 4.4 g fat per 100 ml, bottle ..... 0.75	100 ml		S26 LBW Gold RTF
☞ Liquid 2.3 g protein, 8.6 g carbohydrate and 4.2 g fat per 100 ml, 90 ml bottle			<i>e.g. Pre Nan Gold RTF</i>
☞ Liquid 2.6 g protein, 8.4 g carbohydrate and 3.9 g fat per 100 ml, 70 ml bottle			<i>e.g. Karicare Aptamil Gold+Preterm</i>
<b>☞Restricted</b>			
For infants born before 33 weeks' gestation or weighing less than 1.5 kg at birth.			
<b>THICKENED FORMULA</b>			
Powder 1.8 g protein, 8.1 g carbohydrate and 3.3 g fat per 100 ml, 900 g can			<i>e.g. Karicare Aptamil Thickened AR</i>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Ketogenic Diet Products</b>			
HIGH FAT FORMULA – <b>Restricted</b> see terms below			
⬇ Powder 15.25 g protein, 3 g carbohydrate and 73 g fat per 100 g, can .....	35.50	300 g	Ketocal 4:1 (Unflavoured) Ketocal 4:1 (Vanilla)
⬇ Powder 15.3 g protein, 7.2 g carbohydrate and 67.7 g fat per 100 g, can .....	35.50	300 g	Ketocal 3:1 (Unflavoured)
➡ <b>Restricted</b>			
For patients with intractable epilepsy, pyruvate dehydrogenase deficiency or glucose transported type-1 deficiency and other conditions requiring a ketogenic diet.			
<b>Paediatric Products</b>			
➡ <b>Restricted</b>			
Both:			
1 Child is aged one to ten years; and			
2 Any of the following:			
2.1 The child is being fed via a tube or a tube is to be inserted for the purposes of feeding; or			
2.2 Any condition causing malabsorption; or			
2.3 Faltering growth in an infant/child; or			
2.4 Increased nutritional requirements; or			
2.5 The child is being transitioned from TPN or tube feeding to oral feeding.			
PAEDIATRIC ORAL FEED – <b>Restricted</b> see terms above			
⬆ Powder 14.9 g protein, 54.3 g carbohydrate and 24.7 g fat per 100 g, can .....	20.00	850 g	Pediasure (Vanilla)
PAEDIATRIC ENTERAL FEED 0.76 KCAL/ML – <b>Restricted</b> see terms above			
⬆ Liquid 2.5 g protein, 12.5 g carbohydrate, 3.3 g fat and 0.7 g fibre per 100 ml, bag .....	4.00	500 ml	Nutrini Low Energy Multifibre RTH
PAEDIATRIC ENTERAL FEED 1 KCAL/ML – <b>Restricted</b> see terms above			
⬆ Liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, bag .....	2.68	500 ml	Pediasure RTH
⬆ Liquid 2.8 g protein, 12.3 g carbohydrate and 4.4 g fat per 100 ml, 500 ml bag .....			<i>e.g. Nutrini RTH</i>
PAEDIATRIC ENTERAL FEED 1.5 KCAL/ML – <b>Restricted</b> see terms above			
⬆ Liquid 4.1 g protein, 18.5 g carbohydrate, 6.7 g fat and 0.8 g fibre per 100 ml, bag .....	6.00	500 ml	Nutrini Energy Multi Fibre
⬆ Liquid 4.1 g protein, 18.5 g carbohydrate and 6.7 g fat per 100 ml, 500 ml bag .....			<i>e.g. Nutrini Energy RTH</i>
PAEDIATRIC ORAL FEED 1 KCAL/ML – <b>Restricted</b> see terms above			
⬆ Liquid 4.2 g protein, 16.7 g carbohydrate and 7.5 g fat per 100 ml, bottle .....	1.07	200 ml	Pediasure (Chocolate) Pediasure (Strawberry) Pediasure (Vanilla) Pediasure (Vanilla)
⬆ Liquid 4.2 g protein, 16.7 g carbohydrate and 7.5 g fat per 100 ml, can .....	1.34	250 ml	
PAEDIATRIC ORAL FEED 1.5 KCAL/ML – <b>Restricted</b> see terms above			
⬆ Liquid 3.4 g protein, 18.8 g carbohydrate and 6.8 g fat per 100 ml, 200 ml bottle .....			<i>e.g. Fortini</i>
⬆ Liquid 4.0 g protein, 18.8 g carbohydrate, 6.8 g fat and 1.5 g fibre per 100 ml, 200 ml bottle .....			<i>e.g. Fortini Multifibre</i>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Renal Products</b>			
LOW ELECTROLYTE ENTERAL FEED 1.8 KCAL/ML – <b>Restricted</b> see terms below			
☞ Liquid 8.1 g protein, 14.74 g carbohydrate, 9.77 g fat and 1.26 g fibre per 100 ml, bottle .....	6.08	500 ml	Nepro HP RTH
☞ <b>Restricted</b> For patients with acute or chronic kidney disease.			
LOW ELECTROLYTE ORAL FEED – <b>Restricted</b> see terms below			
☞ Powder 7.5 g protein, 59 g carbohydrate and 26.3 g fat per 100 g, 400 g can .....			<i>e.g. Kindergen</i>
☞ <b>Restricted</b> For children (up to 18 years) with acute or chronic kidney disease			
LOW ELECTROLYTE ORAL FEED 1.8 KCAL/ML			
☞ Liquid 8 g protein, 14.74 g carbohydrate, 9.77 g fat and 1.26 g fibre per 100 ml, carton .....	2.67	220 ml	Nepro HP (Strawberry) Nepro HP (Vanilla)
☞ <b>Restricted</b> For patients with acute or chronic kidney disease.			
LOW ELECTROLYTE ORAL FEED 2 KCAL/ML – <b>Restricted</b> see terms below			
☞ Liquid 9.1 g protein, 19 g carbohydrate and 10 g fat per 100 ml, carton .....	3.31	237 ml	Novasource Renal (Vanilla)
☞ Liquid 3 g protein, 25.5 g carbohydrate and 9.6 g fat per 100 ml, 237 ml bottle .....			
☞ Liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 ml, 125 ml carton .....			<i>e.g. Renilon 7.5</i>
☞ <b>Restricted</b> For patients with acute or chronic kidney disease.			
<b>Respiratory Products</b>			
LOW CARBOHYDRATE ORAL FEED 1.5 KCAL/ML – <b>Restricted</b> see terms below			
☞ Liquid 6.2 g protein, 10.5 g carbohydrate and 9.32 g fat per 100 ml, bottle .....	1.66	237 ml	Pulmocare (Vanilla)
☞ <b>Restricted</b> For patients with CORD and hypercapnia, defined as a CO <sub>2</sub> value exceeding 55 mmHg			
<b>Surgical Products</b>			
HIGH ARGININE ORAL FEED 1.4 KCAL/ML – <b>Restricted</b> see terms below			
☞ Liquid 7.6 g protein, 18.9 g carbohydrate, 3.9 g fat and 1.4 g fibre per 100 ml, carton .....	4.00	237 ml	Impact Advanced Recovery (Chocolate) Impact Advanced Recovery (Vanilla)
☞ <b>Restricted</b> Three packs per day for 5 to 7 days prior to major gastrointestinal, head or neck surgery			
PREOPERATIVE CARBOHYDRATE FEED 0.5 KCAL/ML – <b>Restricted</b> see terms on the next page			
☞ Oral liq 0 g protein, 12.6 g carbohydrate and 0 g fat per 100 ml, 200 ml bottle .....	6.80	4	preOp

☞ Item restricted (see ☞ above); ☞ Item restricted (see ☞ below)

*e.g. Brand* indicates brand example only. It is not a contracted product.

Price (ex man. excl. GST)	Brand or Generic Manufacturer
\$	Per

➔ **Restricted**

Maximum of 400 ml as part of an Enhanced Recovery After Surgery (ERAS) protocol 2 to 3 hours before major abdominal surgery.

**Standard Feeds**➔ **Restricted**

Any of the following:

- For patients with malnutrition, defined as any of the following:
  - BMI < 18.5; or
  - Greater than 10% weight loss in the last 3-6 months; or
  - BMI < 20 with greater than 5% weight loss in the last 3-6 months; or
- For patients who have, or are expected to, eat little or nothing for 5 days; or
- For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism; or
- For use pre- and post-surgery; or
- For patients being tube-fed; or
- For tube-feeding as a transition from intravenous nutrition; or
- For any other condition that meets the community Special Authority criteria.

ENTERAL FEED 1.5 KCAL/ML – **Restricted** see terms above

⬆ Liquid 5.4 g protein, 13.6 g carbohydrate and 3.3 g fat per 100 ml, 1,000 ml bottle			<i>e.g. Isosource Standard RTH</i>
⬆ Liquid 6 g protein, 18.3 g carbohydrate and 5.8 g fat per 100 ml, bag .....7.00	1,000 ml		Nutrison Energy
⬆ Liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 1.5 g fibre per 100 ml, 1,000 ml bag			<i>e.g. Nutrison Energy Multi Fibre</i>
⬆ Liquid 6.25 g protein, 20 g carbohydrate and 5 g fat per 100 ml, can .....1.75	250 ml		Ensure Plus HN
⬆ Liquid 6.27 g protein, 20.4 g carbohydrate and 4.9 g fat per 100 ml, bag .....7.00	1,000 ml		Ensure Plus HN RTH
⬆ Liquid 6.38 g protein, 21.1 g carbohydrate, 4.9 g fat and 1.2 g fibre per 100 ml, bag .....7.00	1,000 ml		Jevity HiCal RTH

ENTERAL FEED 1 KCAL/ML – **Restricted** see terms above

⬆ Liquid 4 g protein, 13.6 g carbohydrate and 3.4 g fat per 100 ml, bottle .....2.65	500 ml		Osmolite RTH
	1,000 ml		Osmolite RTH
⬆ Liquid 4 g protein, 13.6 g carbohydrate and 3.4 g fat per 100 ml, can .....1.24	250 ml		Osmolite
⬆ Liquid 4 g protein, 14.1 g carbohydrate, 3.47 g fat and 1.76 g fibre per 100 ml, bottle .....2.65	500 ml		Jevity RTH
	1,000 ml		Jevity RTH
⬆ Liquid 4 g protein, 14.1 g carbohydrate, 3.47 g fat and 1.76 g fibre per 100 ml, can .....1.32	237 ml		Jevity
⬆ Liquid 4 g protein, 12.3 g carbohydrate and 3.9 g fat per 100 ml, 1,000 ml bag			<i>e.g. NutrisonStdRTH; NutrisonLowSodium</i>
⬆ Liquid 4 g protein, 12.3 g carbohydrate, 3.9 g fat and 1.5 g fibre per 100 ml, 1000 ml bag			<i>e.g. Nutrison Multi Fibre</i>

ENTERAL FEED 1.2 KCAL/ML – **Restricted** see terms above

⬆ Liquid 5.55 g protein, 15.1 g carbohydrate, 3.93 g fat and 2 g fibre per 100 ml, 1,000 ml bag			<i>e.g. Jevity Plus RTH</i>
--	--	--	-----------------------------

## SPECIAL FOODS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
ORAL FEED – <b>Restricted</b> see terms on the preceding page			
☛ Powder 16 g protein, 59.8 g carbohydrate and 14 g fat per 100 g, can .....	13.00	850 g	Ensure (Chocolate) Ensure (Vanilla)
☛ Powder 21.9 g protein, 53.5 g carbohydrate and 14.5 g fat per 100 g, can .....	3.67	350 g	Fortisip (Vanilla)
☛ Powder 23 g protein, 65 g carbohydrate and 2.5 g fat per 100 g, can .....	14.90	900 g	Sustagen Hospital Formula (Chocolate) Sustagen Hospital Formula (Vanilla)
Note: Community subsidy of Sustagen Hospital Formula is subject to both Special Authority criteria and a manufacturer's surcharge. Higher subsidy by endorsement is available for patients meeting the following endorsement criteria; fat malabsorption, fat intolerance or chyle leak.			
ORAL FEED 1 KCAL/ML – <b>Restricted</b> see terms on the preceding page			
☛ Liquid 3.8 g protein, 23 g carbohydrate and 12.7 g fibre per 100 ml, 237 ml carton			<i>e.g. Resource Fruit Beverage</i>
ORAL FEED 1.5 KCAL/ML – <b>Restricted</b> see terms on the preceding page			
☛ Liquid 5.5 g protein, 21.1 g carbohydrate and 4.81 g fat per 100 ml, can .....	1.33	237 ml	Ensure Plus (Chocolate) Ensure Plus (Vanilla)
☛ Liquid 6.25 g protein, 20.2 g carbohydrate and 4.92 g fat per 100 ml, carton .....	1.26	200 ml	Ensure Plus (Banana) Ensure Plus (Chocolate) Ensure Plus (Fruit of the Forest) Ensure Plus (Vanilla)
☛ Liquid 4 g protein and 33.5 g carbohydrate per 100 ml, 200 ml bottle			<i>e.g. Fortijuice</i>
☛ Liquid 6 g protein, 18.4 g carbohydrate and 5.8 g fat per 100 ml, 200 ml bottle			<i>e.g. Fortisip</i>
☛ Liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 2.3 g fibre per 100 ml, 200 ml bottle			<i>e.g. Fortisip Multi Fibre</i>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Bacterial and Viral Vaccines

DIPHTHERIA, TETANUS, PERTUSSIS AND POLIO VACCINE – **Restricted** see terms below

<p>⚡ Inj 30 IU diphtheria toxoid with 30IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin and 80 D-antigen units poliomyelitis virus in 0.5 ml syringe</p> <p>– 1% DV Jul-14 to 2017 .....</p>	0.00	10	Infanrix IPV
---	------	----	--------------

### ➔Restricted

Funded for any of the following:

- 1 A single dose for children up to the age of 7 who have completed primary immunisation; or
- 2 A course of up to four vaccines is funded for catch up programmes for children (to the age of 10 years) to complete full primary immunisation; or
- 3 An additional four doses (as appropriate) are funded for (re-)immunisation for patients post HSCT, or chemotherapy; pre- or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or
- 4 Five doses will be funded for children requiring solid organ transplantation.

Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes

DIPHTHERIA, TETANUS, PERTUSSIS, POLIO, HEPATITIS B AND HAEMOPHILUS INFLUENZAE TYPE B VACCINE – **Restricted** see terms below

<p>⚡ Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin, 80 D-antigen units poliomyelitis virus, 10 mcg hepatitis B surface antigen in 0.5 ml syringe (1) and inj 10 mcg haemophilus influenzae type B vaccine vial</p> <p>– 1% DV Jul-14 to 2017 .....</p>	0.00	10	Infanrix-hexa
---	------	----	---------------

### ➔Restricted

Funded for patients meeting any of the following criteria:

- 1 Up to four doses for children up to the age of 10 for primary immunisation; or
- 2 Up to four doses (as appropriate) for children are funded for (re-)immunisation for patients post HSCT, or chemotherapy; pre- or post splenectomy; renal dialysis and other severely immunosuppressive regimens; or
- 3 Up to five doses for children up to the age of 10 receiving solid organ transplantation.

Note: A course of up-to four vaccines is funded for catch up programmes for children (to the age of 10 years) to complete full primary immunisation. Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

## Bacterial Vaccines

ADULT DIPHTHERIA AND TETANUS VACCINE

<p>⚡ Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid in 0.5 ml syringe –</p> <p>1% DV Jul-14 to 2017 .....</p>	0.00	5	ADT Booster
---	------	---	-------------

### ➔Restricted

Any of the following:

- 1 For vaccination of patients aged 45 and 65 years old; or
- 2 For vaccination of previously unimmunised or partially immunised patients; or
- 3 For revaccination following immunosuppression; or
- 4 For boosting of patients with tetanus-prone wounds; or
- 5 For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

BACILLUS CALMETTE-GUERIN VACCINE – **Restricted** see terms on the next page

<p>⚡ Inj Mycobacterium bovis BCG (Bacillus Calmette-Guerin), Danish strain 1331, live attenuated, vial Danish strain 1331, live attenuated, vial with diluent</p> <p>– 1% DV Oct-14 to 2017 .....</p>	0.00	10	BCG Vaccine
---	------	----	-------------

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>➡Restricted</b>			
For infants at increased risk of tuberculosis			
Note: increased risk is defined as:			
1 Living in a house or family with a person with current or past history of TB; or 2 Having one or more household members or carers who within the last 5 years lived in a country with a rate of TB > or equal to 40 per 100,000 for 6 months or longer; or 3 During their first 5 years will be living 3 months or longer in a country with a rate of TB > or equal to 40 per 100,000.			
Note: A list of countries with high rates of TB are available at <a href="http://www.health.govt.nz/tuberculosis">http://www.health.govt.nz/tuberculosis</a> (Search for Downloads) or <a href="http://www.bcgatlas.org/index.php">www.bcgatlas.org/index.php</a>			
<b>DIPHTHERIA, TETANUS AND PERTUSSIS VACCINE – Restricted</b> see terms below			
⚡ Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid, 8 mcg pertussis toxoid, 8 mcg pertussis filamentous haemagglutinin and 2.5 mcg pertactin in 0.5 ml syringe – 1% <b>DV Jul-14 to 2017</b> .....	0.00	1 10	<b>Boostrix</b> <b>Boostrix</b>
<b>➡Restricted</b>			
Funded for any of the following:			
1 A single vaccine for pregnant woman between gestational weeks 28 and 38 during epidemics. 2 A course of up to four vaccines is funded for children from age 7 to 17 years inclusive to complete full primary immunisation. 3 A course of up to four vaccines is funded for children from age 7 to 17 years inclusive for reinmunisation following immunosuppression			
Note: Tdap is not registered for patients aged less than 10 years. Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.			
<b>HAEMOPHILUS INFLUENZAE TYPE B VACCINE – Restricted</b> see terms below			
⚡ Inj 10 mcg vial with diluent syringe – 1% <b>DV Jul-14 to 2017</b> .....	0.00	1	<b>Act-HIB</b>
<b>➡Restricted</b>			
One dose for patients meeting any of the following:			
1 For primary vaccination in children; or 2 For revaccination of children following immunosuppression; or 3 For children aged 0-18 years with functional asplenia; or 4 For patients pre- and post-splenectomy; or 5 For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.			
<b>MENINGOCOCCAL (A, C, Y AND W-135) CONJUGATE VACCINE – Restricted</b> see terms below			
⚡ Inj 4 mcg or each meningococcal polysaccharide conjugated to a total of approximately 48 mcg of diphtheria toxoid carrier per 0.5 ml vial – 1% <b>DV Jul-14 to 2017</b> .....	0.00	1	<b>Menactra</b>
<b>➡Restricted</b>			
Any of the following:			
1 Up to three doses for patients pre- and post splenectomy and patients with functional or anatomic asplenia; or 2 One dose every five years for patients with HIV, complement deficiency (acquired or inherited), functional or anatomic asplenia or pre or post solid organ transplant; or 3 One dose for close contacts of meningococcal cases; or 4 A maximum of two doses for bone marrow transplant patients; or 5 A maximum of two doses for patients following immunosuppression*.			
Note: children under seven years of age require a second dose three years after the first and then five yearly.			
*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.			
<b>MENINGOCOCCAL C CONJUGATE VACCINE – Restricted</b> see terms on the next page			
⚡ Inj 10 mcg in 0.5 ml syringe – 1% <b>DV Jul-14 to 2017</b> .....	0.00	1 10	<b>Neisvac-C</b> <b>Neisvac-C</b>



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

### ➔Restricted

Any of the following:

- 1 Up to three doses for patients pre- and post splenectomy and patients with functional or anatomic asplenia; or
- 2 One dose every five years for patients with HIV, complement deficiency (acquired or inherited), functional or anatomic asplenia or pre or post solid organ transplant; or
- 3 One dose for close contacts of meningococcal cases; or
- 4 A maximum of two doses for bone marrow transplant patients; or
- 5 A maximum of two doses for patients following immunosuppression\*.

Note: children under seven years of age require a second dose three years after the first and then five yearly.

\*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

PNEUMOCOCCAL (PCV13) CONJUGATE VACCINE – **Restricted** see terms below

⌚ Inj 30.8 mcg in 0.5 ml syringe – 1% DV Oct-14 to 2017 .....	0.00	1	<b>Prevenar 13</b>
		10	<b>Prevenar 13</b>

### ➔Restricted

Any of the following:

- 1 A primary course of up to four doses for previously unvaccinated individuals up to the age of 59 months inclusive; or
- 2 Up to three doses as appropriate to complete the primary course of immunisation for individuals under the age of 59 months who have received one to three doses of PCV10; or
- 3 One dose is funded for high risk children who have previously received four doses of PCV10; or
- 4 Up to an additional four doses (as appropriate) are funded for (re-)immunisation for patients with HIV, patients post HSCT, or chemotherapy; pre- or post splenectomy; functional asplenia, pre- or post- solid organ transplant, renal dialysis and other severely immunosuppressive regimens up to the age of 18; or
- 5 For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes

PNEUMOCOCCAL (PPV23) POLYSACCHARIDE VACCINE – **Restricted** see terms below

⌚ Inj 575 mcg in 0.5 ml vial (25 mcg of each 23 pneumococcal serotype) – 1% DV Jul-14 to 2017 .....	0.00	1	<b>Pneumovax 23</b>
--	------	---	---------------------

### ➔Restricted

Any of the following:

- 1 Up to three doses for patients pre- or post-splenectomy or with functional asplenia; or
- 2 Up to two doses are funded for high risk children to the age of 18; or
- 3 For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

SALMONELLA TYPHI VACCINE – **Restricted** see terms below

⌚ Inj 25 mcg in 0.5 ml syringe

### ➔Restricted

For use during typhoid fever outbreaks

## Viral Vaccines

HEPATITIS A VACCINE – **Restricted** see terms below

⌚ Inj 720 ELISA units in 0.5 ml syringe – 1% DV Jul-14 to 2017 .....	0.00	1	<b>Havrix Junior</b>
⌚ Inj 1440 ELISA units in 1 ml syringe – 1% DV Jul-14 to 2017 .....	0.00	1	<b>Havrix</b>

### ➔Restricted

Funded for patients meeting any of the following criteria:

- 1 Two vaccinations for use in transplant patients; or
- 2 Two vaccinations for use in children with chronic liver disease; or
- 3 One dose of vaccine for close contacts of known hepatitis A cases.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>HEPATITIS B RECOMBINANT VACCINE</b>			
☞ Inj 40 mcg per 1 ml vial – 1% DV Jul-14 to 2017 .....	0.00	1	<b>HBvaxPRO</b>
☞ <b>Restricted</b>			
Funded for any of the following criteria:			
1 For dialysis patients; or			
2 For liver or kidney transplant patient.			
☞ Inj 5 mcg in 0.5 ml vial – 1% DV Jul-14 to 2017 .....	0.00	1	<b>HBvaxPRO</b>
☞ <b>Restricted</b>			
Funded for any of the following criteria:			
1 For household or sexual contacts of known hepatitis B carriers; or			
2 For children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or			
3 For children up to the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination; or			
4 For HIV positive patients; or			
5 For hepatitis C positive patients; or			
6 For patients following immunosuppression; or			
7 For transplant patients.			
☞ Inj 10 mcg in 1 ml vial – 1% DV Jul-14 to 2017 .....	0.00	1	<b>HBvaxPRO</b>
☞ <b>Restricted</b>			
Funded for any of the following criteria:			
1 For household or sexual contacts of known hepatitis B carriers; or			
2 For children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or			
3 For children up to the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination; or			
4 For HIV positive patients; or			
5 For hepatitis C positive patients; or			
6 For patients following immunosuppression; or			
7 For transplant patients.			
<b>HUMAN PAPILLOMAVIRUS (6, 11, 16 AND 18) VACCINE [HPV] – Restricted</b> see terms below			
☞ Inj 120 mcg in 0.5 ml syringe – 1% DV Jul-14 to 2017 .....	0.00	10	<b>Gardasil</b>
☞ <b>Restricted</b>			
Maximum of three doses for patient meeting any of the following criteria:			
1 Females aged under 20 years old; or			
2 Patients aged under 26 years old with confirmed HIV infection; or			
3 For use in transplant patients.			
<b>INFLUENZA VACCINE – Restricted</b> see terms below			
☞ Inj 45 mcg in 0.5 ml syringe .....	90.00	10	Fluarix Influvac
☞ <b>Restricted</b>			
Any of the following:			
1 All people 65 years of age and over; or			
2 People under 65 years of age who:			
2.1 Have any of the following cardiovascular diseases:			
2.1.1 Ischaemic heart disease; or			
2.1.2 Congestive heart disease; or			
2.1.3 Rheumatic heart disease; or			

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
continued...			
2.1.4 Congenital heart disease; or			
2.1.5 Cerebro-vascular disease; or			
2.2 Have any of the following chronic respiratory diseases:			
2.2.1 Asthma, if on a regular preventative therapy; or			
2.2.2 Other chronic respiratory disease with impaired lung function; or			
2.3 Have diabetes;			
2.4 Have chronic renal disease;			
2.5 Have any cancer, excluding basal and squamous skin cancers if not invasive;			
2.6 Have any of the following other conditions:			
2.6.1 Autoimmune disease;			
2.6.2 Immune suppression;			
2.6.3 HIV;			
2.6.4 Transplant recipients;			
2.6.5 Neuromuscular and CNS diseases;			
2.6.6 Haemoglobinopathies;			
2.6.7 Are children on long term aspirin; or			
2.7 Are pregnant; or			
2.8 Are children aged four and under who have been hospitalised for respiratory illness or have a history of significant respiratory illness.			
Note: The following conditions are excluded from funding:			
<ul style="list-style-type: none"> <li>• asthma not requiring regular preventative therapy; and</li> <li>• hypertension and/or dyslipidaemia without evidence of end-organ disease.</li> </ul>			
MEASLES, MUMPS AND RUBELLA VACCINE – <b>Restricted</b> see terms below			
⚡ Inj 1000 TCID50 measles, 12500 TCID50 mumps and 1000 TCID50 rubella vial with diluent – 1% <b>DV Jul-14 to 2017</b> .....	0.00	10	M-M-R-II
➡ <b>Restricted</b>			
A maximum of two doses for any patient meeting the following criteria:			
1 For primary vaccination in children; or 2 For revaccination following immunosuppression; or 3 For any individual susceptible to measles, mumps or rubella			
Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes.			
POLIOMYELITIS VACCINE – <b>Restricted</b> see terms below			
⚡ Inj 80 D-antigen units in 0.5 ml syringe – 1% <b>DV Jul-14 to 2017</b> .....	0.00	1	IPOL
➡ <b>Restricted</b>			
Up to three doses for patients meeting either of the following:			
1 For partially vaccinated or previously unvaccinated individuals; or 2 For revaccination following immunosuppression.			
Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.			
RABIES VACCINE			
Inj 2.5 IU vial with diluent			
ROTAVIRUS LIVE REASSORTANT ORAL VACCINE – <b>Restricted</b> see terms below			
⚡ Oral susp G1, G2, G3, G4, P1(8) 11.5 million CCID50 units per 2 ml, tube – 1% <b>DV Jul-14 to 2017</b> .....	0.00	10	RotaTeg
➡ <b>Restricted</b>			
Maximum of three doses for patients meeting the following:			
1 First dose to be administered in infants aged under 15 weeks of age; and 2 No vaccination being administered to children aged 8 months or over.			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
VARICELLA VACCINE [CHICKEN POX VACCINE] – <b>Restricted</b> see terms below			
☞ Inj 2,000 PFU vial with diluent – 1% DV Jul-14 to 2017 .....	0.00	1	<b>Varilrix</b>

## ☞Restricted

Maximum of two doses for any of the following:

- 1 For non-immune patients:
  - 1.1 With chronic liver disease who may in future be candidates for transplantation; or
  - 1.2 With deteriorating renal function before transplantation; or
  - 1.3 Prior to solid organ transplant; or
  - 1.4 Prior to any elective immunosuppression\*.
- 2 For patients at least 2 years after bone marrow transplantation, on advice of their specialist.
- 3 For patients at least 6 months after completion of chemotherapy, on advice of their specialist.
- 4 For HIV positive non immune to varicella with mild or moderate immunosuppression on advice of HIV specialist.
- 5 For patients with inborn errors of metabolism at risk of major metabolic decompensation, with no clinical history of varicella.
- 6 For household contacts of paediatric patients who are immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella.
- 7 For household contacts of adult patients who have no clinical history of varicella and who are severely immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella

\* immunosuppression due to steroid or other immunosuppressive therapy must be for a treatment period of greater than 28 days

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Optional Pharmaceuticals</b>			
<b>NOTE:</b>			
In addition to the products expressly listed here in Part III: Optional Pharmaceuticals, a number of additional Optional Pharmaceuticals, including some wound care products and disposable laparoscopic equipment, are listed in an addendum to Part III which is available at <a href="http://www.pharmac.govt.nz">www.pharmac.govt.nz</a> . The Optional Pharmaceuticals listed in the addendum are deemed to be listed in Part III, and the Rules of the Pharmaceutical Schedule applying to products listed in Part III apply to them.			
<b>BLOOD GLUCOSE DIAGNOSTIC TEST METER</b>			
1 meter with 50 lancets, a lancing device, and 10 diagnostic test strips .....	20.00	1	Caresens II
			Caresens N
			Caresens N POP
Meter .....	9.00	1	FreeStyle Lite
			On Call Advanced
	19.00		Accu-Chek Performa
<b>BLOOD GLUCOSE DIAGNOSTIC TEST STRIP</b>			
Blood glucose test strips .....	10.56	50 test	CareSens
			CareSens N
	21.65		FreeStyle Lite
	28.75		Accu-Chek Performa
			Freestyle Optium
Blood glucose test strips × 50 and lancets × 5 .....	19.10	50 test	On Call Advanced
<b>BLOOD KETONE DIAGNOSTIC TEST METER</b>			
Meter .....	40.00	1	Freestyle Optium
<b>INSULIN PEN NEEDLES</b>			
29 g × 12.7 mm .....	10.50	100	B-D Micro-Fine
31 g × 5 mm .....	11.75	100	B-D Micro-Fine
31 g × 6 mm .....	10.50	100	ABM
31 g × 8 mm .....	10.50	100	ABM
			B-D Micro-Fine
32 g × 4 mm .....	10.50	100	B-D Micro-Fine
<i>(ABM 31 g × 8 mm to be delisted 1 May 2015)</i>			
<b>INSULIN SYRINGES, DISPOSABLE WITH ATTACHED NEEDLE</b>			
Syringe 0.3 ml with 29 g × 12.7 mm needle .....	13.00	100	B-D Ultra Fine
Syringe 0.3 ml with 31 g × 8 mm needle .....	13.00	100	B-D Ultra Fine II
Syringe 0.5 ml with 29 g × 12.7 mm needle .....	13.00	100	B-D Ultra Fine
Syringe 0.5 ml with 31 g × 8 mm needle .....	13.00	100	B-D Ultra Fine II
Syringe 1 ml with 29 g × 12.7 mm needle .....	13.00	100	ABM
			B-D Ultra Fine
Syringe 1 ml with 31 g × 8 mm needle .....	13.00	100	ABM
			B-D Ultra Fine II
<i>(ABM Syringe 1 ml with 29 g × 12.7 mm needle to be delisted 1 May 2015)</i>			
<i>(ABM Syringe 1 ml with 31 g × 8 mm needle to be delisted 1 May 2015)</i>			
<b>KETONE BLOOD BETA-KETONE ELECTRODES</b>			
Test strips .....	15.50	10 strip	Freestyle Optium Ketone
<b>MASK FOR SPACER DEVICE</b>			
Size 2 .....	2.99	1	EZ-fit Paediatric Mask
<b>PEAK FLOW METER</b>			
Low Range .....	11.44	1	Breath-Alert
Normal Range .....	11.44	1	Breath-Alert

## PART III - OPTIONAL PHARMACEUTICALS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>PREGNANCY TEST - HCG URINE</b>			
Cassette .....	22.80	40 test	Innovacon hCG One Step Pregnancy Test
<b>SODIUM NITROPRUSSIDE</b>			
Test strip .....	6.00	50 strip	Accu-Chek Ketur-Test
<b>SPACER DEVICE</b>			
230 ml (single patient) .....	4.72	1	Space Chamber Plus
800 ml .....	8.50	1	Volumatic

<b>- Symbols -</b>	
8-methoxypsoralen .....	53
<b>- A -</b>	
A-Scabies .....	50
Abacavir sulphate .....	82
Abacavir sulphate with lamivudine .....	82
Abciximab .....	146
Abilify .....	118
ABM Hydroxocobalamin .....	25
Acarbose .....	17
Accarb .....	17
Accu-Chek Ketur-Test .....	214
Accu-Chek Performa .....	213
Accuretic 10 .....	38
Accuretic 20 .....	38
Acetadote .....	182
Acetazolamide .....	179
Acetic acid	
Extemporaneously	
Compounded	
Preparations .....	190
Genito-Urinary .....	55
Acetic acid with hydroxyquinoline, glycerol and ricinoleic acid .....	55
Acetic acid with propylene glycol .....	181
Acetylcholine chloride .....	180
Acetylcysteine .....	182
Aciclovir	
Infections .....	88
Sensory .....	176
Acid Citrate Dextrose A .....	31
Acidex .....	14
Acipimox .....	45
Acitretin .....	53
Aclasta .....	94
Act-HIB .....	208
Actavis .....	120
Actemra .....	165
Actinomycin D .....	128
Adalimumab .....	146
Adapalene .....	50
Adefin XL .....	42
Adefovir dipivoxil .....	85
Adenosine .....	39–40
Adenuric .....	98
Adrenaline .....	46
ADT Booster .....	207
Adult diphtheria and tetanus vaccine .....	207
Advantan .....	52
Advate .....	30
Aerrane .....	103
Afinitor .....	168
Agents Affecting the Renin-Angiotensin System .....	38
Agents for Parkinsonism and Related Disorders .....	102
Agents Used in the Treatment of Poisonings .....	182
Ajmaline .....	40
Alanase .....	170
Albendazole .....	79
Alendronate sodium .....	92–93
Alendronate sodium with cholecalciferol .....	93
Alfacalcidol .....	26
Alfentanil .....	107
Alinia .....	80
Alitraq .....	199
Allersoothe .....	171
Allopurinol .....	97
Alpha tocopheryl acetate .....	26
Alpha-Adrenoceptor Blockers .....	39
Alprazolam .....	122
Alprostadil hydrochloride .....	47
Alteplase .....	34
Alum .....	190
Aluminium hydroxide .....	14
Aluminium hydroxide with magnesium hydroxide and simethicone .....	14
Amantadine hydrochloride .....	102
AmBisome .....	75
Ambrisentan .....	47
Amethocaine .....	106, 178
Nervous .....	106
Sensory .....	178
Amikacin .....	69
Amiloride hydrochloride .....	43
Amiloride hydrochloride with furosemide .....	43
Amiloride hydrochloride with hydrochlorothiazide .....	43
Aminophylline .....	174
Amiodarone hydrochloride .....	40
Amisulpride .....	118
Amitriptyline .....	111
Amlodipine .....	42
Amorolfine .....	49
Amoxicillin .....	72
Amoxicillin Actavis .....	72
Amoxicillin with clavulanic acid .....	72
Amphotericin B	
Alimentary .....	24
Infections .....	75–76
Amsacrine .....	130
Amyl nitrite .....	47
Anabolic Agents .....	59
Anaesthetics .....	103
Anagrelide hydrochloride .....	130
Analgesics .....	106
Anastrozole .....	140
Andriol Testocaps .....	59
Androderm .....	59
Androgen Agonists and Antagonists .....	59
Anexate .....	182
Antabuse .....	127
Antacids and Antiflatulents .....	14
Anti-Infective Agents .....	55
Anti-Infective Preparations	
Dermatological .....	49
Sensory .....	176
Anti-Inflammatory Preparations .....	177
Antiacne Preparations .....	50
Antiallergy Preparations .....	170
Antianemics .....	28
Antiarrhythmics .....	39
Antibacterials .....	69
Anticholinergic Agents .....	171
Anticholinesterases .....	92
Antidepressants .....	111
Antidiarrhoeals and Intestinal Anti-Inflammatory Agents .....	14
Antiepilepsy Drugs .....	113
Antifibrinolytics, Haemostatics and Local Sclerosants .....	29
Antifungals .....	75
Antihypotensives .....	40
Antimigraine Preparations .....	117
Antimycobacterials .....	77
Antinaus .....	118
Antinausea and Vertigo Agents .....	117
Antiparasitics .....	79
Antipruritic Preparations .....	50
Antipsychotic Agents .....	118
Antiretrovirals .....	80
Antirheumatoid Agents .....	92
Antiseptics and Disinfectants .....	184
Antispasmodics and Other	

Agents Altering Gut Motility .....	16	Aripiprazole .....	118	Atazanavir sulphate .....	84
Antithrombotics .....	31	Aristocort .....	52	Atenolol .....	40
Antithymocyte globulin (equine) .....	168	Aromasin .....	140	Atenolol-AFT .....	40
Antithymocyte globulin (rabbit) .....	168	Arrow - Clopid .....	33	ATGAM .....	168
Antitumorants .....	16	Arrow-Amitriptyline .....	111	Ativan .....	122
Antivirals .....	85	Arrow-Bendrofluazide .....	44	Atomoxetine .....	124
Anxiolytics .....	122	Arrow-Brimonidine .....	180	Atorvastatin .....	44
Apidra .....	18	Arrow-Calcium .....	22	Atovaquone with proguanil hydrochloride .....	79
Apidra Solostar .....	18	Arrow-Citalopram .....	112	Atracurium besylate .....	98
Apo-Allopurinol .....	97	Arrow-Diazepam .....	122	Atripila .....	83
Apo-Amiloride .....	43	Arrow-Doxorubicin .....	128	Atropine sulphate Cardiovascular .....	40
Apo-Amlodipine .....	42	Arrow-Etidronate .....	94	Sensory .....	180
Apo-Amoxi .....	72	Arrow-Fluoxetine .....	112	Atropt .....	180
Apo-Azithromycin .....	71	Arrow-Gabapentin .....	113	Augmentin .....	72
Apo-Cilazapril/ Hydrochlorothiazide .....	38	Arrow-Iloprost .....	48	Auranofin .....	92
Apo-Clarithromycin .....	71	Arrow-Lamotrigine .....	115	Ava 20 ED .....	55
Apo-Clomipramine .....	111	Arrow-Lisinopril .....	38	Ava 30 ED .....	55
Apo-Diclo .....	100	Arrow-Losartan & Hydrochlorothiazide .....	39	Avanza .....	111
Apo-Diltiazem CD .....	42	Arrow-Morphine LA .....	109	Avelox .....	73
Apo-Doxazosin .....	39	Arrow-Norfloxacin .....	73	Avelox IV 400 .....	73
Apo-Imiquimod Cream 5% .....	54	Arrow-Ornidazole .....	80	Avonex .....	123
Apo-Megestrol .....	138	Arrow-Quinapril 10 .....	38	Avonex Pen .....	123
Apo-Moclobemide .....	111	Arrow-Quinapril 20 .....	38	Azacididine .....	129
Apo-Nadolol .....	41	Arrow-Quinapril 5 .....	38	Azactam .....	74
Apo-Nicotinic Acid .....	45	Arrow-Roxithromycin .....	71	Azamun .....	168
Apo-Oxybutynin .....	58	Arrow-Sertraline .....	113	Azathioprine .....	168
Apo-Perindopril .....	38	Arrow-Simva .....	44	Azithromycin .....	71
Apo-Pindolol .....	41	Arrow-Sumatriptan .....	117	Azol .....	62
Apo-Prazosin .....	39	Arrow-Timolol .....	179	AZT .....	83
Apo-Prednisone .....	60	Arrow-Tolterodine .....	58	Aztreonam .....	74
Apo-Prednisone S29 .....	60	Arrow-Topiramate .....	116		
Apo-Propranolol .....	41	Arrow-Tramadol .....	110		
Apo-Pyridoxine .....	26	Arrow-Venlafaxine XR .....	112		
Apo-Ropinirole .....	103	Arsenic trioxide .....	130		
Apo-Zopiclone .....	124	Artemether with lumefantrine .....	79		
Apomine .....	102	Artesunate .....	79		
Apomorphine hydrochloride .....	102	Articaine hydrochloride .....	104		
Apraclonidine .....	180	Articaine hydrochloride with adrenaline .....	104		
Aprepitant .....	117	Asacol .....	15		
Apresoline .....	47	Asamax .....	15		
Aprotinin .....	29	Ascorbic acid Alimentary .....	26		
Aqueous cream .....	51	Extemporaneously Compounded .....			
Arachis oil [Peanut oil] .....	190	Preparations .....	190		
Arava .....	92	Aspen Adrenaline .....	46		
Aremed .....	140	Aspen Ciprofloxacin .....	73		
Arginine Alimentary .....	21	Aspirin Blood .....	33		
Various .....	187	Nervous .....	106		
Argipressin [Vasopressin] .....	67	Asthalin .....	172		

## - B -

B-D Micro-Fine .....	213
B-D Ultra Fine .....	213
B-D Ultra Fine II .....	213
Bacillus calmette-guerin (BCG) .....	168
Bacillus calmette-guerin vaccine .....	207
Baclofen .....	98
Bacterial and Viral Vaccines .....	207
Bacterial Vaccines .....	207
Baraclude .....	85
Barium sulphate .....	186
Barium sulphate with sodium bicarbonate .....	186
Barrier Creams and Emollients .....	50
Basiliximab .....	152
BCG Vaccine .....	207
Beclazone 100 .....	172
Beclazone 250 .....	172



Beclazone 50 .....	172	Bile and Liver Therapy .....	17	Buprenorphine with	
Beclomethasone		Biliscopin .....	187	naloxone .....	126
dipropionate .....	170, 172	Bimatoprost .....	180	Bupropion hydrochloride .....	126
Bee venom .....	170	Biodone .....	108	Burinex .....	43
Bendrofluazide .....	44	Biodone Extra Forte .....	108	Buscopan .....	16
Bendroflumethiazide		Biodone Forte .....	108	Buserelin .....	62
[Bendrofluazide] .....	44	Biotin .....	22	Buspirone hydrochloride .....	122
BeneFIX .....	30	Bisacodyl .....	21	Busulfan .....	128
Benzathine benzylpenicillin .....	72	Bismuth subgallate .....	190	Butacort Aqueous .....	170
Benzbromaron AL 100 .....	97	Bismuth subnitrate and iodoform			
Benzbromarone .....	97	paraffin .....	188		
Benzocaine .....	104	Bismuth trioxide .....	17		
Benzoïn .....	190	Bisoprolol fumarate .....	41		
Benzoyl peroxide .....	50	Bivalirudin .....	31		
Benztrop .....	102	Bleomycin sulphate .....	128		
Benztropine mesylate .....	102	Blood glucose diagnostic test			
Benzylamine hydrochloride .....	24	meter .....	213		
Benzylamine hydrochloride with		Blood glucose diagnostic test			
cetylpyridinium chloride .....	24	strip .....	213		
Benzylpenicillin sodium [Penicillin		Blood ketone diagnostic test			
G] .....	72	meter .....	213		
Beractant .....	175	Boceprevir .....	88		
Beta Scalp .....	53	Bonney's blue dye .....	187		
Beta-Adrenoceptor Agonists .....	172	Boostrix .....	208		
Beta-Adrenoceptor Blockers .....	40	Boric acid .....	190		
Betadine .....	184	Bortezomib .....	131		
Betadine Skin Prep .....	184	Bosentan .....	48		
Betagan .....	179	Bosvate .....	41		
Betahistine dihydrochloride .....	117	Botox .....	98		
Betaine .....	22	Botulism antitoxin .....	182		
Betamethasone .....	59	Breath-Alert .....	213		
Betamethasone dipropionate .....	52	Bridion .....	99		
Betamethasone dipropionate		Brilinta .....	33		
with calcipotriol .....	53	Brimonidine tartrate .....	180		
Betamethasone sodium		Brimonidine tartrate with			
phosphate with		timolol .....	180		
betamethasone acetate .....	59	Brinzolamide .....	179		
Betamethasone .....		Bromocriptine .....	102		
valerate .....	52–53	Brufen SR .....	100		
Betamethasone valerate with		Budesonide			
clioquinol .....	53	Alimentary .....	14		
Betamethasone valerate with		Respiratory .....	170, 172		
fusidic acid .....	53	Budesonide with			
Betaxolol .....	179	efomoterol .....	174		
Betoptic .....	179	Bumetanide .....	43		
Betoptic S .....	179	Bupafen .....	105		
Bevacizumab .....	152	Bupivacaine hydrochloride .....	104		
Bezafibrate .....	44	Bupivacaine hydrochloride with			
Bezalip .....	44	adrenaline .....	104		
Bezalip Retard .....	44	Bupivacaine hydrochloride with			
Bicalaccord .....	138	fentanyl .....	105		
Bicalutamide .....	138	Bupivacaine hydrochloride with			
Bicillin LA .....	72	glucose .....	105		

### - C -

Cabergoline .....	61
Caffeine .....	124
Caffeine citrate .....	174
Cal-d-Forte .....	26
Calamine .....	50
Calcipotriol .....	53
Calcitonin .....	59
Calcitriol .....	26
Calcitriol-AFT .....	26
Calcium carbonate .....	14, 22
Calcium Channel Blockers .....	42
Calcium chloride .....	34
Calcium chloride with	
magnesium chloride,	
potassium chloride, sodium	
acetate, sodium chloride and	
sodium citrate .....	178
Calcium folinate .....	138
Calcium Folate Ebewe .....	138
Calcium gluconate	
Blood .....	34
Dermatological .....	54
Calcium Homeostasis .....	59
Calcium polystyrene	
sulphonate .....	37
Calcium Resonium .....	37
Calsource .....	22
Cancidas .....	77
Candesartan cilexetil .....	39
Candestar .....	39
Capecitabine .....	129
Capecitabine Winthrop .....	129
Capoten .....	38
Capsaicin	
Musculoskeletal System .....	101
Nervous .....	106
Captopril .....	38
Carbaccord .....	133
Carbamazepine .....	113
Carbasorb-X .....	183
Carbimazole .....	67
Carbomer .....	181

Carboplatin .....	133	Chlorambucil .....	128	Cisplatin Ebewe .....	133
Carboplatin Ebewe .....	133	Chloramphenicol		Citalopram hydrobromide .....	112
Carboprost trometamol .....	57	Infections .....	74	Citanest .....	106
Carboxymethylcellulose		Sensory .....	176	Citric acid .....	190
Alimentary .....	24	Chlorhexidine		Citric acid with magnesium oxide	
Extemporaneously		Genito-Urinary .....	55	and sodium picosulfate .....	20
Compounded		Various .....	184, 188	Citric acid with sodium	
Preparations .....	190	Chlorhexidine gluconate		bicarbonate .....	186
Cardinol LA .....	41	Alimentary .....	24	Cladribine .....	130
Cardizem CD .....	42	Extemporaneously		Clarithromycin .....	71
CareSens .....	213	Compounded		Clexane .....	32
Caresens II .....	213	Preparations .....	190	Clindamycin .....	74
Caresens N .....	213	Genito-Urinary .....	55	Clindamycin ABM .....	74
Caresens N .....	213	Chlorhexidine with		Clobazam .....	113
Caresens N POP .....	213	cetrimide .....	184, 188	Clobetasol propionate .....	52, 54
Carmellose sodium .....	181	Chlorhexidine with ethanol .....	184	Clobetasone butyrate .....	52
Carmustine .....	128	Chloroform .....	190	Clofazimine .....	77
Carvedilol .....	41	Chloroquine phosphate .....	79	Clomazol .....	49, 55
Caspofungin .....	77	Chlorothiazide .....	44	Clomiphene citrate .....	61
Catapres .....	43	Chlorpheniramine maleate .....	170	Clomipramine hydrochloride .....	111
Catapres-TTS-1 .....	43	Chlorpromazine		Clonazepam .....	113, 122
Catapres-TTS-2 .....	43	hydrochloride .....	119	Clonidine .....	43
Catapres-TTS-3 .....	43	Chlorsig .....	176	Clonidine BNM .....	43
Ceenu .....	128	Chlortalidone		Clonidine hydrochloride .....	43
Cefaclor .....	70	[Chlortalidone] .....	44	Clopidogrel .....	33
Cefalexin .....	70	Chlortalidone .....	44	Clopine .....	119
Cefalexin Sandoz .....	70	Choice TT380 Short .....	56	Clopixol .....	121, 122
Cefazolin .....	70	Choice TT380 Standard .....	56	Clostridium botulinum type A	
Cefepime .....	70	Cholecalciferol .....	26	toxin .....	98
Cefotaxime .....	70	Cholestyramine .....	44	Clotrimazole	
Cefotaxime Sandoz .....	70	Choline salicylate with		Dermatological .....	49
Cefoxitin .....	70	cetalkonium chloride .....	24	Genito-Urinary .....	55
Ceftaroline fosamil .....	70	Cholvastin .....	44	Clove oil .....	190
Ceftazidime .....	70	Choriogonadotropin alfa .....	63	Clozapine .....	119
Ceftriaxone .....	70	Ciclopiox olamine .....	49	Clozaril .....	119
Ceftriaxone-AFT .....	70	Ciclosporin .....	140	Co-trimoxazole .....	75
Cefuroxime .....	70	Cidofovir .....	88	Coal tar .....	190
Celecoxib .....	99	Cilazapril .....	38	Coal tar with salicylic acid and	
Celiprolol .....	41	Cilazapril with		sulphur .....	53
CelCept .....	169	hydrochlorothiazide .....	38	Coal tar with triethanolamine	
Celol .....	41	Cilicaine .....	72	lauryl sulphate and	
Centrally-Acting Agents .....	43	Cilicaine VK .....	72	fluorescein .....	53
Cephalexin ABM .....	70	Cimetidine .....	16	Cocaine hydrochloride .....	105
Cetirizine hydrochloride .....	170	Cinchocaine hydrochloride with		Cocaine hydrochloride with	
Cetomacrogol .....	51	hydrocortisone .....	15	adrenaline .....	105
Cetomacrogol with glycerol .....	51	Cipflox .....	73	Codeine phosphate	
Cetrimide .....	190	Ciprofloxacin		Extemporaneously	
Champix .....	127	Infections .....	73	Compounded	
Charcoal .....	183	Sensory .....	176	Preparations .....	190
Chemotherapeutic Agents .....	128	Ciprofloxacin with		Nervous .....	107
Chicken pox vaccine .....	211	hydrocortisone .....	176	Cogentin .....	102
Chlorafast .....	176	Ciproxin HC Otic .....	176	Colaspase [L-asparaginase] .....	131
Chloral hydrate .....	123	Cisplatin .....	133	Colchicine .....	98

Colestimethate .....	74
Colestipol hydrochloride .....	45
Colgout .....	98
Colifoam .....	15
Colistin sulphomethate [Colestimethate] .....	74
Colistin-Link .....	74
Colloidion flexible .....	190
Colofac .....	16
Colony-Stimulating Factors .....	34
Coloxyl .....	20
Compound electrolytes .....	34, 37
Compound electrolytes with glucose .....	34, 37
Compound hydroxybenzoate .....	190
Compound sodium lactate [Hartmann's solution] .....	35
Compound sodium lactate with glucose .....	35
Concerta .....	125
Condyline .....	54
Contraceptives .....	55
Contrast Media .....	185
Cordarone-X .....	40
Corticosteroids Dermatological .....	52
Hormone Preparations .....	59
Corticotrorelin (ovine) .....	62
Cosopt .....	179
Cough Suppressants .....	172
Crotamiton .....	50
Crystaderm .....	49
CT Plus+ .....	186
Curam Duo .....	72
Curosurf .....	175
Cvite .....	26
Cyclizine hydrochloride .....	117
Cyclizine lactate .....	117
Cyclogyl .....	180
Cyclopentolate hydrochloride .....	180
Cyclophosphamide .....	128
Cycloserine .....	78
Cyklokapron .....	30
Cymevene .....	88
Cyproheptadine hydrochloride .....	170
Cyproterone acetate .....	59
Cyproterone acetate with ethinyloestradiol .....	55
Cysteamine hydrochloride .....	190
Cytarabine .....	130

**- D -**

D-Penamine .....	92
Dabigatran .....	31
Dacarbazine .....	131
Dactinomycin [Actinomycin D] .....	128
Daivobet .....	53
Daivonex .....	53
Dalacin C .....	74
Dalteparin .....	31
Danaparoid .....	31
Danazol .....	62
Danthron with poloxamer .....	21
Dantrium .....	98
Dantrolene .....	98
Dapa-Tabs .....	44
Dapsone Contracted .....	78
Infections .....	78
Daptomycin .....	74
Darunavir .....	84
Dasatinib .....	133
Daunorubicin .....	128
DBL Amikacin .....	69
DBL Aminophylline .....	174
DBL Cefepime .....	70
DBL Cefotaxime .....	70
DBL Docetaxel .....	137
DBL Epirubicin Hydrochloride .....	129
DBL Ergometrine .....	57
DBL Leucovorin Calcium .....	138
DBL Meropenem .....	69
DBL Morphine Sulphate .....	109
DBL Pethidine Hydrochloride .....	110
DBL Rocuronium Bromide .....	99
DBL Tobramycin .....	69
DDI .....	82
De-Nol .....	17
De-Worm .....	79
Decongestants .....	172
Decongestants and Antiallergics .....	177
Decozol .....	24
Deferasirox .....	183
Deferiprone .....	183
Defibrotide .....	31
Definity .....	187
Demeclocycline hydrochloride .....	73
Deoxycoformycin .....	132

Depo-Medrol .....	60
Depo-Medrol with Lidocaine .....	60
Depo-Provera .....	56
Depo-Testosterone .....	59
Deprim .....	75
Dermol .....	52, 54
Desferrioxamine mesilate .....	183
Dexflurane .....	103
Desmopressin acetate .....	67
Desmopressin-PH&T .....	67
Dexamethasone Hormone Preparations .....	60
Sensory .....	177
Dexamethasone phosphate .....	60
Dexamethasone with framycetin and gramicidin .....	176
Dexamethasone with neomycin sulphate and polymyxin B sulphate .....	177
Dexamethasone with tobramycin .....	177
Dexamethasone-hameln .....	60
Dexamfetamine sulfate .....	125
Dexmedetomidine .....	103
Dextrose .....	17, 35, 190
Alimentary .....	17
Blood .....	35
Extemporaneously Compounded Preparations .....	190
Dextrose with sodium citrate and citric acid [Acid Citrate Dextrose A] .....	31
DHC Continus .....	107
Diabetes .....	17
Diacomit .....	116
Diagnostic Agents .....	187
Diagnostic and Surgical Preparations .....	178
Diamide Relief .....	14
Diamox .....	179
Diatrizoate meglumine with sodium amidotrizoate .....	185
Diatrizoate sodium .....	185
Diazepam .....	113, 122
Diazoxide Alimentary .....	17
Cardiovascular .....	47
Dichlorobenzyl alcohol with amylmetacresol .....	24
Diclax SR .....	100
Diclofenac sodium Musculoskeletal System .....	100

Sensory .....	177	Dopamine hydrochloride .....	46	Emtricitabine .....	83
Dicobalt edetate .....	183	Dopergin .....	103	Emtricitabine with tenofovir disoproxil fumarate .....	83
Didanosine [DDI] .....	83	Dopress .....	111	Emtriva .....	83
Diflucan .....	76	Dornase alfa .....	174	Emulsifying ointment .....	51
Diflucortolone valerate .....	52	Dorzolamide .....	179	Enalapril maleate .....	38
Digestives Including Enzymes .....	19	Dorzolamide with timolol .....	179	Enalapril maleate with hydrochlorothiazide .....	38
Digoxin .....	40	Dostinex .....	61	Enbrel .....	140
Digoxin immune Fab .....	182	Dotarem .....	186	Endocrine Therapy .....	138
Dihydrocodeine tartrate .....	107	Dothiepin hydrochloride .....	111	Endoxan .....	128
Dihydroergotamine mesylate .....	117	Doxapram .....	175	Enfuvirtide .....	80
Dilatrend .....	41	Doxazosin .....	39	Enoxaparin .....	32
Diltiazem hydrochloride .....	42	Doxepin hydrochloride .....	111	Ensure (Chocolate) .....	206
Dilzem .....	42	Doxine .....	73	Ensure (Vanilla) .....	206
Dimercaprol .....	183	Doxorubicin hydrochloride .....	128	Ensure Plus (Banana) .....	206
Dimercaptosuccinic acid .....	184	Doxycycline .....	73	Ensure Plus (Chocolate) .....	206
Dimethicone .....	50	DP Fusidic Acid Cream .....	49	Ensure Plus (Fruit of the Forest) .....	206
Dimethyl sulfoxide .....	188	DP Lotn HC .....	52	Ensure Plus (Vanilla) .....	206
Dinoprostone .....	57	DP-Anastrozole .....	140	Ensure Plus HN .....	205
Diphemanil metilsulfate .....	54	Dr Reddy's Omeprazole .....	16	Ensure Plus HN RTH .....	205
Diphenoxylate hydrochloride with atropine sulphate .....	14	Dr Reddy's Ondansetron .....	118	Entacapone .....	103
Diphtheria antitoxin .....	182	Dr Reddy's Terbinafine .....	77	Entapone .....	103
Diphtheria, tetanus and pertussis vaccine .....	208	Droperidol .....	117	Entecavir .....	85
Diphtheria, tetanus, pertussis and polio vaccine .....	207	Drugs Affecting Bone Metabolism .....	92	Enzymes .....	97
Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine .....	207	Dulcolax .....	21	Ephedrine .....	46
Diprivan .....	104	Duolin .....	171	Epirubicin Ebewe .....	129
Dipyridamole .....	33	Duovisc .....	179	Epirubicin hydrochloride .....	129
Disodium edetate .....	179	Duride .....	45	Epoetin alfa [Erythropoietin alfa] .....	28
Disodium hydrogen phosphate with sodium dihydrogen phosphate .....	190	Dynastat .....	101	Eprex .....	28
Disopyramide phosphate .....	40	Dysport .....	98	Eptacog alfa [Recombinant factor VIIa] .....	30
Disulfiram .....	127	- E -		Eptifibatide .....	33
Dithranol .....	190	E-Mycin .....	71	Ergometrine maleate .....	57
Diuretics .....	43	E-Z-Cat Dry .....	186	Ergotamine tartrate with caffeine .....	117
Diurin 40 .....	43	E-Z-Gas II .....	186	Erlotinib .....	134
Dobutamine hydrochloride .....	46	E-Z-Paste .....	186	Ertapenem .....	69
Docetaxel .....	137	Econazole nitrate .....	49	Erythrocin IV .....	71
Docusate sodium Alimentary .....	20	Edrophonium chloride .....	92	Erythromycin (as ethylsuccinate) .....	71
Sensory .....	181	Efavirenz .....	82	Erythromycin (as lactobionate) .....	71
Docusate sodium with sennosides .....	20	Efavirenz with emtricitabine and tenofovir disoproxil fumarate .....	83	Erythromycin (as stearate) .....	71
Domperidone .....	117	Efexor XR .....	112	Erythropoietin alfa .....	28
Donepezil hydrochloride .....	126	Effient .....	33	Escitalopram .....	112
Donepezil-Rex .....	126	Eformoterol fumarate .....	173	Esmolol hydrochloride .....	41
		Efudix .....	54	Etanercept .....	140
		Elecare (Unflavoured) .....	201	Ethambutol hydrochloride .....	78
		Elecare (Vanilla) .....	201	Ethanol .....	182
		Elecare LCP (Unflavoured) .....	201	Ethanol with glucose .....	182
		Electrolytes .....	189		
		Eligard .....	63		
		Eltrombopag .....	29		
		Emend Tri-Pack .....	117		
		EMLA .....	106		

Ethanol, dehydrated .....	182	acid .....	23	Fluticasone with salmeterol .....	174
Ethics Aspirin EC .....	33	Ferrous sulphate with folic acid .....	23	Foban .....	49
Ethics Enalapril .....	38	Ferrum H .....	23	Folic acid .....	29
Ethinylestradiol .....	62	Fexofenadine hydrochloride .....	171	Fondaparinux sodium .....	32
Ethinylestradiol with desogestrel .....	55	Filgrastim .....	34	Food Modules .....	193
Ethinylestradiol with levonorgestrel .....	55	Finasteride .....	58	Food/Fluid Thickeners .....	194
Ethinylestradiol with norethisterone .....	55	Fingolimod .....	123	Forteo .....	97
Ethosuximide .....	113	Finpro .....	58	Fortisip (Vanilla) .....	206
Ethyl chloride .....	105	Flagyl .....	80	Fortum .....	70
Etidronate disodium .....	94	Flagyl-S .....	80	Fosamax .....	92
Etomidate .....	103	Flamazine .....	49	Fosamax Plus .....	93
Etopophos .....	131	Flecainide acetate .....	40	Foscarnet sodium .....	88
Etoposide .....	131	Fleet Phosphate Enema .....	21	Fosfomycin .....	74
Etoposide (as phosphate) .....	131	Flixonase Hayfever & Allergy .....	170	Fragmin .....	31
Etoricoxib .....	100	Flixotide .....	173	Framycetin sulphate .....	176
Etravirine .....	82	Flixotide Accuhaler .....	173	Freeflex .....	36
Everolimus .....	168	Florinef .....	60	FreeStyle Lite .....	213
Evista .....	96	Fluanxol .....	121	Freestyle Optium .....	213
Exelon .....	126	Fluarix .....	210	Freestyle Optium Ketone .....	213
Exemestane .....	140	Flucloxacillin .....	72	Fresofol 1% .....	104
Exjade .....	183	Flucloxin .....	72	Frusemide-Clarix .....	43
Extemporaneously Compounded Preparations .....	190	Flucon .....	177	Fucidin .....	74
EZ-fit Paediatric Mask .....	213	Fluconazole .....	76	Fucithalmic .....	176
Ezetimibe .....	45	Fluconazole-Clarix .....	76	Fungilin .....	24
Ezetimibe with simvastatin .....	45	Flucytosine .....	77	Furosemide (frusemide) .....	43
<b>- F -</b>		Fludara Oral .....	130	Fusidic acid	
Factor eight inhibitors bypassing agent .....	30	Fludarabine Ebewe .....	130	Dermatological .....	49
Febuxostat .....	98	Fludarabine phosphate .....	130	Infections .....	74
FEIBA .....	30	Fludrocortisone acetate .....	60	Sensory .....	176
Felodipine .....	42	Fluids and Electrolytes .....	34	Fuzeon .....	80
Fenpaed .....	100	Flumazenil .....	182	<b>- G -</b>	
Fentanyl .....	108	Flumetasone pivalate with clioquinol .....	177	Gabapentin .....	113
Fentanyl Sandoz .....	108	Fluocortolone caproate with fluocortolone pivalate and cinchocaine .....	15	Gadobenic acid .....	186
Ferinject .....	23	Fluorescein sodium .....	178	Gadobutrol .....	186
Ferodan .....	23	Fluorescein sodium with lignocaine hydrochloride .....	178	Gadodiamide .....	186
Ferric carboxymaltose .....	23	Fluorescite .....	178	Gadoteric acid .....	186
Ferric subsulfate .....	29	Fluorometholone .....	177	Gadovist .....	186
Ferriprox .....	183	Fluorouracil .....	130	Gadoxetate disodium .....	187
Ferro-F-Tabs .....	23	Fluorouracil Ebewe .....	130	Gamma benzene hexachloride .....	49
Ferro-tab .....	23	Fluorouracil sodium .....	54	Ganciclovir	
Ferrograd .....	23	Fluoxetine hydrochloride .....	112	Infections .....	88
Ferrous fumarate .....	23	Flupenthixol decanoate .....	121	Sensory .....	176
Ferrous fumarate with folic acid .....	23	Fluphenazine decanoate .....	121	Gardasil .....	210
Ferrous gluconate with ascorbic acid .....	23	Flutamide .....	138	Gastrografin .....	185
Ferrous sulphate .....	23	Flutamin .....	138	Gastrosoothe .....	16
Ferrous sulphate with ascorbic acid .....	23	Fluticasone .....	173	Gefitinib .....	134
		Fluticasone propionate .....	170	Gelafusal .....	37
				Gelatine, succinylated .....	37
				Gelofusine .....	37
				Gemcitabine .....	130
				Gemcitabine Ebewe .....	130
				Gemfibrozil .....	44

Genoptic .....	176	Granisetron .....	117	Hydrocortisone acetate	
Genox .....	140			Alimentary .....	15
Gentamicin sulphate		- H -		Dermatological .....	52
Infections .....	69	Habitrol .....	127	Hydrocortisone and paraffin	
Sensory .....	176	Habitrol (Classic) .....	127	liquid and lanolin .....	52
Gestrinone .....	62	Habitrol (Fruit) .....	127	Hydrocortisone butyrate .....	52, 54
Gilenya .....	123	Habitrol (Mint) .....	127	Hydrocortisone with	
Ginet .....	55	Haem arginate .....	22	miconazole .....	53
Glatiramer acetate .....	123	Haemophilus influenzae type B		Hydrocortisone with natamycin	
Glaucoma Preparations .....	179	vaccine .....	208	and neomycin .....	53
Glibenclamide .....	19	Haldol .....	121	Hydrocortisone with paraffin and	
Gliclazide .....	19	Haldol Concentrate .....	121	wool fat .....	52
Glipizide .....	19	Haloperidol .....	119	Hydrogen peroxide .....	49
Glivec .....	134	Haloperidol decanoate .....	121	Hydroxocobalamin .....	182
Glizide .....	19	Hameln .....	107	Hydroxocobalamin acetate .....	25
Glucagen Hypokit .....	17	Hartmann's solution .....	34	Hydroxychloroquine .....	92
Glucagon hydrochloride .....	17	Havrix .....	209	Hydroxyethyl starch 130/0.4 with	
Glucerna Select (Vanilla) .....	198	Havrix Junior .....	209	magnesium chloride,	
Glucerna Select RTH		HBvaxPRO .....	210	potassium chloride, sodium	
(Vanilla) .....	198	Healon GV .....	179	acetate and sodium	
Glucose [Dextrose]		healthE Dimethicone 5% .....	50	chloride .....	37
Alimentary .....	17	healthE Fatty Cream .....	51	Hydroxyethyl starch 130/0.4 with	
Blood .....	35	Heparin sodium .....	32	sodium chloride .....	37
Extemporaneously		Heparinised saline .....	32	Hydroxyurea .....	131
Compounded		Heparon Junior .....	199	Hygrotan .....	44
Preparations .....	191	Hepatitis A vaccine .....	209	Hylo-Fresh .....	181
Glucose with potassium		Hepatitis B recombinant		Hyoscine butylbromide .....	16
chloride .....	35	vaccine .....	210	Hyoscine	
Glucose with potassium chloride		Hepsera .....	85	hydrobromide .....	117-118
and sodium chloride .....	35	Herceptin .....	167	Hyperuricaemia and Antigout .....	97
Glucose with sodium chloride .....	35	Hexamine hippurate .....	74	Hypnovel .....	124
Glucose with sucrose and		Histaclear .....	170	Hypromellose .....	178, 181
fructose .....	17	Histamine acid phosphate .....	187	Hypromellose with dextran .....	181
Glycerin with sodium		Holoxan .....	128	Hysite .....	180
saccharin .....	191	Hormone Replacement			
Glycerin with sucrose .....	191	Therapy .....	61	- I -	
Glycerol		HPV .....	210	Ibiamox .....	72
Alimentary .....	21	Humalog Mix 25 .....	18	Ibuprofen .....	100
Extemporaneously		Humalog Mix 50 .....	18	Idarubicin hydrochloride .....	129
Compounded		Human papillomavirus (6, 11, 16		Ifosfamide .....	128
Preparations .....	191	and 18) vaccine [HPV] .....	210	Ikorel .....	47
Glycerol with paraffin .....	51	Humatin .....	69	Iloprost .....	48
Glyceryl trinitrate		Humira .....	146	Imatinib mesilate .....	134-135
Alimentary .....	16	HumiraPen .....	146	Imatinib-AFT .....	135
Cardiovascular .....	45	Hyaluronidase .....	97	Imiglucerase .....	22
Glycine .....	188	Hybloc .....	41	Imipenem with cilastatin .....	69
Glycopyrronium .....	171	Hydralazine hydrochloride .....	47	Imipramine hydrochloride .....	111
Glycopyrronium bromide .....	16	Hydrea .....	131	Imiquimod .....	54
Glypressin .....	68	Hydrocortisone		Immune Modulators .....	90
Glytrin .....	45	Dermatological .....	52	Immunosuppressants .....	140
Gonadorelin .....	62	Extemporaneously		Impact Advanced Recovery	
Goserelin .....	62	Compounded		(Chocolate) .....	204
Granirex .....	117	Preparations .....	191	Impact Advanced Recovery	
		Hormone Preparations .....	60		

(Vanilla) .....	204	Irinotecan hydrochloride .....	131	L-ornithine L-aspartate .....	17
Imuran .....	168	Iron polymaltose .....	23	Labetalol .....	41
Indacaterol .....	173	Iron sucrose .....	23	Lacosamide .....	114
Indapamide .....	44	Irrigation Solutions .....	188	Lactose .....	191
Indigo carmine .....	187	Isentress .....	85	Lactulose .....	21
Indinavir .....	84	Ismo 40 Retard .....	45	Laevolac .....	21
Indocyanine green .....	187	Ismo-20 .....	45	Lamictal .....	115
Indomethacin .....	100	Isoflurane .....	103	Lamivudine .....	83, 86
Infanrix IPV .....	207	Isoniazid .....	78	Lamotrigine .....	115
Infanrix-hexa .....	207	Isoniazid with rifampicin .....	78	Lansoprazole .....	16
Infliximab .....	152	Isoprenaline .....	46	Lantus .....	18
Influenza vaccine .....	210	Isopropyl alcohol .....	184	Lantus SoloStar .....	18
Influvac .....	210	Isoptin .....	42	Lapatinib .....	135
Inhaled Corticosteroids .....	172	Isopto Carpine .....	180	Lariam .....	79
Innovacon hCG One Step Pregnancy Test .....	214	Isosorbide mononitrate .....	45	Latanoprost .....	180
Insulin aspart .....	18	Isotretinoin .....	50	Lax-Sachets .....	21
Insulin aspart with insulin aspart protamine .....	18	Ispaghula (psyllium) husk .....	20	Lax-Tabs .....	21
Insulin glargine .....	18	Isradipine .....	42	Laxatives .....	20
Insulin glulisine .....	18	Itch-Soothe .....	50	Laxsol .....	20
Insulin isophane .....	18	Itraconazole .....	76	Leflunomide .....	92
Insulin lispro .....	18	Itrazole .....	76	Lenalidomide .....	131
Insulin lispro with insulin lispro protamine .....	18	Ivermectin .....	79	Letraccord .....	140
Insulin neutral .....	18	<b>- J -</b>		Letrozole .....	140
Insulin neutral with insulin isophane .....	18	Jadelle .....	56	Leukotriene Receptor Antagonists .....	173
Insulin pen needles .....	213	Jevity .....	205	Leunase .....	131
Insulin syringes, disposable with attached needle .....	213	Jevity HiCal RTH .....	205	Leuporelin acetate .....	63
Integrilin .....	33	Jevity RTH .....	205	Leustatin .....	130
Intelence .....	82	<b>- K -</b>		Levetiracetam .....	115
Interferon alfa-2a .....	90	Kaletra .....	84	Levetiracetam-Rex .....	115
Interferon alfa-2b .....	90	Kenacomb .....	177	Levobunolol hydrochloride .....	179
Interferon beta-1-alpha .....	123	Kenacort-A 10 .....	60	Levocabastine .....	177
Interferon beta-1-beta .....	123	Kenacort-A 40 .....	60	Levocarnitine .....	22
Interferon gamma .....	90	Kenalog in Orabase .....	24	Levodopa with benserazide .....	103
Intra-uterine device .....	56	Ketamine .....	103	Levodopa with carbidopa .....	103
Invanz .....	69	Ketocal 3:1 (Unflavoured) .....	203	Levomepromazine .....	119
Invega Sustenna .....	121	Ketocal 4:1 (Unflavoured) .....	203	Levonorgestrel .....	56
Iodine .....	67	Ketocal 4:1 (Vanilla) .....	203	Levosimendan .....	46
Iodine with ethanol .....	184	Ketoconazole .....		Levothyroxine .....	67
Iodised oil .....	185	Dermatological .....	49	Lidocaine [Lignocaine] hydrochloride .....	105
Iodixanol .....	185	Infections .....	75	Lidocaine [Lignocaine] hydrochloride with adrenaline .....	105
Iohexol .....	185	Ketone blood beta-ketone electrodes .....	213	Lidocaine [Lignocaine] hydrochloride with adrenaline and tetracaine hydrochloride .....	105
Iopidine .....	180	Ketoprofen .....	100	Lidocaine [Lignocaine] hydrochloride with chlorhexidine .....	105
Ioscan .....	185	Ketorolac trometamol .....	177	Lidocaine [Lignocaine] hydrochloride with chlorhexidine .....	105
IPOL .....	211	Kivexa .....	82	Lidocaine [Lignocaine] hydrochloride .....	105
Ipratropium bromide .....	170-171	Klacid .....	71	Lidocaine [Lignocaine] hydrochloride with chlorhexidine .....	105
Iressa .....	134	Klean Prep .....	20	Lidocaine [Lignocaine] hydrochloride .....	105
Irinotecan Actavis 100 .....	131	Kogenate FS .....	30	Lidocaine [Lignocaine] hydrochloride .....	105
Irinotecan Actavis 40 .....	131	Konakion MM .....	31	Lidocaine [Lignocaine] hydrochloride .....	105
		Konsyl-D .....	20	Lidocaine [Lignocaine] hydrochloride .....	105
		<b>- L -</b>		Lidocaine [Lignocaine] hydrochloride .....	105
		L-asparaginase .....	131	Lidocaine [Lignocaine] hydrochloride .....	105

phenylephrine hydrochloride	105		
Lidocaine [Lignocaine] with prilocaine	106		
Lidocaine-Claris	105		
Lignocaine	105		
Lincomycin	74		
Lindane (Gamma benzene hexachloride)	49		
Linezolid	75		
Lioresal Intrathecal	98		
Liothyronine sodium	67		
Lipazil	44		
Lipid-Modifying Agents	44		
Lipiodol Ultra Fluid	185		
Liquibar	186		
Liquifilm Forte	181		
Liquifilm Tears	181		
Lisinopril	38		
Lissamine green	178		
Lisuride hydrogen maleate	103		
Lithicarb FC	119		
Lithium carbonate	119		
Local Preparations for Anal and Rectal Disorders	15		
Locoid	52, 54		
Locoid Crelo	52		
Locoid Lipocream	52		
Lodoxamide	177		
Logem	115		
Lomide	177		
Lomustine	128		
Long-Acting Beta-Adrenoceptor Agonists	173		
Loniten	47		
Loperamide hydrochloride	14		
Lopinavir with ritonavir	84		
Lopresor	41		
Lorafix	171		
LoraPaed	171		
Loratadine	171		
Lorazepam	113, 122		
Lormetazepam	123		
Losartan Actavis	39		
Losartan potassium	39		
Losartan potassium with hydrochlorothiazide	39		
Lovir	88		
Loxalate	112		
Loxamine	112		
Lucrin Depot PDS	63		
Lycinate	45		
Lyderm	50		
		<b>- M -</b>	
m-Amoxiclav	72		
m-Eslon	109		
M-M-R-II	211		
m-Mometasone	52		
Mabthera	158		
Macrogl 3350 with ascorbic acid, potassium chloride and sodium chloride	20		
Macrogl 3350 with potassium chloride, sodium bicarbonate and sodium chloride	21		
Macrogl 3350 with potassium chloride, sodium bicarbonate, sodium chloride and sodium sulphate	20		
Macrogl 400 and propylene glycol	181		
Madopar 125	103		
Madopar 250	103		
Madopar 62.5	103		
Madopar HBS	103		
Madopar Rapid	103		
Mafenide acetate	49		
Magnesium hydroxide Alimentary	23		
Extemporaneously Compounded Preparations	191		
Magnesium oxide	23		
Magnesium sulphate	23		
Magnevist	187		
Malarone	79		
Malarone Junior	79		
Malathion [Maldison]	50		
Malathion with permethrin and piperonyl butoxide	50		
Maldison	49		
Mannitol	43		
Maprotiline hydrochloride	111		
Marcaïn	104		
Marcaïn Heavy	105		
Marcaïn Isobaric	104		
Marcaïn with Adrenaline	104		
Marevan	33		
Marine Blue Lotion SPF 50+	54		
Martindale Acetylcysteine	182		
Mask for spacer device	213		
Mast Cell Stabilisers	174		
Maxidex	177		
Maxitrol	177		
Measles, mumps and rubella			
vaccine	211		
Mebendazole	79		
Mebeverine hydrochloride	16		
Medrol	60		
Medroxyprogesterone	62		
Medroxyprogesterone acetate Genito-Urinary Hormone Preparations	56 61		
Mefenamic acid	100		
Mefloquine	79		
Megestrol acetate	138		
Meglumine gadopentetate	187		
Meglumine iotroxate	187		
Melatonin	123		
Meloxicam	100		
Melphalan	128		
Menactra	208		
Meningococcal (A, C, Y and W-135) conjugate vaccine	208		
Meningococcal C conjugate vaccine	208		
Menthol	191		
Mepivacaine hydrochloride	106		
Mercaptopurine	130		
Meropenem	69		
Mesalazine	15		
Mesna	138		
Mestinon	92		
Metabolic Disorder Agents	21		
Metabolic Products	195		
Metamide	118		
Metaraminol	46		
Metformin	19		
Methacholine chloride	187		
Methadone hydrochloride Extemporaneously Compounded Preparations	191		
Nervous	108		
Methatabs	108		
Methohexital sodium	103		
Methopt	181		
Methotrexate	130		
Methotrexate Ebewe	130		
Methotrexate Sandoz	130		
Methoxsalen [8-methoxypsoralen]	53		
Methoxyflurane	106		
Methyl aminolevulinate hydrochloride	54		
Methyl hydroxybenzoate	191		
Methylcellulose	191		



Methylcellulose with glycerin and sodium saccharin .....	191	Mirtazapine .....	111	Natamycin .....	176
Methylcellulose with glycerin and sucrose .....	191	Misoprostol .....	16	Natulan .....	132
Methyldopa .....	43	Mitomycin C .....	129	Nausicalm .....	117
Methylene blue .....	187	Mitozantrone .....	129	Navelbine .....	138
Methylphenidate hydrochloride .....	125	Mitozantrone Ebewe .....	129	Nedocromil .....	174
Methylprednisolone (as sodium succinate) .....	60	Mivacron .....	99	Nefopam hydrochloride .....	106
Methylprednisolone aceponate .....	52	Mivacurium chloride .....	99	Neisvac-C .....	208
Methylprednisolone acetate .....	60	Moclobemide .....	111	Neocate Advance (Vanilla) .....	201
Methylprednisolone acetate with lignocaine .....	60	Modafinil .....	125	Neocate Gold (Unflavoured) .....	201
Methylthioninium chloride [Methylene blue] .....	187	Moderate .....	121	Neoral .....	140
Methylxanthines .....	174	Mogine .....	115	Neostigmine metilsulfate .....	92
Metoclopramide hydrochloride .....	118	Mometasone furoate .....	52	Neostigmine metilsulfate with glycopyrronium bromide .....	92
Metoclopramide hydrochloride with paracetamol .....	117	Monosodium glutamate with sodium aspartate .....	189	Neosynephrine HCL .....	47
Metolazone .....	44	Monosodium l-aspartate .....	189	Nepro HP (Strawberry) .....	204
Metoprolol - AFT CR .....	41	Montelukast .....	173	Nepro HP (Vanilla) .....	204
Metoprolol succinate .....	41	Morocrocog alfa [Recombinant factor VIII] .....	30	Nepro HP RTH .....	204
Metoprolol tartrate .....	41	Morphine hydrochloride .....	108	Neulastim .....	34
Metronidazole Dermatological .....	49	Morphine sulphate .....	109	Neupogen .....	34
Metronidazole Infections .....	80	Morphine tartrate .....	109	NeuroTabs .....	23
Metryapone .....	62	Motetis .....	102	Nevirapine .....	82
Mexiletine hydrochloride .....	40	Mouth and Throat .....	24	Nevirapine Alphapharm .....	82
Mexiletine Hydrochloride USP .....	40	Moxifloxacin .....	73	Nicorandil .....	47
Miacalcic .....	59	Mucolytics and Expectorants .....	174	Nicotine .....	127
Mianserin hydrochloride .....	111	Multihance .....	186	Nicotinic acid .....	45
Micolette .....	21	Multiple Sclerosis Treatments .....	123	Nifedipine .....	42
Miconazole .....	24	Multivitamins .....	25	Nilotinib .....	135
Miconazole nitrate Dermatological .....	49	Mupirocin .....	49	Nilstat .....	24, 76
Miconazole nitrate Genito-Urinary .....	55	Muscle Relaxants and Related Agents .....	98	Nimodipine .....	42
Micreme .....	55	Myambutol .....	78	Nitazoxanide .....	80
Micreme H .....	53	Mycobutin .....	78	Nitrados .....	124
Microgynon 50 ED .....	55	MycoNail .....	49	Nitrates .....	45
Midazolam .....	124	Mycophenolate mofetil .....	169	Nitrazepam .....	124
Midodrine .....	40	Mydriacyl .....	180	Nitroderm TTS 10 .....	45
Mifepristone .....	57	Mydriatics and Cycloplegics .....	180	Nitroderm TTS 5 .....	45
Milrinone .....	47	Mylan Atenolol .....	40	Nitrofurantoin .....	75
Minerals .....	22	Mylan Fentanyl Patch .....	108	Nitronal .....	45
Minidiab .....	19	Myleran .....	128	Noflam 250 .....	101
Minirin .....	67	- N -		Noflam 500 .....	101
MiniTT380 Slimline .....	56	Nadolol .....	41	Non-Steroidal Anti-Inflammatory Drugs .....	99
Minocycline .....	74	Naloxone hydrochloride .....	182	Nonacog alfa [Recombinant factor IX] .....	30
Minoxidil .....	47	Naltracord .....	127	Noradrenaline .....	46
		Naltrexone hydrochloride .....	127	Norethisterone Genito-Urinary .....	56
		Naphazoline hydrochloride .....	178	Norethisterone Hormone Preparations .....	62
		Naphcon Forte .....	178	Norethisterone with mestranol .....	55
		Naproxen .....	101	Norfloracin .....	73
		Naropin .....	106	Normison .....	124
		Natalizumab .....	123	Norpress .....	111
				Nortriptyline hydrochloride .....	111

Norvir .....	84	OncoTICE .....	168	Ozole .....	76
Novasource Renal (Vanilla) .....	204	Ondanaccord .....	118	<b>- P -</b>	
Novatretin .....	53	Ondansetron .....	118		
NovoMix 30 FlexPen .....	18	Ondansetron ODT-DRLA .....	118	Pacifen .....	98
NovoRapid FlexPen .....	18	One-Alpha .....	26	Pacific Buspiron .....	122
NovoSeven RT .....	30	Onkotrone .....	129	Paclitaxel .....	138
Noxafil .....	76	Onrex .....	118	Paclitaxel Ebewe .....	138
Nupentin .....	113	Optional Pharmaceuticals .....	213	Paliperidone .....	121
Nutrini Energy Multi Fibre .....	203	Ora-Blend .....	191	Pamidronate disodium .....	94
Nutrini Low Energy Multifibre		Ora-Blend SF .....	191	Pamisol .....	94
RTH .....	203	Ora-Plus .....	191	Panadol .....	107
Nutrison Concentrated .....	199	Ora-Sweet .....	191	Pancreatic enzyme .....	19
Nutrison Energy .....	205	Ora-Sweet SF .....	191	Pancuronium bromide .....	99
Nyefax Retard .....	42	Oracort .....	24	Pantoprazole .....	17
Nystatin		Oratane .....	50	Pantoprazole Actavis 20 .....	17
Alimentary .....	24	Ornidazole .....	80	Pantoprazole Actavis 40 .....	17
Dermatological .....	49	Orphenadrine citrate .....	99	Papaverine hydrochloride .....	47
Genito-Urinary .....	55	Orphenadrine hydrochloride .....	102	Paper wasp venom .....	170
Infections .....	76	Oruvail SR .....	100	Para-aminosalicylic Acid .....	78
<b>- O -</b>		Oseltamivir .....	89	Paracare .....	107
Obstetric Preparations .....	57	Osmolite .....	205	Paracare Double Strength .....	107
Octocog alfa [Recombinant factor		Osmolite RTH .....	205	Paracetamol .....	107
VIII] .....	30	Other Cardiac Agents .....	46	Paracetamol + Codeine	
Octreotide .....	139	Other Endocrine Agents .....	61	(Relieve) .....	110
Ocular Lubricants .....	181	Other Oestrogen		Paracetamol with codeine .....	110
Oestradiol .....	61-62	Preparations .....	62	Paraffin	
Oestradiol valerate .....	61	Other Otolological		Alimentary .....	20
Oestradiol with norethisterone		Preparations .....	181	Dermatological .....	51
acetate .....	61	Other Progestogen		Extemporaneously	
Oestriol		Preparations .....	62	Compounded	
Genito-Urinary .....	57	Other Skin Preparations .....	54	Preparations .....	191
Hormone Preparations .....	62	Ox-Pam .....	123	Paraffin liquid with soft white	
Oestrogens .....	57	Oxaliplatin .....	133	paraffin .....	181
Oestrogens (conjugated		Oxaliplatin Actavis 100 .....	133	Paraffin liquid with wool fat .....	181
equine) .....	61	Oxaliplatin Actavis 50 .....	133	Paraffin with wool fat .....	51
Oestrogens with		Oxandrolone .....	59	Paraldehyde .....	113
medroxyprogesterone		Oxazepam .....	123	Paracoxib .....	101
acetate .....	61	Oxpentifylline .....	47	Paromomycin .....	69
Oil in water emulsion .....	51	Oxybuprocaine		Paroxetine hydrochloride .....	112
Oily phenol [Phenol oily] .....	16	hydrochloride .....	178	Paser .....	78
Olanzapine .....	119, 121	Oxybutynin .....	58	Patent blue V .....	187
Olive oil .....	191	Oxycodone ControlledRelease		Paxam .....	122
Olopatadine .....	177	Tablets(BNM) .....	110	Pazopanib .....	136
Olsalazine .....	15	Oxycodone hydrochloride .....	110	Peak flow meter .....	213
Omalizumab .....	157	Oxycodone Orion .....	110	Peanut oil .....	190
Omeprazole .....	16	OxyContin .....	110	Pediasure (Chocolate) .....	203
Omezol Relief .....	16	OxyContin .....	110	Pediasure (Strawberry) .....	203
Omnipaque .....	185	Oxymetazoline		Pediasure (Vanilla) .....	203
Omniscan .....	186	hydrochloride .....	172	Pediasure RTH .....	203
Omnitrope .....	63	OxyNorm .....	110	Pegaspargase .....	132
On Call Advanced .....	213	Oxytocin .....	57	Pegasus RBV Combination	
Onbrez Breezhaler .....	173	Oxytocin BNM .....	57	Pack .....	90
Oncaspar .....	132	Oxytocin with ergometrine		Pegasys .....	90
		maleate .....	57	Pegfilgrastim .....	34

Pegylated interferon alfa-2a .....	90	Pinorax Forte .....	21	ethanol .....	184
Penicillamine .....	92	Pioglitazone .....	19	Pradaxa .....	31
Penicillin G .....	72	Piperacillin with tazobactam .....	72	Pralidoxime iodide .....	182
Penicillin V .....	72	Pipothiazine palmitate .....	122	Pramipexole hydrochloride .....	103
Pentacarinat .....	80	Pituitary and Hypothalamic Hormones and Analogues .....	62	Prasugrel .....	33
Pentagastrin .....	62	Pivmecillinam .....	75	Pravastatin .....	44
Pentamidine isethionate .....	80	Pizacord .....	19	Praziquantel .....	79
Pentasa .....	15	Pizotifen .....	117	Prazosin .....	39
Pentostatin [Deoxycofomycin] .....	132	PKU Anamix Junior LQ (Berry) .....	196	Precedex .....	103
Pentoxifylline [Oxpentifylline] .....	47	PKU Anamix Junior LQ (Orange) .....	196	Prednisolone .....	60
Peptamen OS 1.0 (Vanilla) .....	199	PKU Anamix Junior LQ (Unflavoured) .....	196	Prednisolone acetate .....	177
Peptisoothe .....	16	Plaquenil .....	92	Prednisolone sodium phosphate .....	177
Perfalgan .....	107	Plendil ER .....	42	Prednisone .....	60
Perflutren .....	187	pms-Bosentan .....	48	Pregnancy test - hCG urine .....	214
Perhexiline maleate .....	42	Pneumococcal (PCV13) conjugate vaccine .....	209	preOp .....	204
Pericyazine .....	120	Pneumococcal (PPV23) polysaccharide vaccine .....	209	Prevenar 13 .....	209
Perindopril .....	38	Pneumovax 23 .....	209	Prezista .....	84
Permethrin .....	50	Podophyllotoxin .....	54	Prilocaine hydrochloride .....	106
Peteha .....	78	Polidocanol .....	29	Prilocaine hydrochloride with felypressin .....	106
Pethidine hydrochloride .....	110	Poliomyelitis vaccine .....	211	Primaquine phosphate .....	80
Pexsig .....	42	Poloxamer .....	20	Primaxin .....	69
Phenelzine sulphate .....	111	Poly Gel .....	181	Primidone .....	115
Phenindione .....	32	Poly-Tears .....	181	Primolut N .....	62
Phenobarbitone .....	115, 124	Poly-Visc .....	181	Primovist .....	187
Phenobarbitone sodium .....	191	Polyhexamethylene biguanide .....	191	Probenecid .....	98
Phenol Extemporaneously Compounded Preparations .....	191	Polyvinyl alcohol .....	181	Procaine penicillin .....	72
Various .....	188	Polyvinyl alcohol with povidone .....	181	Procarbazine hydrochloride .....	132
Phenol oily .....	16	Poractant alfa .....	175	Prochlorperazine .....	118
Phenol with ioxaglic acid .....	188	Posaconazole .....	76	Proctosedyl .....	15
Phenoxybenzamine hydrochloride .....	39	Postinor-1 .....	56	Procydiline hydrochloride .....	102
Phenoxyethylpenicillin [Penicillin V] .....	72	Potassium chloride .....	35, 37	Procytox .....	128
Phentolamine mesylate .....	39	Potassium chloride with sodium chloride .....	36	Prodopa .....	43
Phenylephrine hydrochloride Cardiovascular .....	47	Potassium citrate .....	58	Progesterone .....	57
Sensory .....	180	Potassium dihydrogen phosphate .....	36	Proglidem .....	17
Phenytoin .....	115	Potassium iodate .....	23	Proglycem .....	17
Phenytoin sodium .....	113, 115	Alimentary .....	23	Prokinex .....	117
Pholcodine .....	172	Hormone Preparations .....	67	Promethazine hydrochloride .....	171
Phosphorus .....	37	Potassium iodate with iodine .....	23	Promethazine theoclate .....	118
Phytomenadione .....	31	Potassium perchlorate .....	67	Propafenone hydrochloride .....	40
Picibanil .....	169	Potassium permanganate .....	53	Propamidine isethionate .....	176
Pilocarpine hydrochloride .....	180	Povidone K30 .....	191	Propofol .....	104
Pilocarpine nitrate .....	191	Povidone-iodine .....	184	Propranolol .....	41
Pimafucort .....	53	Povidone-iodine with ethanol .....	184	Propylene glycol .....	191
Pindolol .....	41			Propylthiouracil .....	67
Pinetarsol .....	53			Prostin E2 .....	57
Pinorax .....	21			Prostin VR .....	47
				Protamine sulphate .....	32
				Protionamide .....	78
				Protirelin .....	67
				Provera .....	61, 62
				Provisc .....	179

Provine MCT-LCT 1% .....	104	ReoPro .....	146	Salamol .....	172
Proxymetacaine hydrochloride .....	178	Resource Beneprotein .....	194	Salazopyrin .....	15
Pseudoephedrine hydrochloride .....	172	Resource Diabetic (Vanilla) .....	198	Salazopyrin EN .....	15
Psoriasis and Eczema Preparations .....	53	Respiratory Stimulants .....	175	Salbutamol .....	172
PTU .....	67	Retinol .....	25	Salbutamol with ipratropium bromide .....	171
Pulmocare (Vanilla) .....	204	Retinol Palmitate .....	181	Salicylic acid .....	192
Pulmonary Surfactants .....	175	Retrovir .....	83	Salmeterol .....	173
Pulmozyme .....	174	Retrovir IV .....	83	Salmonella typhi vaccine .....	209
Puri-nethol .....	130	Reutenox .....	101	Sandimmun .....	140
Pyrazinamide .....	78	Revlimid .....	131	Sandomigran .....	117
Pyridostigmine bromide .....	92	Revolade .....	29	Sandostatil LAR .....	139
PyridoxADE .....	26	Reyataz .....	84	Scalp Preparations .....	53
Pyridoxal-5-phosphate .....	22	Riboflavin 5-phosphate .....	179	Scandonest 3% .....	106
Pyridoxine hydrochloride .....	26	Rifabutin .....	78	Sclerosing Agents .....	175
Pyrimethamine .....	80	Rifadin .....	78	Scopoderm TTS .....	117
Pytazen SR .....	33	Rifampicin .....	78	Sebizole .....	49
<b>- Q -</b>		Rifaximin .....	17	Securin pentahydrochloride .....	187
Q 300 .....	80	Rilutek .....	102	Sedatives and Hypnotics .....	123
Quetapel .....	120	Riluzole .....	102	Seebri Breezhaler .....	171
Quetiapine .....	120	Ringer's solution .....	36	Selegiline hydrochloride .....	103
Quinapril .....	38	Riodine .....	184	Sennosides .....	21
Quinapril with hydrochlorothiazide .....	38	Risedronate .....	94	Serenace .....	119
Quinine dihydrochloride .....	80	Risedronate sodium .....	94	Seretide .....	174
Quinine sulphate .....	80	Risperdal Consta .....	122	Seretide Accuhaler .....	174
Qvar .....	172	Risperdal Quicklet .....	120	Serevent .....	173
<b>- R -</b>		Risperidone .....	120, 122	Serevent Accuhaler .....	173
RA-Morph .....	108	Risperon .....	120	Serophene .....	61
Rabies vaccine .....	211	Ritalin .....	125	Sertraline .....	113
Raloxifene .....	96	Ritalin LA .....	125	Sevoflurane .....	104
Raltegravir potassium .....	85	Ritalin SR .....	125	Sevredol .....	109
Ramipex .....	103	Ritonavir .....	84	SII-Onco-BCG .....	168
Ranbaxy-Cefaclor .....	70	Rituximab .....	158	Silagra .....	48
Ranibizumab .....	158	Rivaroxaban .....	32	Sildenafil .....	48
Ranitidine .....	16	Rivastigmine .....	126	Silver nitrate .....	
Ranitidine Relief .....	16	Rivotril .....	113	Dermatological .....	54
Rapamune .....	169	Rizamelit .....	117	Extemporaneously Compounded Preparations .....	192
Rasburicase .....	98	Rizatriptan .....	117	Simethicone .....	14
Readi-CAT 2 .....	186	Rocuronium bromide .....	99	Simulect .....	152
Reandron 1000 .....	59	Ropinirole hydrochloride .....	103	Simvastatin .....	44
Recombinant factor IX .....	30	Ropivacaine hydrochloride .....	106	Sincalide .....	187
Recombinant factor VIIa .....	30	Ropivacaine hydrochloride with fentanyl .....	106	Sinemet .....	103
Recombinant factor VIII .....	30	Rose bengal sodium .....	178	Sinemet CR .....	103
Rectogesic .....	16	RotaTeg .....	211	Singulair .....	173
Red back spider antivenom .....	183	Rotavirus live reassortant oral vaccine .....	211	Sirolimus .....	169
Redipred .....	60	Roxane .....	14	Siterone .....	59
Relenza Rotadisk .....	89	Roxithromycin .....	71	Slow-Lopresor .....	41
Remicade .....	152	Rubifen .....	125	Snake antivenom .....	183
Remifentanil hydrochloride .....	110	Rubifen SR .....	125	Sodibic .....	37
<b>- S -</b>		<b>- S -</b>		Sodium acetate .....	36
		S-26 Gold Premgro .....	202	Sodium acid phosphate .....	36
		S26 LBW Gold RTF .....	202		

Sodium alginate with magnesium alginate ..... 14	phosphoric acid ..... 21	Surgical Preparations ..... 188
Sodium alginate with sodium bicarbonate and calcium carbonate ..... 14	Sodium polystyrene sulphonate ..... 37	Survanta ..... 175
Sodium aurothiomalate ..... 92	Sodium stibogluconate ..... 80	Sustagen Diabetic (Vanilla) ..... 198
Sodium benzoate ..... 22	Sodium tetradecyl sulphate ..... 29	Sustagen Hospital Formula (Chocolate) ..... 206
Sodium bicarbonate	Sodium thiosulfate ..... 182	Sustagen Hospital Formula (Vanilla) ..... 206
Blood ..... 36–37	Sodium valproate ..... 115	Sutent ..... 136
Extemporaneously Compounded	Sodium with potassium ..... 189	Suxamethonium chloride ..... 99
Preparations ..... 192	Solian ..... 118	Symmetrel ..... 102
Sodium calcium edetate ..... 184	Solifenacin succinate ..... 58	Sympathomimetics ..... 46
Sodium carboxymethylcellulose with pectin and gelatine ..... 24	Solox ..... 16	Synacthen ..... 62
Sodium chloride	Solu-Cortef ..... 60	Synacthen Depot ..... 62
Blood ..... 36–37	Solu-Medrol ..... 60	Syntometrine ..... 57
Respiratory ..... 172, 175	Somatropin ..... 63	Syrup ..... 192
Various ..... 188	Sotacor ..... 41	Systane Unit Dose ..... 181
Sodium chloride with sodium bicarbonate ..... 172	Sotalol ..... 41	
Sodium citrate	Soya oil ..... 182	<b>- T -</b>
Alimentary ..... 14	Space Chamber Plus ..... 214	Tacrolimus ..... 140
Extemporaneously Compounded	Spacer device ..... 214	Tacrolimus Sandoz ..... 140
Preparations ..... 192	Span-K ..... 37	Tagitol V ..... 186
Sodium citrate with sodium chloride and potassium	Specialised Formulas ..... 197	Talc ..... 175
chloride ..... 32	Spiractin ..... 43	Tambocor ..... 40
Sodium citrate with sodium lauryl sulphoacetate ..... 21	Spiramycin ..... 80	Tambocor CR ..... 40
Sodium citro-tartrate ..... 58	Spiriva ..... 171	Tamoxifen citrate ..... 140
Sodium cromoglycate	Spirolactone ..... 43	Tamsulosin ..... 58
Alimentary ..... 15	Sprycel ..... 133	Tamsulosin-Rex ..... 58
Respiratory ..... 170, 174	Standard Feeds ..... 205	Tarceva ..... 134
Sensory ..... 177	Staphlex ..... 72	Tasigna ..... 135
Sodium dihydrogen phosphate [Sodium acid phosphate] ..... 36	Starch ..... 192	Tasmar ..... 103
Sodium fluoride ..... 23	Stavudine ..... 83	Tazocin EF ..... 72
Sodium hyaluronate	Sterculia with frangula ..... 20	Tegretol ..... 113
Alimentary ..... 24	Stesolid ..... 113	Tegretol CR ..... 113
Sensory ..... 179, 181	Stimulants / ADHD	Teicoplanin ..... 75
Sodium hyaluronate with chondroitin sulphate ..... 179	Treatments ..... 124	Temaccord ..... 132
Sodium hypochlorite ..... 184	Stiripentol ..... 116	Temazepam ..... 124
Sodium metabisulfite ..... 192	Stocrin ..... 82	Temozolomide ..... 132
Sodium nitrite ..... 182	Strattera ..... 124	Tenecteplase ..... 34
Sodium nitroprusside	Streptomycin sulphate ..... 69	Tenofovir disoproxil fumarate ..... 86
Cardiovascular ..... 47	Stromectol ..... 79	Tenoxicam ..... 101
Part III - OPTIONAL	Suboxone ..... 126	Terazosin ..... 39
PHARMACEUTICALS ..... 214	Sucralfate ..... 17	Terbinafine ..... 77
Sodium phenylbutyrate ..... 22	Sucrose ..... 107	Terbutaline ..... 57
Sodium phosphate with	Sugammadex ..... 99	Terbutaline sulphate ..... 172
phosphoric acid ..... 21	Sulindac ..... 101	Teriparatide ..... 97
Sodium polystyrene sulphonate ..... 37	Sulphacetamide sodium ..... 176	Terlipressin ..... 68
Sodium stibogluconate ..... 80	Sulphadiazine ..... 75	Testosterone ..... 59
Sodium tetradecyl sulphate ..... 29	Sulphadiazine silver ..... 49	Testosterone cypionate ..... 59
Sodium thiosulfate ..... 182	Sulphasalazine ..... 15	Testosterone esters ..... 59
Sodium valproate ..... 115	Sulphur ..... 192	Testosterone undecanoate ..... 59
Sodium with potassium ..... 189	Sumatriptan ..... 117	Tetrabenazine ..... 102
Solian ..... 118	Sunitinib ..... 136	Tetracaine [Amethocaine] hydrochloride
Solifenacin succinate ..... 58	Sunscreen, proprietary ..... 54	Nervous ..... 106
Solox ..... 16	Suprane ..... 103	

Sensory .....	178	Tramal SR 200 .....	110	Univent .....	170, 171
Tetracosactide .....		Trandolapril .....	38	Ural .....	58
[Tetracosactrin] .....	62	Tranexamic acid .....	30	Urea .....	
Tetracosactrin .....	62	Tranylcypromine sulphate .....	111	Dermatological .....	51
Tetracyclin Wolff .....	74	Trastuzumab .....	167	Extemporaneously .....	
Tetracycline .....	74	Travoprost .....	180	Compounded .....	
Thalidomide .....	133	Treatments for Dementia .....	126	Preparations .....	192
Thalomid .....	133	Treatments for Substance .....		Urex Forte .....	43
Theobroma oil .....	192	Dependence .....	126	Urografin .....	185
Theophylline .....	174	Tretinoin .....		Urokinase .....	34
Thiamine hydrochloride .....	26	Dermatological .....	50	Urologicals .....	58
Thioguanine .....	130	Oncology .....	133	Uromitexan .....	138
Thiopental [Thiopentone] .....		Trexate .....	130	Ursodeoxycholic acid .....	19
sodium .....	104	Tri-sodium citrate .....	192	Ursosan .....	19
Thiopentone .....	104	Triamcinolone acetonide .....		Utrogestan .....	57
Thiotepa .....	128	Alimentary .....	24		
Thrombin .....	29	Dermatological .....	52	- V - .....	
Thymol glycerin .....	24	Hormone Preparations .....	60	Valaciclovir .....	88
Thyroid and Antithyroid .....		Triamcinolone acetonide with .....		Valcyte .....	89
Preparations .....	67	gramicidin, neomycin and .....		Valganciclovir .....	89
Thyrotropin alfa .....	62	nystatin .....	177	Valtrex .....	88
Ticagrelor .....	33	Triamcinolone acetonide with .....		Vancomycin .....	75
Ticarcillin with clavulanic acid .....	72	neomycin sulphate, gramicidin .....		Varenicline .....	127
Ticlopidine .....	33	and nystatin .....	53	Varibar - Honey .....	186
Tigecycline .....	74	Triamcinolone hexacetonide .....	60	Varibar - Nectar .....	186
Timolol .....	179	Triazolam .....	124	Varibar - Pudding .....	186
Timolol maleate .....	41	Trichloroacetic acid .....	192	Varibar - Thin Liquid .....	186
Timoptol XE .....	179	Trichozole .....	80	Varicella vaccine [Chicken pox .....	
Tiotropium bromide .....	171	Trientine dihydrochloride .....	22	vaccine] .....	212
TMP .....	75	Trifluoperazine .....		Varilrix .....	212
TOBI .....	69	hydrochloride .....	120	Vasodilators .....	47
Tobradex .....	177	Trimeprazine tartrate .....	171	Vasopressin .....	67
Tobramycin .....		Trimethoprim .....	75	Vasopressin Agents .....	67
Infections .....	69	Trimethoprim with .....		Vecuronium bromide .....	99
Sensory .....	176	sulphamethoxazole .....		Velcade .....	131
Tobrex .....	176	[Co-trimoxazole] .....	75	Venlafaxine .....	112
Tocilizumab .....	165	Trisodium citrate .....	32	Venofer .....	23
Tofranil .....	111	Trometamol .....	188	Ventavis .....	48
Tolcapone .....	103	Tropicamide .....	180	Ventolin .....	172
Tolterodine tartrate .....	58	Tropisetron .....	118	Vepesid .....	131
Topamax .....	116	Tropisetron-AFT .....	118	Verapamil hydrochloride .....	42
Topical Products for Joint and .....		Truvada .....	83	Vergo 16 .....	117
Muscular Pain .....	101	TT380 Slimline .....	56	Verpamil SR .....	42
Topiramate .....	116	Tuberculin, purified protein .....		Vesanoid .....	133
Topiramate Actavis .....	116	derivative .....	187	Vesicare .....	58
Tracleer .....	48	Two Cal HN .....	199	Vfend .....	77
Tracrium .....	98	TwoCal HN RTH (Vanilla) .....	199	Victrelis .....	88
Tramadol hydrochloride .....	110	Tykerb .....	135	Vidaza .....	129
Tramal 100 .....	110	Tysabri .....	123	Vigabatrin .....	116
Tramal 50 .....	110			Vimpat .....	114
Tramal SR 100 .....	110	- U - .....		Vinblastine sulphate .....	138
Tramal SR 150 .....	110	Ultiva .....	110	Vincristine sulphate .....	138
		Ultraproct .....	15	Vinorelbine .....	138
				Viral Vaccines .....	209

Viramune Suspension .....	82	Extemporaneously		Zinc	
Viread .....	86	Compounded		Alimentary .....	23
Visipaque .....	185	Preparations .....	192	Dermatological .....	50
Vistil .....	181	- X -		Zinc and castor oil .....	50
Vistil Forte .....	181	X-Opaque-HD .....	186	Zinc chloride .....	24
VitA-POS .....	181	Xanthan .....	192	Zinc oxide .....	192
Vital HN .....	199	Xarelto .....	32	Zinc sulphate .....	24
Vitamin A with vitamins D and		Xifaxan .....	17	Zinc with wool fat .....	51
C .....	25	Xolair .....	157	Zincaps .....	24
Vitamin B complex .....	26	Xylocaine .....	105	Zinforo .....	70
Vitamin B6 25 .....	26	Xylocaine Viscous .....	105	Zinnat .....	70
Vitamins .....	25	Xylometazoline		Ziprasidone .....	120
Vivonex Paediatric .....	201	hydrochloride .....	172	Zithromax .....	71
Vivonex TEN .....	198	Xyntha .....	30	Zoladex .....	62
Volibris .....	47	- Y -		Zoledronic acid	
Voltaren .....	100	Yellow jacket wasp venom .....	170	Hormone Preparations .....	59
Voltaren D .....	100	- Z -		Musculoskeletal System .....	94
Voltaren Ophtha .....	177	Zanamivir .....	89	Zometa .....	59
Volulyte 6% .....	37	Zantac .....	16	Zopiclone .....	124
Volumatic .....	214	Zapril .....	38	Zostrix .....	101
VoLumen .....	186	Zarator .....	44	Zostrix HP .....	106
Voluven .....	37	Zarzio .....	34	Zovirax IV .....	88
Voriconazole .....	77	Zavedos .....	129	Zuclopenthixol acetate .....	120
Votrient .....	136	Zeffix .....	86	Zuclopenthixol decanoate .....	122
- W -		Zeldox .....	120	Zuclopenthixol	
Warfarin sodium .....	33	Zetop .....	170	hydrochloride .....	121
Wart Preparations .....	54	Ziagen .....	82	Zyban .....	126
Water		Zidovudine [AZT] .....	83	Zypine .....	119
Blood .....	37	Zidovudine [AZT] with		Zypine ODT .....	119
Various .....	188	lamivudine .....	83	Zyprexa Relprevv .....	121
Wool fat		Zinacef .....	70		
Dermatological .....	51				





